Efficacy and Safety of Nintedanib in Idiopathic Pulmon

New England Journal of Medicine
370, 2071-2082
DOI: 10.1056/nejmoa1402584

Citation Report

#	Article	IF	Citations
2	Upregulation of activin-B and follistatin in pulmonary fibrosis â€“ a translational study using human biopsies and a specific inhibitor in mouse fibrosis models. BMC Pulmonary Medicine, 2014, 14, 170.	0.8	17
3	Hypoxia-sensitive pathways in inflammation-driven fibrosis. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2014, 307, R1369-R1380.	0.9	40
4	Molecular Mechanism and Treatment of Viral Hepatitis-Related Liver Fibrosis. International Journal of Molecular Sciences, 2014, 15, 10578-10604.	1.8	60
5	Open-Access Biorepository for Idiopathic Pulmonary Fibrosis. The Way Forward. Annals of the American Thoracic Society, 2014, 11, 1171-1175.	1.5	15
7	Measuring diffusion limitation with a perfusion-limited gasâ€"Hyperpolarized ¹²⁹Xe gas-transfer spectroscopy in patients with idiopathic pulmonary fibrosis. Journal of Applied Physiology, 2014, 117, 577-585.	1.2	77
9	Novel approaches to pulmonary fibrosis. Clinical Medicine, 2014, 14, s45-s49.	0.8	9
10	A new era of drug therapy for idiopathic pulmonary fibrosis. Lancet Respiratory Medicine,the, 2014, 2, 964-966.	5.2	1
11	Improving care for patients with idiopathic pulmonary fibrosis (IPF) in the UK: a round table discussion. Thorax, 2014, 69, 1136-1140.	2.7	31
12	ALK and ROS1 non-small-cell lung cancer: two molecular subgroups sensitive to targeted therapy. Lancet Respiratory Medicine,the, 2014, 2, 966-968.	5.2	14
13	Moving stem cell therapy to patients with idiopathic pulmonary fibrosis. Respirology, 2014, 19, 950-951.	1.3	8
14	Computed Tomography: Revolutionizing the Practice of Medicine for 40 Years. Radiology, 2014, 273, S45-S74.	3.6	128
15	Pulmonary Hypertension due to Fibrotic Lung Disease: Hidden Value in a Neutral Trial. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 131-132.	2.5	3
16	New Therapeutic Avenues for Treatment of Fibrosis: Can We Learn from Other Diseases?. Digestive Diseases, 2014, 32, 39-49.	0.8	12
18	Nintedanib for the treatment of patients with advanced non-small-cell lung cancer. Expert Review of Clinical Pharmacology, 2014, 7, 579-590.	1.3	9
19	Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis. Respiratory Research, 2014, 15, 157.	1.4	199
20	Clinical significance of epithelial mesenchymal transition (EMT) in chronic obstructive pulmonary disease (COPD): potential target for prevention of airway fibrosis and lung cancer. Clinical and Translational Medicine, 2014, 3, 33.	1.7	65
21	Acute exacerbations complicating interstitial lung disease. Current Opinion in Pulmonary Medicine, 2014, 20, 436-441.	1.2	29
22	IPF clinical trial design and endpoints. Current Opinion in Pulmonary Medicine, 2014, 20, 463-471.	1.2	58

#	Article	IF	Citations
23	Treatment strategies for idiopathic interstitial pneumonias. Current Opinion in Pulmonary Medicine, 2014, 20, 442-448.	1.2	19
24	Idiopathic and Autoimmune Interstitial Lung Disease. , 2014, , 1105-1123.		0
25	A New Hope for Idiopathic Pulmonary Fibrosis. New England Journal of Medicine, 2014, 370, 2142-2143.	13.9	50
26	Combination therapy: the future of management for idiopathic pulmonary fibrosis?. Lancet Respiratory Medicine,the, 2014, 2, 933-942.	5.2	128
28	Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia. Cancer Cell, 2014, 26, 605-622.	7.7	1,184
29	Hope for Disease-Modifying Treatment of Systemic Sclerosis/Scleroderma. Journal of Pharmacology and Experimental Therapeutics, 2014, 350, 480-482.	1.3	0
30	Beyond TGFÎ² â€“ Novel ways to target airway and parenchymal fibrosis. Pulmonary Pharmacology and Therapeutics, 2014, 29, 166-180.	1.1	14
32	Landmark approvals in idiopathic pulmonary fibrosis. Nature Biotechnology, 2014, 32, 1069-1070.	9.4	8
34	Fibrosis pulmonar idiopÃ¡tica. Medicine, 2014, 11, 3799-3807.	0.0	0
35	Treatments for Idiopathic Pulmonary Fibrosis. New England Journal of Medicine, 2014, 371, 781-784.	13.9	31
36	New Therapeutic Targets in Idiopathic Pulmonary Fibrosis. Aiming to Rein in Runaway Wound-Healing Responses. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 867-878.	2.5	209
37	Review: Interstitial Lung Disease Associated With Systemic Sclerosis and Idiopathic Pulmonary Fibrosis: How Similar and Distinct?. Arthritis and Rheumatology, 2014, 66, 1967-1978.	2.9	162
38	Reply to: Comment on: CT analysis of the effect of pirfenidone in patients with idiopathic pulmonary fibrosis. European Journal of Radiology, 2014, 83, 1990.	1.2	0
40	Interstitial lung disease in systemic sclerosis. Presse Medicale, 2014, 43, e329-e343.	0.8	48
41	Lung transplantation for interstitial lung disease. Current Respiratory Care Reports, 2014, 3, 96-102.	0.6	1
42	Lung transplantation in idiopathic pulmonary fibrosis: a systematic review of the literature. BMC Pulmonary Medicine, 2014, 14, 139.	0.8	115
43	Recent Evidence for Pharmacological Treatment of Idiopathic Pulmonary Fibrosis. Annals of Pharmacotherapy, 2014, 48, 1611-1619.	0.9	14
45	Hot off the breath: a big step forward for idiopathic pulmonary fibrosis. Thorax, 2014, 69, 791-792.	2.7	11

#	Article	IF	Citations
47	2014, 103, 105b-105b.	0.0	0
48	Interstitial lung disease: raising the index of suspicion in primary care. Npj Primary Care Respiratory Medicine, 2014, 24, 14054.	1.1	15
49	Elements: in this month's issue. QJM - Monthly Journal of the Association of Physicians, 2014, 107, 503-503.	0.2	0
50	Management of Idiopathic Pulmonary Fibrosis in the Elderly Patient. Chest, 2015, 148, 242-252.	0.4	36
52	The Future of Lung Transplantation. Chest, 2015, 147, 309-316.	0.4	37
53	Which Patients With ARDS Benefit From Lung Biopsy?. Chest, 2015, 148, 1073-1082.	0.4	32
54	17(R)-resolvin D1 ameliorates bleomycin-induced pulmonary fibrosis in mice. Physiological Reports, 2015, 3, e12628.	0.7	35
55	<scp>HRCT</scp> of fibrosing lung disease. Respirology, 2015, 20, 859-872.	1.3	54
56	Changes in the current classification of <scp>IIP</scp>: A critical review. Respirology, 2015, 20, 699-704.	1.3	14
57	Molecular classification of idiopathic pulmonary fibrosis: Personalized medicine, genetics and biomarkers. Respirology, 2015, 20, 1010-1022.	1.3	44
58	Mesenchymal Stromal Cells in Animal Bleomycin Pulmonary Fibrosis Models: A Systematic Review. Stem Cells Translational Medicine, 2015, 4, 1500-1510.	1.6	94
59	Organisation of diagnosis and treatment of idiopathic pulmonary fibrosis and other interstitial lung diseases in the Nordic countries. European Clinical Respiratory Journal, 2015, 2, 28348.	0.7	9
60	Preventive effects of vitamin D treatment on bleomycin-induced pulmonary fibrosis. Scientific Reports, 2015, 5, 17638.	1.6	35
62	Pharmacological treatment of idiopathic pulmonary fibrosis â€“ preclinical and clinical studies of pirfenidone, nintedanib, and N-acetylcysteine. European Clinical Respiratory Journal, 2015, 2, 26385.	0.7	78
63	Profile of nintedanib in the treatment of solid tumors: the evidence to date. OncoTargets and Therapy, 2015, 8, 3691.	1.0	58
64	Myriad Functions of Stanniocalcin-1 (STC1) Cover Multiple Therapeutic Targets in the Complicated Pathogenesis of Idiopathic Pulmonary Fibrosis (IPF). Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, 2015, 9s1, CCRPM.S23285.	0.5	22
65	CD248/Endosialin: A Novel Pericyte Target in Renal Fibrosis. Nephron, 2015, 131, 262-264.	0.9	6
66	Idiopathic Pulmonary Fibrosis: Diagnosis and Clinical Manifestations. Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, 2015, 9s1, CCRPM.S39897.	0.5	16

#	Article	IF	Citations
67	Idiopathic Pulmonary Fibrosis: Treatment and Prognosis. Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, 2015, 9s1, CCRPM.S23321.	0.5	42
68	Recent Treatments of Interstitial Lung Disease with Systemic Sclerosis. Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, 2015, 9s1, CCRPM.S23315.	0.5	12
69	Ovarian cancer standard of care: are there real alternatives?. Chinese Journal of Cancer, 2015, 34, 17-27.	4.9	79
71	Current and Future Therapies for Idiopathic Pulmonary Fibrosis. Pulmonary Therapy, 2015, 1, 1-18.	1.1	2
72	Incorporating genetics into the identification and treatment of Idiopathic Pulmonary Fibrosis. BMC Medicine, 2015, 13, 191.	2.3	30
74	Design, synthesis and biological evaluation of deuterated nintedanib for improving pharmacokinetic properties. Journal of Labelled Compounds and Radiopharmaceuticals, 2015, 58, 308-312.	0.5	8
75	Adherence to guidelines in idiopathic pulmonary fibrosis: a follow-up national survey. ERJ Open Research, 2015, 1, 00032-2015.	1.1	12
76	Structural and functional correlations in a large animal model of bleomycin-induced pulmonary fibrosis. BMC Pulmonary Medicine, 2015, 15, 81.	0.8	29
77	A comparison of visual and quantitative methods to identify interstitial lung abnormalities. BMC Pulmonary Medicine, 2015, 15, 134.	0.8	39
78	A functional genomic model for predicting prognosis in idiopathic pulmonary fibrosis. BMC Pulmonary Medicine, 2015, 15, 147.	0.8	42
79	Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis. BMC Pulmonary Medicine, 2015, 15, 167.	0.8	57
80	Idiopathic pulmonary fibrosis and cancer: do they really look similar?. BMC Medicine, 2015, 13, 220.	2.3	92
81	Idiopathic pulmonary fibrosis: moving forward. BMC Medicine, 2015, 13, 231.	2.3	4
82	Idiopathic pulmonary fibrosis in BRIC countries: the cases of Brazil, Russia, India, and China. BMC Medicine, 2015, 13, 237.	2.3	34
83	Levels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments. BMC Medicine, 2015, 13, 277.	2.3	23
84	Increased FGF1-FGFRc expression in idiopathic pulmonary fibrosis. Respiratory Research, 2015, 16, 83.	1.4	89
85	Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis. Respiratory Research, 2015, 16, 116.	1.4	114
86	Pleiotropic effect of the proton pump inhibitor esomeprazole leading to suppression of lung inflammation and fibrosis. Journal of Translational Medicine, 2015, 13, 249.	1.8	105

#	Article	IF	Citations
87	Nilotinib (Tasignaâ„¢) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial. Arthritis Research and Therapy, 2015, 17, 213.	1.6	83
88	Personalized medicine in idiopathic pulmonary fibrosis. Current Opinion in Pulmonary Medicine, 2015, 21, 470-478.	1.2	46
89	Biomarkers for Staging and Evaluating the Therapy for Idiopathic Pulmonary Fibrosis. Clinical Pulmonary Medicine, 2015, 22, 165-171.	0.3	1
90	Epigenetics in lung fibrosis. Current Opinion in Pulmonary Medicine, 2015, 21, 454-462.	1.2	55
91	Honeycomb Lung: Time for a Change. Archives of Pathology and Laboratory Medicine, 2015, 139, 1398-1399.	1.2	5
92	Reply: Weight-Loss Effect on FVC in Nintedanib Idiopathic Pulmonary Fibrosis Trials?. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 1020-1021.	2.5	0
93	Taking the â€œIâ€•out of IPF. European Respiratory Journal, 2015, 45, 1539-1541.	3.1	3
94	Clinical highlights: messages from Munich. ERJ Open Research, 2015, 1, 00002-2015.	1.1	0
95	A novel profibrotic mechanism mediated by <scp>TGFÎ²</scp>â€stimulated collagen prolyl hydroxylase expression in fibrotic lung mesenchymal cells. Journal of Pathology, 2015, 236, 384-394.	2.1	40
96	The <scp>A</scp>kt inhibitor, triciribine, ameliorates chronic hypoxiaâ€induced vascular pruning and <scp>TGF</scp>Î²â€induced pulmonary fibrosis. British Journal of Pharmacology, 2015, 172, 4173-4188.	2.7	37
97	Practical considerations in the pharmacologic treatment of idiopathic pulmonary fibrosis. Current Opinion in Pulmonary Medicine, 2015, 21, 479-489.	1.2	38
98	Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib. Drug Design, Development and Therapy, 2015, 9, 6407.	2.0	37
99	Functional improvement in patients with idiopathic pulmonary fibrosis undergoing single lung transplantation. Jornal Brasileiro De Pneumologia, 2015, 41, 299-304.	0.4	9
100	Idiopathic pulmonary fibrosis biomarkers: clinical utility and a way of understanding disease pathogenesis. Current Biomarker Findings, 0, , 21.	0.4	3
101	Developments in the management of idiopathic pulmonary fibrosis: Table:. Drug and Therapeutics Bulletin, 2015, 53, 78-81.	0.3	2
104	Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis. Core Evidence, 2015, 10, 89.	4.7	22
105	Idiopathic fibrotic lung disease at a university hospital setting: management and prognostic factors. European Clinical Respiratory Journal, 2015, 2, 26915.	0.7	3
106	Visual vs Fully Automatic Histogram-Based Assessment of Idiopathic Pulmonary Fibrosis (IPF) Progression Using Sequential Multidetector Computed Tomography (MDCT). PLoS ONE, 2015, 10, e0130653.	1.1	40

#	Article	IF	Citations
107	CD8+ T Cell Response to Gammaherpesvirus Infection Mediates Inflammation and Fibrosis in Interferon Gamma Receptor-Deficient Mice. PLoS ONE, 2015, 10, e0135719.	1.1	13
108	mTOR Overactivation and Compromised Autophagy in the Pathogenesis of Pulmonary Fibrosis. PLoS ONE, 2015, 10, e0138625.	1.1	77
109	Mesothelial cells in tissue repair and fibrosis. Frontiers in Pharmacology, 2015, 6, 113.	1.6	158
110	Update on diagnosis and treatment of idiopathic pulmonary fibrosis. Jornal Brasileiro De Pneumologia, 2015, 41, 454-466.	0.4	27
111	Role and New Insights of Pirfenidone in Fibrotic Diseases. International Journal of Medical Sciences, 2015, 12, 840-847.	1.1	103
112	Update on therapeutic management of idiopathic pulmonary fibrosis. Therapeutics and Clinical Risk Management, 2015, 11, 359.	0.9	51
113	Exploring Clinical and Epidemiological Characteristics of Interstitial Lung Diseases: Rationale, Aims, and Design of a Nationwide Prospective Registryâ€"The EXCITING-ILD Registry. BioMed Research International, 2015, 2015, 1-9.	0.9	42
114	Novel Therapeutic Strategies for Reducing Right Heart Failure Associated Mortality in Fibrotic Lung Diseases. BioMed Research International, 2015, 2015, 1-16.	0.9	5
115	Inflammatory Response Mechanisms Exacerbating Hypoxemia in Coexistent Pulmonary Fibrosis and Sleep Apnea. Mediators of Inflammation, 2015, 2015, 1-13.	1.4	27
116	Smoking-Related Interstitial Lung Disease. Deutsches Ärzteblatt International, 2015, 112, 43-50.	0.6	26
117	Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives. BioMed Research International, 2015, 2015, 1-10.	0.9	60
119	The role of biologics in treatment of connective tissue disease-associated interstitial lung disease. QJM - Monthly Journal of the Association of Physicians, 2015, 108, 683-688.	0.2	7
120	Asbestosis and environmental causes of usual interstitial pneumonia. Current Opinion in Pulmonary Medicine, 2015, 21, 1.	1.2	41
121	The role of tyrosine kinases in the pathogenesis of idiopathic pulmonary fibrosis. European Respiratory Journal, 2015, 45, 1426-1433.	3.1	146
122	Nilotinib reduces muscle fibrosis in chronic muscle injury by promoting TNF-mediated apoptosis of fibro/adipogenic progenitors. Nature Medicine, 2015, 21, 786-794.	15.2	540
123	Antifibrotic Therapies in the Liver. Seminars in Liver Disease, 2015, 35, 184-198.	1.8	65
124	The Syndrome of Combined Pulmonary Fibrosis and Emphysema. , 2015, , 327-347.		2
125	Nintedanib: A Review of Its Use in Patients with Idiopathic Pulmonary Fibrosis. Drugs, 2015, 75, 1131-1140.	4.9	33

#	Article	IF	Citations
126	Efficacy of pirfenidone for idiopathic pulmonary fibrosis: An Italian real life study. Respiratory Medicine, 2015, 109, 904-913.	1.3	72
127	CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a Position Paper from the Fleischner society. Lancet Respiratory Medicine,the, 2015, 3, 483-496.	5.2	149
128	Development of Novel Agents for Idiopathic Pulmonary Fibrosis. Chest, 2015, 148, 1083-1092.	0.4	22
129	Second-line docetaxel for patients with platinum-refractory advanced non-small cell lung cancer and interstitial pneumonia. Cancer Chemotherapy and Pharmacology, 2015, 76, 69-74.	1.1	37
130	Transcriptional phenotyping of fibrotic lung disease: a new gold standard?. Lancet Respiratory Medicine,the, 2015, 3, 423-424.	5.2	1
131	Classification of usual interstitial pneumonia in patients with interstitial lung disease: assessment of a machine learning approach using high-dimensional transcriptional data. Lancet Respiratory Medicine,the, 2015, 3, 473-482.	5.2	112
132	Pirfenidone: an orphan drug for treating idiopathic pulmonary fibrosis. Expert Opinion on Orphan Drugs, 2015, 3, 587-597.	0.5	2
133	Endotyping idiopathic pulmonary fibrosis should improve outcomes for all patients with progressive fibrotic lung disease. Thorax, 2015, 70, 9-10.	2.7	4
135	FK506-Binding Protein 10, a Potential Novel Drug Target for Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 455-467.	2.5	80
136	Rare (pulmonary) disease day: â€œfeeding the breath, energy for life!â€• European Respiratory Journal, 2015, 45, 297-300.	3.1	7
139	Idiopathic interstitial pneumonias in 2015: A new era. Respirology, 2015, 20, 697-698.	1.3	3
140	Functional capacity in idiopathic pulmonary fibrosis: Looking beyond the lungs. Respirology, 2015, 20, 857-858.	1.3	11
141	Dasatinib attenuated bleomycin-induced pulmonary fibrosis in mice. Growth Factors, 2015, 33, 366-375.	0.5	41
142	Advances in the treatment of idiopathic pulmonary fibrosis. Expert Opinion on Emerging Drugs, 2015, 20, 537-552.	1.0	8
143	Epidemiological studies in idiopathic pulmonary fibrosis: pitfalls in methodologies and data interpretation. European Respiratory Review, 2015, 24, 436-444.	3.0	47
144	The Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet). Chest, 2015, 148, 1034-1042.	0.4	37
145	Self-Report Daily Life Activity as a Prognostic Marker of Idiopathic Pulmonary Fibrosis. Respiration, 2015, 90, 460-467.	1.2	17
146	Pneumopathies interstitielles diffuses. Revue Des Maladies Respiratoires Actualites, 2015, 7, S54-S64.	0.0	0

#	Article	IF	Citations
147	Fibrose pulmonaire idiopathique: le point sur l'imagerie tomodensitomÃ©trique. Revue Des Maladies Respiratoires Actualites, 2015, 7, 265-269.	0.0	0
148	Association of early suspected acute exacerbations of idiopathic pulmonary fibrosis with subsequent clinical outcomes and healthcare resource utilization. Respiratory Medicine, 2015, 109, 1582-1588.	1.3	9
149	Lung-Dominant Connective Tissue Disease. Chest, 2015, 148, 1438-1446.	0.4	49
150	Cough in interstitial lung disease. Pulmonary Pharmacology and Therapeutics, 2015, 35, 122-128.	1.1	13
151	Personalizing Therapy in Idiopathic Pulmonary Fibrosis: A Glimpse of the Future?. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 1409-1411.	2.5	3
152	Dasatinib inhibits TGFÎ²-induced myofibroblast differentiation through Src-SRF Pathway. European Journal of Pharmacology, 2015, 769, 134-142.	1.7	26
153	Pharmacologic inhibition of lactate production prevents myofibroblast differentiation. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2015, 309, L1305-L1312.	1.3	50
154	MMP-9 1562C>T Gene Polymorphism and Efficacy of Glucocorticoid Therapy in Idiopathic Pulmonary Fibrosis Patients. Genetic Testing and Molecular Biomarkers, 2015, 19, 591-597.	0.3	10
155	Weight-Loss Effect on FVC in Nintedanib Idiopathic Pulmonary Fibrosis Trials?. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 1020-1020.	2.5	0
156	Cognitive function in idiopathic pulmonary fibrosis. Chronic Respiratory Disease, 2015, 12, 365-372.	1.0	30
158	New Treatments for Idiopathic Pulmonary Fibrosis: â€˜Die Another Day' if Diagnosed Early?. Respiration, 2015, 90, 352-352.	1.2	9
159	Interstitial Lung Disease Evaluation: Detecting Connective Tissue Disease. Respiration, 2015, 90, 177-184.	1.2	38
160	Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis. European Respiratory Journal, 2015, 45, 1382-1392.	3.1	171
161	The INPULSIS enigma: exacerbations in idiopathic pulmonary fibrosis. Thorax, 2015, 70, 508-510.	2.7	14
162	Nintedanib: First Global Approval. Drugs, 2015, 75, 129-139.	4.9	91
163	Update in Diffuse Parenchymal Lung Disease 2013. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 270-274.	2.5	6
164	Management of Connective Tissue Diseaseâ€“associated Interstitial Lung Disease. Rheumatic Disease Clinics of North America, 2015, 41, 279-294.	0.8	14
165	Idiopathic pulmonary fibrosis: An update. Annals of Medicine, 2015, 47, 15-27.	1.5	97

#	Article	IF	Citations
166	Essential rules and requirements for global clinical trials in rare lung diseases: A sponsor×3s standpoint. Respiratory Investigation, 2015, 53, 2-6.	0.9	8
167	Nintedanib and Pirfenidone. New Antifibrotic Treatments Indicated for Idiopathic Pulmonary Fibrosis Offer Hopes and Raises Questions. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 252-254.	2.5	135
168	Pharmacologic therapies for idiopathic pulmonary fibrosis, past and future. Annals of Medicine, 2015, 47, 100-105.	1.5	26
169	Ten things you should know about protein kinases: <scp>IUPHAR R</scp>eview 14. British Journal of Pharmacology, 2015, 172, 2675-2700.	2.7	270
170	Management of Scleroderma-Associated Pulmonary Involvement. Current Treatment Options in Rheumatology, 2015, 1, 51-67.	0.6	0
171	Diverse origins of the myofibroblastâ€"implications for kidney fibrosis. Nature Reviews Nephrology, 2015, 11, 233-244.	4.1	210
172	Pharmacological treatment of idiopathic pulmonary fibrosis: an update. Drug Discovery Today, 2015, 20, 514-524.	3.2	26
173	Pirfenidone: A Review of Its Use in Idiopathic Pulmonary Fibrosis. Drugs, 2015, 75, 219-230.	4.9	81
174	Quantitative Proteomics of Bronchoalveolar Lavage Fluid in Idiopathic Pulmonary Fibrosis. Journal of Proteome Research, 2015, 14, 1238-1249.	1.8	79
175	Identifying the Benefits and Risks of Emerging Treatments for Idiopathic Pulmonary Fibrosis: A Qualitative Study. Patient, 2015, 8, 85-92.	1.1	20
177	Disruption of Calcium Signaling in Fibroblasts and Attenuation of Bleomycin-Induced Fibrosis by Nifedipine. American Journal of Respiratory Cell and Molecular Biology, 2015, 53, 450-458.	1.4	42
178	Principles of Rehabilitation and Reactivation: Interstitial Lung Disease, Sarcoidosis and Rheumatoid Disease with Respiratory Involvement. Respiration, 2015, 89, 89-99.	1.2	42
179	Targeting defective Toll-like receptor-3 function and idiopathic pulmonary fibrosis. Expert Opinion on Therapeutic Targets, 2015, 19, 507-514.	1.5	23
180	Nintedanib modulates surfactant protein-D expression in A549 human lung epithelial cells via the c-Jun N-terminal kinase-activator protein-1 pathway. Pulmonary Pharmacology and Therapeutics, 2015, 32, 29-36.	1.1	20
181	Effet de l'emphysÃ¨me sur la rÃ©duction du dÃ©clin de la CVF avec le nintÃ©danib dans les Ã©tudes INPULSIS. Revue Des Maladies Respiratoires Actualites, 2015, 7, 146-147.	0.0	0
182	Effet du nintÃ©danib sur le dÃ©clin de la fonction pulmonaire selon la CVF initiale dans la fibrose pulmonaire idiopathique : rÃ©sultats des Ã©tudes INPULSIS. Revue Des Maladies Respiratoires Actualites, 2015, 7, 151-153.	0.0	0
183	Interpretation of data from studies of effects of nintedanib on surfactant protein-D expression in human lung epithelial cells. Pulmonary Pharmacology and Therapeutics, 2015, 33, 15-16.	1.1	2
184	Nintedanib Is a Highly Effective Therapeutic for Neuroendocrine Carcinoma of the Pancreas (PNET) in the Rip1Tag2 Transgenic Mouse Model. Clinical Cancer Research, 2015, 21, 4856-4867.	3.2	25

#	Article	IF	Citations
185	Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications. Cancer and Metastasis Reviews, 2015, 34, 479-496.	2.7	101
186	Update on New Treatments for Idiopathic Pulmonary Fibrosis. Current Emergency and Hospital Medicine Reports, 2015, 3, 134-138.	0.6	0
187	Mortality on the Waiting List for Lung Transplantation in Patients with Idiopathic Pulmonary Fibrosis: A Single-Centre Experience. Lung, 2015, 193, 677-681.	1.4	40
188	Platelet-Derived Growth Factor Signaling in the Lung. From Lung Development and Disease to Clinical Studies. American Journal of Respiratory Cell and Molecular Biology, 2015, 52, 263-284.	1.4	76
189	Insights into idiopathic pulmonary fibrosis in the real world. European Respiratory Journal, 2015, 46, 16-18.	3.1	6
190	A novel segmental challenge model for bleomycin-induced pulmonary fibrosis in sheep. Experimental Lung Research, 2015, 41, 115-134.	0.5	26
191	Mechanisms of Alveolar Epithelial Injury, Repair, and Fibrosis. Annals of the American Thoracic Society, 2015, 12, S16-S20.	1.5	142
192	Characteristic Patterns in the Fibrotic Lung. Comparing Idiopathic Pulmonary Fibrosis with Chronic Lung Allograft Dysfunction. Annals of the American Thoracic Society, 2015, 12, S34-S41.	1.5	16
193	Pulmonary Resection for Lung Cancer in Patients With Idiopathic Interstitial Pneumonia. Annals of Thoracic Surgery, 2015, 100, 954-960.	0.7	66
194	Rebuilding the Injured Lung. Annals of the American Thoracic Society, 2015, 12, S64-S69.	1.5	1
195	An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2015, 192, e3-e19.	2.5	1,521
196	Critically Ill Patients with Interstitial Lung Disease. Clinics in Chest Medicine, 2015, 36, 497-510.	0.8	4
197	Role of Î±1 and Î±2 chains of type IV collagen in early fibrotic lesions of idiopathic interstitial pneumonias and migration of lung fibroblasts. Laboratory Investigation, 2015, 95, 872-885.	1.7	31
198	A fast, sensitive, and high throughput method for the determination of nintedanib in mouse plasma by UPLC-MS/MS. Analytical Methods, 2015, 7, 6561-6565.	1.3	5
199	Nintedanib in the treatment of idiopathic pulmonary fibrosis. Therapeutic Advances in Respiratory Disease, 2015, 9, 121-129.	1.0	57
200	Matrix Metalloproteinases as Therapeutic Targets for Idiopathic Pulmonary Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2015, 53, 585-600.	1.4	341
201	Where do we go from here? Clinical drug development in idiopathic pulmonary fibrosis. European Respiratory Journal, 2015, 45, 1218-1220.	3.1	5
202	Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials. Lancet Respiratory Medicine,the, 2015, 3, 388-396.	5.2	69

#	Article	IF	Citations
203	Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial. Lancet, The, 2015, 385, 1748-1757.	6.3	160
204	Inhibition of Myocardin-Related Transcription Factor/Serum Response Factor Signaling Decreases Lung Fibrosis and Promotes Mesenchymal Cell Apoptosis. American Journal of Pathology, 2015, 185, 969-986.	1.9	138
205	Nintedanib: examining the development and mechanism of action of a novel triple angiokinase inhibitor. Expert Review of Anticancer Therapy, 2015, 15, 579-594.	1.1	17
206	The genetic basis of idiopathic pulmonary fibrosis. European Respiratory Journal, 2015, 45, 1717-1727.	3.1	160
207	Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis. Chest, 2015, 148, 196-201.	0.4	35
208	ROCK and Rho. American Journal of Pathology, 2015, 185, 909-912.	1.9	17
209	AhR-dependent secretion of PDGF-BB by human classically activated macrophages exposed to DEP extracts stimulates lung fibroblast proliferation. Toxicology and Applied Pharmacology, 2015, 285, 170-178.	1.3	24
210	Long-Term Effects of a 12-Week Exercise Training Program on Clinical Outcomes in Idiopathic Pulmonary Fibrosis. Lung, 2015, 193, 345-354.	1.4	95
211	Acute exacerbation of idiopathic pulmonary fibrosis: a clinical review. Internal and Emergency Medicine, 2015, 10, 401-411.	1.0	37
212	Current <scp>A</scp>ustralasian practice for diagnosis and management of idiopathic pulmonary fibrosis: Where are we now?. Respirology, 2015, 20, 647-653.	1.3	9
213	Treatment of acute exacerbation of idiopathic pulmonary fibrosis with direct hemoperfusion using a polymyxin B-immobilized fiber column improves survival. BMC Pulmonary Medicine, 2015, 15, 15.	0.8	66
214	Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study. Lancet Respiratory Medicine,the, 2015, 3, 462-472.	5.2	252
215	Comparing new treatments for idiopathic pulmonary fibrosis â€“ a network meta-analysis. BMC Pulmonary Medicine, 2015, 15, 37.	0.8	47
216	Fibrotic Response to Biomaterials and all Associated Sequence of Fibrosis. , 2015, , 189-237.		14
217	Fibrosis â€” A Common Pathway to Organ Injury and Failure. New England Journal of Medicine, 2015, 372, 1138-1149.	13.9	942
218	Combination therapy in idiopathic pulmonary fibrosis: the way ahead will be hard. European Respiratory Journal, 2015, 45, 1208-1210.	3.1	11
219	A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials. European Respiratory Journal, 2015, 46, 243-249.	3.1	48
220	The changing treatment landscape in idiopathic pulmonary fibrosis. European Respiratory Review, 2015, 24, 65-68.	3.0	19

#	Article	IF	Citations
221	Bleomycin in the setting of lung fibrosis induction: From biological mechanisms to counteractions. Pharmacological Research, 2015, 97, 122-130.	3.1	338
222	Idiopathic pulmonary fibrosis: Recent advances on pharmacological therapy. , 2015, 152, 18-27.		74
223	Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. European Respiratory Journal, 2015, 45, 1434-1445.	3.1	667
224	Advances in Understanding of the Pathogenesis of Acute Respiratory Distress Syndrome. Respiration, 2015, 89, 420-434.	1.2	66
225	Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry. European Respiratory Journal, 2015, 46, 186-196.	3.1	194
226	The diagnosis and management of interstitial lung diseases. BMJ, The, 2015, 350, h2072-h2072.	3.0	52
227	Natural history of idiopathic pulmonary fibrosis. Respiratory Medicine, 2015, 109, 661-670.	1.3	129
228	Novel Treatments for Idiopathic Pulmonary Fibrosis. American Journal of Medicine, 2015, 128, 447-449.	0.6	9
229	Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A proâ€con perspective. Respirology, 2015, 20, 389-394.	1.3	7
230	Year in review 2014: Interstitial lung disease, physiology, sleep and ventilation, acute respiratory distress syndrome, cystic fibrosis, bronchiectasis and rare lung disease. Respirology, 2015, 20, 834-845.	1.3	3
231	Orphan drug approvals of 2014: Europe and the United States. Expert Opinion on Orphan Drugs, 2015, 3, 445-455.	0.5	6
232	Inherent weaknesses of the current ICD coding system regarding idiopathic pulmonary fibrosis. European Respiratory Journal, 2015, 45, 1194-1196.	3.1	8
233	Childrenâ€™s Interstitial and Diffuse Lung Disease. Progress and Future Horizons. Annals of the American Thoracic Society, 2015, 12, 1451-1457.	1.5	13
234	An endostatin-derived peptide orally exerts anti-fibrotic activity in a murine pulmonary fibrosis model. International Immunopharmacology, 2015, 28, 1102-1105.	1.7	20
235	Molecular Phenotyping. A Guide to Improving Detection of Interstitial Lung Disease in Patients with Rheumatoid Arthritis. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 1349-1350.	2.5	0
236	Re-evaluation of diagnostic parameters is crucial for obtaining accurate data on idiopathic pulmonary fibrosis. BMC Pulmonary Medicine, 2015, 15, 92.	0.8	36
237	Therapeutic benefits of young, but not old, adipose-derived mesenchymal stem cells in a chronic mouse model of bleomycin-induced pulmonary fibrosis. Translational Research, 2015, 166, 554-567.	2.2	68
238	In the end it's a replication problem: What measuring telomere length can tell us about idiopathic pulmonary fibrosis. Respirology, 2015, 20, 855-856.	1.3	3

#	Article	IF	Citations
239	Fibrose pulmonaire idiopathique: nintedanib, pirfÃ©nidone, rÃ©sultats complÃ©mentaires des essais cliniques. Revue Des Maladies Respiratoires Actualites, 2015, 7, 256-262.	0.0	0
240	Prognostic Value of Dual-Time-Point ¹⁸F-FDG PET for Idiopathic Pulmonary Fibrosis. Journal of Nuclear Medicine, 2015, 56, 1869-1875.	2.8	33
242	Acute exacerbation of idiopathic pulmonary fibrosis: shifting the paradigm. European Respiratory Journal, 2015, 46, 512-520.	3.1	164
243	Drug development for chronic lung disease â€•Mission impossible?. Respirology, 2015, 20, 13-14.	1.3	4
244	Combination pirfenidone and inhaled <scp>N</scp>â€acetylcysteine therapy for <scp>IPF</scp>: Does it take these two to tango?. Respirology, 2015, 20, 359-360.	1.3	2
245	Elevated protein arginine methyltransferase 1 expression regulates fibroblast motility in pulmonary fibrosis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2015, 1852, 2678-2688.	1.8	13
246	New guideline on treatment of idiopathic pulmonary fibrosis. Lancet Respiratory Medicine,the, 2015, 3, e31-e32.	5.2	4
247	A randomised, phase II study of nintedanib or sunitinib in previously untreated patients with advanced renal cell cancer: 3-year results. British Journal of Cancer, 2015, 113, 1140-1147.	2.9	30
248	The 2015 guidelines for idiopathic pulmonary fibrosis: an important chapter in the evolution of the management of patients with IPF. European Respiratory Journal, 2015, 46, 883-886.	3.1	18
249	Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review. European Respiratory Journal, 2015, 46, 1113-1130.	3.1	328
250	Idiopathic pulmonary fibrosis: from clinical trials to real-life experiences. European Respiratory Review, 2015, 24, 420-427.	3.0	28
251	Biomarkers in interstitial lung disease: moving towards composite indexes and multimarkers?. Current Pulmonology Reports, 2015, 4, 125-129.	0.5	0
252	Idiopathic pulmonary fibrosis and sleep disorders: no longer strangers in the night. European Respiratory Review, 2015, 24, 327-339.	3.0	59
253	Permanent alveolar collapse is the predominant mechanism in idiopathic pulmonary fibrosis. Expert Review of Respiratory Medicine, 2015, 9, 411-418.	1.0	35
254	Update in Interstitial Lung Disease 2014. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 538-543.	2.5	7
255	Missing data in IPF trials: do not let methodological issues undermine a major therapeutic breakthrough. European Respiratory Journal, 2015, 46, 607-614.	3.1	9
256	Pharmacological In Vivo Inhibition of S-Nitrosoglutathione Reductase Attenuates Bleomycin-Induced Inflammation and Fibrosis. Journal of Pharmacology and Experimental Therapeutics, 2015, 355, 13-22.	1.3	13
257	Nintedanib in idiopathic pulmonary fibrosis: a guide to its use. Drugs and Therapy Perspectives, 2015, 31, 329-333.	0.3	1

#	Article	IF	Citations
258	Simultaneous determination of nintedanib and its metabolite BIBF 1202 in different tissues of mice by UPLCâ€“MS/MS and its application in drug tissue distribution study. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2015, 1002, 239-244.	1.2	15
259	Switching to nintedanib after discontinuation of pirfenidone due to adverse events in IPF. European Respiratory Journal, 2015, 46, 1217-1221.	3.1	38
260	Dissecting fibrosis: therapeutic insights from the small-molecule toolbox. Nature Reviews Drug Discovery, 2015, 14, 693-720.	21.5	181
261	ATS Core Curriculum 2015. Part I: Adult Pulmonary Medicine. Annals of the American Thoracic Society, 2015, 12, 1387-1397.	1.5	2
262	Pulmonary Fibrosis Treated with Inhaled Interferon-gamma (IFN-Î³). Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2015, 28, 406-410.	0.7	16
263	Nintedanib: a new treatment for idiopathic pulmonary fibrosis. Clinical Investigation, 2015, 5, 621-632.	0.0	12
264	Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review. Therapeutic Advances in Musculoskeletal Disease, 2015, 7, 247-267.	1.2	75
265	Identifying Mechanisms of Homeostatic Signaling in Fibroblast Differentiation. Bulletin of Mathematical Biology, 2015, 77, 1556-1582.	0.9	18
266	Kinase profiling in early stage drug discovery: sorting things out. Drug Discovery Today: Technologies, 2015, 18, 52-61.	4.0	7
267	Health Care Utilization and Costs of Idiopathic Pulmonary Fibrosis in U.S. Medicare Beneficiaries Aged 65 Years and Older. Annals of the American Thoracic Society, 2015, 12, 981-987.	1.5	85
268	Invited Commentary. Annals of Thoracic Surgery, 2015, 100, 960.	0.7	0
269	The pathogenesis of bleomycin-induced lung injury in animals and its applicability to human idiopathic pulmonary fibrosis. Experimental Lung Research, 2015, 41, 57-73.	0.5	113
270	Nintedanib: From Discovery to the Clinic. Journal of Medicinal Chemistry, 2015, 58, 1053-1063.	2.9	250
271	Mesenchymal Stem Cells Correct Inappropriate Epithelialâ€“mesenchyme Relation in Pulmonary Fibrosis Using Stanniocalcin-1. Molecular Therapy, 2015, 23, 549-560.	3.7	85
272	Fibroblast Growth Factor 2 Is Required for Epithelial Recovery, but Not for Pulmonary Fibrosis, in Response to Bleomycin. American Journal of Respiratory Cell and Molecular Biology, 2015, 52, 116-128.	1.4	75
273	Nintedanib for treating idiopathic pulmonary fibrosis. British Journal of Health Care Management, 2016, 22, 250-251.	0.1	0
274	Uranium Workers Demonstrate Lower Lobe Predominant Irregular Pneumoconiotic Opacities on Chest Radiographs. Journal of Health Care for the Poor and Underserved, 2016, 27, 116-127.	0.4	2
275	The Impact of Iterative Reconstruction in Low-Dose Computed Tomography on the Evaluation of Diffuse Interstitial Lung Disease. Korean Journal of Radiology, 2016, 17, 950.	1.5	19

#	Article	IF	Citations
276	Idiopathic pulmonary fibrosis in Sweden: report from the first year of activity of the Swedish IPF-Registry. European Clinical Respiratory Journal, 2016, 3, 31090.	0.7	37
277	Fibrosis. , 2016, , 293-314.		0
278	Increased Cellular NAD⁺Level through NQO1 Enzymatic Action Has Protective Effects on Bleomycin-Induced Lung Fibrosis in Mice. Tuberculosis and Respiratory Diseases, 2016, 79, 257.	0.7	25
279	Patient considerations and drug selection in the treatment of idiopathic pulmonary fibrosis. Therapeutics and Clinical Risk Management, 2016, 12, 563.	0.9	21
280	Molecular Diagnosis and Precision Therapeutic Approaches for Telomere Biology Disorders. , 0, , .		2
281	Clinical characteristics of idiopathic pulmonary fibrosis patients according to their smoking status. Journal of Thoracic Disease, 2016, 8, 1112-1120.	0.6	33
282	Recent advances in understanding idiopathic pulmonary fibrosis. F1000Research, 2016, 5, 1046.	0.8	66
283	Neue Erkenntnisse zur Pathogenese des akuten Atemnotsyndroms. Karger Kompass Pneumologie, 2016, 4, 190-208.	0.0	0
284	III. New Treatment of Idiopathic Pulmonary Fibrosis. The Journal of the Japanese Society of Internal Medicine, 2016, 105, 970-976.	0.0	0
285	2016 Respiratory Effectiveness Group Annual Summit Reportâ€"impact & influence of real-world respiratory evidence. Journal of Thoracic Disease, 2016, 8, S435-S444.	0.6	0
286	Recommendations for the management of idiopathic pulmonary fibrosis in South Africa: a position statement of the South African Thoracic Society. Journal of Thoracic Disease, 2016, 8, 3711-3719.	0.6	7
287	Body mass indexâ€"percent forced vital capacityâ€"respiratory hospitalization: new staging for idiopathic pulmonary fibrosis patients. Journal of Thoracic Disease, 2016, 8, 3596-3604.	0.6	34
289	A global perspective of lung transplantation: Part 1 - Recipient selection and choice of procedure. Global Cardiology Science & Practice, 2016, 2016, e201605.	0.3	5
290	The Canadian Registry for Pulmonary Fibrosis: Design and Rationale of a National Pulmonary Fibrosis Registry. Canadian Respiratory Journal, 2016, 2016, 1-7.	0.8	45
291	Pirfenidone in the treatment of idiopathic pulmonary fibrosis: an evidence-based review of its place in therapy. Core Evidence, 2016, Volume 11, 11-22.	4.7	61
292	Real World Experiences: Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary Fibrosis. Journal of Clinical Medicine, 2016, 5, 78.	1.0	139
293	Emerging strategies for treatment of systemic sclerosis. Journal of Scleroderma and Related Disorders, 2016, 1, 186-193.	1.0	41
294	Patterns and Economic Burden of Hospitalizations and Exacerbations Among Patients Diagnosed with Idiopathic Pulmonary Fibrosis. Journal of Managed Care & Specialty Pharmacy, 2016, 22, 414-423.	0.5	31

#	Article	IF	Citations
295	Understanding and optimizing health-related quality of life and physical functional capacity in idiopathic pulmonary fibrosis. Patient Related Outcome Measures, 2016, 7, 29.	0.7	17
296	Skewed Lung CCR4 to CCR6 CD4+ T Cell Ratio in Idiopathic Pulmonary Fibrosis Is Associated with Pulmonary Function. Frontiers in Immunology, 2016, 7, 516.	2.2	29
297	Transcriptome of Cultured Lung Fibroblasts in Idiopathic Pulmonary Fibrosis: Meta-Analysis of Publically Available Microarray Datasets Reveals Repression of Inflammation and Immunity Pathways. International Journal of Molecular Sciences, 2016, 17, 2091.	1.8	28
299	Occurrence of idiopathic pulmonary fibrosis during immunosuppressive treatment: a case report. Journal of Medical Case Reports, 2016, 10, 127.	0.4	2
300	Cardiac manifestations of idiopathic pulmonary fibrosis. Intractable and Rare Diseases Research, 2016, 5, 70-75.	0.3	28
301	Potential Mechanistic Links Between Aging and IPF. , 2016, , 409-429.		0
302	Insights from the German Compassionate Use Program of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis. Respiration, 2016, 92, 98-106.	1.2	52
303	Impact of Comorbidities on Mortality in Patients with Idiopathic Pulmonary Fibrosis. PLoS ONE, 2016, 11, e0151425.	1.1	223
304	Deletion of mTORC1 Activity in CD4+ T Cells Is Associated with Lung Fibrosis and Increased Î³Î´ T Cells. PLoS ONE, 2016, 11, e0163288.	1.1	5
305	Clinical Course and Changes in High-Resolution Computed Tomography Findings in Patients with Idiopathic Pulmonary Fibrosis without Honeycombing. PLoS ONE, 2016, 11, e0166168.	1.1	30
306	Increased Expression of CC16 in Patients with Idiopathic Pulmonary Fibrosis. PLoS ONE, 2016, 11, e0168552.	1.1	37
307	Computational Modeling Predicts Simultaneous Targeting of Fibroblasts and Epithelial Cells Is Necessary for Treatment of Pulmonary Fibrosis. Frontiers in Pharmacology, 2016, 7, 183.	1.6	35
308	A high-content EMT screen identifies multiple receptor tyrosine kinase inhibitors with activity on TGFÎ² receptor. Oncotarget, 2016, 7, 25983-26002.	0.8	20
309	Pulmonary Abscess as a Complication of Transbronchial Lung Cryobiopsy. Journal of Bronchology and Interventional Pulmonology, 2016, 23, 63-66.	0.8	10
310	Cardiovascular and antacid treatment and mortality in oxygenâ€dependent pulmonary fibrosis: A populationâ€based longitudinal study. Respirology, 2016, 21, 705-711.	1.3	19
311	Understanding the priorities for women diagnosed with lymphangioleiomyomatosis: a patient perspective. ERJ Open Research, 2016, 2, 00102-2015.	1.1	5
312	Confluent fibrosis and fibroblast foci in fibrotic nonâ€specific interstitial pneumonia. Histopathology, 2016, 69, 128-135.	1.6	7
313	Pharmacokinetic Properties of Nintedanib in Healthy Volunteers and Patients With Advanced Cancer. Journal of Clinical Pharmacology, 2016, 56, 1387-1394.	1.0	36

#	Article	IF	Citations
314	Galectin-3: Distant Biomarker or Relevant Target?. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 7-9.	2.5	4
315	ATS Core Curriculum 2016. Part IV. Adult Pulmonary Medicine Core Curriculum. Annals of the American Thoracic Society, 2016, 13, 1160-1169.	1.5	1
316	First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity ofÂâ‰50Â% of Predicted Value. Lung, 2016, 194, 739-743.	1.4	102
317	Basic FGF and PDGF-BB synergistically stimulate hyaluronan and IL-6 production by orbital fibroblasts. Molecular and Cellular Endocrinology, 2016, 433, 94-104.	1.6	24
318	Sunitinib, a Small-Molecule Kinase Inhibitor, Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice. Tohoku Journal of Experimental Medicine, 2016, 239, 251-261.	0.5	18
319	WISP1 mediates IL-6-dependent proliferation in primary human lung fibroblasts. Scientific Reports, 2016, 6, 20547.	1.6	50
320	Marked Improvement with Pirfenidone in a Patient with Idiopathic Pulmonary Fibrosis. Internal Medicine, 2016, 55, 657-661.	0.3	6
321	End-of-life care in oxygen-dependent ILD compared with lung cancer: a national population-based study. Thorax, 2016, 71, 510-516.	2.7	88
322	A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711ÂL (PEOPLE Study). Respiratory Research, 2016, 17, 90.	1.4	93
323	Safety and efficacy of bridging to lung transplantation with antifibrotic drugs in idiopathic pulmonary fibrosis: a case series. BMC Pulmonary Medicine, 2016, 16, 156.	0.8	58
324	Repositioning compounds from cancer drug discovery to IPF: PI3K inhibition. Thorax, 2016, 71, 675-676.	2.7	6
325	MicroRNA-29c regulates apoptosis sensitivity via modulation of the cell-surface death receptor, Fas, in lung fibroblasts. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2016, 311, L1050-L1061.	1.3	31
326	Alveolar epithelial disintegrity in pulmonary fibrosis. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2016, 311, L185-L191.	1.3	52
328	Pulmonary fibrosis in the era of stratified medicine. Thorax, 2016, 71, 1154-1160.	2.7	67
329	Nintedanib for idiopathic pulmonary fibrosis: <scp>A</scp>n <scp>A</scp>sian perspective. Respirology, 2016, 21, 1342-1343.	1.3	0
330	Non-invasive Imaging of Idiopathic Pulmonary Fibrosis Using Cathepsin Protease Probes. Scientific Reports, 2016, 6, 19755.	1.6	97
331	Pulmonary issues in the elderly. , 2016, , 298-310.		0
332	Pharmacogenetics and interstitial lung disease. Current Opinion in Pulmonary Medicine, 2016, 22, 456-465.	1.2	8

#	Article	IF	Citations
333	Phase I study of nintedanib in Japanese patients with advanced hepatocellular carcinoma and liver impairment. Cancer Science, 2016, 107, 1791-1799.	1.7	6
334	Mission CPLF 2016 : les pneumopathies interstitielles Ã lâ€™honneur !. Revue Des Maladies Respiratoires Actualites, 2016, 8, 176-179.	0.0	0
335	Antifibrotics in chronic liver disease: tractable targets and translational challenges. The Lancet Gastroenterology and Hepatology, 2016, 1, 328-340.	3.7	36
338	Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis. Thorax, 2016, 71, 429-435.	2.7	151
339	Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF. Thorax, 2016, 71, 701-711.	2.7	153
340	Idiopathic pulmonary fibrosis: securing a confident diagnosis for every patient. European Respiratory Journal, 2016, 47, 1057-1059.	3.1	4
341	â€œScar-cinomaâ€• viewing the fibrotic lung mesenchymal cell in the context of cancer biology. European Respiratory Journal, 2016, 47, 1842-1854.	3.1	25
342	Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis. Lancet Respiratory Medicine,the, 2016, 4, 381-389.	5.2	189
343	Autotaxin activity increases locally following lung injury, but is not required for pulmonary lysophosphatidic acid production or fibrosis. FASEB Journal, 2016, 30, 2435-2450.	0.2	38
345	What if we made stratified medicine work for patients?. Lancet Respiratory Medicine,the, 2016, 4, 8-10.	5.2	12
346	Orphan drug approvals of 2015: Europe and the United States. Expert Opinion on Orphan Drugs, 2016, 4, 491-500.	0.5	2
347	Multicentre evaluation of multidisciplinary team meeting agreement on diagnosis in diffuse parenchymal lung disease: a case-cohort study. Lancet Respiratory Medicine,the, 2016, 4, 557-565.	5.2	337
348	Pulmonary fibrosis. Medicina ClÃnica (English Edition), 2016, 146, 115-116.	0.1	1
349	213th ENMC International Workshop: Outcome measures and clinical trial readiness in idiopathic inflammatory myopathies, Heemskerk, The Netherlands, 18â€“20 September 2015. Neuromuscular Disorders, 2016, 26, 523-534.	0.3	19
350	Idiopathic pulmonary fibrosis: Physicians' perceptions of patient treatment with recently approved drugs. Contemporary Clinical Trials Communications, 2016, 3, 80-85.	0.5	2
351	A safety evaluation of pirfenidone for the treatment of idiopathic pulmonary fibrosis. Expert Opinion on Drug Safety, 2016, 15, 975-982.	1.0	3
352	Pruebas de funciÃ³n pulmonar en la fibrosis pulmonar idiopÃ¡tica: Â¿mÃ¡s allÃ¡ de la espirometrÃa?. Archivos De Bronconeumologia, 2016, 52, 457-458.	0.4	2
353	Usefulness of Cyclophosphamide Pulse Therapy in Interstitial Lung Diseases. Respiration, 2016, 91, 296-301.	1.2	22

#	Article	IF	Citations
354	Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS® trials. Respiratory Medicine, 2016, 113, 74-79.	1.3	335
355	New targets in idiopathic pulmonary fibrosis: from inflammation and immunity to remodeling and repair. Expert Opinion on Orphan Drugs, 2016, 4, 511-520.	0.5	4
356	Update on Pulmonary Fibrosis: Not All Fibrosis Is Created Equally. Archives of Pathology and Laboratory Medicine, 2016, 140, 221-229.	1.2	42
357	FGF9 and FGF18 in idiopathic pulmonary fibrosis promote survival and migration and inhibit myofibroblast differentiation of human lung fibroblasts in vitro. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2016, 310, L615-L629.	1.3	75
358	An American Thoracic Society Official Research Statement: Future Directions in Lung Fibrosis Research. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 792-800.	2.5	22
359	Successful Concomitant Therapy with Pirfenidone and Nintedanib in Idiopathic Pulmonary Fibrosis: A Case Report. Respiration, 2016, 91, 327-332.	1.2	15
360	Idiopathic Pulmonary Fibrosis and the Elderly: Diagnosis and Management Considerations. Drugs and Aging, 2016, 33, 321-334.	1.3	45
361	To Suppress the Radicals We Must Have Biomarkers of Oxidative Stress. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 817-819.	2.5	1
362	Daily Home Spirometry: An Effective Tool for Detecting Progression in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 989-997.	2.5	138
363	Advances in understanding the immunopathology of sarcoidosis and implications on therapy. Expert Review of Clinical Immunology, 2016, 12, 973-988.	1.3	20
364	Immune Mechanisms in Pulmonary Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2016, 55, 309-322.	1.4	245
365	Matriptase, Protease-activated Receptor 2, and Idiopathic Pulmonary Fibrosis. Further Evidence for Signaling Pathway Redundancy in this Difficult-to-Treat Disease?. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 816-817.	2.5	6
366	Targeted treatment of idiopathic pulmonary fibrosis: one step at a time. European Respiratory Journal, 2016, 47, 1321-1323.	3.1	3
367	Newer developments in idiopathic pulmonary fibrosis in the era of anti-fibrotic medications. Expert Review of Respiratory Medicine, 2016, 10, 699-711.	1.0	10
368	Guidelines or guidance for better idiopathic pulmonary fibrosis management?. BMC Medicine, 2016, 14, 24.	2.3	9
369	Idiopathic pulmonary fibrosis: combating on a new turf. Lancet Respiratory Medicine,the, 2016, 4, 430-432.	5.2	6
370	Imaging of Diffuse Lung Disease. Journal of Thoracic Imaging, 2016, 31, 64.	0.8	0
371	A bundled care approach to patients with idiopathic pulmonary fibrosis improves transplant-free survival. Respiratory Medicine, 2016, 115, 33-38.	1.3	11

#	Article	IF	Citations
372	Inhibitory effects of amines from Citrus reticulata on bleomycin-induced pulmonary fibrosis in rats. International Journal of Molecular Medicine, 2016, 37, 339-346.	1.8	23
373	Cough in idiopathic pulmonary fibrosis. European Respiratory Review, 2016, 25, 278-286.	3.0	82
374	A New Era in the Treatment of Scleroderma-associated Interstitial Lung Disease?. Journal of Rheumatology, 2016, 43, 1619-1621.	1.0	0
375	Ockhamâ€™s razor for the MET-driven invasive growth linking idiopathic pulmonary fibrosis and cancer. Journal of Translational Medicine, 2016, 14, 256.	1.8	16
376	Emerging Therapies for Progressive Metastatic Medullary Thyroid Cancer. , 2016, , 173-181.		0
377	Combination therapeutics in complex diseases. Journal of Cellular and Molecular Medicine, 2016, 20, 2231-2240.	1.6	76
378	End-of-life care of patients with idiopathic pulmonary fibrosis. BMC Palliative Care, 2016, 15, 85.	0.8	79
379	Danazol Treatment for Telomere Diseases. New England Journal of Medicine, 2016, 375, 1095-1096.	13.9	49
380	Influences of innate immunity, autophagy, and fibroblast activation in the pathogenesis of lung fibrosis. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2016, 311, L590-L601.	1.3	74
381	Mesenchymal stem cells in the treatment of chronic lung disease. Respirology, 2016, 21, 1366-1375.	1.3	52
382	Idiopathic pulmonary fibrosis: an Australian perspective. Internal Medicine Journal, 2016, 46, 663-668.	0.5	7
383	Imaging of Idiopathic Pulmonary Fibrosis. Radiologic Clinics of North America, 2016, 54, 997-1014.	0.9	10
384	Therapeutic targets in fibrotic pathways. Cytokine, 2016, 88, 193-195.	1.4	8
385	Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis. Pulmonary Pharmacology and Therapeutics, 2016, 40, 95-103.	1.1	112
386	Predictors of idiopathic pulmonary fibrosis in absence of radiologic honeycombing: A cross sectional analysis in ILD patients undergoing lung tissue sampling. Respiratory Medicine, 2016, 118, 88-95.	1.3	44
387	Laparoscopic anti-reflux surgery for idiopathic pulmonary fibrosis at a single centre. European Respiratory Journal, 2016, 48, 826-832.	3.1	47
388	Treatment of Idiopathic Pulmonary Fibrosis. , 2016, , 81-97.		0
389	Guide to Clinical Management of Idiopathic Pulmonary Fibrosis. , 2016, , .		0

#	Article	IF	Citations
390	Economics. American Journal of Transplantation, 2016, 16, 169-194.	2.6	4
391	Unclassifiable interstitial lung disease: A review. Respirology, 2016, 21, 51-56.	1.3	60
392	Underâ€recognised coâ€morbidities in idiopathic pulmonary fibrosis: A review. Respirology, 2016, 21, 995-1004.	1.3	8
393	Symptomâ€based management of the idiopathic interstitial pneumonia. Respirology, 2016, 21, 1357-1365.	1.3	25
394	Idiopathic pulmonary fibrosis: Diagnosis, epidemiology and natural history. Respirology, 2016, 21, 427-437.	1.3	137
395	Year in review 2015: Interstitial lung disease, pulmonary vascular disease, pulmonary function, sleep and ventilation, cystic fibrosis and paediatric lung disease. Respirology, 2016, 21, 556-566.	1.3	4
396	Pharmacological management of IPF. Respirology, 2016, 21, 615-625.	1.3	32
397	Acute and subacute idiopathic interstitial pneumonias. Respirology, 2016, 21, 810-820.	1.3	50
398	Studying human respiratory disease in animals â€“ role of induced and naturally occurring models. Journal of Pathology, 2016, 238, 220-232.	2.1	51
399	How we will diagnose IPF in the future. QJM - Monthly Journal of the Association of Physicians, 2016, 109, 581-583.	0.2	3
400	Lung Pericytes and Resident Fibroblasts. American Journal of Pathology, 2016, 186, 2519-2531.	1.9	99
401	Lung Function Testing in Idiopathic Pulmonary Fibrosis: More Than Just Spirometry?. Archivos De Bronconeumologia, 2016, 52, 457-458.	0.4	1
402	Therapeutic Approach to Adult Fibrotic Lung Diseases. Chest, 2016, 150, 1371-1386.	0.4	39
403	The safety of new drug treatments for idiopathic pulmonary fibrosis. Expert Opinion on Drug Safety, 2016, 15, 1483-1489.	1.0	21
404	Texture-Based Automated Quantitative Assessment of Regional Patterns on Initial CT in Patients With Idiopathic Pulmonary Fibrosis: Relationship to Decline in Forced Vital Capacity. American Journal of Roentgenology, 2016, 207, 976-983.	1.0	59
405	IPF in 2016: towards a better diagnosis. Lancet Respiratory Medicine,the, 2016, 4, 945-947.	5.2	3
406	The extracellular matrix â€“ the underâ€recognized element in lung disease?. Journal of Pathology, 2016, 240, 397-409.	2.1	195
407	JNK inhibition reduces lung remodeling and pulmonary fibrotic systemic markers. Clinical and Translational Medicine, 2016, 5, 36.	1.7	88

#	Article	IF	Citations
408	Plexin C1 deficiency permits synaptotagmin 7â€“mediated macrophage migration and enhances mammalian lung fibrosis. FASEB Journal, 2016, 30, 4056-4070.	0.2	50
409	Connective tissue disease-related interstitial lung disease. Best Practice and Research in Clinical Rheumatology, 2016, 30, 39-52.	1.4	41
410	Exercise training in idiopathic pulmonary fibrosis: is it ofÂbenefit?. Breathe, 2016, 12, 130-138.	0.6	35
411	Ambulatory and short-burst oxygen for interstitial lung disease. The Cochrane Library, 2016, 2016, CD011716.	1.5	22
412	Fibroblast growth factor-1 attenuates TGF-Î²1-induced lung fibrosis. Journal of Pathology, 2016, 240, 197-210.	2.1	81
413	Clinical impact of the interstitial lung disease multidisciplinary service. Respirology, 2016, 21, 1438-1444.	1.3	84
414	Age-driven developmental drift in the pathogenesis of idiopathic pulmonary fibrosis. European Respiratory Journal, 2016, 48, 538-552.	3.1	96
415	Risk factors for an acute exacerbation of idiopathic pulmonary fibrosis. Respiratory Research, 2016, 17, 79.	1.4	53
416	Subgroup analysis of <scp>A</scp>sian patients in the <scp>INPULSIS</scp>^{Â®} trials of nintedanib in idiopathic pulmonary fibrosis. Respirology, 2016, 21, 1425-1430.	1.3	31
417	Treatment of primary SjÃ¶gren syndrome. Nature Reviews Rheumatology, 2016, 12, 456-471.	3.5	137
418	Blood-based Diagnosis of Idiopathic Pulmonary Fibrosis. Fantasy or Reality?. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 1182-1184.	2.5	4
419	Transforming Growth Factor (TGF)-Î² Promotes de Novo Serine Synthesis for Collagen Production. Journal of Biological Chemistry, 2016, 291, 27239-27251.	1.6	102
420	Chronic breathlessness in patients with idiopathic pulmonary fibrosis: a major challenge for caregivers. Expert Review of Respiratory Medicine, 2016, 10, 1295-1303.	1.0	11
421	Is the imaging inconsistent with usual interstitial pneumonia? Think about idiopathic pulmonary fibrosis then!. Respirology, 2016, 21, 782-784.	1.3	2
422	The role of myofibroblasts in wound healing. Current Research in Translational Medicine, 2016, 64, 171-177.	1.2	207
423	Nintedanib (OFEV) in the treatment of idiopathic pulmonary fibrosis. Expert Review of Respiratory Medicine, 2016, 10, 1247-1254.	1.0	17
424	Patient eligibility for anti-fibrotic therapy in idiopathic pulmonary fibrosis can be altered by use of different sets of reference values for calculation of FVC percent predicted. Respiratory Medicine, 2016, 120, 131-133.	1.3	8
425	The utility of comprehensive autoantibody testing to differentiate connective tissue disease associated and idiopathic interstitial lung disease subgroup cases. Rheumatology, 2016, 56, kew320.	0.9	8

#	Article	IF	Citations
427	Pirfenidon plus Nintedanib bei idiopathischer pulmonaler Fibrose. Karger Kompass Pneumologie, 2016, 4, 222-224.	0.0	0
428	Posttransplant Solid Organ Malignancies in Lung Transplant Recipients: A Single-center Experience and Review of the Literature. Tumori, 2016, 102, 574-581.	0.6	9
432	New Treatments for Idiopathic Pulmonary Fibrosis. Clinical Pulmonary Medicine, 2016, 23, 241-251.	0.3	4
433	New insights on patient-reported outcome measures in idiopathic pulmonary fibrosis. Current Opinion in Pulmonary Medicine, 2016, 22, 434-441.	1.2	19
434	Increased hemoglobin-oxygen affinity ameliorates bleomycin-induced hypoxemia and pulmonary fibrosis. Physiological Reports, 2016, 4, e12965.	0.7	10
436	Involvement of PARK2-Mediated Mitophagy in Idiopathic Pulmonary Fibrosis Pathogenesis. Journal of Immunology, 2016, 197, 504-516.	0.4	102
437	Systematic phenotyping and correlation of biomarkers with lung function and histology in lung fibrosis. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2016, 310, L919-L927.	1.3	21
438	Development and Progression of Interstitial Lung Abnormalities in the Framingham Heart Study. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 1514-1522.	2.5	233
439	POINT: Should All Patients With Idiopathic Pulmonary Fibrosis, Even Those With More Than Moderate Impairment, Be Treated With Nintedanib or Pirfenidone? Yes. Chest, 2016, 150, 273-275.	0.4	13
440	COUNTERPOINT: Should All Patients With Idiopathic Pulmonary Fibrosis, Even Those With More Than Moderate Impairment, Be Treated With Nintedanib or Pirfenidone? No. Chest, 2016, 150, 276-278.	0.4	9
441	Acetylcysteine in IPF: the knockout blow?. Lancet Respiratory Medicine,the, 2016, 4, 420-421.	5.2	7
442	Impact of angiopoietin-1 and -2 on clinical course of idiopathic pulmonary fibrosis. Respiratory Medicine, 2016, 114, 18-26.	1.3	10
443	Sildenafil for pulmonary hypertension complicating idiopathic pulmonary fibrosis: a rationale grounded in basic science. European Respiratory Journal, 2016, 47, 1615-1617.	3.1	7
444	â€œThe Long and Winding Roadâ€•seeking specific drugs for idiopathic pulmonary fibrosis. Respiratory Investigation, 2016, 54, 1.	0.9	0
445	Treatment patterns, resource use and costs of idiopathic pulmonary fibrosis in Spain â€“ results of a Delphi Panel. BMC Pulmonary Medicine, 2016, 16, 7.	0.8	20
446	Evaluating the interstitial lung disease multidisciplinary meeting: a survey of expert centres. BMC Pulmonary Medicine, 2016, 16, 22.	0.8	45
447	Administration of nintedanib after discontinuation for acute exacerbation of idiopathic pulmonary fibrosis: a case report. BMC Pulmonary Medicine, 2016, 16, 38.	0.8	4
448	Role of CD248 as a potential severity marker in idiopathic pulmonary fibrosis. BMC Pulmonary Medicine, 2016, 16, 51.	0.8	24

#	Article	IF	Citations
449	Combined Pulmonary Fibrosis and Emphysema, a clinical review. COPD Research and Practice, 2016, 2, .	0.7	5
450	Clinical and economic burden of idiopathic pulmonary fibrosis: a retrospective cohort study. BMC Pulmonary Medicine, 2016, 16, 2.	0.8	75
451	Multicenter study of quantitative computed tomography analysis using a computer-aided three-dimensional system in patients with idiopathic pulmonary fibrosis. Japanese Journal of Radiology, 2016, 34, 16-27.	1.0	18
452	Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 265-275.	2.5	1,006
453	Idiopathic nonâ€specific interstitial pneumonia. Respirology, 2016, 21, 259-268.	1.3	73
454	High Oxygen Delivery to Preserve Exercise Capacity in Patients with Idiopathic Pulmonary Fibrosis Treated with Nintedanib. Methodology of the HOPE-IPF Study. Annals of the American Thoracic Society, 2016, 13, 1640-1647.	1.5	37
455	Impact of idiopathic pulmonary fibrosis on advanced non-small cell lung cancer survival. Journal of Cancer Research and Clinical Oncology, 2016, 142, 1855-1865.	1.2	56
456	Idiopathic Pulmonary Fibrosis. Journal of Thoracic Imaging, 2016, 31, 127-139.	0.8	23
457	An exploratory trial of intravenous immunoglobulin therapy for idiopathic pulmonary fibrosis: a preliminary multicenter report. Clinical Respiratory Journal, 2016, 10, 746-755.	0.6	7
458	miR-200/ZEB axis regulates sensitivity to nintedanib in non-small cell lung cancer cells. International Journal of Oncology, 2016, 48, 937-944.	1.4	66
459	Raf/ERK drives the proliferative and invasive phenotype of BMPR2-silenced pulmonary artery endothelial cells. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2016, 310, L187-L201.	1.3	39
460	The INPULSIS trials of idiopathic pulmonary fibrosis treatment: explaining further discrepancies on exacerbations. European Respiratory Journal, 2016, 47, 344-345.	3.1	3
461	NICE guidance on nintedanib for treating idiopathic pulmonary fibrosis. Lancet Respiratory Medicine,the, 2016, 4, 176-177.	5.2	10
462	Broad Therapeutic Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 112-113.	2.5	9
463	Current and emerging treatment options for interstitial lung disease in patients with rheumatic disease. Expert Review of Clinical Immunology, 2016, 12, 509-520.	1.3	16
464	Nintedanib in advanced NSCLC: management of adverse events. Lung Cancer Management, 2016, 5, 29-41.	1.5	9
465	Molecular Endotyping of Pulmonary Fibrosis. Chest, 2016, 149, 228-237.	0.4	30
466	Drug Treatment of Idiopathic Pulmonary Fibrosis. Chest, 2016, 149, 756-766.	0.4	155

#	Article	IF	Citations
467	Targeted Therapy for Idiopathic Pulmonary Fibrosis: Where To Now?. Drugs, 2016, 76, 291-300.	4.9	44
468	Ten years of anti-vascular endothelial growth factor therapy. Nature Reviews Drug Discovery, 2016, 15, 385-403.	21.5	724
469	Fibroblast Activation Protein (FAP) Accelerates Collagen Degradation and Clearance from Lungs in Mice. Journal of Biological Chemistry, 2016, 291, 8070-8089.	1.6	82
470	Efficacy and safety of inhaled N-acetylcysteine in idiopathic pulmonary fibrosis: A prospective, single-arm study. Respiratory Investigation, 2016, 54, 156-161.	0.9	9
471	Diagnosis of Usual Interstitial Pneumonitis in the Absence of Honeycombing: Evaluation of Specific CT Criteria With Clinical Follow-Up in 38 Patients. American Journal of Roentgenology, 2016, 206, 472-480.	1.0	28
472	Bioluminescent kinase strips: A novel approach to targeted and flexible kinase inhibitor profiling. Analytical Biochemistry, 2016, 495, 9-20.	1.1	6
473	New perspectives on management of idiopathic pulmonary fibrosis. Therapeutic Advances in Chronic Disease, 2016, 7, 108-120.	1.1	31
474	Therapeutic advances in idiopathic pulmonary fibrosis. Clinical Pharmacology and Therapeutics, 2016, 99, 30-32.	2.3	6
475	Mechanisms of Lung Fibrosis Resolution. American Journal of Pathology, 2016, 186, 1066-1077.	1.9	100
476	Lung transplantation in <scp>IIP</scp>: A review. Respirology, 2016, 21, 1173-1184.	1.3	31
477	Precision Medicine: The New Frontier in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 1213-1218.	2.5	59
478	Association Between Interstitial Lung Abnormalities and All-Cause Mortality. JAMA - Journal of the American Medical Association, 2016, 315, 672.	3.8	333
479	Patients With Fibrotic Interstitial Lung Disease Hospitalized for Acute Respiratory Worsening. Chest, 2016, 149, 1205-1214.	0.4	78
480	Recombinant human pentraxin-2 therapy in patients with idiopathic pulmonary fibrosis: safety, pharmacokinetics and exploratory efficacy. European Respiratory Journal, 2016, 47, 889-897.	3.1	75
481	Nintedanib in restrictive chronic lung allograft dysfunction after lung transplantation. Journal of Heart and Lung Transplantation, 2016, 35, 939-940.	0.3	22
482	Not yet known side effects of pirfenidone in the treatment of idiopathic pulmonary fibrosis?. Revista Portuguesa De Pneumologia, 2016, 22, 126-127.	0.7	3
483	Gastroesophageal Reflux in Idiopathic Pulmonary Fibrosis: More than a Gut Feeling?. Respiration, 2016, 91, 1-2.	1.2	4
484	Interplay of multiple interaction forces: Binding of tyrosine kinase inhibitor nintedanib with human serum albumin. Journal of Photochemistry and Photobiology B: Biology, 2016, 157, 70-76.	1.7	91

#	Article	IF	Citations
485	Antifibrotic and anticancer action of 5-ene amino/iminothiazolidinones. European Journal of Medicinal Chemistry, 2016, 112, 180-195.	2.6	47
486	Treatment of idiopathic pulmonary fibrosis: a network meta-analysis. BMC Medicine, 2016, 14, 18.	2.3	79
487	Novel drug targets for idiopathic pulmonary fibrosis. Expert Review of Respiratory Medicine, 2016, 10, 393-405.	1.0	27
488	Self-assembled Micelle Interfering RNA for Effective and Safe Targeting of Dysregulated Genes in Pulmonary Fibrosis. Journal of Biological Chemistry, 2016, 291, 6433-6446.	1.6	34
489	European IPF Patient Charter: an SOS to the world. European Respiratory Journal, 2016, 47, 403-405.	3.1	1
490	Therapeutic advances in idiopathic pulmonary fibrosis. Clinical Medicine, 2016, 16, 42-51.	0.8	16
491	Rationale for and design of the Idiopathic Pulmonary Fibrosisâ€“PRospective Outcomes (IPF-PRO) registry. BMJ Open Respiratory Research, 2016, 3, e000108.	1.2	38
492	Increased volume of conducting airways in idiopathic pulmonary fibrosis is independent of disease severity: a volumetric capnography study. Journal of Breath Research, 2016, 10, 016005.	1.5	19
493	p70 ribosomal S6 kinase regulates subpleural fibrosis following transforming growth factor-Î± expression in the lung. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2016, 310, L175-L186.	1.3	19
494	Qualitative European survey of patients with idiopathic pulmonary fibrosis: patientsâ€™ perspectives of the disease and treatment. BMC Pulmonary Medicine, 2016, 16, 10.	0.8	83
495	The Value of a Multidisciplinary Approach to the Diagnosis of Usual Interstitial Pneumonitis and Idiopathic Pulmonary Fibrosis: Radiology, Pathology, and Clinical Correlation. American Journal of Roentgenology, 2016, 206, 463-471.	1.0	34
496	CT in Idiopathic Pulmonary Fibrosis: Diagnosis and Beyond. American Journal of Roentgenology, 2016, 206, 495-507.	1.0	42
497	Consensus document for the diagnosis and treatment of idiopathic pulmonary fibrosis. Revista Portuguesa De Pneumologia, 2016, 22, 112-122.	0.7	7
498	Surface proteome analysis identifies platelet derived growth factor receptor-alpha as a critical mediator of transforming growth factor-beta-induced collagen secretion. International Journal of Biochemistry and Cell Biology, 2016, 74, 44-59.	1.2	14
499	Predictors of Mortality Poorly Predict Common Measures of Disease Progression in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 711-718.	2.5	72
500	Interaction of the recently approved anticancer drug nintedanib with human acute phase reactant Î± 1-acid glycoprotein. Journal of Molecular Structure, 2016, 1115, 171-179.	1.8	13
501	Therapy for idiopathic pulmonary fibrosis: lessons from pooled data analyses. European Respiratory Journal, 2016, 47, 27-30.	3.1	9
502	Targeting collagen for diagnostic imaging and therapeutic delivery. Journal of Controlled Release, 2016, 240, 323-331.	4.8	96

#	Article	IF	Citations
503	Treatment of Idiopathic Pulmonary Fibrosis. Annals of the American Thoracic Society, 2016, 13, 115-117.	1.5	19
504	Salidroside protects against bleomycin-induced pulmonary fibrosis: activation of Nrf2-antioxidant signaling, and inhibition of NF-Î²B and TGF-Î²1/Smad-2/-3 pathways. Cell Stress and Chaperones, 2016, 21, 239-249.	1.2	78
506	European IPF Patient Charter: unmet needs and a call to action for healthcare policymakers. European Respiratory Journal, 2016, 47, 597-606.	3.1	101
507	Systemic sclerosis and localized sclerodermaâ€"current concepts and novel targets for therapy. Seminars in Immunopathology, 2016, 38, 87-95.	2.8	79
508	Exercise training in idiopathic pulmonary fibrosis. Expert Review of Respiratory Medicine, 2016, 10, 69-77.	1.0	20
509	Treatment of rapidly progressive systemic sclerosis: current and futures perspectives. Expert Opinion on Orphan Drugs, 2016, 4, 31-47.	0.5	20
510	Membrane-anchored Serine Protease Matriptase Is a Trigger of Pulmonary Fibrogenesis. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 847-860.	2.5	47
511	Simultaneous determination of nintedanib and its metabolite by UPLCâ€"MS/MS in rat plasma and its application to a pharmacokinetic study. Journal of Pharmaceutical and Biomedical Analysis, 2016, 117, 173-177.	1.4	17
513	Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis across Prespecified Subgroups in INPULSIS. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 178-185.	2.5	209
514	Common Pathways in IPF and Lung Cancer. , 2016, , 217-247.		0
515	Purinergic signaling in scarring. FASEB Journal, 2016, 30, 3-12.	0.2	65
516	Src inhibition blocks renal interstitial fibroblast activation and ameliorates renal fibrosis. Kidney International, 2016, 89, 68-81.	2.6	93
517	Cathepsin K Contributes to Cavitation and Collagen Turnover in Pulmonary Tuberculosis. Journal of Infectious Diseases, 2016, 213, 618-627.	1.9	27
518	Reversal of the Transcriptome by Prostaglandin E₂ during Myofibroblast Dedifferentiation. American Journal of Respiratory Cell and Molecular Biology, 2016, 54, 114-127.	1.4	59
519	Novel Mechanisms for the Antifibrotic Action of Nintedanib. American Journal of Respiratory Cell and Molecular Biology, 2016, 54, 51-59.	1.4	163
520	Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis. Annals of the Rheumatic Diseases, 2016, 75, 883-890.	0.5	154
521	Idiopathic Interstitial Pneumonias. , 2016, , 1118-1152.e19.		1
523	Effect of Nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic Criteria. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 78-85.	2.5	147

#	Article	IF	Citations
524	Treatment with nintedanib for acute exacerbation of idiopathic pulmonary fibrosis. Respirology Case Reports, 2017, 5, e00215.	0.3	21
525	Hospital cost and length of stay in idiopathic pulmonary fibrosis. Journal of Medical Economics, 2017, 20, 518-524.	1.0	25
526	The effect of mTOR inhibitors on respiratory infections in lymphangioleiomyomatosis. European Respiratory Review, 2017, 26, 160004.	3.0	13
527	The clinical impact of major comorbidities on idiopathic pulmonary fibrosis. Respiratory Investigation, 2017, 55, 94-103.	0.9	29
528	Toward understanding patient experience in idiopathic pulmonary fibrosis. European Respiratory Journal, 2017, 49, 1602202.	3.1	1
529	Fibrosis pulmonar idiopÃ¡tica. Medicina ClÃnica, 2017, 148, 170-175.	0.3	26
531	Safety management of treatment with nintedanib in clinical practice of IPF. Respiratory Investigation, 2017, 55, 1.	0.9	2
532	Inhibition of the K_{Ca}3.1 Channel Alleviates Established Pulmonary Fibrosis in a Large Animal Model. American Journal of Respiratory Cell and Molecular Biology, 2017, 56, 539-550.	1.4	26
533	Genetics of idiopathic pulmonary fibrosis: from mechanistic pathways to personalised medicine. Journal of Medical Genetics, 2017, 54, 93-99.	1.5	50
534	A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK. Pharmacoeconomics, 2017, 35, 479-491.	1.7	28
535	Lung Cancer Complicated with Interstitial Lung Diseases. , 2017, , 239-252.		0
536	Interstitial lung abnormalities: risk and opportunity. Lancet Respiratory Medicine,the, 2017, 5, 95-96.	5.2	10
537	The fibrogenic actions of lung fibroblast-derived urokinase: a potential drug target in IPF. Scientific Reports, 2017, 7, 41770.	1.6	26
538	Targeting coagulation factor receptors â€“ proteaseâ€activated receptors in idiopathic pulmonary fibrosis. Journal of Thrombosis and Haemostasis, 2017, 15, 597-607.	1.9	42
539	Plasma membrane wounding and repair in pulmonary diseases. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2017, 312, L371-L391.	1.3	34
540	Idiopathic pulmonary fibrosis: current and future directions. Clinical Radiology, 2017, 72, 343-355.	0.5	8
541	Investigation of viral infection in idiopathic pulmonary fibrosis among Iranian patients in Tehran. Microbial Pathogenesis, 2017, 104, 171-174.	1.3	10
542	Epidemiology, survival, incidence and prevalence of idiopathic pulmonary fibrosis in the USA and Canada. European Respiratory Journal, 2017, 49, 1602384.	3.1	12

#	Article	IF	Citations
543	Classification of idiopathic interstitial pneumonias using antiâ€“myxovirus resistance-protein 1 autoantibody. Scientific Reports, 2017, 7, 43201.	1.6	14
544	The importance of subpleural fibrosis in the prognosis of patients with idiopathic interstitial pneumonias. European Journal of Radiology, 2017, 90, 106-113.	1.2	20
545	Drug Repurposing of Histone Deacetylase Inhibitors That Alleviate Neutrophilic Inflammation in Acute Lung Injury and Idiopathic Pulmonary Fibrosis via Inhibiting Leukotriene A4 Hydrolase and Blocking LTB4 Biosynthesis. Journal of Medicinal Chemistry, 2017, 60, 1817-1828.	2.9	30
546	Taking It Off: New Insights into the Role of Tyrosine Phosphorylationâ€“dependent Pathways in the Pathogenesis of Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 418-420.	2.5	1
547	Extracellular matrix remodeling in idiopathic pulmonary fibrosis. It is the â€˜bedâ€™ that counts and not â€˜the sleepersâ€™. Expert Review of Respiratory Medicine, 2017, 11, 299-309.	1.0	42
548	Optimizing quality of life in patients with idiopathic pulmonary fibrosis. Therapeutic Advances in Respiratory Disease, 2017, 11, 157-169.	1.0	83
549	Diagnosing idiopathic pulmonary fibrosis without a lung biopsy: honeycombing not required. Thorax, 2017, 72, 391-392.	2.7	4
550	Role of IL-17A in murine models of COPD airway disease. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2017, 312, L122-L130.	1.3	45
551	Effects of nintedanib on the microvascular architecture in a lung fibrosis model. Angiogenesis, 2017, 20, 359-372.	3.7	107
552	Understanding COPD-overlap syndromes. Expert Review of Respiratory Medicine, 2017, 11, 285-298.	1.0	47
554	Translation and validation of the Kingâ€™s Brief Interstitial Lung Disease (K-BILD) questionnaire in French, Italian, Swedish, and Dutch. Chronic Respiratory Disease, 2017, 14, 140-150.	1.0	19
555	Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry. European Respiratory Journal, 2017, 49, 1601592.	3.1	174
556	Epithelial and endothelial cell plasticity in chronic obstructive pulmonary disease (COPD). Respiratory Investigation, 2017, 55, 104-113.	0.9	54
557	The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia. Thorax, 2017, 72, 424-429.	2.7	103
558	Healthâ€related quality of life in idiopathic pulmonary fibrosis: Data from the <scp>A</scp>ustralian <scp>IPF R</scp>egistry. Respirology, 2017, 22, 950-956.	1.3	85
559	A Novel Antifibrotic Mechanism of Nintedanib and Pirfenidone. Inhibition of Collagen Fibril Assembly. American Journal of Respiratory Cell and Molecular Biology, 2017, 57, 77-90.	1.4	125
561	The earlier, the better: Impact of early diagnosis on clinical outcome in idiopathic pulmonary fibrosis. Pulmonary Pharmacology and Therapeutics, 2017, 44, 7-15.	1.1	27
562	SIRT3 deficiency promotes lung fibrosis by augmenting alveolar epithelial cell mitochondrial DNA damage and apoptosis. FASEB Journal, 2017, 31, 2520-2532.	0.2	96

#	Article	IF	Citations
563	Improving Survival in Idiopathic Pulmonary Fibrosis. Chest, 2017, 151, 527-528.	0.4	8
564	Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. Thorax, 2017, 72, 340-346.	2.7	191
565	Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis. Thorax, 2017, 72, 148-153.	2.7	66
566	Reply: Is a Trial of Vitamin K Antagonists and Bisphosphonates Possible in IPF?. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 271-272.	2.5	0
567	TAZ contributes to pulmonary fibrosis by activating profibrotic functions of lung fibroblasts. Scientific Reports, 2017, 7, 42595.	1.6	84
569	Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone. Respiration, 2017, 93, 415-423.	1.2	63
570	Clinical trial research in focus: why do so many clinical trials fail in IPF?. Lancet Respiratory Medicine,the, 2017, 5, 372-374.	5.2	27
571	Computed tomographic findings in subjects who died from respiratory disease in the National Lung Screening Trial. European Respiratory Journal, 2017, 49, 1601814.	3.1	26
572	Magnetic resonance imaging of disease progression and resolution in a transgenic mouse model of pulmonary fibrosis. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2017, 312, L488-L499.	1.3	5
573	Lung carcinogenesis and fibrosis taken together. Current Opinion in Pulmonary Medicine, 2017, 23, 290-297.	1.2	5
574	Idiopathic Pulmonary Fibrosis in Switzerland: Diagnosis and Treatment. Respiration, 2017, 93, 363-378.	1.2	26
575	Pulmonary fibrosis requires cell-autonomous mesenchymal fibroblast growth factor (FGF) signaling. Journal of Biological Chemistry, 2017, 292, 10364-10378.	1.6	50
576	IL-13 and idiopathic pulmonary fibrosis: Possible links and new therapeutic strategies. Pulmonary Pharmacology and Therapeutics, 2017, 45, 95-100.	1.1	59
577	Idiopathic Pulmonary Fibrosis: Molecular Endotypes of Fibrosis Stratifying Existing and Emerging Therapies. Respiration, 2017, 93, 379-395.	1.2	22
578	Repurposing Pentoxifylline for the Treatment of Fibrosis: An Overview. Advances in Therapy, 2017, 34, 1245-1269.	1.3	40
579	Coping with missing data in phase III pivotal registration trials: Tolvaptan in subjects with kidney disease, a case study. Pharmaceutical Statistics, 2017, 16, 250-266.	0.7	5
580	Reply: Effect of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1275-1275.	2.5	0
581	AJRCCM: 100-Y<scp>ear</scp> A<scp>nniversary</scp>.Progress in Interstitial Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1104-1107.	2.5	4

#	Article	IF	Citations
582	Lymphatic Changes in Respiratory Diseases: More than Just Remodeling of the Lung?. American Journal of Respiratory Cell and Molecular Biology, 2017, 57, 272-279.	1.4	41
583	The long-term outcome of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies. Respiratory Medicine, 2017, 127, 57-64.	1.3	37
584	Posttreatment with Protectin DX ameliorates bleomycin-induced pulmonary fibrosis and lung dysfunction in mice. Scientific Reports, 2017, 7, 46754.	1.6	36
585	Identification of 4-(Aminomethyl)-6-(trifluoromethyl)-2-(phenoxy)pyridine Derivatives as Potent, Selective, and Orally Efficacious Inhibitors of the Copper-Dependent Amine Oxidase, Lysyl Oxidase-Like 2 (LOXL2). Journal of Medicinal Chemistry, 2017, 60, 4403-4423.	2.9	48
586	The peripheral blood proteome signature of idiopathic pulmonary fibrosis is distinct from normal and is associated with novel immunological processes. Scientific Reports, 2017, 7, 46560.	1.6	51
587	Intestinal fibrosis. Current Opinion in Gastroenterology, 2017, 33, 239-245.	1.0	50
588	Diffuse parenchymal lung disease. European Respiratory Review, 2017, 26, 170004.	3.0	11
589	Reference values for forced vital capacity in idiopathic pulmonary fibrosis. Respiratory Medicine, 2017, 125, 102.	1.3	0
590	Antifibrotic drugs as treatment of nonidiopathic pulmonary fibrosis interstitial pneumonias. Current Opinion in Pulmonary Medicine, 2017, 23, 418-425.	1.2	17
591	Evaluation and management approaches for scleroderma lung disease. Therapeutic Advances in Respiratory Disease, 2017, 11, 327-340.	1.0	19
592	Acute exacerbations in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis. European Respiratory Journal, 2017, 49, 1601339.	3.1	109
593	Multidisciplinary evaluation of interstitial lung diseases: current insights. European Respiratory Review, 2017, 26, 170002.	3.0	44
594	Interstitial Lung Disease, Body Mass Index, Energy Expenditure and Malnutritionâ€”a Review. Current Pulmonology Reports, 2017, 6, 70-74.	0.5	5
595	Mortality and Respiratory Failure After Thoracoscopic Lung Biopsy for Interstitial Lung Disease. Annals of Thoracic Surgery, 2017, 104, 465-470.	0.7	29
596	The role of high-resolution computed tomography in the follow-up of diffuse lung disease. European Respiratory Review, 2017, 26, 170008.	3.0	41
597	Protective and therapeutic effect of felodipine against bleomycin-induced pulmonary fibrosis in mice. Scientific Reports, 2017, 7, 3439.	1.6	17
598	â€œAn Ounce of Prevention . . . â€¦ Will This Be the Future for Idiopathic Pulmonary Fibrosis?. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1240-1241.	2.5	0
599	Idiopathic pulmonary fibrosis: Clinical behavior and aging associated comorbidities. Respiratory Medicine, 2017, 129, 46-52.	1.3	39

#	Article	IF	Citations
600	NLRP3 participates in the regulation of EMT in bleomycin-induced pulmonary fibrosis. Experimental Cell Research, 2017, 357, 328-334.	1.2	97
601	Acute exacerbations of interstitial lung disease. Current Opinion in Pulmonary Medicine, 2017, 23, 411-417.	1.2	26
602	Pirfenidone inhibits myofibroblast differentiation and lung fibrosis development during insufficient mitophagy. Respiratory Research, 2017, 18, 114.	1.4	72
603	Update in Interstitial Lung Disease 2016. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 132-138.	2.5	7
604	New treatment directions for IPF: current status of ongoing and upcoming clinical trials. Expert Review of Respiratory Medicine, 2017, 11, 533-548.	1.0	13
605	Recent advances in connective tissue disease related interstitial lung disease. Expert Review of Respiratory Medicine, 2017, 11, 591-603.	1.0	21
606	Acute exacerbations of idiopathic pulmonary fibrosis: tough to define; tougher to manage. European Respiratory Journal, 2017, 49, 1700811.	3.1	8
607	Lung Manifestations in the Rheumatic Diseases. Chest, 2017, 152, 1283-1295.	0.4	97
609	Therapeutic pro-fibrogenic signaling pathways in fibroblasts. Advanced Drug Delivery Reviews, 2017, 121, 57-84.	6.6	51
610	Current approaches to the management of idiopathic pulmonary fibrosis. Respiratory Medicine, 2017, 129, 24-30.	1.3	52
611	The safety and tolerability of nintedanib in the treatment of idiopathic pulmonary fibrosis. Expert Opinion on Drug Safety, 2017, 16, 857-865.	1.0	19
612	Hypersensitivity Pneumonitis: Perspectives in Diagnosis and Management. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 680-689.	2.5	338
613	Combination therapy in pulmonary arterial hypertension: recent accomplishments and future challenges. Pulmonary Circulation, 2017, 7, 312-325.	0.8	37
614	Nintedanib reduces ventilationâ€augmented bleomycinâ€induced epithelialâ€“mesenchymal transition and lung fibrosis through suppression of the Src pathway. Journal of Cellular and Molecular Medicine, 2017, 21, 2937-2949.	1.6	45
615	Patient-centered Outcomes in Idiopathic Pulmonary Fibrosis Clinical Trials. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 674-675.	2.5	1
616	Lung cancer in patients with idiopathic pulmonary fibrosis. Pulmonary Pharmacology and Therapeutics, 2017, 45, 1-10.	1.1	129
617	Microencapsulation of Lefty-secreting engineered cells for pulmonary fibrosis therapy in mice. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2017, 312, L741-L747.	1.3	2
618	Normativa sobre el tratamiento farmacolÃ³gico de la fibrosis pulmonar idiopÃ¡tica. Archivos De Bronconeumologia, 2017, 53, 263-269.	0.4	40

#	Article	IF	Citations
619	Are physicians in primary health care able to recognize pulmonary fibrosis?. European Clinical Respiratory Journal, 2017, 4, 1290339.	0.7	21
620	Pulmonary fibrosis, part I: epidemiology, pathogenesis, and diagnosis. Expert Review of Respiratory Medicine, 2017, 11, 1-17.	1.0	103
621	Pulmonary fibrosis, part II: state-of-the-art patient management. Expert Review of Respiratory Medicine, 2017, 11, 1-16.	1.0	8
622	Type I collagenâ€“targeted PET probe for pulmonary fibrosis detection and staging in preclinical models. Science Translational Medicine, 2017, 9, .	5.8	128
623	Added value of prone CT in the assessment of honeycombing and classification of usual interstitial pneumonia pattern. European Journal of Radiology, 2017, 91, 66-70.	1.2	25
624	Domino carbometalation/coupling reactions of N-arylpropiolamides: a novel and promising synthetic strategy toward stereocontrolled preparation of highly substituted 3-methyleneindolinones. RSC Advances, 2017, 7, 19061-19072.	1.7	27
625	Blood Biomarkers in Idiopathic Pulmonary Fibrosis. Lung, 2017, 195, 273-280.	1.4	110
626	Idiopathic pulmonary fibrosis. Lancet, The, 2017, 389, 1941-1952.	6.3	1,199
628	Development and Pretesting of a Questionnaire to Assess Patient Experiences and Satisfaction with Medications (PESaM Questionnaire). Patient, 2017, 10, 629-642.	1.1	14
629	Guidelines for the Medical Treatment of Idiopathic Pulmonary Fibrosis. Archivos De Bronconeumologia, 2017, 53, 263-269.	0.4	21
630	Oxygen Therapy for Interstitial Lung Disease. A Mismatch between Patient Expectations and Experiences. Annals of the American Thoracic Society, 2017, 14, 888-895.	1.5	48
631	Interstitial Lung Disease in India. Keep Searching and Youâ€™ll Keep Finding. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 714-715.	2.5	4
632	Idiopathic Interstitial Pneumonia Associated With Autoantibodies. Chest, 2017, 152, 103-112.	0.4	45
633	Sex steroid receptor expression in idiopathic pulmonary fibrosis. Human Pathology, 2017, 66, 200-205.	1.1	9
634	Asiatic acid ameliorates pulmonary fibrosis induced by bleomycin (BLM) via suppressing pro-fibrotic and inflammatory signaling pathways. Biomedicine and Pharmacotherapy, 2017, 89, 1297-1309.	2.5	63
635	Treatment-Related Toxicity in Patients With Early-Stage Non-Small Cell Lung Cancer and Coexisting Interstitial Lung Disease: A Systematic Review. International Journal of Radiation Oncology Biology Physics, 2017, 98, 622-631.	0.4	107
636	Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: Tolerability and adverse drug reactions. Respirology, 2017, 22, 1171-1178.	1.3	170
637	The diagnosis of idiopathic pulmonary fibrosis: current and future approaches. Lancet Respiratory Medicine,the, 2017, 5, 61-71.	5.2	79

#	Article	IF	Citations
638	Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial. Lancet Respiratory Medicine,the, 2017, 5, 22-32.	5.2	200
639	<scp>COPD A</scp>ssessment <scp>T</scp>est for measurement of health status in patients with idiopathic pulmonary fibrosis: <scp>A</scp> crossâ€sectional study. Respirology, 2017, 22, 721-727.	1.3	36
640	Diagnosis and Treatment of Fibrotic Hypersensitivity Pneumonia. Where We Stand and Where We Need to Go. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 690-699.	2.5	176
641	Increased deposition of glycosaminoglycans and altered structure of heparan sulfate in idiopathic pulmonary fibrosis. International Journal of Biochemistry and Cell Biology, 2017, 83, 27-38.	1.2	53
642	Etiology and treatment of cough in idiopathic pulmonary fibrosis. Respiratory Medicine, 2017, 123, 98-104.	1.3	28
643	A multitechnique approach to probe the interaction of a therapeutic tyrosine kinase inhibitor nintedanib and bovine serum albumin. Preparative Biochemistry and Biotechnology, 2017, 47, 655-663.	1.0	7
644	Feasibility of the administration of chemotherapy using cisplatin plus etoposide for non-small cell lung cancer patients with interstitial lung disease on chest computed tomography. Cancer Treatment and Research Communications, 2017, 10, 6-11.	0.7	3
645	Tissue remodelling in pulmonary fibrosis. Cell and Tissue Research, 2017, 367, 607-626.	1.5	114
646	Understanding and overcoming metformin gastrointestinal intolerance. Diabetes, Obesity and Metabolism, 2017, 19, 473-481.	2.2	141
647	Great expectations for simtuzumab in IPF fall short. Lancet Respiratory Medicine,the, 2017, 5, 2-3.	5.2	10
648	The Objective Identification and Quantification of Interstitial Lung Abnormalities in Smokers. Academic Radiology, 2017, 24, 941-946.	1.3	37
649	Nintedanib in Japanese patients with idiopathic pulmonary fibrosis: A subgroup analysis of the INPULSISÂ® randomized trials. Respirology, 2017, 22, 750-757.	1.3	37
650	Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association study. Lancet Respiratory Medicine,the, 2017, 5, 869-880.	5.2	233
651	Idiopathic pulmonary fibrosis: lessons from clinical trials over the past 25â€...years. European Respiratory Journal, 2017, 50, 1701209.	3.1	108
652	French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosisÂâ€“Â2017 update. Full-length version. Revue Des Maladies Respiratoires, 2017, 34, 900-968.	1.7	51
654	French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosisÂâ€“Â2017 update. Short-length version. Revue Des Maladies Respiratoires, 2017, 34, 852-899.	1.7	2
656	Severe idiopathic pulmonary fibrosis: what can be done?. European Respiratory Review, 2017, 26, 170047.	3.0	33
657	Recent lessons learned in the management of acute exacerbation of idiopathic pulmonary fibrosis. European Respiratory Review, 2017, 26, 170050.	3.0	54

#	Article	IF	Citations
658	Pharmacotherapy for idiopathic pulmonary fibrosis: current landscape and future potential. European Respiratory Review, 2017, 26, 170071.	3.0	30
659	Anti-inflammatory and anti-fibrotic effects of intravenous adipose-derived stem cell transplantation in a mouse model of bleomycin-induced interstitial pneumonia. Scientific Reports, 2017, 7, 14608.	1.6	49
660	Use of multitarget tyrosine kinase inhibitors to attenuate platelet-derived growth factor signalling in lung disease. European Respiratory Review, 2017, 26, 170061.	3.0	13
661	Airway Complications After Lung Transplantation. Clinics in Chest Medicine, 2017, 38, 693-706.	0.8	33
662	When to start and when to stop antifibrotic therapies. European Respiratory Review, 2017, 26, 170053.	3.0	39
663	Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease. Nature Reviews Drug Discovery, 2017, 16, 755-772.	21.5	251
664	Beneficial effects of bile acid receptor agonists in pulmonary disease models. Expert Opinion on Investigational Drugs, 2017, 26, 1215-1228.	1.9	18
665	COUNTERPOINT: Should BAL Be Routinely Performed in the Diagnostic Evaluation of Idiopathic Pulmonary Fibrosis? No. Chest, 2017, 152, 919-922.	0.4	9
666	Reactive oxygen species as signaling molecules in the development of lung fibrosis. Translational Research, 2017, 190, 61-68.	2.2	67
667	Palliative care in interstitial lung disease: living well. Lancet Respiratory Medicine,the, 2017, 5, 968-980.	5.2	185
668	Idiopathic pulmonary fibrosis. Nature Reviews Disease Primers, 2017, 3, 17074.	18.1	786
669	The activity of nintedanib in an animal model of allogenic left lung transplantation resembling aspects of allograft rejection. Experimental Lung Research, 2017, 43, 259-270.	0.5	5
670	PTP4A1 promotes TGFÎ² signaling and fibrosis in systemic sclerosis. Nature Communications, 2017, 8, 1060.	5.8	46
671	Treatment of idiopathic pulmonary fibrosis in <scp>A</scp>ustralia and <scp>N</scp>ew Zealand: <scp>A</scp> position statement from the <scp>T</scp>horacic <scp>S</scp>ociety of <scp>A</scp>ustralia and <scp>N</scp>ew <scp>Z</scp>ealand and the <scp>L</scp>ung <scp>F</scp>oundation <scp>A</scp>ustralia. Respirology, 2017, 22, 1436-1458.	1.3	39
672	Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international caseâ€“cohort study. European Respiratory Journal, 2017, 50, 1700936.	3.1	75
673	Using evidence in clinical practice: A dream coming true in idiopathic pulmonary fibrosis. Revista Portuguesa De Pneumologia, 2017, 23, 245-246.	0.7	0
674	Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease. BMJ Open Respiratory Research, 2017, 4, e000212.	1.2	151
675	Low body surface area predicts hepatotoxicity of nintedanib in patients with idiopathic pulmonary fibrosis. Scientific Reports, 2017, 7, 10811.	1.6	33

#	Article	IF	Citations
676	Evaluating disease severity in idiopathic pulmonary fibrosis. European Respiratory Review, 2017, 26, 170051.	3.0	63
677	The interstitial lung disease multidisciplinary meeting: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia. Respirology, 2017, 22, 1459-1472.	1.3	41
678	Pneumopathies interstitielles diffuses au cours de la polyarthrite rhumatoÃ¯de. Revue Du Rhumatisme Monographies, 2017, 84, 347-351.	0.0	1
679	Are newly launched pharmacotherapies efficacious in treating idiopathic pulmonary fibrosis? Or is there still more work to be done?. Expert Opinion on Pharmacotherapy, 2017, 18, 1583-1594.	0.9	4
680	Managing Idiopathic Pulmonary Fibrosis: Which Drug for Which Patient?. Drugs and Aging, 2017, 34, 647-653.	1.3	10
681	Safety and efficacy of carboplatin plus nab-paclitaxel for treating advanced non-small-cell lung cancer with interstitial lung disease. Molecular and Clinical Oncology, 2017, 7, 604-608.	0.4	21
682	MicroRNA-29b inhibits supernatants from silica-treated macrophages from inducing extracellular matrix synthesis in lung fibroblasts. Toxicology Research, 2017, 6, 878-888.	0.9	17
683	Pirfenidone in Idiopathic Pulmonary Fibrosis â€œRECAP-itulating Safety into the Real Worldâ€• Respiration, 2017, 94, 405-407.	1.2	4
684	Time for an International Consensus on Hypersensitivity Pneumonitis. A Call to Arms. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 665-666.	2.5	18
685	Toward Early Identification of Clinically Relevant Interstitial Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1368-1369.	2.5	6
686	A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology, 2017, 146, 554-559.	0.6	15
687	Modelâ€based Metaâ€Analysis on the Efficacy of Pharmacological Treatments for Idiopathic Pulmonary Fibrosis. CPT: Pharmacometrics and Systems Pharmacology, 2017, 6, 695-704.	1.3	10
688	Home spirometry for idiopathic pulmonary fibrosis: ready for prime time?. European Respiratory Journal, 2017, 50, 1701403.	3.1	1
689	Scleroderma-related interstitial lung disease. Respiratory Medicine Case Reports, 2017, 22, 109-112.	0.2	13
690	Therapeutic targets in idiopathic pulmonary fibrosis. Respiratory Medicine, 2017, 131, 49-57.	1.3	92
691	Mesenchymal Stem Cells in Fibrotic Disease. Cell Stem Cell, 2017, 21, 166-177.	5.2	309
692	An Official American Thoracic Society Workshop Report: Translational Research in Rare Respiratory Diseases. Annals of the American Thoracic Society, 2017, 14, 1239-1247.	1.5	4
693	Investigational drugs for idiopathic pulmonary fibrosis. Expert Opinion on Investigational Drugs, 2017, 26, 1019-1031.	1.9	18

#	Article	IF	Citations
694	Pulmonary CCR2⁺CD4⁺T cells are immune regulatory and attenuate lung fibrosis development. Thorax, 2017, 72, 1007-1020.	2.7	26
695	Oxygen Therapy for Interstitial Lung Disease: Physiciansâ€™ Perceptions and Experiences. Annals of the American Thoracic Society, 2017, 14, 1772-1778.	1.5	16
696	Olodaterol shows antiâ€fibrotic efficacy in in vitro and in vivo models of pulmonary fibrosis. British Journal of Pharmacology, 2017, 174, 3848-3864.	2.7	15
698	Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis. Annals of the Rheumatic Diseases, 2017, 76, 1941-1948.	0.5	149
700	Clinical use of nintedanib in patients with idiopathic pulmonary fibrosis. BMJ Open Respiratory Research, 2017, 4, e000192.	1.2	30
701	Use of Patterned Collagen Coated Slides to Study Normal and Scleroderma Lung Fibroblast Migration. Scientific Reports, 2017, 7, 2628.	1.6	4
702	Senolytic drugs targetÂalveolar epithelial cell function and attenuate experimental lung fibrosisex vivo. European Respiratory Journal, 2017, 50, 1602367.	3.1	267
704	Epidemiology of Rare Lung Diseases: The Challenges and Opportunities to Improve Research and Knowledge. Advances in Experimental Medicine and Biology, 2017, 1031, 419-442.	0.8	10
705	Mitochondrial Dysfunction in Pulmonary Fibrosis. Annals of the American Thoracic Society, 2017, 14, S383-S388.	1.5	72
706	An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study. Lancet Respiratory Medicine,the, 2017, 5, 946-955.	5.2	190
707	Lysyl oxidases regulate fibrillar collagen remodelling in idiopathic pulmonary fibrosis. DMM Disease Models and Mechanisms, 2017, 10, 1301-1312.	1.2	110
708	Clubbing in patients with fibrotic interstitial lung diseases. Respiratory Medicine, 2017, 132, 226-231.	1.3	18
709	Discovery of BI-2545: A Novel Autotaxin Inhibitor That Significantly Reduces LPA Levels in Vivo. ACS Medicinal Chemistry Letters, 2017, 8, 1252-1257.	1.3	27
710	Variants of the ABCA3 gene might contribute to susceptibility to interstitial lung diseases in the Chinese population. Scientific Reports, 2017, 7, 4097.	1.6	16
711	Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG S0905). Journal of Thoracic Oncology, 2017, 12, 1299-1308.	0.5	24
712	Effect of nintedanib on airway inflammation and remodeling in a murine chronic asthma model. Experimental Lung Research, 2017, 43, 187-196.	0.5	28
713	Pirfenidone may revert the epithelial-to-mesenchymal transition in human lung adenocarcinoma. Oncology Letters, 2017, 14, 944-950.	0.8	27
714	Delving Deep into the Proteome of Lung Fibrosis Brings Plasma Cells to the Surface. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1238-1240.	2.5	0

#	Article	IF	Citations
715	Pitfalls in developing new compounds for idiopathic pulmonary fibrosis. Current Opinion in Pulmonary Medicine, 2017, 23, 426-431.	1.2	2
716	Functional and prognostic effects when emphysema complicates idiopathic pulmonary fibrosis. European Respiratory Journal, 2017, 50, 1700379.	3.1	71
717	The instructive extracellular matrix of the lung: basic composition and alterations in chronic lung disease. European Respiratory Journal, 2017, 50, 1601805.	3.1	341
718	Home monitoring improves endpoint efficiency in idiopathic pulmonary fibrosis. European Respiratory Journal, 2017, 50, 1602406.	3.1	66
720	Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?. Lancet Respiratory Medicine,the, 2017, 5, 591-598.	5.2	71
721	Idiopathic pulmonary fibrosis in the era of antifibrotic therapy: Searching for new opportunities grounded in evidence. Revista Portuguesa De Pneumologia, 2017, 23, 287-293.	0.7	11
722	Delayed Presentation of Hepatocellular Liver Injury After Nintedanib Administration. American Journal of Therapeutics, 2017, 24, e107-e108.	0.5	6
723	Mechanical ventilation in idiopathic pulmonary fibrosis: a nationwide analysis of ventilator use, outcomes, and resource burden. BMC Pulmonary Medicine, 2017, 17, 84.	0.8	29
724	The St. Georgeâ€™s Respiratory Questionnaire as a prognostic factor in IPF. Respiratory Research, 2017, 18, 18.	1.4	59
725	Differential Expression of VEGF-A_{xxx} Isoforms Is Critical for Development of Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 479-493.	2.5	58
726	Unwinding the Collagen Fibrils: Elucidating the Mechanism of Pirfenidone and Nintedanib in Pulmonary Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2017, 57, 10-11.	1.4	10
727	Genetic Evaluation and Testing of Patients and Families with Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1423-1428.	2.5	71
728	Referral to Palliative Care Infrequent in Patients with Idiopathic Pulmonary Fibrosis Admitted to an Intensive Care Unit. Journal of Palliative Medicine, 2017, 20, 134-140.	0.6	31
729	Idiopathic Pulmonary Fibrosis: Current Status, Recent Progress, and Emerging Targets. Journal of Medicinal Chemistry, 2017, 60, 527-553.	2.9	103
730	SH2 Domainâ€“Containing Phosphatase-2 Is a Novel Antifibrotic Regulator in Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 500-514.	2.5	49
731	Treatment of idiopathic pulmonary fibrosis: a position paper from a Nordic expert group. Journal of Internal Medicine, 2017, 281, 149-166.	2.7	27
732	Assessing the Therapeutic Response to Pirfenidone in Idiopathic Pulmonary Fibrosis: Can We Do Better than with Forced Vital Capacity Alone?. Lung, 2017, 195, 101-105.	1.4	8
733	Fibroblast growth factors and pulmonary fibrosis: it's more complex than it sounds. Journal of Pathology, 2017, 241, 6-9.	2.1	24

#	Article	IF	Citations
734	A new era in idiopathic interstitial pneumonias: <scp>E</scp>pilogue to a review series. Respirology, 2017, 22, 14-16.	1.3	1
735	MicroRNAs in non-small cell lung cancer and idiopathic pulmonary fibrosis. Journal of Human Genetics, 2017, 62, 57-65.	1.1	70
736	Duration of benefit following completion of pulmonary rehabilitation in interstitial lung diseaseâ€"an observational study. QJM - Monthly Journal of the Association of Physicians, 2017, 110, 17-22.	0.2	29
737	Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities. Lancet Respiratory Medicine,the, 2017, 5, 72-84.	5.2	137
738	Utility of Transbronchial vsÂSurgical Lung Biopsy in the Diagnosis of Suspected Fibrotic Interstitial Lung Disease. Chest, 2017, 151, 389-399.	0.4	87
740	Toll-like receptors and autophagy in interstitial lung diseases. European Journal of Pharmacology, 2017, 808, 28-34.	1.7	11
741	Use of biologics to treat acute exacerbations and manage disease in asthma, COPD and IPF. , 2017, 169, 1-12.		7
742	Idiopathic interstitial pneumonia-associated pulmonary hypertension: A target for therapy?. Respiratory Medicine, 2017, 122, S10-S13.	1.3	15
743	Pirfenidone and mortality in idiopathic pulmonary fibrosis. Lancet Respiratory Medicine,the, 2017, 5, 3-5.	5.2	4
744	Diagnostic Approach to Advanced Fibrotic Interstitial Lung Disease: Bringing Together Clinical, Radiologic, and Histologic Clues. Archives of Pathology and Laboratory Medicine, 2017, 141, 901-915.	1.2	28
745	Acupuncture for idiopathic pulmonary fibrosis. Medicine (United States), 2017, 96, e9114.	0.4	2
746	Integrated Transitions of Care for Patients With Rare Pulmonary Diseases. Professional Case Management, 2017, 22, 54-63.	0.2	11
747	Suspected accelerated disease progression after discontinuation of nintedanib in patients with idiopathic pulmonary fibrosis. Medicine (United States), 2017, 96, e9081.	0.4	4
748	Effects of herbal extracts and compounds and pharmacological agents on pulmonary fibrosis in animal models: a review. Journal of Integrative Medicine, 2017, 15, 433-441.	1.4	12
749	Nintedanib selectively inhibits the activation and tumour-promoting effects of fibroblasts from lung adenocarcinoma patients. British Journal of Cancer, 2017, 117, 1128-1138.	2.9	45
750	Relaxing Effect of TSU-68, an Antiangiogenic Agent, on Mouse Airway Smooth Muscle. Cellular Physiology and Biochemistry, 2017, 41, 2350-2362.	1.1	10
751	mMRC dyspnoea scale indicates impaired quality of life and increased pain in patients with idiopathic pulmonary fibrosis. ERJ Open Research, 2017, 3, 00084-2017.	1.1	62
752	Current Treatments in the Management of Idiopathic Pulmonary Fibrosis: Pirfenidone and Nintedanib. Clinical Medicine Insights Therapeutics, 2017, 9, 1179559X1771912.	0.4	5

#	Article	IF	Citations
753	M24â€...Do antifibrotics impact on lung transplantation outcomes in idiopathic pulmonary fibrosis?. , 2017, , .		0
754	M25â€...Weight loss has a significant impact on anti-fibrotic drug tolerance in patients with idiopathic pulmonary fibrosis. , 2017, , .		0
755	M26â€...Geographic variation in anti-fibrotic prescriptions for idiopathic pulmonary fibrosis persists and is not fully-explained by indices of multiple deprivation. , 2017, , .		0
757	The Mighty Fibroblast and Its Utility in Scleroderma Research. Journal of Scleroderma and Related Disorders, 2017, 2, 100-107.	1.0	57
759	The Processes and Mechanisms of Cardiac and Pulmonary Fibrosis. Frontiers in Physiology, 2017, 8, 777.	1.3	162
760	Idiopathic pulmonary fibrosis in East Asian. Intractable and Rare Diseases Research, 2017, 6, 80-86.	0.3	2
761	Efficacy of Idebenone to Preserve Respiratory Function above Clinically Meaningful Thresholds for Forced Vital Capacity (FVC) in Patients with Duchenne Muscular Dystrophy. Journal of Neuromuscular Diseases, 2017, 4, 189-198.	1.1	32
762	Depression Is Significantly Associated with the Health Status in Patients with Idiopathic Pulmonary Fibrosis. Internal Medicine, 2017, 56, 1637-1644.	0.3	32
763	Systematic Review and Network Meta-analysis of Idiopathic Pulmonary Fibrosis Treatments. Journal of Managed Care & Specialty Pharmacy, 2017, 23, S5-S16.	0.5	26
764	MicroRNAs in Idiopathic Pulmonary Fibrosis. , 2017, , 179-202.		3
765	A Systematic Review of the Role of Dysfunctional Wound Healing in the Pathogenesis and Treatment of Idiopathic Pulmonary Fibrosis. Journal of Clinical Medicine, 2017, 6, 2.	1.0	78
766	P2Y6 Receptor Activation Promotes Inflammation and Tissue Remodeling in Pulmonary Fibrosis. Frontiers in Immunology, 2017, 8, 1028.	2.2	27
767	Exploring Animal Models That Resemble Idiopathic Pulmonary Fibrosis. Frontiers in Medicine, 2017, 4, 118.	1.2	213
768	Comorbid Conditions in Idiopathic Pulmonary Fibrosis: Recognition and Management. Frontiers in Medicine, 2017, 4, 123.	1.2	67
769	Diagnosis of Idiopathic Pulmonary Fibrosis â€œPragmatic Challenges in Clinical Practiceâ€• Frontiers in Medicine, 2017, 4, 151.	1.2	14
770	Genetics in Idiopathic Pulmonary Fibrosis Pathogenesis, Prognosis, and Treatment. Frontiers in Medicine, 2017, 4, 154.	1.2	97
771	Acute Exacerbation in Interstitial Lung Disease. Frontiers in Medicine, 2017, 4, 176.	1.2	101
772	Integrating Patient Perspectives into Personalized Medicine in Idiopathic Pulmonary Fibrosis. Frontiers in Medicine, 2017, 4, 226.	1.2	25

#	Article	IF	Citations
773	Pulmonary Hypertension Associated with Idiopathic Pulmonary Fibrosis: Current and Future Perspectives. Canadian Respiratory Journal, 2017, 2017, 1-12.	0.8	61
774	Challenges in idiopathic interstitial lung disease: an update. Minerva Respiratory Medicine, 2017, 56, .	0.1	1
775	Predicting Life Expectancy for Pirfenidone in Idiopathic Pulmonary Fibrosis. Journal of Managed Care & Specialty Pharmacy, 2017, 23, S17-S24.	0.5	65
776	Idiopathic Pulmonary Fibrosis: A Case Discussion. The Consultant Pharmacist, 2017, 32, 406-411.	0.4	1
777	Novel form of miR-29b suppresses bleomycin-induced pulmonary fibrosis. PLoS ONE, 2017, 12, e0171957.	1.1	12
778	Effectiveness and safety of mycophenolate mofetil in idiopathic pulmonary fibrosis. PLoS ONE, 2017, 12, e0176312.	1.1	11
779	Establishment of an indirect ELISA for detection of the novel antifibrotic peptide M10. PLoS ONE, 2017, 12, e0188588.	1.1	6
781	Gene expression profiling of idiopathic interstitial pneumonias (IIPs): identification of potential diagnostic markers and therapeutic targets. BMC Medical Genetics, 2017, 18, 88.	2.1	26
782	Prognosis and longitudinal changes of physical activity in idiopathic pulmonary fibrosis. BMC Pulmonary Medicine, 2017, 17, 104.	0.8	51
783	Exploring efficacy and safety of oral Pirfenidone for progressive, non-IPF lung fibrosis (RELIEF) - a randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial. BMC Pulmonary Medicine, 2017, 17, 122.	0.8	94
784	Unmet needs in the treatment of idiopathic pulmonary fibrosisâ€•insights from patient chart review in five European countries. BMC Pulmonary Medicine, 2017, 17, 124.	0.8	77
785	Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry. Respiratory Research, 2017, 18, 139.	1.4	135
786	Anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity. Respiratory Research, 2017, 18, 172.	1.4	73
787	Early clinical experiences with nintedanib in three UK tertiary interstitial lung disease centres. Clinical and Translational Medicine, 2017, 6, 41.	1.7	32
788	Evaluation of patients with fibrotic interstitial lung disease: A Canadian Thoracic Society position statement. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2017, 1, 133-141.	0.2	15
789	Trends in diagnosis and management of idiopathic pulmonary fibrosis in Canada. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2017, 1, 71-76.	0.2	5
791	Colitis Associated with Nintedanib Therapy for Idiopathic Pulmonary Fibrosis (IPF). Internal Medicine, 2017, 56, 1267-1268.	0.3	8
792	Translating Autoimmune Pathogenesis into Targeted Therapies for Systemic Sclerosis. , 2017, , .		0

#	Article	IF	Citations
793	Role of pirfenidone in the management of pulmonary fibrosis. Therapeutics and Clinical Risk Management, 2017, Volume 13, 427-437.	0.9	38
794	Drug Discovery in Tissue Fibrosis. , 2017, , 694-713.		2
795	Mortality from idiopathic pulmonary fibrosis: a temporal trend analysis in Brazil, 1979-2014. Jornal Brasileiro De Pneumologia, 2017, 43, 445-450.	0.4	12
796	Recent advances in managing systemic sclerosis. F1000Research, 2017, 6, 88.	0.8	3
797	3D pulmospheres serve as a personalized and predictive multicellular model for assessment of antifibrotic drugs. JCI Insight, 2017, 2, e91377.	2.3	42
798	Antifibrotic role of vascular endothelial growth factor in pulmonary fibrosis. JCI Insight, 2017, 2, .	2.3	51
799	Idiopathic pulmonary fibrosis: a holistic approach to disease management in the antifibrotic age. Journal of Thoracic Disease, 2017, 9, 4700-4707.	0.6	22
800	Recipient selection process and listing for lung transplantation. Journal of Thoracic Disease, 2017, 9, 3372-3384.	0.6	15
801	Surgical lung biopsies in elderly patients with interstitial lung disease: Weighing up the pros and cons. Respirology, 2018, 23, 444-445.	1.3	1
802	Anti-fibrotic Effects of CXCR4-Targeting i-body AD-114 in Preclinical Models of Pulmonary Fibrosis. Scientific Reports, 2018, 8, 3212.	1.6	42
804	Idiopathic pulmonary fibrosis. Nurse Practitioner, 2018, 43, 48-54.	0.2	5
805	Understanding the informational needs of patients with IPF and their caregivers: â€˜You get diagnosed, and you ask this question right away, what does this mean?â€™. BMJ Open Quality, 2018, 7, e000207.	0.4	33
806	The fibrogenic actions of the coagulant and plasminogen activation systems in pulmonary fibrosis. International Journal of Biochemistry and Cell Biology, 2018, 97, 108-117.	1.2	49
807	Design, Rationale, Methodology, and Aims of a Greek Prospective Idiopathic Pulmonary Fibrosis Registry: Investigating Idiopathic Pulmonary Fibrosis in Greece (INDULGE IPF). Respiration, 2018, 96, 41-47.	1.2	6
808	The impaired proteases and anti-proteases balance in Idiopathic Pulmonary Fibrosis. Matrix Biology, 2018, 68-69, 382-403.	1.5	56
809	Feixian Recipe inhibits pulmonary fibrosis by targeting pulmonary microvascular endothelial cells and VEGF/VEGFR2 signaling pathway. Traditional Medicine and Modern Medicine, 2018, 01, 59-67.	0.2	1
810	Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis. Respiration, 2018, 95, 301-309.	1.2	66
811	Interstitial lung abnormality is prevalent and associated with worse outcome in patients undergoing transcatheter aortic valve replacement. Respiratory Medicine, 2018, 137, 55-60.	1.3	14

#	Article	IF	Citations
812	Effect of antifibrotics on short-term outcome after bilateral lung transplantation: a multicentre analysis. European Respiratory Journal, 2018, 51, 1800503.	3.1	21
813	Predicting Outcomes in Idiopathic Pulmonary Fibrosis Using Automated Computed Tomographic Analysis. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 767-776.	2.5	140
814	Nonalcoholic fatty liver disease is associated with decreased lung function. Liver International, 2018, 38, 2091-2100.	1.9	25
815	The TAMing of the Idiopathic Pulmonary Fibrosis Myofibroblast. One Step Closer?. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1377-1378.	2.5	4
816	Personalised medicine in interstitial lung diseases. European Respiratory Review, 2018, 27, 170117.	3.0	16
817	Pulmonary administration of a dry powder formulation of the antifibrotic drug tilorone reduces silica-induced lung fibrosis in mice. International Journal of Pharmaceutics, 2018, 544, 121-128.	2.6	9
818	Multiple breath washout: A new and promising lung function test for patients with idiopathic pulmonary fibrosis. Respirology, 2018, 23, 764-770.	1.3	14
819	Burden, resilience and coping in caregivers of patients with interstitial lung disease. Heart and Lung: Journal of Acute and Critical Care, 2018, 47, 264-268.	0.8	23
820	Idiopathic pulmonary fibrosis: Epithelial-mesenchymal interactions and emerging therapeutic targets. Matrix Biology, 2018, 71-72, 112-127.	1.5	178
821	Astilbin ameliorates pulmonary fibrosis via blockade of Hedgehog signaling pathway. Pulmonary Pharmacology and Therapeutics, 2018, 50, 19-27.	1.1	21
822	Hydroxamic Acids Constitute a Novel Class of Autotaxin Inhibitors that Exhibit in Vivo Efficacy in a Pulmonary Fibrosis Model. Journal of Medicinal Chemistry, 2018, 61, 3697-3711.	2.9	27
823	Lung transplantation in idiopathic pulmonary fibrosis. Expert Review of Respiratory Medicine, 2018, 12, 375-385.	1.0	52
824	Performance of the St Georgeâ€™s Respiratory Questionnaire in patients with connective tissue diseaseâ€associated interstitial lung disease. Respirology, 2018, 23, 851-859.	1.3	16
825	Safety of nintedanib before lung transplant: an Italian case series. Respirology Case Reports, 2018, 6, e00312.	0.3	20
826	Targeting of TAM Receptors Ameliorates Fibrotic Mechanisms in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1443-1456.	2.5	66
827	Incidence, Prevalence, and Survival of Patients with Idiopathic Pulmonary Fibrosis in the UK. Advances in Therapy, 2018, 35, 724-736.	1.3	134
828	Neotuberostemonine inhibits the differentiation of lung fibroblasts into myofibroblasts in mice by regulating HIF-1Î± signaling. Acta Pharmacologica Sinica, 2018, 39, 1501-1512.	2.8	24
829	Anticancer drug treatment for advanced lung cancer with interstitial lung disease. Respiratory Investigation, 2018, 56, 307-311.	0.9	17

#	Article	IF	Citations
830	Modeling Idiopathic Pulmonary Fibrosis in Humanized Severe Combined Immunodeficient Mice. American Journal of Pathology, 2018, 188, 891-903.	1.9	24
831	Safer approaches to therapeutic modulation of TGF-Î² signaling for respiratory disease. , 2018, 187, 98-113.		35
832	Time for a change: is idiopathic pulmonary fibrosis still idiopathic and only fibrotic?. Lancet Respiratory Medicine,the, 2018, 6, 154-160.	5.2	137
833	Severe idiopathic pulmonary fibrosis: A clinical approach. European Journal of Internal Medicine, 2018, 50, 20-27.	1.0	4
834	Safety and efficacy of nintedanib in idiopathic pulmonary fibrosis: A real-life observational study in Greece. Pulmonary Pharmacology and Therapeutics, 2018, 49, 61-66.	1.1	49
835	The controversial role of mast cells in fibrosis. Immunological Reviews, 2018, 282, 198-231.	2.8	93
836	Analysis of the Histologic Features Associated With Interobserver Variation in Idiopathic Pulmonary Fibrosis. American Journal of Surgical Pathology, 2018, 42, 672-678.	2.1	17
837	Best supportive care for idiopathic pulmonary fibrosis: current gaps and future directions. European Respiratory Review, 2018, 27, 170076.	3.0	40
838	Physiology of the lung in idiopathic pulmonary fibrosis. European Respiratory Review, 2018, 27, 170062.	3.0	159
839	Is chronic exposure to air pollutants a risk factor for the development of idiopathic pulmonary fibrosis?. European Respiratory Journal, 2018, 51, 1702663.	3.1	10
840	Health economic evaluation in idiopathic pulmonary fibrosis in France. Current Medical Research and Opinion, 2018, 34, 1731-1740.	0.9	9
841	Diverse functions of clusterin promote and protect against the development of pulmonary fibrosis. Scientific Reports, 2018, 8, 1906.	1.6	21
842	Synergistic role of HSP90Î± and HSP90Î² to promote myofibroblast persistence in lung fibrosis. European Respiratory Journal, 2018, 51, 1700386.	3.1	41
843	Is It Idiopathic Pulmonary Fibrosis or Not?. Journal of the American Board of Family Medicine, 2018, 31, 151-162.	0.8	21
844	Pulmonary 18F-FDG uptake helps refine current risk stratification in idiopathic pulmonary fibrosis (IPF). European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 806-815.	3.3	60
845	Emerging and potential treatment options for sarcoidosis. Expert Opinion on Orphan Drugs, 2018, 6, 17-33.	0.5	2
846	German Guideline for Idiopathic Pulmonary Fibrosis â€“ Update on Pharmacological Therapies 2017. Pneumologie, 2018, 72, 155-168.	0.1	47
847	Statin Therapy and Outcomes in Trials of Nintedanib in Idiopathic Pulmonary Fibrosis. Respiration, 2018, 95, 317-326.	1.2	42

#	Article	IF	Citations
848	Longitudinal outcomes of patientsÂenrolled in a phase Ib clinical trial of the adiposeâ€derived stromal cellsâ€stromal vascular fraction in idiopathic pulmonary fibrosis. Clinical Respiratory Journal, 2018, 12, 2084-2089.	0.6	37
849	Challenges in Pulmonary Hypertension: Controversies in Treating the Tip of the Iceberg. A Joint National Institutes of Health Clinical Center and Pulmonary Hypertension Association Symposium Report. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 166-174.	2.5	17
850	Trends in mortality from idiopathic pulmonary fibrosis in the European Union: an observational study of the WHO mortality database from 2001â€“2013. European Respiratory Journal, 2018, 51, 1701603.	3.1	69
851	Treprostinil inhibits proliferation and extracellular matrix deposition by fibroblasts through cAMP activation. Scientific Reports, 2018, 8, 1087.	1.6	35
852	The increasing mortality of idiopathic pulmonary fibrosis: fact or fallacy?. European Respiratory Journal, 2018, 51, 1702420.	3.1	33
853	Pulmonary Rehabilitation in Restrictive Thoracic Disorders. , 2018, , 379-390.		1
854	Gene Network Analysis of Interstitial Macrophages After Treatment with Induced Pluripotent Stem Cells Secretome (iPSC-cm) in the Bleomycin Injured Rat Lung. Stem Cell Reviews and Reports, 2018, 14, 412-424.	5.6	14
855	Disease staging and sub setting of interstitial lung disease associated with systemic sclerosis: impact on therapy. Expert Review of Clinical Immunology, 2018, 14, 127-135.	1.3	8
856	Nintedanib for the treatment of idiopathic pulmonary fibrosis. Expert Opinion on Pharmacotherapy, 2018, 19, 167-175.	0.9	53
857	A model of human lung fibrogenesis for the assessment of anti-fibrotic strategies in idiopathic pulmonary fibrosis. Scientific Reports, 2018, 8, 342.	1.6	34
858	Transbronchial Cryobiopsies for the Diagnosis of Diffuse Parenchymal Lung Diseases: Expert Statement from the Cryobiopsy Working Group on Safety and Utility and a Call for Standardization of the Procedure. Respiration, 2018, 95, 188-200.	1.2	273
859	Collagen Biosynthesis in Pulmonary Fibrosis: Unraveling the Metabolic Web. American Journal of Respiratory Cell and Molecular Biology, 2018, 58, 545-546.	1.4	5
860	An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis. Expert Opinion on Emerging Drugs, 2018, 23, 159-172.	1.0	20
861	Associations between comorbidities, their treatment and survival in patients with interstitial lung diseases â€“ a claims data analysis. Respiratory Research, 2018, 19, 73.	1.4	47
862	Sulforaphane attenuates pulmonary fibrosis by inhibiting the epithelial-mesenchymal transition. BMC Pharmacology & Toxicology, 2018, 19, 13.	1.0	69
863	The inhibition of human lung fibroblast proliferation and differentiation by Gs-coupled receptors is not predicted by the magnitude of cAMP response. Respiratory Research, 2018, 19, 56.	1.4	27
864	Therapeutic antibodies: A new era in the treatment of respiratory diseases?. , 2018, 189, 149-172.		32
865	Decoding fibrosis: Mechanisms and translational aspects. Matrix Biology, 2018, 68-69, 1-7.	1.5	31

#	Article	IF	Citations
866	Randomised clinical trial of an early palliative care intervention (SUPPORT) for patients with idiopathic pulmonary fibrosis (IPF) and their caregivers: protocol and key design considerations. BMJ Open Respiratory Research, 2018, 5, e000272.	1.2	28
867	Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth In Vivo. Clinical Cancer Research, 2018, 24, 3729-3740.	3.2	24
868	Safety of nintedanib for treatment of fibrotic lung disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2018, 53, 1218-1220.	1.3	10
869	Nintedanib in Severe Idiopathic Pulmonary Fibrosis: Effectiveness through Compassion. Respiration, 2018, 95, 401-402.	1.2	3
870	Therapeutic Strategies for Interstitial Lung Diseases in Rheumatoid Arthritis. , 2018, , 141-148.		0
871	Safety, tolerability and pharmacokinetics of GSK3008348, a novel integrin Î±vÎ²6 inhibitor, in healthy participants. European Journal of Clinical Pharmacology, 2018, 74, 701-709.	0.8	52
872	Ibrutinib Exacerbates Bleomycin-Induced Pulmonary Fibrosis via Promoting Inflammation. Inflammation, 2018, 41, 904-913.	1.7	13
873	Fibroblastâ€“matrix interplay: Nintedanib and pirfenidone modulate the effect of IPF fibroblastâ€conditioned matrix on normal fibroblast phenotype. Respirology, 2018, 23, 756-763.	1.3	32
874	Chronic Lung Allograft Dysfunction: Evolving Concepts and Therapies. Seminars in Respiratory and Critical Care Medicine, 2018, 39, 155-171.	0.8	37
875	A Real-Life Multicenter National Study on Nintedanib in Severe Idiopathic Pulmonary Fibrosis. Respiration, 2018, 95, 433-440.	1.2	44
876	Treatment of Gastroesophageal Reflux in Patients With Idiopathic Pulmonary Fibrosis. Chest, 2018, 153, 1405-1415.	0.4	44
877	High burden of Aspergillus fumigatus infection among chronic respiratory diseases. Chronic Respiratory Disease, 2018, 15, 279-285.	1.0	13
878	Pulmonary fibrolysis in a patient with idiopathic pulmonary fibrosis: improvement of clinical and radiological pattern after treatment with pirfenidone. Clinical Respiratory Journal, 2018, 12, 347-351.	0.6	2
879	Treatment Rationale and Design for J-SONIC: AÂRandomized Study of Carboplatin Plus Nab-paclitaxel With or Without Nintedanib for Advanced Nonâ€“Small-cell Lung Cancer With Idiopathic Pulmonary Fibrosis. Clinical Lung Cancer, 2018, 19, e5-e9.	1.1	44
880	Epithelialâ€“mesenchymal transition, a spectrum of states: Role in lung development, homeostasis, and disease. Developmental Dynamics, 2018, 247, 346-358.	0.8	190
881	Outcome of lung transplantation in idiopathic pulmonary fibrosis with previous anti-fibrotic therapy. Journal of Heart and Lung Transplantation, 2018, 37, 268-274.	0.3	40
882	Anti-fibrotic nintedanibâ€”a new opportunity for systemic sclerosis patients?. Clinical Rheumatology, 2018, 37, 1123-1127.	1.0	10
883	Treatment doses in idiopathic pulmonary fibrosis: The devil is in the detail. Respirology, 2018, 23, 244-245.	1.3	3

#	Article	IF	Citations
884	Reduced incidence of lung cancer in patients with idiopathic pulmonary fibrosis treated with pirfenidone. Respiratory Investigation, 2018, 56, 72-79.	0.9	52
885	Reversal of lung fibrosis: an unexpected finding in survivor of acute respiratory distress syndrome. QJM - Monthly Journal of the Association of Physicians, 2018, 111, 47-48.	0.2	6
886	Seeing Deeply into the Lung in Interstitial Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 857-858.	2.5	0
887	Cellâ€specific expression of runtâ€related transcription factor 2 contributes to pulmonary fibrosis. FASEB Journal, 2018, 32, 703-716.	0.2	28
888	Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension. Thorax, 2018, 73, 581-583.	2.7	59
889	EMPIRE Registry, Czech Part: Impact of demographics, pulmonary function and HRCT on survival and clinical course in idiopathic pulmonary fibrosis. Clinical Respiratory Journal, 2018, 12, 1526-1535.	0.6	55
890	Using hyperpolarized ¹²⁹Xe MRI to quantify regional gas transfer in idiopathic pulmonary fibrosis. Thorax, 2018, 73, 21-28.	2.7	110
891	Do Randomized Clinical Trials Always Provide Certain Results? The Case of Tralokinumab in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 9-10.	2.5	6
892	Body sizeâ€adjusted dose analysis of pirfenidone in patients with interstitial pneumonia. Respirology, 2018, 23, 318-324.	1.3	27
893	Formulation for a novel inhaled peptide therapeutic for idiopathic pulmonary fibrosis. Drug Development and Industrial Pharmacy, 2018, 44, 184-198.	0.9	7
894	Interstitial lung disease in the connective tissue diseases; a paradigm shift in diagnosis and treatment. Clinical Immunology, 2018, 186, 71-73.	1.4	9
895	Endobronchial Optical Coherence Tomography for Low-Risk Microscopic Assessment and Diagnosis of Idiopathic Pulmonary Fibrosis In Vivo. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 949-952.	2.5	40
896	Prediction of survival by texture-based automated quantitative assessment of regional disease patterns on CT in idiopathic pulmonary fibrosis. European Radiology, 2018, 28, 1293-1300.	2.3	35
897	Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 356-363.	2.5	193
898	Molecular Diagnosis and Targeting for Lung Cancer. Current Human Cell Research and Applications, 2018, , 1-32.	0.1	0
899	A Phase II Clinical Trial of Low-Dose Inhaled Carbon Monoxide in Idiopathic Pulmonary Fibrosis. Chest, 2018, 153, 94-104.	0.4	66
901	PD-1/PD-L1 Pathway Mediates the Alleviation of Pulmonary Fibrosis by Human Mesenchymal Stem Cells in Humanized Mice. American Journal of Respiratory Cell and Molecular Biology, 2018, 58, 684-695.	1.4	73
902	Screening for Lung Cancer: Incidental Pulmonary Parenchymal Findings. American Journal of Roentgenology, 2018, 210, 503-513.	1.0	22

#	Article	IF	Citations
903	Patients with IPF and lung cancer: diagnosis and management. Lancet Respiratory Medicine,the, 2018, 6, 86-88.	5.2	67
904	Computer-based quantitative computed tomography image analysis in idiopathic pulmonary fibrosis: A mini review. Respiratory Investigation, 2018, 56, 5-13.	0.9	31
905	Unfavourable outcome of glucocorticoid treatment in suspected idiopathic pulmonary fibrosis. Respirology, 2018, 23, 311-317.	1.3	13
906	Efficacy and Safety of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis: An Update. Drugs in R and D, 2018, 18, 19-25.	1.1	37
907	The Rho Kinase Isoforms ROCK1 and ROCK2 Each Contribute to the Development of Experimental Pulmonary Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2018, 58, 471-481.	1.4	86
908	Reliability and Minimal Clinically Important Differences of FVC. Results from the Scleroderma Lung Studies (SLS-I and SLS-II). American Journal of Respiratory and Critical Care Medicine, 2018, 197, 644-652.	2.5	77
909	Pharmacokinetics of Nintedanib in Subjects With Hepatic Impairment. Journal of Clinical Pharmacology, 2018, 58, 357-363.	1.0	21
910	Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. Lancet Respiratory Medicine,the, 2018, 6, 138-153.	5.2	739
911	CT Features of the Usual Interstitial Pneumonia Pattern: Differentiating Connective Tissue Diseaseâ€"Associated Interstitial Lung Disease From Idiopathic Pulmonary Fibrosis. American Journal of Roentgenology, 2018, 210, 307-313.	1.0	98
912	The prognostic significance of pneumothorax in patients with idiopathic pulmonary fibrosis. Respirology, 2018, 23, 519-525.	1.3	35
913	Lysyl Oxidaseâ€"Like 1 Protein Deficiency Protects Mice from Adenoviral Transforming Growth Factor-Î²1â€"induced Pulmonary Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2018, 58, 461-470.	1.4	44
914	Population pharmacokinetics of nintedanib, an inhibitor of tyrosine kinases, in patients with non-small cell lung cancer or idiopathic pulmonary fibrosis. Cancer Chemotherapy and Pharmacology, 2018, 81, 89-101.	1.1	14
915	Clinical experience in idiopathic pulmonary fibrosis: a retrospective study. Acta Clinica Belgica, 2018, 73, 139-143.	0.5	9
916	Population pharmacokinetics of nintedanib in patients with idiopathic pulmonary fibrosis. Pulmonary Pharmacology and Therapeutics, 2018, 48, 136-143.	1.1	17
917	Highly Selective Endothelin-1 Receptor A Inhibition Prevents Bleomycin-Induced Pulmonary Inflammation and Fibrosis in Mice. Respiration, 2018, 95, 122-136.	1.2	14
918	Exposure to Ambient Particulate Matter Is Associated With Accelerated Functional Decline in Idiopathic Pulmonary Fibrosis. Chest, 2018, 153, 1221-1228.	0.4	116
919	Increased Expiratory Computed Tomography Density Reveals Possible Abnormalities in Radiologically Preserved Lung Parenchyma in Idiopathic Pulmonary Fibrosis. Investigative Radiology, 2018, 53, 45-51.	3.5	13
920	A Phase 2 Randomized Controlled Study of Tralokinumab in Subjects with Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 94-103.	2.5	95

#	Article	IF	Citations
921	Pathobiology of Novel Approaches to Treatment. , 2018, , 25-37.		0
922	Idiopathic Interstitial Pneumonias. , 2018, , 327-346.e1.		0
923	Triple kinase inhibitor with phosphodiesterase-5 inhibitor for idiopathic pulmonary fibrosis. Journal of Thoracic Disease, 2018, 10, 5974-5978.	0.6	2
924	Lung cancer and interstitial lung disease: a literature review. Journal of Thoracic Disease, 2018, 10, 3829-3844.	0.6	126
925	NeumonÃas intersticiales idiopÃ¡ticas. Medicine, 2018, 12, 3917-3928.	0.0	1
926	Idiopathic Pulmonary Fibrosis-Unknown Cause, Global Occurrence and New Medical Possibilities. Internal Medicine: Open Access, 2018, 08, .	0.0	0
927	Palliative and End-of-Life Care in Idiopathic Pulmonary Fibrosis. , 2018, , 97-106.		0
928	Acute Exacerbations in Patients With Idiopathic Pulmonary Fibrosis. , 2018, , 131-139.		1
929	Des essais cliniques nÃ©gatifs et des molÃ©cules prometteuses : le point sur les nouvelles thÃ©rapeutiques de la fibrose pulmonaire idiopathique. Revue Des Maladies Respiratoires Actualites, 2018, 10, 108-113.	0.0	0
932	Transbronchiale Kryobiopsien in der Diagnostik diffuser interstitieller Lungenerkrankungen: Sicherheit, Einsetzbarkeit und Standardisierung des Verfahrens. Karger Kompass Pneumologie, 2018, 6, 91-92.	0.0	0
933	Quantitative CT analysis using functional imaging is superior in describing disease progression in idiopathic pulmonary fibrosis compared to forced vital capacity. Respiratory Research, 2018, 19, 213.	1.4	24
934	Idiopathic Pulmonary Fibrosis Is a Genetic Disease Involving Mucus and the Peripheral Airways. Annals of the American Thoracic Society, 2018, 15, S192-S197.	1.5	40
935	A standardized herbal extract PM014 ameliorates pulmonary fibrosis by suppressing the TGF-Î²1 pathway. Scientific Reports, 2018, 8, 16860.	1.6	17
936	The Role of TGF-Î² Signaling in Lung Cancer Associated with Idiopathic Pulmonary Fibrosis. International Journal of Molecular Sciences, 2018, 19, 3611.	1.8	66
937	Delay and inequalities in the treatment of idiopathic pulmonary fibrosis: the case of two Nordic countries. Multidisciplinary Respiratory Medicine, 2018, 13, 14.	0.6	22
938	Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis. PLoS ONE, 2018, 13, e0207915.	1.1	38
939	Interstitial Lung Disease and Pulmonary Fibrosis: A Practical Approach for General Medicine Physicians with Focus on the Medical History. Journal of Clinical Medicine, 2018, 7, 476.	1.0	51
940	Marked deterioration in the quality of life of patients with idiopathic pulmonary fibrosis during the last two years of life. BMC Pulmonary Medicine, 2018, 18, 172.	0.8	38

#	Article	IF	Citations
941	Pirfenidone improves survival in IPF: results from a real-life study. BMC Pulmonary Medicine, 2018, 18, 177.	0.8	65
942	Management of Idiopathic Pulmonary Fibrosis. , 2018, , 55-63.		1
943	Psychometric properties of the St Georgeâ€™s Respiratory Questionnaire in patients with idiopathic pulmonary fibrosis: insights from the INPULSIS trials. BMJ Open Respiratory Research, 2018, 5, e000278.	1.2	54
944	Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice. ERJ Open Research, 2018, 4, 00049-2018.	1.1	24
945	Healthcare utilisation and costs in the diagnosis and treatment of progressive-fibrosing interstitial lung diseases. European Respiratory Review, 2018, 27, 180078.	3.0	20
946	A high bioavailability and sustained-release nano-delivery system for nintedanib based on electrospray technology. International Journal of Nanomedicine, 2018, Volume 13, 8379-8393.	3.3	32
947	Baseline clinical characteristics, comorbidities and prescribed medication in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry. BMJ Open Respiratory Research, 2018, 5, e000331.	1.2	42
948	Utility of the six-minute walk test in patients with idiopathic pulmonary fibrosis. Multidisciplinary Respiratory Medicine, 2018, 13, 45.	0.6	34
949	Pharmacological management of progressive-fibrosing interstitial lung diseases: a review of the current evidence. European Respiratory Review, 2018, 27, 180074.	3.0	73
950	Systematic review of content and quality of idiopathic pulmonary fibrosis review articles. ERJ Open Research, 2018, 4, 00156-2018.	1.1	2
951	Blockade of platelet-derived growth factor receptor-Î², not receptor-Î± ameliorates bleomycin-induced pulmonary fibrosis in mice. PLoS ONE, 2018, 13, e0209786.	1.1	46
952	Southâ€“West of Englandâ€™s Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF). Frontiers in Pharmacology, 2018, 9, 1480.	1.6	34
953	Acute exacerbations of progressive-fibrosing interstitial lung diseases. European Respiratory Review, 2018, 27, 180071.	3.0	109
954	Patients' perceptions and patient-reported outcomes in progressive-fibrosing interstitial lung diseases. European Respiratory Review, 2018, 27, 180075.	3.0	45
955	Current Status and Future Opportunities in Lung Precision Medicine Research with a Focus on Biomarkers. An American Thoracic Society/National Heart, Lung, and Blood Institute Research Statement. American Journal of Respiratory and Critical Care Medicine, 2018, 198, e116-e136.	2.5	49
956	Targeting interleukin-13 in idiopathic pulmonary fibrosis: from promising path to dead end. European Respiratory Journal, 2018, 52, 1802111.	3.1	23
957	Idiopathic Pulmonary Fibrosis: Epidemiology, Natural History, Phenotypes. Medical Sciences (Basel,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.3	68
958	Unraveling SSc Pathophysiology; The Myofibroblast. Frontiers in Immunology, 2018, 9, 2452.	2.2	103

#	Article	IF	Citations
959	Idiopathic Pulmonary Fibrosis. Chest, 2018, 154, 1359-1370.	0.4	44
960	Impact of novel antifibrotic therapy on patient outcomes in idiopathic pulmonary fibrosis: patient selection and perspectives. Patient Related Outcome Measures, 2018, Volume 9, 321-328.	0.7	33
961	A Volumetric Computed Tomography Analysis of the Normal Lung in Idiopathic Pulmonary Fibrosis: The Relationship with the Survival. Internal Medicine, 2018, 57, 929-937.	0.3	5
962	Comprehensive management of fibrotic interstitial lung diseases: A Canadian Thoracic Society position statement. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2018, 2, 234-243.	0.2	8
963	Mitochondrial dysfunction contributes to the senescent phenotype of <scp>IPF</scp> lung fibroblasts. Journal of Cellular and Molecular Medicine, 2018, 22, 5847-5861.	1.6	65
964	Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience. Therapeutic Advances in Respiratory Disease, 2018, 12, 175346661880061.	1.0	59
965	Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trial. BMJ Open Respiratory Research, 2018, 5, e000289.	1.2	48
966	Nintedanib prevented fibrosis progression and lung cancer growth in idiopathic pulmonary fibrosis. Respirology Case Reports, 2018, 6, e00363.	0.3	18
967	Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial of BMS-986020, a Lysophosphatidic Acid Receptor Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis. Chest, 2018, 154, 1061-1069.	0.4	140
968	Short and long-term effects of pulmonary rehabilitation in interstitial lung diseases: a randomised controlled trial. Respiratory Research, 2018, 19, 182.	1.4	85
969	Endothelial Colony-Forming Cells Do Not Participate to Fibrogenesis in a Bleomycin-Induced Pulmonary Fibrosis Model in Nude Mice. Stem Cell Reviews and Reports, 2018, 14, 812-822.	5.6	12
970	Characteristics of lung cancer among patients with idiopathic pulmonary fibrosis and interstitial lung disease â€“ analysis of institutional and population data. Respiratory Research, 2018, 19, 195.	1.4	49
972	New era of Idiopathic Pulmonary Fibrosis. Respiratory Investigation, 2018, 56, 427-429.	0.9	2
973	Diagnosis of Idiopathic Pulmonary Fibrosis in a Possible Usual Interstitial Pneumonia Pattern: a meta-analysis. Scientific Reports, 2018, 8, 15886.	1.6	6
974	Antifibrotic effects of a novel pirfenidone derivative in vitro and in vivo. Pulmonary Pharmacology and Therapeutics, 2018, 53, 100-106.	1.1	12
975	Utility of nintedanib for severe idiopathic pulmonary fibrosis: a single-center retrospective study. Drug Design, Development and Therapy, 2018, Volume 12, 3369-3375.	2.0	19
976	Connective Tissue Related Interstitial Lung Disease. Current Pulmonology Reports, 2018, 7, 133-148.	0.5	0
977	Imaging biomarkers and staging in IPF. Current Opinion in Pulmonary Medicine, 2018, 24, 445-452.	1.2	16

#	Article	IF	Citations
978	Approved and Experimental Therapies for Idiopathic Pulmonary Fibrosis. Current Pulmonology Reports, 2018, 7, 107-117.	0.5	2
979	SAR156597 in idiopathic pulmonary fibrosis: a phase 2 placebo-controlled study (DRI11772). European Respiratory Journal, 2018, 52, 1801130.	3.1	59
980	MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease. New England Journal of Medicine, 2018, 379, 2209-2219.	13.9	326
981	Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis. Respiratory Research, 2018, 19, 203.	1.4	57
982	Risk Factors for the Development of Idiopathic Pulmonary Fibrosis: a Review. Current Pulmonology Reports, 2018, 7, 118-125.	0.5	46
983	Recent progress in systemic sclerosis-interstitial lung disease. Current Opinion in Rheumatology, 2018, 30, 570-575.	2.0	8
984	Lung Transplantation in Interstitial Lung Disease. , 2018, , 107-119.		0
985	Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis. New England Journal of Medicine, 2018, 379, 1722-1731.	13.9	207
986	Differential effects of Nintedanib and Pirfenidone on lung alveolar epithelial cell function in ex vivo murine and human lung tissue cultures of pulmonary fibrosis. Respiratory Research, 2018, 19, 175.	1.4	90
987	Diagnosis of Idiopathic Pulmonary Fibrosis: Differential Diagnosis. Medical Sciences (Basel,) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T	1.3	26
988	Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial. Lancet Respiratory Medicine,the, 2018, 6, 759-770.	5.2	145
989	Ambulatory oxygen and quality of life in interstitial lung disease. Lancet Respiratory Medicine,the, 2018, 6, 730-731.	5.2	1
990	Diffuse Parenchymal Lung Diseases in the Elderly. Current Geriatrics Reports, 2018, 7, 174-180.	1.1	0
991	Emodin Attenuates Bleomycin-Induced Pulmonary Fibrosis via Anti-Inflammatory and Anti-Oxidative Activities in Rats. Medical Science Monitor, 2018, 24, 1-10.	0.5	61
992	Identification of MMP28 as a biomarker for the differential diagnosis of idiopathic pulmonary fibrosis. PLoS ONE, 2018, 13, e0203779.	1.1	19
993	Carcinoembryonic antigen predicts waitlist mortality in lung transplant candidates with idiopathic pulmonary fibrosis. European Journal of Cardio-thoracic Surgery, 2018, 54, 847-852.	0.6	6
994	Anti-Fibrotic Therapies from Other Organs: What the Gut Can Learn from the Liver, Skin, Lung and Heart. , 2018, , 347-385.		0
995	Investigating the effects of nintedanib on biomarkers of extracellular matrix turnover in patients with IPF: design of the randomised placebo-controlled INMARKÂ®trial. BMJ Open Respiratory Research, 2018, 5, e000325.	1.2	14

#	Article	IF	Citations
996	Recommendations for evaluating and managing idiopathic pulmonary fibrosis. JAAPA: Official Journal of the American Academy of Physician Assistants, 2018, 31, 21-26.	0.1	7
997	Anti-acid therapy in idiopathic pulmonary fibrosis: insights from the INPULSISÂ® trials. Respiratory Research, 2018, 19, 167.	1.4	42
998	Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2018, 198, e44-e68.	2.5	2,678
999	Disparities in pulmonary fibrosis care in the United States: an analysis from the Nationwide Inpatient Sample. BMC Health Services Research, 2018, 18, 618.	0.9	19
1000	FGF21 attenuates pulmonary fibrogenesis through ameliorating oxidative stress in vivo and in vitro. Biomedicine and Pharmacotherapy, 2018, 103, 1516-1525.	2.5	35
1001	The Lung in Rheumatoid Arthritis. Arthritis and Rheumatology, 2018, 70, 1544-1554.	2.9	198
1002	C-proSP-B: A Possible Biomarker for Pulmonary Diseases?. Respiration, 2018, 96, 117-126.	1.2	15
1003	Visual analogue scales for interstitial lung disease: a prospective validation study. QJM - Monthly Journal of the Association of Physicians, 2018, 111, 531-539.	0.2	15
1004	Pulmonary function tests as outcomes for systemic sclerosis interstitial lung disease. European Respiratory Review, 2018, 27, 170102.	3.0	53
1005	Optimising experimental research in respiratory diseases: an ERS statement. European Respiratory Journal, 2018, 51, 1702133.	3.1	98
1006	Emerging multitarget tyrosine kinase inhibitors in the treatment of neuroendocrine neoplasms. Endocrine-Related Cancer, 2018, 25, R453-R466.	1.6	39
1007	Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis in the USA. European Respiratory Journal, 2018, 52, 1702106.	3.1	28
1008	Fibrotic microtissue array to predict anti-fibrosis drug efficacy. Nature Communications, 2018, 9, 2066.	5.8	102
1009	What's in a name? That which we call IPF, by any other name would act the same. European Respiratory Journal, 2018, 51, 1800692.	3.1	226
1010	Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis. JAMA - Journal of the American Medical Association, 2018, 319, 2299.	3.8	170
1011	Clinical Trials in Idiopathic Pulmonary Fibrosis in the â€œPosttreatment Eraâ€• JAMA - Journal of the American Medical Association, 2018, 319, 2275.	3.8	7
1012	Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial. Lancet Respiratory Medicine,the, 2018, 6, 627-635.	5.2	173
1013	Heterogeneity in Unclassifiable Interstitial Lung Disease. A Systematic Review and Meta-Analysis. Annals of the American Thoracic Society, 2018, 15, 854-863.	1.5	74

#	Article	IF	Citations
1014	Systemic sclerosis phase III clinical trials: Hope on the horizon?. Journal of Scleroderma and Related Disorders, 2018, 3, 193-200.	1.0	5
1015	The Importance of Tyrosine Phosphorylation Control of Cellular Signaling Pathways in Respiratory Disease: pY and pY Not. American Journal of Respiratory Cell and Molecular Biology, 2018, 59, 535-547.	1.4	13
1016	Economic consequences of idiopathic pulmonary fibrosis in Denmark. ERJ Open Research, 2018, 4, 00045-2017.	1.1	4
1017	Acquired platelet antagonism: offâ€target antiplatelet effects of malignancy treatment with tyrosine kinase inhibitors. Journal of Thrombosis and Haemostasis, 2018, 16, 1686-1699.	1.9	29
1018	Role of pericytes in vascular immunosurveillance. Frontiers in Bioscience - Landmark, 2018, 23, 767-781.	3.0	24
1019	Targeting the Myofibroblast in Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 834-835.	2.5	13
1020	Phosphodiesterase 4 inhibition reduces lung fibrosis following targeted type II alveolar epithelial cell injury. Physiological Reports, 2018, 6, e13753.	0.7	35
1021	Quercetin ameliorates pulmonary fibrosis by inhibiting SphK1/S1P signaling. Biochemistry and Cell Biology, 2018, 96, 742-751.	0.9	45
1022	Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis. European Respiratory Journal, 2018, 52, 1800230.	3.1	95
1023	Stability or improvement in forced vital capacity with nintedanib in patients with idiopathic pulmonary fibrosis. European Respiratory Journal, 2018, 52, 1702593.	3.1	29
1024	Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trials. Lancet Respiratory Medicine,the, 2018, 6, 615-626.	5.2	87
1025	Effects of panax notoginseng saponin on the pathological ultrastructure and serum ILâ€6 and ILâ€8 in pulmonary fibrosis in rabbits. Journal of Cellular Biochemistry, 2018, 119, 8410-8418.	1.2	15
1026	Efficacy and Tolerability of High-Flow Nasal Cannula Oxygen Therapy for Hypoxemic Respiratory Failure in Patients with Interstitial Lung Disease with Do-Not-Intubate Orders: A Retrospective Single-Center Study. Respiration, 2018, 96, 323-329.	1.2	63
1027	Dasatinib Suppresses TGFÎ²-Mediated Epithelialâ€“Mesenchymal Transition in Alveolar Epithelial Cells and Inhibits Pulmonary Fibrosis. Lung, 2018, 196, 531-541.	1.4	18
1028	Diagnosis and management of idiopathic pulmonary fibrosis: Thoracic Society of Australia and New Zealand and Lung Foundation Australia position statements summary. Medical Journal of Australia, 2018, 208, 82-88.	0.8	13
1029	Improvement in Patient-Reported Outcomes and Forced Vital Capacity during Nintedanib Treatment of Idiopathic Pulmonary Fibrosis. Tohoku Journal of Experimental Medicine, 2018, 245, 107-114.	0.5	5
1030	Fibroblast senescence in the pathology of idiopathic pulmonary fibrosis. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2018, 315, L162-L172.	1.3	114
1031	Casein Kinase 1Î´/Îµ Inhibitor, PF670462 Attenuates the Fibrogenic Effects of Transforming Growth Factor-Î² in Pulmonary Fibrosis. Frontiers in Pharmacology, 2018, 9, 738.	1.6	28

#	Article	IF	Citations
1032	Adaptive Fibrogenic Reprogramming of Osteosarcoma Stem Cells Promotes Metastatic Growth. Cell Reports, 2018, 24, 1266-1277.e5.	2.9	32
1033	New treatment paradigms for connective tissue disease-associated interstitial lung disease. Current Opinion in Pulmonary Medicine, 2018, 24, 453-460.	1.2	10
1034	Unclassifiable interstitial lung disease. Current Opinion in Pulmonary Medicine, 2018, 24, 461-468.	1.2	15
1035	Nintedanib reduces pulmonary fibrosis in a model of rheumatoid arthritis-associated interstitial lung disease. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2018, 314, L998-L1009.	1.3	63
1036	Treating heart failure with preserved ejection fraction: learning from pulmonary fibrosis. European Journal of Heart Failure, 2018, 20, 1385-1391.	2.9	38
1037	An Adaptogen: Withaferin A Ameliorates in Vitro and in Vivo Pulmonary Fibrosis by Modulating the Interplay of Fibrotic, Matricelluar Proteins, and Cytokines. Frontiers in Pharmacology, 2018, 9, 248.	1.6	53
1038	Amifostine Analog, DRDE-30, Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice. Frontiers in Pharmacology, 2018, 9, 394.	1.6	13
1039	Proton Pump Inhibitors in IPF: A Call for Clinical Trials. Frontiers in Pharmacology, 2018, 9, 499.	1.6	15
1040	Interstitial Pneumonia With Autoimmune Features. Arthritis and Rheumatology, 2018, 70, 1901-1913.	2.9	38
1041	Impact of mediastinal lymph node enlargement on the prognosis of idiopathic pulmonary fibrosis. PLoS ONE, 2018, 13, e0201154.	1.1	9
1042	<scp>FDA</scp> Breakthrough Therapy Designation: Evaluating the Quality of the Evidence behind the Drug Approvals. Pharmacotherapy, 2018, 38, 967-980.	1.2	9
1043	Cell division cycle 7 kinase is a negative regulator of cell-mediated collagen degradation. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2018, 315, L360-L370.	1.3	3
1044	Tissue and Bronchoalveolar Lavage Biomarkers in Idiopathic Pulmonary Fibrosis Patients on Pirfenidone. Lung, 2018, 196, 543-552.	1.4	13
1045	Idiopathic pulmonary fibrosis: time for greater expectations?. European Respiratory Journal, 2018, 52, 1801312.	3.1	2
1046	The Role of Immune and Inflammatory Cells in Idiopathic Pulmonary Fibrosis. Frontiers in Medicine, 2018, 5, 43.	1.2	216
1047	Clinical Genetics in Interstitial Lung Disease. Frontiers in Medicine, 2018, 5, 116.	1.2	19
1048	Mesenchymal Stem Cells for the Treatment of Idiopathic Pulmonary Fibrosis. Frontiers in Medicine, 2018, 5, 142.	1.2	60
1049	Management of acute respiratory failure in interstitial lung diseases: overview and clinical insights. BMC Pulmonary Medicine, 2018, 18, 70.	0.8	53

#	Article	IF	Citations
1051	SIS3, a specific inhibitor of smad3, attenuates bleomycin-induced pulmonary fibrosis in mice. Biochemical and Biophysical Research Communications, 2018, 503, 757-762.	1.0	21
1052	Japanese guideline for the treatment of idiopathic pulmonary fibrosis. Respiratory Investigation, 2018, 56, 268-291.	0.9	72
1053	Macitentan reduces progression of TGF-Î²1-induced pulmonary fibrosis andÂpulmonary hypertension. European Respiratory Journal, 2018, 52, 1701857.	3.1	46
1054	Reducing protein oxidation reverses lung fibrosis. Nature Medicine, 2018, 24, 1128-1135.	15.2	88
1055	Pirfenidone suppresses polarization to M2 phenotype macrophages and the fibrogenic activity of rat lung fibroblasts. Journal of Clinical Biochemistry and Nutrition, 2018, 63, 58-65.	0.6	31
1056	The Role of the Mammalian Target of Rapamycin (mTOR) in Pulmonary Fibrosis. International Journal of Molecular Sciences, 2018, 19, 778.	1.8	129
1057	VEGF (Vascular Endothelial Growth Factor) and Fibrotic Lung Disease. International Journal of Molecular Sciences, 2018, 19, 1269.	1.8	75
1058	Novel formononetin-7-sal ester ameliorates pulmonary fibrosis via MEF2c signaling pathway. Toxicology and Applied Pharmacology, 2018, 356, 15-24.	1.3	10
1059	Mesenchymal Stem Cell Therapy of Pulmonary Fibrosis. Cell Transplantation, 2018, 27, 1581-1587.	1.2	41
1060	LTBP2 is secreted from lung myofibroblasts and is a potential biomarker for idiopathic pulmonary fibrosis. Clinical Science, 2018, 132, 1565-1580.	1.8	37
1061	Treatment of Interstitial Lung Disease Associated Cough. Chest, 2018, 154, 904-917.	0.4	50
1062	Metformin Does Not Affect Clinically Relevant Outcomes in Patients with Idiopathic Pulmonary Fibrosis. Respiration, 2018, 96, 314-322.	1.2	41
1063	The Management of Patients With Idiopathic Pulmonary Fibrosis. Frontiers in Medicine, 2018, 5, 148.	1.2	42
1064	Idiopathic pulmonary fibrosis: pathogenesis and management. Respiratory Research, 2018, 19, 32.	1.4	339
1065	Barriers to timely diagnosis of interstitial lung disease in the real world: the INTENSITY survey. BMC Pulmonary Medicine, 2018, 18, 9.	0.8	112
1066	Management and attitudes about IPF (Idiopathic Pulmonary Fibrosis) among physicians from Latin America. BMC Pulmonary Medicine, 2018, 18, 5.	0.8	9
1067	Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry. BMC Pulmonary Medicine, 2018, 18, 19.	0.8	58
1068	Acute exacerbation of idiopathic pulmonary fibrosis: lessons learned from acute respiratory distress syndrome?. Critical Care, 2018, 22, 80.	2.5	66

#	Article	IF	Citations
1069	The Efficacy and Mechanism Evaluation of Treating Idiopathic Pulmonary fibrosis with the Addition of Co-trimoxazole (EME-TIPAC): study protocol for a randomised controlled trial. Trials, 2018, 19, 89.	0.7	19
1070	Pneumatosis Intestinalis Associated with the Tyrosine Kinase Inhibitor Nintedanib. Lung, 2018, 196, 373-375.	1.4	5
1072	Pneumopathies interstitielles diffuses au cours de la polyarthrite rhumatoÃ¯de. Revue Du Rhumatisme Monographies, 2018, 85, 153-159.	0.0	0
1073	Epithelial cell-derived cytokines CST3 and GDF15 as potential therapeutics for pulmonary fibrosis. Cell Death and Disease, 2018, 9, 506.	2.7	27
1074	N-acetylcysteine exposure is associated with improved survival in anti-nuclear antibody seropositive patients with usual interstitial pneumonia. BMC Pulmonary Medicine, 2018, 18, 30.	0.8	5
1075	Idiopathic Pulmonary Fibrosis. New England Journal of Medicine, 2018, 378, 1811-1823.	13.9	1,177
1076	Comprehensive gene expression profiling identifies distinct and overlapping transcriptional profiles in non-specific interstitial pneumonia and idiopathic pulmonary fibrosis. Respiratory Research, 2018, 19, 153.	1.4	66
1077	Synthesis and anti-fibrosis activity study of 14-deoxyandrographolide-19-oic acid and 14-deoxydidehydroandrographolide-19-oic acid derivatives. European Journal of Medicinal Chemistry, 2018, 157, 805-816.	2.6	8
1078	Mechanisms and consequences of oxidative stress in lung disease: therapeutic implications for an aging populace. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2018, 314, L642-L653.	1.3	95
1079	Feifukang ameliorates pulmonary fibrosis by inhibiting JAK-STAT signaling pathway. BMC Complementary and Alternative Medicine, 2018, 18, 234.	3.7	20
1080	Greater cellular stiffness in fibroblasts from patients with idiopathic pulmonary fibrosis. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2018, 315, L59-L65.	1.3	37
1081	Interpretation of HRCT Scans in the Diagnosis of IPF: Improving Communication Between Pulmonologists and Radiologists. Lung, 2018, 196, 561-567.	1.4	13
1082	Novel management strategies for idiopathic pulmonary fibrosis. Expert Review of Respiratory Medicine, 2018, 12, 831-842.	1.0	9
1083	Idiopathic Pulmonary Fibrosis and Antifibrotic Treatments: Focus on Experimental Studies. Archives of Pathology and Laboratory Medicine, 2018, 142, 1090-1097.	1.2	6
1084	ILDgenDB: integrated genetic knowledge resource for interstitial lung diseases (ILDs). Database: the Journal of Biological Databases and Curation, 2018, 2018, .	1.4	2
1085	Cell Therapy in Idiopathic Pulmonary Fibrosisâ€. Medical Sciences (Basel, Switzerland), 2018, 6, 64.	1.3	17
1086	LEM domainâ€“containing protein 3 antagonizes TGFÎ²â€“SMAD2/3 signaling in a stiffness-dependent manner in both the nucleus and cytosol. Journal of Biological Chemistry, 2018, 293, 15867-15886.	1.6	20
1087	Lung cancer in idiopathic pulmonary fibrosis: A systematic review and meta-analysis. PLoS ONE, 2018, 13, e0202360.	1.1	47

#	Article	IF	Citations
1088	Protective Effects of Nintedanib against Polyhexamethylene Guanidine Phosphate-Induced Lung Fibrosis in Mice. Molecules, 2018, 23, 1974.	1.7	19
1089	Idiopathic Pulmonary Fibrosis (IPF): An Overview. Journal of Clinical Medicine, 2018, 7, 201.	1.0	215
1090	Laparoscopic anti-reflux surgery for the treatment of idiopathic pulmonary fibrosis (WRAP-IPF): a multicentre, randomised, controlled phase 2 trial. Lancet Respiratory Medicine,the, 2018, 6, 707-714.	5.2	109
1091	Palliative and end of life care in idiopathic pulmonary fibrosis. Primary Health Care, 2018, 28, 27-35.	0.0	1
1092	Fibroblast growth factor 2 decreases bleomycinâ€induced pulmonary fibrosis and inhibits fibroblast collagen production and myofibroblast differentiation. Journal of Pathology, 2018, 246, 54-66.	2.1	65
1093	Clinical behaviour of patients exposed to organic dust and diagnosed with idiopathic pulmonary fibrosis. Respirology, 2018, 23, 1160-1165.	1.3	19
1094	Use of zonal distribution of lung crackles during inspiration and expiration to assess disease severity in idiopathic pulmonary fibrosis. Postgraduate Medical Journal, 2018, 94, 381-385.	0.9	5
1095	Clinical spectrum and prognostic factors of possible UIP pattern on high-resolution CT in patients who underwent surgical lung biopsy. PLoS ONE, 2018, 13, e0193608.	1.1	13
1096	An expert consensus to standardise definitions, diagnosis and treatment targets for antiâ€fibrotic stricture therapies in Crohn's disease. Alimentary Pharmacology and Therapeutics, 2018, 48, 347-357.	1.9	157
1097	Mortality in interstitial lung disease: do race and skin colour matter?. European Respiratory Journal, 2018, 51, 1800892.	3.1	3
1098	Analysis of protein-altering variants in telomerase genes and their association with MUC5B common variant status in patients with idiopathic pulmonary fibrosis: a candidate gene sequencing study. Lancet Respiratory Medicine,the, 2018, 6, 603-614.	5.2	133
1099	Assessment of Interstitial Lung Disease Using Lung Ultrasound Surface Wave Elastography. Journal of Thoracic Imaging, 2019, 34, 313-319.	0.8	28
1100	Influence of Idiopathic Pulmonary Fibrosis Progression on Healthcare Resource Use. PharmacoEconomics - Open, 2019, 3, 81-91.	0.9	2
1101	Developmental pathways in the pathogenesis of lung fibrosis. Molecular Aspects of Medicine, 2019, 65, 56-69.	2.7	284
1102	Mitogen-activated Protein Kinaseâ€“activated Protein Kinase 2 Inhibition Attenuates Fibroblast Invasion and Severe Lung Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2019, 60, 41-48.	1.4	18
1103	Effects of emphysema on physiological and prognostic characteristics of lung function in idiopathic pulmonary fibrosis. Respirology, 2019, 24, 55-62.	1.3	24
1104	Histopathological and molecular analysis of idiopathic pulmonary fibrosis lungs from patients treated with pirfenidone or nintedanib. Histopathology, 2019, 74, 341-349.	1.6	20
1105	Comparing effectiveness of prognostic tests in idiopathic pulmonary fibrosis. Expert Review of Respiratory Medicine, 2019, 13, 993-1004.	1.0	5

#	Article	IF	Citations
1106	Progressive fibrosing interstitial lung disease associated with systemic autoimmune diseases. Clinical Rheumatology, 2019, 38, 2673-2681.	1.0	38
1107	New Therapies for the Treatment of Renal Fibrosis. Advances in Experimental Medicine and Biology, 2019, 1165, 625-659.	0.8	32
1108	Current and EmergingÂDrug Therapies for Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD). Drugs, 2019, 79, 1511-1528.	4.9	35
1111	Outcomes following decline in forced vital capacity in patients with idiopathic pulmonary fibrosis: Results from the INPULSIS and INPULSIS-ON trials of nintedanib. Respiratory Medicine, 2019, 156, 20-25.	1.3	22
1112	Choice of Methodology Impacts Outcome in Indirect Comparisons of Drugs for Idiopathic Pulmonary Fibrosis. Medicina (Lithuania), 2019, 55, 443.	0.8	1
1113	Defining a pathological role for the vasculature in the development of fibrosis and pulmonary hypertension in interstitial lung disease. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2019, 317, L431-L433.	1.3	9
1115	Transbronchial Lung Cryobiopsy in Idiopathic Pulmonary Fibrosis: A State of the Art Review. Advances in Therapy, 2019, 36, 2193-2204.	1.3	7
1116	The Anti-Fibrotic Effects of CG-745, an HDAC Inhibitor, in Bleomycin and PHMG-Induced Mouse Models. Molecules, 2019, 24, 2792.	1.7	12
1117	Nintedanib and Sildenafil in Patients with Idiopathic Pulmonary Fibrosis and Right Heart Dysfunction. A Prespecified Subgroup Analysis of a Double-Blind Randomized Clinical Trial (INSTAGE). American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1505-1512.	2.5	50
1118	Biomarkers and early treatment of idiopathic pulmonary fibrosis. Lancet Respiratory Medicine,the, 2019, 7, 725-727.	5.2	4
1119	Mobile Health Monitoring in Patients with Idiopathic Pulmonary Fibrosis. Annals of the American Thoracic Society, 2019, 16, 1327-1329.	1.5	26
1120	Novel plasma peptide markers involved in the pathology of CKD identified using mass spectrometric approach. Journal of Molecular Medicine, 2019, 97, 1451-1463.	1.7	10
1121	Interstitial Pneumonia with Autoimmune Features. Clinics in Chest Medicine, 2019, 40, 609-616.	0.8	5
1122	Nintedanib and Sildenafil in Patients with Idiopathic Pulmonary Fibrosis. Echoes of the Past, Lessons for the Future. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1459-1461.	2.5	4
1123	Gastrointestinal adverse effects of nintedanib and the associated risk factors in patients with idiopathic pulmonary fibrosis. Scientific Reports, 2019, 9, 12062.	1.6	45
1124	Morphological and molecular motifs of fibrosing pulmonary injury patterns. Journal of Pathology: Clinical Research, 2019, 5, 256-271.	1.3	16
1125	Patient journey and treatment patterns in adults with IPF based on health care data in Sweden from 2001 to 2015. Respiratory Medicine, 2019, 155, 72-78.	1.3	18
1126	Cost-effectiveness of pirfenidone compared to all available strategies for the treatment of idiopathic pulmonary fibrosis in France. Journal of Market Access & Health Policy, 2019, 7, 1626171.	0.8	7

#	Article	IF	Citations
1127	New radiological diagnostic criteria: impact on idiopathic pulmonary fibrosis diagnosis. European Respiratory Journal, 2019, 54, 1900905.	3.1	4
1128	Longitudinal prediction of outcome in idiopathic pulmonary fibrosis using automated CT analysis. European Respiratory Journal, 2019, 54, 1802341.	3.1	22
1129	Outcome of lung transplantation in nonâ€idiopathic pulmonary fibrosis interstitial lung disease. Clinical Transplantation, 2019, 33, e13661.	0.8	4
1130	Management of Idiopathic Pulmonary Fibrosis. Annals of Pharmacotherapy, 2019, 53, 1238-1248.	0.9	27
1131	Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases. European Respiratory Journal, 2019, 54, 1900161.	3.1	164
1133	The Role of Surgical Lung Biopsy in Antifibrotic Therapy for Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1084-1085.	2.5	0
1134	Nintedanib ameliorates experimental pulmonary arterial hypertension via inhibition of endothelial mesenchymal transition and smooth muscle cell proliferation. PLoS ONE, 2019, 14, e0214697.	1.1	31
1135	Weekly paclitaxel in combination with carboplatin for advanced non-small-cell lung cancer complicated by idiopathic interstitial pneumonias: a single-arm phase II study. International Journal of Clinical Oncology, 2019, 24, 1543-1548.	1.0	16
1136	Differences in tolerability of pirfenidone between elderly and younger patients with idiopathic pulmonary fibrosis . Drug Design, Development and Therapy, 2019, Volume 13, 2295-2303.	2.0	13
1137	Assessing quality of life of idiopathic pulmonary fibrosis patients: the INSTAGE study. Breathe, 2019, 15, 144-146.	0.6	2
1138	The Role of Telomerase and Telomeres in Interstitial Lung Diseases: From Molecules to Clinical Implications. International Journal of Molecular Sciences, 2019, 20, 2996.	1.8	28
1139	Clinical Meaning of Transbronchial Cryobiopsy. , 2019, , 103-108.		0
1140	Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study. Lancet Respiratory Medicine,the, 2019, 7, 657-664.	5.2	73
1141	Statin Therapy and Lung Disorders. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 921-923.	2.5	1
1142	The Its Not JUST Idiopathic pulmonary fibrosis Study (INJUSTIS): description of the protocol for a multicentre prospective observational cohort study identifying biomarkers of progressive fibrotic lung disease. BMJ Open Respiratory Research, 2019, 6, e000439.	1.2	12
1143	King's Brief Interstitial Lung Disease questionnaire: responsiveness and minimum clinically important difference. European Respiratory Journal, 2019, 54, 1900281.	3.1	37
1144	Noninvasive Multimodal Methods to Differentiate Inflamed vs Fibrotic Strictures in Patients With Crohn's Disease. Clinical Gastroenterology and Hepatology, 2019, 17, 2397-2415.	2.4	43
1145	Real-World Comprehensive Disease Management of Patients With Idiopathic Pulmonary Fibrosis. Current Respiratory Medicine Reviews, 2019, 15, 4-15.	0.1	1

#	Article	IF	Citations
1146	Nintedanib for Systemic Sclerosisâ€“Associated Interstitial Lung Disease. New England Journal of Medicine, 2019, 381, 1595-1597.	13.9	12
1147	Pharmacotherapy and adjunctive treatment for idiopathic pulmonary fibrosis (IPF). Journal of Thoracic Disease, 2019, 11, S1740-S1754.	0.6	89
1148	Epithelial Alarmins in Serum and Exhaled Breath in Patients with Idiopathic Pulmonary Fibrosis: A Prospective One-Year Follow-Up Cohort Study. Journal of Clinical Medicine, 2019, 8, 1590.	1.0	10
1149	An Immune Gene Expression Signature Associated With Development of Human Hepatocellular Carcinoma Identifies Mice That Respond to Chemopreventive Agents. Gastroenterology, 2019, 157, 1383-1397.e11.	0.6	62
1150	Rheumatoid Arthritis-Associated Interstitial Lung Disease: Clinical Characteristics and Predictors of Mortality. Respiration, 2019, 98, 455-460.	1.2	47
1151	Methotrexate-Associated Pneumonitis and Rheumatoid Arthritis-Interstitial Lung Disease: Current Concepts for the Diagnosis and Treatment. Frontiers in Medicine, 2019, 6, 238.	1.2	73
1152	Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry. Respiratory Research, 2019, 20, 227.	1.4	59
1153	Phase II study of nabâ€paclitaxelÂ+Âcarboplatin for patients with nonâ€smallâ€cell lung cancer and interstitial lung disease. Cancer Science, 2019, 110, 3738-3745.	1.7	49
1154	MUC5B variant is associated with visually and quantitatively detected preclinical pulmonary fibrosis. Thorax, 2019, 74, 1131-1139.	2.7	43
1156	Real-life comparison of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis: A 24-month assessment. Respiratory Medicine, 2019, 159, 105803.	1.3	50
1158	A prospective phase II study of carboplatin and nab-paclitaxel in patients with advanced non-small cell lung cancer and concomitant interstitial lung disease (HOT1302). Lung Cancer, 2019, 138, 65-71.	0.9	32
1159	A homozygous SFTPA1 mutation drives necroptosis of type II alveolar epithelial cells in patients with idiopathic pulmonary fibrosis. Journal of Experimental Medicine, 2019, 216, 2724-2735.	4.2	49
1160	Longitudinal clinical outcomes in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry. Respiratory Research, 2019, 20, 231.	1.4	18
1161	Enhanced Brutonâ€™s tyrosine kinase in B-cells and autoreactive IgA in patients with idiopathic pulmonary fibrosis. Respiratory Research, 2019, 20, 232.	1.4	40
1162	Gas6/TAM System: A Key Modulator of the Interplay between Inflammation and Fibrosis. International Journal of Molecular Sciences, 2019, 20, 5070.	1.8	59
1163	Idiopathic Pulmonary Fibrosis and Lung Transplantation: When it is Feasible. Medicina (Lithuania), 2019, 55, 702.	0.8	16
1164	Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study. Lancet Respiratory Medicine,the, 2019, 7, 771-779.	5.2	65
1165	Tackling MARCKS-PIP3 circuit attenuates fibroblast activation and fibrosis progression. FASEB Journal, 2019, 33, 14354-14369.	0.2	13

#	Article	IF	Citations
1166	Pirfenidone in real life: A retrospective observational multicentre study in Italian patients with idiopathic pulmonary fibrosis. Respiratory Medicine, 2019, 156, 78-84.	1.3	21
1167	Regulatory network of two circRNAs and an miRNA with their targeted genes under astilbin treatment in pulmonary fibrosis. Journal of Cellular and Molecular Medicine, 2019, 23, 6720-6729.	1.6	19
1168	Temporal echocardiographic assessment of pulmonary hypertension in idiopathic pulmonary fibrosis patients treated with nintedanib with or without oxygen therapy. BMC Pulmonary Medicine, 2019, 19, 157.	0.8	3
1169	Nintedanib allows retreatment with atezolizumab of combined non-small cell lung cancer/idiopathic pulmonary fibrosis after atezolizumab-induced pneumonitis: a case report. BMC Pulmonary Medicine, 2019, 19, 156.	0.8	23
1170	Medication persistence rates and predictive factors for discontinuation of antifibrotic agents in patients with idiopathic pulmonary fibrosis: a real-world observational study. Therapeutic Advances in Respiratory Disease, 2019, 13, 175346661987289.	1.0	8
1171	Role of dual-specificity protein phosphatase DUSP10/MKP-5 in pulmonary fibrosis. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2019, 317, L678-L689.	1.3	15
1172	Mitochondrial calcium uniporter regulates PGC-1Î± expression to mediate metabolic reprogramming in pulmonary fibrosis. Redox Biology, 2019, 26, 101307.	3.9	56
1173	Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat. Respiratory Research, 2019, 20, 205.	1.4	166
1174	Discovery of an Orally Bioavailable Pan Î±v Integrin Inhibitor for Idiopathic Pulmonary Fibrosis. Journal of Medicinal Chemistry, 2019, 62, 8796-8808.	2.9	7
1176	The Role of Airway Myofibroblasts in Asthma. Chest, 2019, 156, 1254-1267.	0.4	19
1177	Choice of antifibrotic medication and disease severity predict weight loss in idiopathic pulmonary fibrosis. Pulmonary Pharmacology and Therapeutics, 2019, 59, 101839.	1.1	8
1178	In-Hospital Mortality in Patients with Idiopathic Pulmonary Fibrosis: A US Cohort Study. Lung, 2019, 197, 699-707.	1.4	22
1179	Bullous pemphigoid associated with nintedanib. JAAD Case Reports, 2019, 5, 821-823.	0.4	1
1180	Combined Pulmonary Fibrosis and Emphysema: Pulmonary Function Testing and a Pathophysiology Perspective. Medicina (Lithuania), 2019, 55, 580.	0.8	19
1181	Interleukin-11 is a therapeutic target in idiopathic pulmonary fibrosis. Science Translational Medicine, 2019, 11, .	5.8	189
1182	Physician characteristics associated with treatment initiation patterns in idiopathic pulmonary fibrosis. Chronic Respiratory Disease, 2019, 16, 147997311987967.	1.0	4
1183	Understanding Progressive Fibrosing Interstitial Lung Disease through Therapeutic Trials. New England Journal of Medicine, 2019, 381, 1775-1777.	13.9	9
1184	Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. New England Journal of Medicine, 2019, 381, 1718-1727.	13.9	1,338

#	Article	IF	Citations
1185	Immune Checkpoints as Promising Targets for the Treatment of Idiopathic Pulmonary Fibrosis?. Journal of Clinical Medicine, 2019, 8, 1547.	1.0	30
1186	Current and future perspectives on management of systemic sclerosis-associated interstitial lung disease. Expert Review of Clinical Immunology, 2019, 15, 1009-1017.	1.3	42
1187	Modelling Forced Vital Capacity in Idiopathic Pulmonary Fibrosis: Optimising Trial Design. Advances in Therapy, 2019, 36, 3059-3070.	1.3	4
1188	Sodium Arsenite Inhibits Lung Fibroblast Differentiation and Pulmonary Fibrosis. Pharmacology, 2019, 104, 368-376.	0.9	4
1189	Lung Cryobiopsy for the Diagnosis of Interstitial Lung Diseases: A Series Contribution to a Debated Procedure. Medicina (Lithuania), 2019, 55, 606.	0.8	13
1190	tPA promotes the proliferation of lung fibroblasts and activates the Wnt/Î²-catenin signaling pathway in idiopathic pulmonary fibrosis. Cell Cycle, 2019, 18, 3137-3146.	1.3	17
1191	Treatment of idiopathic pulmonary fibrosis with Nintedanib: an update. Expert Review of Respiratory Medicine, 2019, 13, 1139-1146.	1.0	13
1192	Interstitial Pneumonia With Autoimmune Features (IPAF). Frontiers in Medicine, 2019, 6, 209.	1.2	47
1193	High-Resolution CT Change over Time in Patients with Idiopathic Pulmonary Fibrosis on Antifibrotic Treatment. Journal of Clinical Medicine, 2019, 8, 1469.	1.0	17
1194	Autotaxin and chronic inflammatory diseases. Journal of Autoimmunity, 2019, 104, 102327.	3.0	68
1195	Medical Treatments of Peyronie's Disease: Past, Present, and Future. Urology, 2019, 125, 1-5.	0.5	9
1196	Advances in CT Diagnosis of UIP and IPF. Seminars in Roentgenology, 2019, 54, 6-14.	0.2	3
1197	Scleroderma-related interstitial lung disease: principles of management. Expert Review of Respiratory Medicine, 2019, 13, 357-367.	1.0	7
1198	Progress in Understanding and Treating Idiopathic Pulmonary Fibrosis. Annual Review of Medicine, 2019, 70, 211-224.	5.0	75
1199	Frailty and geriatric conditions in older patients with idiopathic pulmonary fibrosis. Respiratory Medicine, 2019, 148, 6-12.	1.3	31
1200	A single-institution study of concordance of pathological diagnoses for interstitial lung diseases between pre-transplantation surgical lung biopsies and lung explants. BMC Pulmonary Medicine, 2019, 19, 20.	0.8	7
1201	Remarkable Improvement in a Patient with Idiopathic Pulmonary Fibrosis after Treatment with Nintedanib. Internal Medicine, 2019, 58, 1141-1144.	0.3	7
1202	Design of a Study Assessing Disease Behaviour During the Peri-Diagnostic Period in Patients with Interstitial Lung Disease: The STARLINER Study. Advances in Therapy, 2019, 36, 232-243.	1.3	15

#	Article	IF	Citations
1203	Mechanisms of Fibrosis. , 2019, , 9-31.		3
1204	IPF Look-Alikes. , 2019, , 73-88.		0
1205	Natural History of Idiopathic Pulmonary Fibrosis and Disease Monitoring. , 2019, , 89-97.		0
1206	Vitamin D prevents experimental lung fibrosis and predicts survival in patients with idiopathic pulmonary fibrosis. Pulmonary Pharmacology and Therapeutics, 2019, 55, 17-24.	1.1	62
1207	Obstacles to early treatment of idiopathic pulmonary fibrosis: current perspectives. Therapeutics and Clinical Risk Management, 2019, Volume 15, 73-81.	0.9	12
1208	Collecting patient preference information using a Clinical Data Research Network: demonstrating feasibility with idiopathic pulmonary fibrosis . Patient Preference and Adherence, 2019, Volume 13, 795-804.	0.8	2
1209	Design and synthesis of novel pyrazolo[4,3-d]pyrimidines as potential therapeutic agents for acute lung injury. Journal of Enzyme Inhibition and Medicinal Chemistry, 2019, 34, 1121-1130.	2.5	16
1210	Experimental pulmonary fibrosis was suppressed by microRNA-506 through NF-kappa-mediated apoptosis and inflammation. Cell and Tissue Research, 2019, 378, 255-265.	1.5	19
1211	Modeling of Fibrotic Lung Disease Using 3D Organoids Derived from Human Pluripotent Stem Cells. Cell Reports, 2019, 27, 3709-3723.e5.	2.9	175
1212	Application of nintedanib and other potential anti-fibrotic agents in fibrotic diseases. Clinical Science, 2019, 133, 1309-1320.	1.8	26
1213	Diagnosing complications and co-morbidities of fibrotic interstitial lung disease. Expert Review of Respiratory Medicine, 2019, 13, 645-658.	1.0	12
1214	Novel idiopathic pulmonary fibrosis susceptibility variants revealed by deepÂsequencing. ERJ Open Research, 2019, 5, 00071-2019.	1.1	24
1215	Interstitial Lung Disease and ANCA-Associated Vasculitis. Current Treatment Options in Rheumatology, 2019, 5, 213-229.	0.6	1
1216	Acute exacerbation of chronic fibrosing interstitial pneumonia in patients receiving antifibrotic agents: incidence and risk factors from real-world experience. BMC Pulmonary Medicine, 2019, 19, 113.	0.8	18
1217	Idiopathic Pulmonary Fibrosis and Lung Cancer: Finding Similarities within Differences. American Journal of Respiratory Cell and Molecular Biology, 2019, 61, 667-668.	1.4	10
1218	Tyrosine kinase inhibitors relax pulmonary arteries in human and murine precision-cut lung slices. Respiratory Research, 2019, 20, 111.	1.4	19
1219	Transbronchial cryobiopsy in diffuse parenchymal lung disease. , 2019, , .		1
1220	Cryptotanshinone protects against pulmonary fibrosis through inhibiting Smad and STAT3 signaling pathways. Pharmacological Research, 2019, 147, 104307.	3.1	74

#	Article	IF	Citations
1221	A comprehensive and practical approach to the management of idiopathic pulmonary fibrosis. Expert Review of Respiratory Medicine, 2019, 13, 601-614.	1.0	6
1222	Pulmonary Complications of Rheumatoid Arthritis. Seminars in Respiratory and Critical Care Medicine, 2019, 40, 194-207.	0.8	29
1223	Multidisciplinary Evaluation in Patients with Lung Disease Associated with Connective Tissue Disease. Seminars in Respiratory and Critical Care Medicine, 2019, 40, 184-193.	0.8	25
1224	Risk factors for diagnostic delay in idiopathic pulmonary fibrosis. Respiratory Research, 2019, 20, 103.	1.4	78
1225	Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition. Breast Cancer Research, 2019, 21, 69.	2.2	16
1226	Clinical Effectiveness of Antifibrotic Medications for Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 168-174.	2.5	102
1227	Does ambulatory oxygen improve quality of life in patients with fibrotic lung disease? Results from the AmbOx trial. Breathe, 2019, 15, 140-143.	0.6	1
1228	Dysregulation of Mesenchymal Cell Survival Pathways in Severe Fibrotic Lung Disease: The Effect of Nintedanib Therapy. Frontiers in Pharmacology, 2019, 10, 532.	1.6	18
1229	Effect of pirfenidone on breathlessness in patients with idiopathic pulmonary fibrosis. European Respiratory Journal, 2019, 54, 1900399.	3.1	13
1230	Efficacy and safety of Nâ€‘acetylcysteine therapy for idiopathic pulmonary fibrosis: An updated systematic review and metaâ€‘analysis. Experimental and Therapeutic Medicine, 2019, 18, 802-816.	0.8	37
1231	mTORC1 amplifies the ATF4-dependent de novo serine-glycine pathway to supply glycine during TGF-Î² ₁ â€“induced collagen biosynthesis. Science Signaling, 2019, 12, .	1.6	124
1232	Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2). BMJ Open Respiratory Research, 2019, 6, e000422.	1.2	79
1233	Management of Fibrosing Interstitial Lung Diseases. Advances in Therapy, 2019, 36, 1518-1531.	1.3	27
1234	Computational insights into the binding of IN17 inhibitors to MELK. Journal of Molecular Modeling, 2019, 25, 151.	0.8	5
1235	Histological evaluation of nintedanib in non-alcoholic steatohepatitis mice. Life Sciences, 2019, 228, 251-257.	2.0	8
1236	Nintedanib for Systemic Sclerosisâ€“Associated Interstitial Lung Disease. New England Journal of Medicine, 2019, 380, 2518-2528.	13.9	1,025
1237	Gastroesophageal reflux and antacid therapy in IPF: analysis from the Australia IPF Registry. BMC Pulmonary Medicine, 2019, 19, 84.	0.8	26
1238	The Effects of Epigallocatechin Gallate (EGCG) on Pulmonary Fibroblasts of Idiopathic Pulmonary Fibrosis (IPF)â€”A Next-Generation Sequencing and Bioinformatic Approach. International Journal of Molecular Sciences, 2019, 20, 1958.	1.8	27

#	Article	IF	Citations
1239	Diagnostic difficulty in idiopathic pulmonary fibrosis. Respiratory Investigation, 2019, 57, 298-299.	0.9	2
1240	Idiopathic pulmonary fibrosis: the radiologistâ€™s role in making the diagnosis. British Journal of Radiology, 2019, 92, 20181003.	1.0	15
1241	Possible Serological Markers to Predict Mortality in Acute Exacerbation of Idiopathic Pulmonary Fibrosis. Medicina (Lithuania), 2019, 55, 132.	0.8	15
1242	Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment. Respiratory Medicine, 2019, 153, 44-51.	1.3	54
1243	Adjunctive therapies in idiopathic pulmonary fibrosisâ€”where do we stand?. Journal of Thoracic Disease, 2019, 11, 357-360.	0.6	0
1244	Ability to Suppress TGF-Î²-Activated Myofibroblast Differentiation Distinguishes the Anti-pulmonary Fibrosis Efficacy of Two Danshen-Containing Chinese Herbal Medicine Prescriptions. Frontiers in Pharmacology, 2019, 10, 412.	1.6	18
1245	Safety, Pharmacokinetics, and Pharmacodynamics of the Autotaxin Inhibitor GLPG1690 in Healthy Subjects: Phase 1 Randomized Trials. Journal of Clinical Pharmacology, 2019, 59, 1366-1378.	1.0	29
1246	Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib. Clinical Pharmacokinetics, 2019, 58, 1131-1147.	1.6	95
1247	Design of Idiopathic Pulmonary Fibrosis Clinical Trials in the Era of Approved Therapies. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 133-139.	2.5	10
1248	Update in Pulmonary Fibrosis 2018. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 292-300.	2.5	23
1250	Role of fibroblast growth factor 23 and klotho cross talk in idiopathic pulmonary fibrosis. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2019, 317, L141-L154.	1.3	37
1251	POINT: Should Transbronchial Cryobiopsies Be Considered the Initial Biopsy of Choice in Patients With a Possible Interstitial Lung Disease? Yes. Chest, 2019, 155, 893-895.	0.4	4
1252	Systematic review and network meta-analysis of approved medicines for the treatment of idiopathic pulmonary fibrosis. Journal of Drug Assessment, 2019, 8, 55-61.	1.1	22
1253	Treatment of Diffuse Cutaneous Systemic Sclerosis with Biologics, Small Molecules and Stem Cell Transplantation: What Is the Evidence to Date?. Current Treatment Options in Rheumatology, 2019, 5, 104-114.	0.6	0
1254	Rationale for the evaluation of nintedanib as a treatment for systemic sclerosisâ€“associated interstitial lung disease. Journal of Scleroderma and Related Disorders, 2019, 4, 212-218.	1.0	31
1255	Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage. ERJ Open Research, 2019, 5, 00127-2018.	1.1	21
1256	Patient Registries in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 160-167.	2.5	41
1257	Ability of Periostin as a New Biomarker of Idiopathic Pulmonary Fibrosis. Advances in Experimental Medicine and Biology, 2019, 1132, 79-87.	0.8	25

#	Article	IF	Citations
1258	Protective effect of bevacizumab on chemotherapy-related acute exacerbation of interstitial lung disease in patients with advanced non-squamous non-small cell lung cancer. BMC Pulmonary Medicine, 2019, 19, 72.	0.8	29
1259	Negative impact of anorexia and weight loss during prior pirfenidone administration on subsequent nintedanib treatment in patients with idiopathic pulmonary fibrosis. BMC Pulmonary Medicine, 2019, 19, 78.	0.8	15
1260	Design and Synthesis of Matrine Derivatives as Novel Anti-Pulmonary Fibrotic Agents via Repression of the TGFÎ²/Smad Pathway. Molecules, 2019, 24, 1108.	1.7	20
1261	Metabolic Reprogramming as a Driver of Fibroblast Activation in PulmonaryFibrosis. American Journal of the Medical Sciences, 2019, 357, 394-398.	0.4	35
1262	T cell Co-Stimulatory molecules ICOS and CD28 stratify idiopathic pulmonary fibrosis survival. Respiratory Medicine: X, 2019, 1, 100002.	1.4	7
1263	Poor Concordance between Sequential Transbronchial Lung Cryobiopsy and Surgical Lung Biopsy in the Diagnosis of Diffuse Interstitial Lung Diseases. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 1249-1256.	2.5	145
1264	Molecular endpoints for establishing target engagement by novel idiopathic pulmonary fibrosis therapies. European Respiratory Journal, 2019, 53, 1900283.	3.1	0
1265	The clinical course of idiopathic pulmonary fibrosis and its association to quality of life over time: longitudinal data from the INSIGHTS-IPF registry. Respiratory Research, 2019, 20, 59.	1.4	73
1266	Idiopathic Pulmonary Fibrosis: Epidemiology, Diagnosis andOutcomes. American Journal of the Medical Sciences, 2019, 357, 359-369.	0.4	45
1267	Defining the Activated Fibroblast Population in Lung Fibrosis Using Single-Cell Sequencing. American Journal of Respiratory Cell and Molecular Biology, 2019, 61, 74-85.	1.4	143
1268	Idiopathic Pulmonary Fibrosis and Lung Cancer. A Systematic Review and Meta-analysis. Annals of the American Thoracic Society, 2019, 16, 1041-1051.	1.5	54
1269	Therapeutic effects of the rhSOD2-Hirudin fusion protein on bleomycin-induced pulmonary fibrosis in mice. European Journal of Pharmacology, 2019, 852, 77-89.	1.7	11
1270	Diagnostic Delay in Idiopathic Pulmonary Fibrosis: Where the Rubber Meets the Road. Annals of the American Thoracic Society, 2019, 16, 310-312.	1.5	2
1271	Pulmonary alveolar proteinosis. Nature Reviews Disease Primers, 2019, 5, 16.	18.1	244
1272	Gene Expression Changes Associated with Nintedanib Treatment in Idiopathic Pulmonary Fibrosis Fibroblasts: A Next-Generation Sequencing and Bioinformatics Study. Journal of Clinical Medicine, 2019, 8, 308.	1.0	19
1273	Fibrosing interstitial lung diseases: knowns and unknowns. European Respiratory Review, 2019, 28, 180100.	3.0	191
1274	Exercise in Interstitial Lung Diseases. , 2019, , 97-110.		0
1275	Risk of anastomotic dehiscence in patients with pulmonary fibrosis transplanted while receiving anti-fibrotics: Experience of the Australian Lung Transplant Collaborative. Journal of Heart and Lung Transplantation, 2019, 38, 553-559.	0.3	24

#	Article	IF	Citations
1276	Case 10-2019: A 69-Year-Old Man with Progressive Dyspnea. New England Journal of Medicine, 2019, 380, 1268-1277.	13.9	2
1277	Molecular Mechanisms of Pulmonary Fibrogenesis and Its Progression to Lung Cancer: A Review. International Journal of Molecular Sciences, 2019, 20, 1461.	1.8	118
1278	Korean Guidelines for Diagnosis and Management of Interstitial Lung Diseases: Part 2. Idiopathic Pulmonary Fibrosis. Tuberculosis and Respiratory Diseases, 2019, 82, 102.	0.7	22
1279	Characterization of air flow and lung function in the pulmonary acinus by fluid-structure interaction in idiopathic interstitial pneumonias. PLoS ONE, 2019, 14, e0214441.	1.1	8
1280	Idiopathic Pulmonary Fibrosis: New and Emerging Treatment Options. Drugs and Aging, 2019, 36, 485-492.	1.3	20
1281	Therapeutic effect of nintedanib on acute exacerbation of interstitial lung diseases. Respiratory Medicine Case Reports, 2019, 26, 317-320.	0.2	7
1282	Properties of FDA-approved small molecule protein kinase inhibitors. Pharmacological Research, 2019, 144, 19-50.	3.1	377
1283	Evaluation of Glutathione S-Transferase Inhibition Effects on Idiopathic Pulmonary Fibrosis Therapy with a Near-Infrared Fluorescent Probe in Cell and Mice Models. Analytical Chemistry, 2019, 91, 5424-5432.	3.2	43
1284	Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis. Respiratory Research, 2019, 20, 55.	1.4	33
1285	Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy. Journal of Hematology and Oncology, 2019, 12, 27.	6.9	211
1286	Current and Future Idiopathic Pulmonary Fibrosis Therapy. American Journal of the Medical Sciences, 2019, 357, 370-373.	0.4	13
1287	Naftopidil reduced the proliferation of lung fibroblasts and bleomycinâ€induced lung fibrosis in mice. Journal of Cellular and Molecular Medicine, 2019, 23, 3563-3571.	1.6	7
1288	Biologic Treatments in Interstitial Lung Diseases. Frontiers in Medicine, 2019, 6, 41.	1.2	27
1289	Long-Term Effects and Adverse Events of Nintedanib Therapy in Idiopathic Pulmonary Fibrosis Patients with Functionally Advanced Disease. Advances in Therapy, 2019, 36, 1221-1232.	1.3	16
1290	Antiâ€fibrotic mechanisms of angiotensin AT₂â€receptor stimulation. Acta Physiologica, 2019, 227, e13280.	1.8	38
1291	Interstitial Lung Disease in Systemic Sclerosis: Lessons Learned from Idiopathic Pulmonary Fibrosis. Current Treatment Options in Rheumatology, 2019, 5, 127-146.	0.6	0
1292	Alteration of human macrophage phenotypes by the anti-fibrotic drug nintedanib. International Immunopharmacology, 2019, 72, 112-123.	1.7	38
1293	Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials. BMJ Open Respiratory Research, 2019, 6, e000397.	1.2	121

#	Article	IF	Citations
1294	Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSISÂ® trials. Respiratory Research, 2019, 20, 71.	1.4	30
1295	Survival implications of transbronchial cryobiopsy and other diagnostic modalities in idiopathic pulmonary fibrosis. Journal of Thoracic Disease, 2019, 11, E20-E23.	0.6	3
1296	Treatment of severe idiopathic pulmonary fibrosisâ€"is sildenafil the next (in)stage?. Journal of Thoracic Disease, 2019, 11, 339-340.	0.6	1
1297	The immunopathology of lung fibrosis: amphiregulin-producing pathogenic memory T helper-2 cells control the airway fibrotic responses by inducing eosinophils to secrete osteopontin. Seminars in Immunopathology, 2019, 41, 339-348.	2.8	22
1298	In patients with idiopathic pulmonary fibrosis the presence of hiatus hernia isÂassociated with disease progression andÂmortality. European Respiratory Journal, 2019, 53, 1802412.	3.1	20
1299	Eligibility for antiâ€fibrotic treatment in idiopathic pulmonary fibrosis depends on the predictive equation used for pulmonary function testing. Respirology, 2019, 24, 988-995.	1.3	7
1300	High-Resolution Computed Tomography (HRCT) Reflects Disease Progression in Patients with Idiopathic Pulmonary Fibrosis (IPF): Relationship with Lung Pathology. Journal of Clinical Medicine, 2019, 8, 399.	1.0	14
1301	Novel drug targets in idiopathic pulmonary fibrosis. Expert Opinion on Orphan Drugs, 2019, 7, 125-146.	0.5	1
1302	Implementing an interstitial lung disease clinic improves survival without increasing health care resource utilization. Pulmonary Pharmacology and Therapeutics, 2019, 56, 94-99.	1.1	7
1303	Cellular senescence and radiation-induced pulmonary fibrosis. Translational Research, 2019, 209, 14-21.	2.2	66
1304	Pulmonary Rehabilitation for Exercise Tolerance and Quality of Life in IPF Patients: A Systematic Review and Meta-Analysis. BioMed Research International, 2019, 2019, 1-9.	0.9	38
1305	Targeting anti-fibrotic pathways in Crohnâ€™s disease â€“ The final frontier?. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2019, 38-39, 101603.	1.0	12
1306	Airway Microstructure in Idiopathic Pulmonary Fibrosis: Assessment at Hyperpolarized ³He Diffusion-weighted MRI. Radiology, 2019, 291, 223-229.	3.6	26
1307	Efficacy of bone marrow mesenchymal stem cell transplantation in animal models of pulmonary fibrosis after exposure to bleomycin: A metaâ€'analysis. Experimental and Therapeutic Medicine, 2019, 17, 2247-2255.	0.8	11
1308	Revealing Real-Life Experiences With Antifibrotic Drugs in Idiopathic Pulmonary Fibrosis. Archivos De Bronconeumologia, 2019, 55, 73-74.	0.4	0
1309	Interstitial lung disease associated with nanoparticle albumin-bound paclitaxel treatment in patients with lung cancer. Japanese Journal of Clinical Oncology, 2019, 49, 165-173.	0.6	17
1310	Interstitial lung abnormalities: erecting fences in the path towards advanced pulmonary fibrosis. Thorax, 2019, 74, 506-511.	2.7	42
1311	Lung transplantation for idiopathic pulmonary fibrosis. Lancet Respiratory Medicine,the, 2019, 7, 271-282.	5.2	168

#	Article	IF	Citations
1312	Subgroup Analysis for Chinese Patients Included in the INPULSISÂ® Trials on Nintedanib in Idiopathic Pulmonary Fibrosis. Advances in Therapy, 2019, 36, 621-631.	1.3	9
1313	A randomised, placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosis. European Respiratory Journal, 2019, 53, 1801992.	3.1	101
1314	Pulmonary Hypertension Exacerbated by Nintedanib Administration for Idiopathic Pulmonary Fibrosis. Internal Medicine, 2019, 58, 965-968.	0.3	8
1315	Basic Fibroblast Growth Factor Induces Adipogenesis in Orbital Fibroblasts: Implications for the Pathogenesis of Graves' Orbitopathy. Thyroid, 2019, 29, 395-404.	2.4	12
1316	TRAIL signals through the ubiquitin ligase MID1 to promote pulmonary fibrosis. BMC Pulmonary Medicine, 2019, 19, 31.	0.8	20
1317	Longitudinal free-breathing MRI measurement of murine lung physiology in a progressive model of lung fibrosis. Journal of Applied Physiology, 2019, 126, 1138-1149.	1.2	7
1318	Yangyin Yiqi Mixture Ameliorates Bleomycin-Induced Pulmonary Fibrosis in Rats through Inhibiting TGF-Î²1/Smad Pathway and Epithelial to Mesenchymal Transition. Evidence-based Complementary and Alternative Medicine, 2019, 2019, 1-13.	0.5	13
1319	The Role of Infection in Acute Exacerbation of Idiopathic Pulmonary Fibrosis. Mediators of Inflammation, 2019, 2019, 1-10.	1.4	38
1320	Interstitial Pneumonia with Autoimmune Features. Annals of the American Thoracic Society, 2019, 16, 525-533.	1.5	62
1321	Efficacy of corticosteroid and intravenous cyclophosphamide in acute exacerbation of idiopathic pulmonary fibrosis: A propensity scoreâ€matched analysis. Respirology, 2019, 24, 792-798.	1.3	25
1322	Epidermal growth factor receptor paracrine upregulation in idiopathic pulmonary fibrosis fibroblasts is blocked by nintedanib. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2019, 316, L1025-L1034.	1.3	35
1323	Exercise and Sports Pulmonology. , 2019, , .		1
1324	Anesthesia for Patients with End-Stage Lung Disease. , 2019, , 509-533.		0
1325	Surgical lung biopsy for interstitial lung disease: when considered necessary, should these be done in larger and experienced centres only?. European Respiratory Journal, 2019, 53, 1900023.	3.1	9
1326	Pirfenidone Therapy for Familial Pulmonary Fibrosis: A Real-Life Study. Lung, 2019, 197, 147-153.	1.4	13
1327	Translational research in pulmonary fibrosis. Translational Research, 2019, 209, 1-13.	2.2	29
1328	â€˜Itâ€™s difficult, itâ€™s life changing what happens to youâ€™ patient perspective on life with chronic hypersensitivity pneumonitis: a qualitative study. BMJ Open Respiratory Research, 2019, 6, e000522.	1.2	10
1329	Futuro del tratamiento farmacolÃ³gico en fibrosis pulmonar idiopÃ¡tica. Archivos De Bronconeumologia, 2019, 55, 642-647.	0.4	6

#	Article	IF	Citations
1330	Role of bone marrow mesenchymal stem cells in the development of PQâ€'induced pulmonary fibrosis. Molecular Medicine Reports, 2019, 19, 3283-3290.	1.1	12
1331	Demographics and survival of patients with idiopathic pulmonary fibrosis in the FinnishIPF registry. ERJ Open Research, 2019, 5, 00170-2018.	1.1	65
1332	Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis. European Respiratory Review, 2019, 28, 190022.	3.0	89
1333	Cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline in the TOMORROW and INPULSISÂtrials. European Respiratory Journal, 2019, 54, 1801797.	3.1	28
1334	Comorbidities in idiopathic pulmonary fibrosis: an underestimated issue. European Respiratory Review, 2019, 28, 190044.	3.0	66
1335	The genetics of interstitial lung diseases. European Respiratory Review, 2019, 28, 190053.	3.0	41
1336	Gaps in care of patients living with pulmonary fibrosis: a joint patient and expert statement on the results of a Europe-wide survey. ERJ Open Research, 2019, 5, 00124-2019.	1.1	33
1337	Centralized expert HRCT Reading in suspected idiopathic pulmonary fibrosis: Experience from an Eurasian teleradiology program. European Journal of Radiology, 2019, 121, 108719.	1.2	1
1338	Current advances in idiopathic pulmonary fibrosis: the pathogenesis, therapeutic strategies and candidate molecules. Future Medicinal Chemistry, 2019, 11, 2595-2620.	1.1	20
1339	Endotypeâ€"phenotyping may predict a treatment response in progressive fibrosing interstitial lung disease. EBioMedicine, 2019, 50, 379-386.	2.7	41
1340	Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases. BMC Pulmonary Medicine, 2019, 19, 213.	0.8	19
1341	Improving The Oral Absorption Of Nintedanib By A Self-Microemulsion Drug Delivery System: Preparation And In Vitro/In Vivo Evaluation . International Journal of Nanomedicine, 2019, Volume 14, 8739-8751.	3.3	32
1342	The future of pharmacological treatment in idiopathic pulmonary fibrosis. Archivos De Bronconeumologia, 2019, 55, 642-647.	0.4	3
1344	Interstitial Lung Disease. Journal of Computer Assisted Tomography, 2019, 43, 898-905.	0.5	4
1345	Targeting MAP3K19 prevents human lung myofibroblast activation both in vitro and in a humanized SCID model of idiopathic pulmonary fibrosis. Scientific Reports, 2019, 9, 19796.	1.6	10
1346	KCa3.1 channel blockade attenuates microvascular remodelling in a large animal model of bleomycin-induced pulmonary fibrosis. Scientific Reports, 2019, 9, 19893.	1.6	11
1347	Hexokinase 2 couples glycolysis with the profibrotic actions of TGF-Î². Science Signaling, 2019, 12, .	1.6	71
1348	Baseline High-Resolution CT Findings Predict Acute Exacerbation of Idiopathic Pulmonary Fibrosis: German and Japanese Cohort Study. Journal of Clinical Medicine, 2019, 8, 2069.	1.0	8

#	Article	IF	Citations
1349	Orotracheal treprostinil administration attenuates bleomycinâ€induced lung injury, vascular remodeling, and fibrosis in mice. Pulmonary Circulation, 2019, 9, 1-14.	0.8	23
1350	Idebenone has preventative and therapeutic effects on pulmonary fibrosis via preferential suppression of fibroblast activity. Cell Death Discovery, 2019, 5, 146.	2.0	18
1351	Sleep and interstitial lung disease. Current Opinion in Pulmonary Medicine, 2019, 25, 623-628.	1.2	9
1352	Acute Exacerbation of Idiopathic Pulmonary Fibrosis: Who to Treat, How to Treat. Current Pulmonology Reports, 2019, 8, 123-130.	0.5	7
1353	New trajectories in the treatment of interstitial lung disease. Current Opinion in Pulmonary Medicine, 2019, 25, 442-449.	1.2	16
1354	The effect of emphysema on survival in patients with idiopathic pulmonary fibrosis: A retrospective study in Taiwan. Journal of the Chinese Medical Association, 2019, 82, 922-928.	0.6	10
1355	The efficacy of pirfenidone in a sheep model of pulmonary fibrosis. Experimental Lung Research, 2019, 45, 310-322.	0.5	12
1356	Caveolin-1â€“derived peptide limits development of pulmonary fibrosis. Science Translational Medicine, 2019, 11, .	5.8	58
1357	Oncostatin M in the Regulation of Connective Tissue Cells and Macrophages in Pulmonary Disease. Biomedicines, 2019, 7, 95.	1.4	18
1358	Clinical course and management of idiopathic pulmonary fibrosis. Multidisciplinary Respiratory Medicine, 2019, 14, 35.	0.6	18
1360	Kangfuxin Oral Liquid Attenuates Bleomycin-Induced Pulmonary Fibrosis via the TGF-Î²1/Smad Pathway. Evidence-based Complementary and Alternative Medicine, 2019, 2019, 1-14.	0.5	13
1361	P311 Promotes Lung Fibrosis via Stimulation of Transforming Growth Factor-Î²1, -Î²2, and -Î²3 Translation. American Journal of Respiratory Cell and Molecular Biology, 2019, 60, 221-231.	1.4	19
1362	Lung Transplantation for Interstitial Lung Disease. , 2019, , 131-149.		0
1363	Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON. Lancet Respiratory Medicine,the, 2019, 7, 60-68.	5.2	160
1364	Efficacy data in treatment extension studies of idiopathic pulmonary fibrosis: interpret with caution. Lancet Respiratory Medicine,the, 2019, 7, 7-8.	5.2	3
1365	Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre. Pulmonology, 2019, 25, 149-153.	1.0	40
1366	Who and When to Transplant: What Has Changed?. , 2019, , 1-17.		0
1367	Remission of psoriasis with nintedanib for the treatment of idiopathic pulmonary fibrosis. Journal of Dermatology, 2019, 46, e118-e119.	0.6	4

#	Article	IF	Citations
1368	Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis. European Respiratory Journal, 2019, 53, 1800663.	3.1	73
1369	Idiopathic Pulmonary Fibrosis: The Epidemiology and Natural History of Disease. Respiratory Medicine, 2019, , 11-35.	0.1	2
1370	A successful treatment of rheumatoid arthritis-related interstitial pneumonia with nintedanib. Respiratory Medicine Case Reports, 2019, 26, 50-52.	0.2	11
1371	The Keys to Making a Confident Diagnosis of IPF. Respiratory Medicine, 2019, , 299-323.	0.1	0
1372	Idiopathic Pulmonary Fibrosis for Cardiologists: Differential Diagnosis, Cardiovascular Comorbidities, and Patient Management. Advances in Therapy, 2019, 36, 298-317.	1.3	18
1373	Antiinflammatory Therapy. , 2019, , 239-255.		0
1374	Lung transplant candidates with idiopathic pulmonary fibrosis and long-term pirfenidone therapy: Treatment feasibility influences waitlist survival. Respiratory Investigation, 2019, 57, 165-171.	0.9	10
1375	The immunomodulatory role of interleukin-35 in fibrotic diseases. Expert Review of Clinical Immunology, 2019, 15, 431-439.	1.3	13
1376	Tissue Continues to Be the Issue: Role of Histopathology in the Context of Recent Updates in the Radiologic Classification of Interstitial Lung Diseases. Archives of Pathology and Laboratory Medicine, 2019, 143, 30-33.	1.2	0
1377	The mTORC1/4E-BP1 axis represents a critical signaling node during fibrogenesis. Nature Communications, 2019, 10, 6.	5.8	159
1378	The Role of Immunity and Inflammation in IPF Pathogenesis. Respiratory Medicine, 2019, , 97-131.	0.1	7
1379	Prognostic significance of early pulmonary function changes after onset of chronic lung allograft dysfunction. Journal of Heart and Lung Transplantation, 2019, 38, 184-193.	0.3	12
1380	Interstitial Lung Abnormality: Recognition and Perspectives. Radiology, 2019, 291, 1-3.	3.6	70
1381	Hyperpolarised xenon magnetic resonance spectroscopy for the longitudinal assessment of changes in gas diffusion in IPF. Thorax, 2019, 74, 500-502.	2.7	53
1382	No relevant pharmacokinetic drugâ€“drug interaction between nintedanib and pirfenidone. European Respiratory Journal, 2019, 53, 1801060.	3.1	22
1383	Nicotine Modulates Growth Factors and MicroRNA to Promote Inflammatory and Fibrotic Processes. Journal of Pharmacology and Experimental Therapeutics, 2019, 368, 169-178.	1.3	23
1384	Attenuation of pulmonary fibrosis in type I collagen-targeted reporter mice with ALK-5 inhibitors. Pulmonary Pharmacology and Therapeutics, 2019, 54, 31-38.	1.1	16
1385	Fibrotic Signaling in the Lung. Molecular and Translational Medicine, 2019, , 91-119.	0.4	0

#	Article	IF	Citations
1386	Pericytes and T Cells in Lung Injury and Fibroproliferation. Molecular and Translational Medicine, 2019, , 175-195.	0.4	2
1387	Fibrosis and Immune Dysregulation in Systemic Sclerosis. Molecular and Translational Medicine, 2019, , 25-60.	0.4	0
1388	The Role of Mast Cells in the Pathophysiology of Pulmonary Fibrosis. Molecular and Translational Medicine, 2019, , 135-173.	0.4	0
1389	Dynamic Reciprocity: The Role of the Extracellular Matrix Microenvironment in Amplifying and Sustaining Pathological Lung Fibrosis. Molecular and Translational Medicine, 2019, , 239-270.	0.4	1
1390	Lung function outcomes in the INPULSISÂ® trials of nintedanib in idiopathic pulmonary fibrosis. Respiratory Medicine, 2019, 146, 42-48.	1.3	34
1391	Telomerase-related monogenic lung fibrosis presenting with subacute onset: a case report and review of literature. Acta Clinica Belgica, 2019, 74, 445-450.	0.5	0
1392	LOX/LOXL in pulmonary fibrosis: potential therapeutic targets. Journal of Drug Targeting, 2019, 27, 790-796.	2.1	58
1393	Tissue-informed engineering strategies for modeling human pulmonary diseases. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2019, 316, L303-L320.	1.3	24
1394	Diagnosis of asbestos-related lung diseases. Expert Review of Respiratory Medicine, 2019, 13, 241-249.	1.0	12
1395	Federated electronic health records research technology to support clinical trial protocol optimization: Evidence from EHR4CR and the InSite platform. Journal of Biomedical Informatics, 2019, 90, 103090.	2.5	29
1396	Randomised, double-blind, placebo-controlled pilot trial of omeprazole in idiopathic pulmonary fibrosis. Thorax, 2019, 74, 346-353.	2.7	45
1397	Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study. EBioMedicine, 2019, 40, 554-563.	2.7	746
1398	Assessing Patterns of Palliative Care Referral and Location of Death in Patients with Idiopathic Pulmonary Fibrosis: A Sixteen-Year Single-Center Retrospective Cohort Study. Journal of Palliative Medicine, 2019, 22, 538-544.	0.6	14
1399	Therapeutic effects of nintedanib are not influenced by emphysema in the INPULSIS trials. European Respiratory Journal, 2019, 53, 1801655.	3.1	22
1400	Inflammation and immunity in IPF pathogenesis and treatment. Respiratory Medicine, 2019, 147, 79-91.	1.3	259
1401	Existing and emerging treatments for idiopathic pulmonary fibrosis. Expert Review of Respiratory Medicine, 2019, 13, 229-239.	1.0	10
1402	Prolonged Survival in a Patient with Idiopathic Pulmonary Fibrosis Receiving Acupuncture and DHEA-Promoting Herbs with Conventional Management: A Case Report. , 2019, 23, 18-074.		1
1403	Determination of a novel antifibrotic small molecule GDCâ€3280 in human plasma and urine by liquid chromatography tandem mass spectrometry to support its firstâ€inâ€human clinical trial. Biomedical Chromatography, 2019, 33, e4482.	0.8	1

#	Article	IF	Citations
1404	Revealing Real-Life Experiences With Antifibrotic Drugs in Idiopathic Pulmonary Fibrosis. Archivos De Bronconeumologia, 2019, 55, 73-74.	0.4	0
1405	Pirfenidone for Treating Idiopathic Pulmonary Fibrosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 2019, 37, 763-775.	1.7	3
1406	Validity of the Patient Experiences and Satisfaction with Medications (PESaM) Questionnaire. Patient, 2019, 12, 149-162.	1.1	10
1407	The Hypoxic Adenosine Response and Inflammation in Lung Disease. , 2019, , 23-41.		0
1408	The Antifibrotic Activity of Prostacyclin Receptor Agonism Is Mediated through Inhibition of YAP/TAZ. American Journal of Respiratory Cell and Molecular Biology, 2019, 60, 578-591.	1.4	34
1409	Another Weapon in the Battle against Idiopathic Pulmonary Fibrosis?. American Journal of Respiratory Cell and Molecular Biology, 2019, 60, 386-387.	1.4	3
1410	Nintedanib in Idiopathic Pulmonary Fibrosis: Practical Management Recommendations for Potential Adverse Events. Respiration, 2019, 97, 173-184.	1.2	39
1411	The Tyrosine Kinase Inhibitor TAS-115 Attenuates Bleomycin-induced Lung Fibrosis in Mice. American Journal of Respiratory Cell and Molecular Biology, 2019, 60, 478-487.	1.4	15
1412	Longâ€term outcomes in chronic hypersensitivity pneumonitis. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 944-952.	2.7	55
1413	Antifibrotics: Shrinking the Box of Therapeutic Uncertainty. Respiration, 2019, 97, 202-204.	1.2	0
1414	Smoking-Related Lung Disease. Seminars in Ultrasound, CT and MRI, 2019, 40, 229-238.	0.7	9
1415	Determinants of survival in lung transplantation patients with idiopathic pulmonary fibrosis: a retrospective cohort study. Transplant International, 2019, 32, 399-409.	0.8	7
1416	IL-9 Blockade Suppresses Silica-induced Lung Inflammation and Fibrosis in Mice. American Journal of Respiratory Cell and Molecular Biology, 2019, 60, 232-243.	1.4	41
1417	Nintedanib-cyclodextrin complex to improve bio-activity and intestinal permeability. Carbohydrate Polymers, 2019, 204, 68-77.	5.1	47
1418	Immunological Lung Diseases. , 2019, , 967-980.e1.		0
1419	P311 in Scar Wars: Myofibroblasts Lost without Transforming Growth Factor Î² Translation. American Journal of Respiratory Cell and Molecular Biology, 2019, 60, 139-140.	1.4	5
1420	The Future of Lung Transplantation. Chest, 2019, 155, 465-473.	0.4	67
1421	Understanding the patient's experience of care in idiopathic pulmonary fibrosis. Respirology, 2019, 24, 270-277.	1.3	31

#	Article	IF	Citations
1422	Nintedanib for Idiopathic Pulmonary Fibrosis. Journal of Pharmacy Practice, 2019, 32, 199-206.	0.5	14
1423	Effectiveness and Safety of Chinese Medicine for Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. Chinese Journal of Integrative Medicine, 2019, 25, 778-784.	0.7	21
1424	A Randomized, Double-Blinded, Placebo-Controlled, Dose-Escalation Phase 1 Study of Aerosolized Pirfenidone Delivered via the PARI Investigational eFlow Nebulizer in Volunteers and Patients with Idiopathic Pulmonary Fibrosis. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2020, 33, 15-20.	0.7	29
1425	What Patients With Idiopathic Pulmonary Fibrosis and Caregivers Want: Filling the Gaps With Patient Reported Outcomes and Experience Measures. American Journal of Medicine, 2020, 133, 281-289.	0.6	36
1426	Usual interstitial pneumonia in ANCA-associated vasculitis: A poor prognostic factor. Journal of Autoimmunity, 2020, 106, 102338.	3.0	43
1427	Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Respiratory Medicine,the, 2020, 8, 25-33.	5.2	165
1428	Pamrevlumab in idiopathic pulmonary fibrosis. Lancet Respiratory Medicine,the, 2020, 8, 2-3.	5.2	14
1429	First-in-human high-cumulative-dose stem cell therapy in idiopathic pulmonary fibrosis with rapid lung function decline. Stem Cells Translational Medicine, 2020, 9, 6-16.	1.6	71
1430	Twenty percent of secondary publications of randomized controlled trials of drugs did not provide new results relative to the primary publication. Journal of Clinical Epidemiology, 2020, 117, 20-28.	2.4	6
1431	Ventilatory Support and Oxygen Therapy in Elder, Palliative and End-of-Life Care Patients. , 2020, , .		3
1432	Synthesis and discovery of new compounds bearing coumarin scaffold for the treatment of pulmonary fibrosis. European Journal of Medicinal Chemistry, 2020, 185, 111790.	2.6	7
1433	Interstitial lung disease: perhaps unclassifiable, but not untreatable. Lancet Respiratory Medicine,the, 2020, 8, 126-127.	5.2	2
1434	Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respiratory Medicine,the, 2020, 8, 147-157.	5.2	410
1435	In search for a predictive marker of acute exacerbations of idiopathic pulmonary fibrosis. Respirology, 2020, 25, 234-235.	1.3	1
1436	Old but Gold: Tracking the New Guise of Histone Deacetylase 6 (HDAC6) Enzyme as a Biomarker and Therapeutic Target in Rare Diseases. Journal of Medicinal Chemistry, 2020, 63, 23-39.	2.9	69
1437	Identifying â€œRealâ€•Patients in the Real World. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 256-257.	2.5	0
1438	Longâ€term treatment with nintedanib in Asian patients with idiopathic pulmonary fibrosis: Results from INPULSISÂ®â€ON. Respirology, 2020, 25, 410-416.	1.3	23
1439	Prediction of idiopathic pulmonary fibrosis progression using early quantitative changes on CT imaging for a short term of clinical 18â€“24-month follow-ups. European Radiology, 2020, 30, 726-734.	2.3	38

#	Article	IF	Citations
1440	Genetic Determinants of Interstitial Lung Diseases. , 2020, , 405-437.		1
1441	Idiopathic interstitial pneumonias. , 2020, , 29-140.		1
1442	Associations of Serum Adipokines With Subclinical Interstitial Lung Disease Among Community-Dwelling Adults. Chest, 2020, 157, 580-589.	0.4	17
1443	Secretory IgA accumulated in the airspaces of idiopathic pulmonary fibrosis and promoted VEGF, TGF-Î² and IL-8 production by A549 cells. Clinical and Experimental Immunology, 2020, 199, 326-336.	1.1	11
1444	Idiopathic and Autoimmune Interstitial Lung Disease. , 2020, , 1335-1354.		0
1445	Mitochondrial quality control in pulmonary fibrosis. Redox Biology, 2020, 33, 101426.	3.9	66
1446	The Role of Palliative Care in Reducing Symptoms and Improving Quality of Life for Patients with Idiopathic Pulmonary Fibrosis: A Review. Pulmonary Therapy, 2020, 6, 35-46.	1.1	24
1447	Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme. Respiratory Research, 2020, 21, 7.	1.4	19
1448	Idiopathic Pulmonary Fibrosis: A Review of Disease, Pharmacological, and Nonpharmacological Strategies With a Focus on Symptoms, Function, and Health-Related Quality of Life. Journal of Pain and Symptom Management, 2020, 59, 1362-1378.	0.6	20
1449	Metabolic proï¬ling of tyrosine kinase inhibitor nintedanib using metabolomics. Journal of Pharmaceutical and Biomedical Analysis, 2020, 180, 113045.	1.4	11
1450	Lung cancer in patients with Idiopathic Pulmonary Fibrosis. A retrospective multicenter study in Greece. Pulmonary Pharmacology and Therapeutics, 2020, 60, 101880.	1.1	31
1451	Magnetic Resonance in Crohn Disease. Magnetic Resonance Imaging Clinics of North America, 2020, 28, 45-53.	0.6	2
1452	Comparative survival analysis between idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis. Pulmonology, 2020, 26, 3-9.	1.0	19
1453	Targeting c-Src Reverses Accelerated GPX-1 mRNA Decay in Chronic Obstructive Pulmonary Disease Airway Epithelial Cells. American Journal of Respiratory Cell and Molecular Biology, 2020, 62, 598-607.	1.4	8
1454	Idiopathic Pulmonary Fibrosis: Best Practice in Monitoring and Managing a Relentless Fibrotic Disease. Respiration, 2020, 99, 73-82.	1.2	58
1455	Corticosteroid use is not associated with improved outcomes in acute exacerbation of IPF. Respirology, 2020, 25, 629-635.	1.3	47
1456	Nintedanib: New indication for systemic sclerosis-associated interstitial lung disease. Modern Rheumatology, 2020, 30, 225-231.	0.9	29
1457	Ca2+signalling in fibroblasts and the therapeutic potential of KCa3.1 channel blockers in fibrotic diseases. British Journal of Pharmacology, 2020, 177, 1003-1024.	2.7	23

#	Article	IF	Citations
1458	Inhibition of the stem cell factor 248 isoform attenuates the development of pulmonary remodeling disease. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2020, 318, L200-L211.	1.3	8
1460	Quantitative CT Analysis of Diffuse Lung Disease. Radiographics, 2020, 40, 28-43.	1.4	90
1461	Exosome-Derived <i>microRNA</i>-<i>22</i> Ameliorates Pulmonary Fibrosis by Regulating Fibroblast-to-Myofibroblast Differentiation <i>in Vitro</i> and <i>in Vivo</i>. Journal of Nippon Medical School, 2020, 87, 118-128.	0.3	34
1462	An Open-label Study With Pirfenidone on Chronic Hypersensitivity Pneumonitis. Archivos De Bronconeumologia, 2020, 56, 163-169.	0.4	20
1463	Restrictive allograft dysfunction after lung transplantation: is there a place for nintedanib?â€"a case report. Fundamental and Clinical Pharmacology, 2020, 34, 408-411.	1.0	5
1464	Microenvironment-Responsive Small-Molecule Probe for Pulmonary Fibrosis Detection. Analytical Chemistry, 2020, 92, 699-706.	3.2	12
1465	Anti-fibrotic mechanisms of exogenously-expanded mesenchymal stromal cells for fibrotic diseases. Seminars in Cell and Developmental Biology, 2020, 101, 87-103.	2.3	31
1466	Traditional Chinese medicine in the treatment of idiopathic pulmonary fibrosis based on syndrome differentiation: Study protocol of an exploratory trial. Journal of Integrative Medicine, 2020, 18, 163-168.	1.4	14
1467	Pathology of Idiopathic Interstitial Pneumonias. Surgical Pathology Clinics, 2020, 13, 91-118.	0.7	9
1468	Occupational exposures and idiopathic pulmonary fibrosis. Current Opinion in Allergy and Clinical Immunology, 2020, 20, 103-111.	1.1	10
1469	Multiple Traditional Chinese Medicine interventions for idiopathic pulmonary fibrosis. Medicine (United States), 2020, 99, e22396.	0.4	7
1470	Older Idiopathic Pulmonary Fibrosis Male Patients Are at a Higher Risk of Nintedanib Dose Reduction. Respiration, 2020, 99, 646-648.	1.2	5
1471	Interstitial Lung Disease in Patients With Systemic Sclerosis: Toward Personalized-Medicine-Based Prediction and Drug Screening Models of Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD). Frontiers in Immunology, 2020, 11, 1990.	2.2	9
1472	Long-Term Follow-Up of Patients With Idiopathic Pulmonary Fibrosis Treated With Pirfenidone or Nintedanib: A Real-Life Comparison Study. Frontiers in Molecular Biosciences, 2020, 7, 581828.	1.6	48
1473	STRATUS: A Phase II Study of Abituzumab in Patients With Systemic Sclerosisâ€"associated Interstitial Lung Disease. Journal of Rheumatology, 2021, 48, 1295-1298.	1.0	12
1474	Healthcare use and costs among Medicare enrollees on pirfenidone versus nintedanib for idiopathic pulmonary fibrosis. Journal of Comparative Effectiveness Research, 2020, 9, 933-943.	0.6	7
1475	Prognostic significance of forced vital capacity decline prior to and following antifibrotic therapy in idiopathic pulmonary fibrosis. Therapeutic Advances in Respiratory Disease, 2020, 14, 175346662095378.	1.0	3
1476	Drug discovery and development in idiopathic pulmonary fibrosis: challenges and opportunities. Drug Discovery Today, 2020, 25, 2277-2283.	3.2	8

#	Article	IF	Citations
1477	Reprogramming of profibrotic macrophages for treatment of bleomycinâ€induced pulmonary fibrosis. EMBO Molecular Medicine, 2020, 12, e12034.	3.3	51
1478	Baicalein alleviated TGF Î²1-induced type I collagen production in lung fibroblasts via downregulation of connective tissue growth factor. Biomedicine and Pharmacotherapy, 2020, 131, 110744.	2.5	22
1479	Fibroblast Growth Factor Inhibitors in Lung Fibrosis: Friends or Foes?. American Journal of Respiratory Cell and Molecular Biology, 2020, 63, 273-274.	1.4	7
1480	The Pulmonary Fibrosis Foundation Patient Registry. Rationale, Design, and Methods. Annals of the American Thoracic Society, 2020, 17, 1620-1628.	1.5	27
1481	Australasian interstitial lung disease registry (AILDR): objectives, design and rationale of a bi-national prospective database. BMC Pulmonary Medicine, 2020, 20, 257.	0.8	9
1482	Investigation of telomere related gene mutations in idiopathic pulmonary fibrosis. Molecular Biology Reports, 2020, 47, 7851-7860.	1.0	0
1483	A novel phosphodiesterase 4 inhibitor, AA6216, reduces macrophage activity and fibrosis in the lung. European Journal of Pharmacology, 2020, 885, 173508.	1.7	20
1484	Occupational and environmental risk factors for idiopathic pulmonary fibrosis in Australia: caseâ€“control study. Thorax, 2020, 75, 864-869.	2.7	48
1485	Inhibitors of the Autotaxin-Lysophosphatidic Acid Axis and Their Potential in the Treatment of Interstitial Lung Disease: Current Perspectives . Clinical Pharmacology: Advances and Applications, 2020, Volume 12, 97-108.	0.8	13
1486	Idiopathic Nonspecific Interstitial Pneumonia. A Case Series and Literature Review. Open Respiratory Archives, 2020, 2, 192-193.	0.0	0
1487	A near-infrared fluorescent probe for evaluating glutamyl transpeptidase fluctuation in idiopathic pulmonary fibrosis cell and mice models. Sensors and Actuators B: Chemical, 2020, 322, 128565.	4.0	17
1488	Clinical relevance of endpoints in clinical trials for acid sphingomyelinase deficiency enzyme replacement therapy. Molecular Genetics and Metabolism, 2020, 131, 116-123.	0.5	18
1489	The adoption of nintedanib in systemic sclerosis: the SENSCIS study. Breathe, 2020, 16, 200005.	0.6	5
1490	Treatment patterns, healthcare resource utilization, and costs among patients with idiopathic pulmonary fibrosis treated with antifibrotic medications in US-based commercial and Medicare Supplemental claims databases: a retrospective cohort study. BMC Pulmonary Medicine, 2020, 20, 188.	0.8	14
1491	Antifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis. Data from the IPF-PRO Registry. Annals of the American Thoracic Society, 2020, 17, 1413-1423.	1.5	32
1492	Imatinib a Tyrosine Kinase Inhibitor: a potential treatment for SARS- COV-2 induced pneumonia. Alexandria Journal of Medicine, 2020, 56, 68-72.	0.4	8
1493	Pan-transcriptome-based candidate therapeutic discovery for idiopathic pulmonary fibrosis. Therapeutic Advances in Respiratory Disease, 2020, 14, 175346662097114.	1.0	7
1494	Transbronchial cryobiopsy in the diagnosis of interstitial lung diseases: methodologies and perspectives from the Cryo-PID and COLDICE studies. Annals of Translational Medicine, 2020, 8, 1330-1330.	0.7	5

#	Article	IF	Citations
1495	The Potential Effects of Curcumin on Pulmonary Fibroblasts of Idiopathic Pulmonary Fibrosis (IPF)â€"Approaching with Next-Generation Sequencing and Bioinformatics. Molecules, 2020, 25, 5458.	1.7	5
1496	Analysis of body mass index, weight loss and progression of idiopathic pulmonary fibrosis. Respiratory Research, 2020, 21, 312.	1.4	44
1497	Comparison of reversal of rat pulmonary fibrosis of nintedanib, pirfenidone, and human umbilical mesenchymal stem cells from Whartonâ€™s jelly. Stem Cell Research and Therapy, 2020, 11, 513.	2.4	17
1498	Heparanase and the hallmarks of cancer. Journal of Translational Medicine, 2020, 18, 453.	1.8	78
1499	Engeletin ameliorates pulmonary fibrosis through endoplasmic reticulum stress depending on lnc949-mediated TGF-Î²1-Smad2/3 and JNK signalling pathways. Pharmaceutical Biology, 2020, 58, 1114-1123.	1.3	12
1500	Facing the Challenge of Post COVID-19 Pulmonary fibrosis: What is so unique about it?. Bangladesh Critical Care Journal, 2020, 8, 102-107.	0.1	1
1501	Dynamics in diagnoses and pharmacotherapy before and after diagnosing idiopathic pulmonary fibrosis. ERJ Open Research, 2020, 6, 00479-2020.	1.1	3
1503	Clinical experience with antifibrotics in fibrotic hypersensitivity pneumonitis: a 3-year real-life observational study. ERJ Open Research, 2020, 6, 00152-2020.	1.1	15
1504	Fibrosis and cancer: shared features and mechanisms suggest common targeted therapeutic approaches. Nephrology Dialysis Transplantation, 2022, 37, 1024-1032.	0.4	18
1505	Is operation safe for lung cancer patients with interstitial lung disease on computed tomography?. Therapeutic Advances in Respiratory Disease, 2020, 14, 175346662097113.	1.0	2
1506	In-hospital mortality trends among patients with idiopathic pulmonary fibrosis in the United States between 2013-2017: a comparison of academic and non-academic programs. BMC Pulmonary Medicine, 2020, 20, 289.	0.8	13
1507	Transbronchial cryobiopsy for diffuse parenchymal lung diseases: evidence that demands a (favorable) verdict. Annals of Translational Medicine, 2020, 8, 1324-1324.	0.7	0
1508	Acute exacerbations of idiopathic pulmonary fibrosis and theÂrole of corticosteroids. Breathe, 2020, 16, 200086.	0.6	5
1509	Antifibrotic and Regenerative Effects of Treamid in Pulmonary Fibrosis. International Journal of Molecular Sciences, 2020, 21, 8380.	1.8	9
1510	Functional parameters of small airways can guide bronchodilator use in idiopathic pulmonary fibrosis. Scientific Reports, 2020, 10, 18633.	1.6	4
1511	Hypersensitivity pneumonitis. Nature Reviews Disease Primers, 2020, 6, 65.	18.1	75
1512	Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Global Pharmacovigilance Data. Advances in Therapy, 2020, 37, 4209-4219.	1.3	21
1513	Inhalation: A means to explore and optimize nintedanib's pharmacokinetic/pharmacodynamic relationship. Pulmonary Pharmacology and Therapeutics, 2020, 63, 101933.	1.1	9

#	Article	IF	Citations
1514	Oxygen for interstitial lung diseases. Current Opinion in Pulmonary Medicine, 2020, 26, 464-469.	1.2	7
1515	Systemic sclerosis-associated interstitial lung disease. Current Opinion in Pulmonary Medicine, 2020, 26, 487-495.	1.2	3
1516	Recent advances in rheumatoid arthritis-associated interstitial lung disease. Current Opinion in Pulmonary Medicine, 2020, 26, 477-486.	1.2	31
1517	Progressive fibrosing interstitial lung disease: treatable traits and therapeutic strategies. Current Opinion in Pulmonary Medicine, 2020, 26, 436-442.	1.2	18
1518	Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial. Annals of the Rheumatic Diseases, 2020, 79, 1478-1484.	0.5	46
1519	Exhaled Biomarkers in Idiopathic Pulmonary Fibrosisâ€"A Six-Month Follow-up Study in Patients Treated with Pirfenidone. Journal of Clinical Medicine, 2020, 9, 2523.	1.0	4
1520	Impact of angiotensin II type 1 and G-protein-coupled Mas receptor expression on the pulmonary performance of patients with idiopathic pulmonary fibrosis. Peptides, 2020, 133, 170384.	1.2	7
1521	Developments in lung transplantation over the past decade. European Respiratory Review, 2020, 29, 190132.	3.0	71
1522	Bi-directional communication: Conversations between fibroblasts and immune cells in systemic sclerosis. Journal of Autoimmunity, 2020, 113, 102526.	3.0	29
1523	Predictors of acute exacerbation in biopsy-proven idiopathic pulmonary fibrosis. Respiratory Investigation, 2020, 58, 177-184.	0.9	6
1524	Type I Collagen Signaling Regulates Opposing Fibrotic Pathways through Î±₂Î²₁ Integrin. American Journal of Respiratory Cell and Molecular Biology, 2020, 63, 613-622.	1.4	12
1525	A Comprehensive Review of Clinical Cardiotoxicity Incidence of FDA-Approved Small-Molecule Kinase Inhibitors. Frontiers in Pharmacology, 2020, 11, 891.	1.6	48
1526	Exhaled breath analysis by use of eNose technology: a novel diagnostic tool for interstitial lung disease. European Respiratory Journal, 2021, 57, 2002042.	3.1	28
1527	Anticoagulant Use and Bleeding Risk in Central European Patients with Idiopathic Pulmonary Fibrosis (IPF) Treated with Antifibrotic Therapy: Real-World Data from EMPIRE. Drug Safety, 2020, 43, 971-980.	1.4	13
1528	Imidazolium-based ionic liquid functionalized mesoporous silica nanoparticles as a promising nano-carrier: response surface strategy to investigate and optimize loading and release process for Lapatinib delivery. Pharmaceutical Development and Technology, 2020, 25, 1150-1161.	1.1	14
1529	Acute exacerbation of idiopathic interstitial pneumonias related to chemotherapy for lung cancer: nationwide surveillance in Japan. ERJ Open Research, 2020, 6, 00184-2019.	1.1	18
1530	Prognosis of idiopathic pulmonary fibrosis without anti-fibrotic therapy: a systematic review. European Respiratory Review, 2020, 29, 190158.	3.0	48
1531	Patient expectations, experiences and satisfaction with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a quantitative study. Respiratory Research, 2020, 21, 196.	1.4	16

#	Article	IF	Citations
1532	Patient-reported Outcomes for Clinical Trials in Idiopathic Pulmonary Fibrosis: New Opportunities to Understand How Patients Feel and Function. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1620-1622.	2.5	2
1533	The need for a holistic approach for SSc-ILD â€“ achievements and ambiguity in a devastating disease. Respiratory Research, 2020, 21, 197.	1.4	33
1534	Palliation of chronic breathlessness with morphine in patients with fibrotic interstitial lung disease â€“ a randomised placebo-controlled trial. Respiratory Research, 2020, 21, 195.	1.4	22
1535	A longâ€acting isomer of Acâ€SDKP attenuates pulmonary fibrosis through SRPK1 â€mediated PI3K / AKT and Smad2 pathway inhibition. IUBMB Life, 2020, 72, 2611-2626.	1.5	5
1536	New Perspectives on the Aberrant Alveolar Repair of Idiopathic Pulmonary Fibrosis. Frontiers in Cell and Developmental Biology, 2020, 8, 580026.	1.8	12
1537	Response to: â€˜Correspondence on â€˜Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trialâ€™â€™ by Bredemeier. Annals of the Rheumatic Diseases, 2022, 81, e251-e251.	0.5	0
1538	Early diagnosis of idiopathic pulmonary fibrosis: Closer to the goal?. European Journal of Internal Medicine, 2020, 80, 12-13.	1.0	1
1539	New developments in respiratory medicine: a primary immunodeficiency perspective. Current Opinion in Allergy and Clinical Immunology, 2020, 20, 549-556.	1.1	0
1540	Clinical features of patients with small cell lung cancer and idiopathic pulmonary fibrosis treated with chemotherapy or chemoradiotherapy. Therapeutic Advances in Respiratory Disease, 2020, 14, 175346662096386.	1.0	5
1541	Low-Frequency Intrapulmonary Percussive Ventilation Increases Aerosol Penetration in a 2-Compartment Physical Model of Fibrotic Lung Disease. Frontiers in Bioengineering and Biotechnology, 2020, 8, 1022.	2.0	1
1542	Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities. Lancet Respiratory Medicine,the, 2020, 8, 925-934.	5.2	198
1543	Novel Multitarget Therapies for Lung Cancer and Respiratory Disease. Molecules, 2020, 25, 3987.	1.7	14
1544	Rheumatoid Arthritisâ€“Associated Interstitial Lung Disease: Current Update on Prevalence, Risk Factors, and Pharmacologic Treatment. Current Treatment Options in Rheumatology, 2020, 6, 337-353.	0.6	35
1545	â€œA Chain Only as Strong as Its Weakest Linkâ€• An Up-to-Date Literature Review on the Bidirectional Interaction of Pulmonary Fibrosis and COVID-19. Journal of Proteome Research, 2020, 19, 4327-4338.	1.8	33
1546	Mediastinal lymph node enlargement in idiopathic pulmonary fibrosis: relationships with disease progression and pulmonary function trends. BMC Pulmonary Medicine, 2020, 20, 249.	0.8	7
1547	CA 19-9 serum levels in patients with end-stage idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILDs): Correlation with functional decline. Chronic Respiratory Disease, 2020, 17, 147997312095842.	1.0	9
1548	Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respiratory Medicine,the, 2020, 8, 963-974.	5.2	348
1549	Antifibrotic treatment improves clinical outcomes in patients with idiopathic pulmonary fibrosis: a propensity score matching analysis. Scientific Reports, 2020, 10, 15620.	1.6	38

#	Article	IF	Citations
1550	Thrombocytopaenia during nintedanib treatment in a patient with idiopathic pulmonary fibrosis. Respirology Case Reports, 2020, 8, e00628.	0.3	2
1551	Neuraxial anesthesia and nintedanib use: a word of caution. Regional Anesthesia and Pain Medicine, 2020, 45, 482.3-483.	1.1	0
1552	Real-World Data on Bleeding Risk and Anticoagulation in Patients with IPF Treated with Antifibrotics. Drug Safety, 2020, 43, 953-955.	1.4	1
1553	Identification of a unique temporal signature in blood and BAL associated with IPF progression. Scientific Reports, 2020, 10, 12049.	1.6	10
1554	Nintedanib can be used safely and effectively for idiopathic pulmonary fibrosis with predicted forced vital capacity â‰¤ 50%: A multi-center retrospective analysis. PLoS ONE, 2020, 15, e0236935.	1.1	11
1555	The Efficacy and Safety of First-Line Chemotherapy in Patients With Non-small Cell Lung Cancer and Interstitial Lung Disease: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2020, 10, 1636.	1.3	8
1556	Translational pharmacology of an inhaled small molecule Î±vÎ²6 integrin inhibitor for idiopathic pulmonary fibrosis. Nature Communications, 2020, 11, 4659.	5.8	65
1557	Changes in management of idiopathic pulmonary fibrosis: impact on disease severity and mortality. European Clinical Respiratory Journal, 2020, 7, 1807682.	0.7	7
1558	Cell Therapy for Idiopathic Pulmonary Fibrosis: Rationale and Progress to Date. BioDrugs, 2020, 34, 543-556.	2.2	8
1559	Radiation-induced lung toxicity â€“ cellular and molecular mechanisms of pathogenesis, management, and literature review. Radiation Oncology, 2020, 15, 214.	1.2	103
1560	Lung complications of Sjogren syndrome. European Respiratory Review, 2020, 29, 200021.	3.0	31
1561	Nintedanib in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation. Chest, 2020, 158, e89-e91.	0.4	10
1563	Transbronchial cryobiopsy increases diagnostic confidence in interstitial lung disease: a prospective multicentre trial. European Respiratory Journal, 2020, 56, 1901520.	3.1	41
1564	Gender equity in interstitial lung disease. Lancet Respiratory Medicine,the, 2020, 8, 842-843.	5.2	6
1565	Impact of Lung Biopsy on Lung Function in Idiopathic Pulmonary Fibrosis. Respiration, 2020, 99, 1101-1108.	1.2	3
1566	Infections and systemic sclerosis: an emerging challenge. Revista Colombiana De ReumatologÃa (English Edition), 2020, 27, 62-84.	0.1	1
1567	The effect of statin therapy on disease-related outcomes in idiopathic pulmonary fibrosis: A systematic review and meta-analysis. Respiratory Medicine and Research, 2021, 80, 100792.	0.4	1
1568	Galectin-3 levels are elevated following nintedanib treatment. Therapeutic Advances in Chronic Disease, 2020, 11, 204062232096841.	1.1	5

#	Article	IF	Citations
1569	The Role of MSC Therapy in Attenuating the Damaging Effects of the Cytokine Storm Induced by COVID-19 on the Heart and Cardiovascular System. Frontiers in Cardiovascular Medicine, 2020, 7, 602183.	1.1	26
1570	ILDGDB: a manually curated database of genomics, transcriptomics, proteomics and drug information for interstitial lung diseases. BMC Pulmonary Medicine, 2020, 20, 323.	0.8	3
1571	Supportive care of patients with fibrosing interstitial lung disease: answering a great clinical need. Breathe, 2020, 16, 200066.	0.6	0
1572	Nanoapproaches to Modifying Epigenetics of Epithelial Mesenchymal Transition for Treatment of Pulmonary Fibrosis. Frontiers in Pharmacology, 2020, 11, 607689.	1.6	28
1573	Pharmacokinetic evaluation of two pirfenidone formulations in patients with idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis. Heliyon, 2020, 6, e05279.	1.4	8
1574	Airway Redox Homeostasis and Inflammation Gone Awry: From Molecular Pathogenesis to Emerging Therapeutics in Respiratory Pathology. International Journal of Molecular Sciences, 2020, 21, 9317.	1.8	28
1575	Toward Realizing the Full Potential of Registries in Interstitial Lung Disease. Annals of the American Thoracic Society, 2020, 17, 1534-1535.	1.5	0
1576	Effects of Pirfenidone and Nintedanib on Markers of Systemic Oxidative Stress and Inflammation in Patients with Idiopathic Pulmonary Fibrosis: A Preliminary Report. Antioxidants, 2020, 9, 1064.	2.2	21
1577	Peritubular Capillary Rarefaction: An Underappreciated Regulator of CKD Progression. International Journal of Molecular Sciences, 2020, 21, 8255.	1.8	33
1578	Inhaled nintedanib is well-tolerated and delivers key pharmacokinetic parameters required to treat bleomycin-induced pulmonary fibrosis. Pulmonary Pharmacology and Therapeutics, 2020, 63, 101938.	1.1	20
1579	Human pluripotent stem cellâ€derived lung organoids: Potential applications in development and disease modeling. Wiley Interdisciplinary Reviews: Developmental Biology, 2021, 10, e399.	5.9	32
1581	Assessment and Management of Occupational Hypersensitivity Pneumonitis. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 3295-3309.	2.0	7
1582	Cardiovascular and Pulmonary Challenges After Treatment of Childhood Cancer. Pediatric Clinics of North America, 2020, 67, 1155-1170.	0.9	7
1583	Serial CT analysis in idiopathic pulmonary fibrosis: comparison of visual features that determine patient outcome. Thorax, 2020, 75, 648-654.	2.7	26
1584	Tannic acid alleviates experimental pulmonary fibrosis in mice by inhibiting inflammatory response and fibrotic process. Inflammopharmacology, 2020, 28, 1301-1314.	1.9	10
1585	Blockade of Pan-Fibroblast Growth Factor Receptors Mediates Bidirectional Effects in Lung Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2020, 63, 317-326.	1.4	8
1586	Fibrotic Hypersensitivity Pneumonitis: Diagnosis and Management. Lung, 2020, 198, 429-440.	1.4	23
1587	Idiopathic pulmonary fibrosis: Significance of the usual interstitial pneumonia (UIP) CT-scan patterns defined in new international guidelines. Respiratory Medicine and Research, 2020, 77, 72-78.	0.4	7

#	Article	IF	Citations
1588	Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. Lancet Respiratory Medicine,the, 2020, 8, 807-815.	5.2	802
1589	Longitudinal functional changes with clinically significant radiographic progression in idiopathic pulmonary fibrosis: are we following the right parameters?. Respiratory Research, 2020, 21, 119.	1.4	15
1590	A multicentre retrospective observational study on Polish experience of pirfenidone therapy in patients with idiopathic pulmonary fibrosis: the PolExPIR study. BMC Pulmonary Medicine, 2020, 20, 122.	0.8	9
1591	Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry. European Respiratory Journal, 2020, 56, 1902279.	3.1	102
1592	Smoking-associated interstitial lung disease: update and review. Expert Review of Respiratory Medicine, 2020, 14, 825-834.	1.0	23
1593	The world is not enough â€“ the value of increasing registry data in idiopathic pulmonary fibrosis. Respiratory Research, 2020, 21, 105.	1.4	3
1594	Opportunities to diagnose fibrotic lung diseases in routine care: A primary care cohort study. Respirology, 2020, 25, 1274-1282.	1.3	5
1595	Efficacy and safety of nintedanib in a Greek multicentre idiopathic pulmonary fibrosis registry: a retrospective, observational, cohort study. ERJ Open Research, 2020, 6, 00172-2019.	1.1	37
1596	Respiratory surveillance in mineral dust-exposed workers. Breathe, 2020, 16, 190632.	0.6	12
1597	A modified scar model with controlled tension on secondary wound healing in mice. Burns and Trauma, 2020, 8, tkaa013.	2.3	4
1598	Heart failure with preserved ejection fraction diagnosis and treatment: An updated review of the evidence. Progress in Cardiovascular Diseases, 2020, 63, 570-584.	1.6	53
1599	Idiopathic pulmonary fibrosis: airway volume measurement identifies progressive disease on computed tomography scans. ERJ Open Research, 2020, 6, 00290-2019.	1.1	8
1600	Update in Interstitial Lung Disease 2019. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 500-507.	2.5	17
1601	Rethinking respiratory function laboratories in the era of coronavirus disease 2019. Annals of Allergy, Asthma and Immunology, 2020, 125, 210-211.	0.5	3
1602	Asiaticoside attenuates bleomycin-induced pulmonary fibrosis in A2aRâ^'/â^' mice by promoting the BMP7/Smad1/5 signaling pathway. Biochemical and Biophysical Research Communications, 2020, 527, 662-667.	1.0	11
1603	A new therapy for systemic sclerosis-associated interstitial lung disease. Respiratory Investigation, 2020, 58, 227-229.	0.9	0
1604	Meaningful survival benefit for single lung transplantation in idiopathic pulmonary fibrosis patients over 65â€…years of age. European Respiratory Journal, 2020, 56, 1902413.	3.1	7
1605	TRIM72 promotes alveolar epithelial cell membrane repair and ameliorates lung fibrosis. Respiratory Research, 2020, 21, 132.	1.4	13

#	Article	IF	Citations
1606	Single versus bilateral lung transplantation in idiopathic pulmonary fibrosis: A systematic review and meta-analysis. PLoS ONE, 2020, 15, e0233732.	1.1	11
1607	Nintedanib inhibits epithelial-mesenchymal transition in A549 alveolar epithelial cells through regulation of the TGF-Î²/Smad pathway. Respiratory Investigation, 2020, 58, 275-284.	0.9	17
1608	Nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease. Expert Review of Clinical Immunology, 2020, 16, 547-560.	1.3	5
1609	Idiopathic pulmonary fibrosis: do scientists focus on publishing rather than on clinical relevance?. European Respiratory Journal, 2020, 55, 2000811.	3.1	0
1610	Multicenter phase 2 trial of nintedanib in advanced nonpancreatic neuroendocrine tumors. Cancer, 2020, 126, 3689-3697.	2.0	11
1611	Deep learning in interstitial lung diseaseâ€"how long until daily practice. European Radiology, 2020, 30, 6285-6292.	2.3	37
1612	Shedding light on developmental drugs for idiopathic pulmonary fibrosis. Expert Opinion on Investigational Drugs, 2020, 29, 797-808.	1.9	8
1613	The extended utility of antifibrotic therapy in progressive fibrosing interstitial lung disease. Expert Review of Respiratory Medicine, 2020, 14, 1001-1008.	1.0	6
1614	Cluster analysis based clinical profiling of Idiopathic Pulmonary Fibrosis patients according to comorbidities evident prior to diagnosis: a single-center observational study. European Journal of Internal Medicine, 2020, 80, 18-23.	1.0	5
1615	Interstitial lung diseases in children. Presse Medicale, 2020, 49, 103909.	0.8	26
1616	Comprehensive analysis of lncRNA-associated competing endogenous RNA network and immune infiltration in idiopathic pulmonary fibrosis. Journal of Thoracic Disease, 2020, 12, 1856-1865.	0.6	9
1617	Discovery of a Potent and Selective Covalent Inhibitor and Activity-Based Probe for the Deubiquitylating Enzyme UCHL1, with Antifibrotic Activity. Journal of the American Chemical Society, 2020, 142, 12020-12026.	6.6	51
1618	Protein tyrosine phosphatase-Î± amplifies transforming growth factor-Î²-dependent profibrotic signaling in lung fibroblasts. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2020, 319, L294-L311.	1.3	11
1619	Activation of JUN in fibroblasts promotes pro-fibrotic programme and modulates protective immunity. Nature Communications, 2020, 11, 2795.	5.8	69
1620	Rationale and protocol design for the TORG1835/NEXT-SHIP study: a phase II study of carboplatin, etoposide and nintedanib for unresectable limited/extensive disease small cell lung cancer with idiopathic pulmonary fibrosis. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592092343.	1.4	0
1621	Radiation-Induced Lung Fibrosis: Preclinical Animal Models and Therapeutic Strategies. Cancers, 2020, 12, 1561.	1.7	56
1622	Towards the Essence of Progressiveness: Bringing Progressive Fibrosing Interstitial Lung Disease (PF-ILD) to the Next Stage. Journal of Clinical Medicine, 2020, 9, 1722.	1.0	14
1623	Tolerability of nintedanib-related diarrhea in patients with idiopathic pulmonary fibrosis. Pulmonary Pharmacology and Therapeutics, 2020, 62, 101917.	1.1	9

#	Article	IF	Citations
1624	Morphomolecular motifs of pulmonary neoangiogenesis in interstitial lung diseases. European Respiratory Journal, 2020, 55, 1900933.	3.1	51
1625	Circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with idiopathic pulmonary fibrosis in the multicenter IPF-PRO Registry cohort. BMC Pulmonary Medicine, 2020, 20, 64.	0.8	59
1626	Contemporary approaches in the use of extracorporeal membrane oxygenation to support patients waiting for lung transplantation. Annals of Cardiothoracic Surgery, 2020, 9, 29-41.	0.6	9
1627	Improvement in Subjective Symptoms and Tolerability in Response to Nintedanib Treatment in Elderly Patients with Idiopathic Pulmonary Fibrosis. Journal of Clinical Medicine, 2020, 9, 755.	1.0	4
1628	Prominence of IL6, IGF, TLR, and Bioenergetics Pathway Perturbation in Lung Tissues of Scleroderma Patients With Pulmonary Fibrosis. Frontiers in Immunology, 2020, 11, 383.	2.2	40
1629	Nintedanib Inhibits Wnt3a-Induced Myofibroblast Activation by Suppressing the Src/Î²-Catenin Pathway. Frontiers in Pharmacology, 2020, 11, 310.	1.6	11
1630	Hope in Patients With Progressive Fibrosis Interstitial Lung Disease (PF-ILD). Clinical Pulmonary Medicine, 2020, 27, 38-38.	0.3	0
1631	The Prophylactic Use of Macrolide Antibiotics to Prevent Acute Exacerbations in Bronchiectasis. Clinical Pulmonary Medicine, 2020, 27, 37-38.	0.3	0
1632	NADPH Oxidase Inhibition in Fibrotic Pathologies. Antioxidants and Redox Signaling, 2020, 33, 455-479.	2.5	20
1633	FLT1: a potential therapeutic target in sepsis-associated ARDS?. Lancet Respiratory Medicine,the, 2020, 8, 219-220.	5.2	1
1634	Randomised controlled trials in systemic sclerosis: patient selection and endpoints for next generation trials. Lancet Rheumatology, The, 2020, 2, e173-e184.	2.2	12
1635	Pantoea agglomerans chronic exposure induces epithelial-mesenchymal transition in human lung epithelial cells and mice lungs. Ecotoxicology and Environmental Safety, 2020, 194, 110416.	2.9	5
1636	Emerging biomarkers in chronic lung allograft dysfunction. Expert Review of Molecular Diagnostics, 2020, 20, 467-475.	1.5	6
1637	Disease progression across the spectrum of idiopathic pulmonary fibrosis: A multicentre study. Respirology, 2020, 25, 1144-1151.	1.3	6
1638	Patientsâ€™ and Healthcare Professionalsâ€™ Experiences of Idiopathic Pulmonary Fibrosis Treatment with the Pirfenidone 801Âmg Tablet Formulation: A Multinational Survey. Pulmonary Therapy, 2020, 6, 93-105.	1.1	1
1640	Nanoengineered immunosuppressive therapeutics modulating M1/M2 macrophages into the balanced status for enhanced idiopathic pulmonary fibrosis therapy. Nanoscale, 2020, 12, 8664-8678.	2.8	18
1641	Effects of Nintedanib in an Animal Model of Liver Fibrosis. BioMed Research International, 2020, 2020, 1-9.	0.9	19
1642	Anti-oxidative effect of the tyrosine kinase inhibitor nintedanib: a potential therapy for chronic lung allograft dysfunction?. Experimental Lung Research, 2020, 46, 128-145.	0.5	8

#	Article	IF	Citations
1643	The importance of interventional timing in the bleomycin model of pulmonary fibrosis. European Respiratory Journal, 2020, 55, 1901105.	3.1	82
1644	Design and rationale of a multi-center, pragmatic, open-label randomized trial of antimicrobial therapy â€“ the study of clinical efficacy of antimicrobial therapy strategy using pragmatic design in Idiopathic Pulmonary Fibrosis (CleanUP-IPF) clinical trial. Respiratory Research, 2020, 21, 68.	1.4	17
1645	Nintedanib in patients with progressive fibrosing interstitial lung diseasesâ€”subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respiratory Medicine,the, 2020, 8, 453-460.	5.2	331
1646	Transcriptomic profiling reveals disease-specific characteristics of epithelial cells in idiopathic pulmonary fibrosis. Respiratory Research, 2020, 21, 165.	1.4	11
1647	Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society. Lancet Respiratory Medicine,the, 2020, 8, 726-737.	5.2	279
1648	Bring out the stethoscope. Respirology, 2020, 25, 1227-1228.	1.3	0
1649	Development and Initial Validation Analyses of the Living with Idiopathic Pulmonary Fibrosis Questionnaire. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1689-1697.	2.5	27
1650	Genetic Variation in CCL18 Gene Influences CCL18 Expression and Correlates with Survival in Idiopathic Pulmonary Fibrosisâ€”Part B. Journal of Clinical Medicine, 2020, 9, 1993.	1.0	10
1651	Early referral to palliative care in IPF â€“ pitfalls and opportunities in clinical trials. Respiratory Research, 2020, 21, 174.	1.4	2
1652	Safety and efficacy of abatacept in patients with treatment-resistant SARCoidosis (ABASARC) â€“ protocol for a multi-center, single-arm phase IIa trial. Contemporary Clinical Trials Communications, 2020, 19, 100575.	0.5	10
1653	Connective tissue disease-associated interstitial lung disease. Pulmonology, 2022, 28, 113-118.	1.0	23
1654	Novel Therapeutic Approaches for Pulmonary Manifestations of Systemic Sclerosis. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 878-880.	2.5	0
1655	Genetic Variation in CCL18 Gene Influences CCL18 Expression and Correlates with Survival in Idiopathic Pulmonary Fibrosis: Part A. Journal of Clinical Medicine, 2020, 9, 1940.	1.0	18
1656	Progressive fibrosing interstitial lung disease: we know it behaves badly, but what does that mean?. European Respiratory Journal, 2020, 55, 2000894.	3.1	1
1657	An aberrantly sustained emergency granulopoiesis response accelerates postchemotherapy relapse in MLL1-rearranged acute myeloid leukemia in mice. Journal of Biological Chemistry, 2020, 295, 9663-9675.	1.6	2
1658	The myofibroblast at a glance. Journal of Cell Science, 2020, 133, .	1.2	167
1659	Synthesis, structural properties, enzyme inhibition and molecular docking studies of (Z)-N'-(1-allyl-2-oxoindolin-3-ylidene) methanesulfono-hydrazide and (Z)-N'-(1-allyl-2-oxoindolin-3-ylidene)-3-nitrobenzenesulfono-hydrazide. Journal of Molecular Structure, 2020, 1221, 128880.	1.8	6
1660	Update in Imaging of Idiopathic Pulmonary Fibrosis. Advances in Clinical Radiology, 2020, 2, 81-100.	0.1	3

#	Article	IF	Citations
1661	Progressive Fibrosing Interstitial Lung Disease. A Proposed Integrated Algorithm for Management. Annals of the American Thoracic Society, 2020, 17, 1199-1203.	1.5	6
1662	Nintedanib Reduces Neutrophil Chemotaxis via Activating GRK2 in Bleomycin-Induced Pulmonary Fibrosis. International Journal of Molecular Sciences, 2020, 21, 4735.	1.8	22
1663	Histopathologic Assessment of Suspected Idiopathic Pulmonary Fibrosis: Where We Are and Where We Need to Go. Archives of Pathology and Laboratory Medicine, 2020, 144, 1477-1489.	1.2	14
1664	Nintedanib inhibits intrahepatic cholangiocarcinoma aggressiveness via suppression of cytokines extracted from activated cancer-associated fibroblasts. British Journal of Cancer, 2020, 122, 986-994.	2.9	44
1665	A Unique Protein Self-Assembling Nanoparticle with Significant Advantages in Vaccine Development and Production. Journal of Nanomaterials, 2020, 2020, 1-10.	1.5	20
1666	Therapeutic Options for the Treatment of Interstitial Lung Disease Related to Connective Tissue Diseases. A Narrative Review. Journal of Clinical Medicine, 2020, 9, 407.	1.0	40
1667	Impact of Depression on Patients With Idiopathic Pulmonary Fibrosis. Frontiers in Medicine, 2020, 7, 29.	1.2	18
1668	Probable usual interstitial pneumonia pattern on chest CT: is it sufficient for a diagnosis of idiopathic pulmonary fibrosis?. European Respiratory Journal, 2020, 55, 1802465.	3.1	25
1669	Antibody-based therapies for idiopathic pulmonary fibrosis. Expert Opinion on Biological Therapy, 2020, 20, 779-786.	1.4	13
1670	Deterioration of high-resolution computed tomography findings predicts disease progression after initial decline in forced vital capacity in idiopathic pulmonary fibrosis patients treated with pirfenidone. Respiratory Investigation, 2020, 58, 185-189.	0.9	5
1671	Parametric Timeâ€toâ€Event Model for Acute Exacerbations in Idiopathic Pulmonary Fibrosis. CPT: Pharmacometrics and Systems Pharmacology, 2020, 9, 87-95.	1.3	4
1672	Left ventricular dysfunction in an idiopathic pulmonary fibrosis patient on nintedanib. Respirology Case Reports, 2020, 8, e00533.	0.3	2
1673	Early decrease in erector spinae muscle area and future risk of mortality in idiopathic pulmonary fibrosis. Scientific Reports, 2020, 10, 2312.	1.6	38
1674	Reference values for high attenuation areas on chest CT in a healthy, neverâ€smoker, multiâ€ethnic sample: The MESA study. Respirology, 2020, 25, 855-862.	1.3	13
1675	Acute exacerbation of idiopathic pulmonary fibrosis: international survey and call for harmonisation. European Respiratory Journal, 2020, 55, 1901760.	3.1	61
1676	Patient gender bias on the diagnosis of idiopathic pulmonary fibrosis. Thorax, 2020, 75, 407-412.	2.7	30
1677	Acute Exacerbation of Interstitial Lung Disease in Adult Patients With Idiopathic Inflammatory Myopathies: A Retrospective Case-Control Study. Frontiers in Medicine, 2020, 7, 12.	1.2	12
1678	Small airways pathology in idiopathic pulmonary fibrosis: a retrospective cohort study. Lancet Respiratory Medicine,the, 2020, 8, 573-584.	5.2	70

#	Article	IF	Citations
1679	Sepsis-associated acute respiratory distress syndrome in individuals of European ancestry: a genome-wide association study. Lancet Respiratory Medicine,the, 2020, 8, 258-266.	5.2	38
1680	Three Steps to Cure Pulmonary Fibrosis. Step 1: The Runaway Train or Groundhog Day?. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 1172-1174.	2.5	4
1681	Efficacy and Safety of Traditional Chinese Medicine in Idiopathic Pulmonary Fibrosis: A Meta-Analysis. Evidence-based Complementary and Alternative Medicine, 2020, 2020, 1-11.	0.5	15
1682	Imaging research in fibrotic lung disease; applying deep learning to unsolved problems. Lancet Respiratory Medicine,the, 2020, 8, 1144-1153.	5.2	47
1683	An Open-label Study With Pirfenidone on Chronic Hypersensitivity Pneumonitis. Archivos De Bronconeumologia, 2020, 56, 163-169.	0.4	7
1684	SILAC-based proteomic profiling of the suppression of TGF-Î²1-induced lung fibroblast-to-myofibroblast differentiation by trehalose. Toxicology and Applied Pharmacology, 2020, 391, 114916.	1.3	9
1685	Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis. BMC Pulmonary Medicine, 2020, 20, 3.	0.8	61
1686	Maximizing Deep Lung Deposition in Healthy and Fibrotic Subjects During Jet Nebulization. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2020, 33, 108-115.	0.7	11
1687	Classification of Interstitial Lung Abnormality Patterns with an Ensemble of Deep Convolutional Neural Networks. Scientific Reports, 2020, 10, 338.	1.6	61
1688	Screening for YAP Inhibitors Identifies Statins as Modulators of Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2020, 62, 479-492.	1.4	36
1689	Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium. PharmacoEconomics - Open, 2020, 4, 449-458.	0.9	14
1690	A framework for advancing our understanding of cancer-associated fibroblasts. Nature Reviews Cancer, 2020, 20, 174-186.	12.8	2,012
1691	Characterizing Health Outcomes in Idiopathic Pulmonary Fibrosis using US Health Claims Data. Respiration, 2020, 99, 108-118.	1.2	8
1692	Silicaâ€related diseases in the modern world. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2805-2817.	2.7	184
1693	Applications and Approaches for Three-Dimensional Precision-Cut Lung Slices. Disease Modeling and Drug Discovery. American Journal of Respiratory Cell and Molecular Biology, 2020, 62, 681-691.	1.4	79
1694	Idiopathic Pulmonary Fibrosis: Pathogenesis and the Emerging Role of Long Non-Coding RNAs. International Journal of Molecular Sciences, 2020, 21, 524.	1.8	41
1695	Disease Severity and Quality of Life in Patients With Idiopathic Pulmonary Fibrosis. Chest, 2020, 157, 1188-1198.	0.4	21
1696	The European MultiPartner IPF registry (EMPIRE): validating long-term prognostic factors in idiopathic pulmonary fibrosis. Respiratory Research, 2020, 21, 11.	1.4	42

#	Article	IF	Citations
1697	Acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF): an overview of current and future therapeutic strategies. Expert Review of Respiratory Medicine, 2020, 14, 405-414.	1.0	19
1698	Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis. BMC Pulmonary Medicine, 2020, 20, 27.	0.8	26
1699	Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSISÂ® trials. Respiratory Research, 2020, 21, 36.	1.4	29
1700	Acute exacerbations in IPF: A clarion call for collaborative research. Respirology, 2020, 25, 572-573.	1.3	0
1701	Near-infrared-persistent luminescence/bioluminescence imaging tracking of transplanted mesenchymal stem cells in pulmonary fibrosis. Biomaterials Science, 2020, 8, 3095-3105.	2.6	11
1702	The dietary antioxidant quercetin reduces hallmarks of bleomycin-induced lung fibrogenesis in mice. BMC Pulmonary Medicine, 2020, 20, 112.	0.8	34
1703	Interstitial lung disease. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2020, 4, S21-S24.	0.2	0
1705	Juglanin alleviates bleomycin-induced lung injury by suppressing inflammation and fibrosis via targeting sting signaling. Biomedicine and Pharmacotherapy, 2020, 127, 110119.	2.5	27
1706	Design, synthesis and discovery of 2(1H)-quinolone derivatives for the treatment of pulmonary fibrosis through inhibition of TGF-Î²/smad dependent and independent pathway. European Journal of Medicinal Chemistry, 2020, 197, 112259.	2.6	11
1707	Clinical Decision-Making in Hypersensitivity Pneumonitis: Diagnosis and Management. Seminars in Respiratory and Critical Care Medicine, 2020, 41, 214-228.	0.8	11
1708	Nonspecific Interstitial Pneumonia. Seminars in Respiratory and Critical Care Medicine, 2020, 41, 184-201.	0.8	7
1709	Home Monitoring in Patients with Idiopathic Pulmonary Fibrosis. A Randomized Controlled Trial. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 393-401.	2.5	79
1710	Pulse oximetry saturation can predict prognosis of idiopathic pulmonary fibrosis. Respiratory Investigation, 2020, 58, 190-195.	0.9	6
1711	Practical Considerations for the Diagnosis and Treatment of Fibrotic Interstitial Lung Disease During the Coronavirus Disease 2019 Pandemic. Chest, 2020, 158, 1069-1078.	0.4	57
1712	Nintedanib-induced glomerular microangiopathy: a case report. CEN Case Reports, 2020, 9, 295-300.	0.5	8
1713	Effect of nintedanib on nonâ€small cell lung cancer in a patient with idiopathic pulmonary fibrosis: A case report and literature review. Thoracic Cancer, 2020, 11, 1720-1723.	0.8	22
1714	Combination Therapy with Nintedanib and Sarilumab for the Management of Rheumatoid Arthritis Related Interstitial Lung Disease. Case Reports in Medicine, 2020, 2020, 1-4.	0.3	9
1715	CXXC5 Attenuates Pulmonary Fibrosis in a Bleomycin-Induced Mouse Model and MLFs by Suppression of the CD40/CD40L Pathway. BioMed Research International, 2020, 2020, 1-15.	0.9	4

#	Article	IF	Citations
1716	Patient-reported outcome measures in systemic sclerosisâ€“related interstitial lung disease for clinical practice and clinical trials. Journal of Scleroderma and Related Disorders, 2020, 5, 48-60.	1.0	13
1717	The natural history of progressive fibrosing interstitial lung diseases. European Respiratory Journal, 2020, 55, 2000085.	3.1	148
1718	Vascular permeability in the fibrotic lung. European Respiratory Journal, 2020, 56, 1900100.	3.1	52
1719	Alveolar Epithelial Type II Cells as Drivers of Lung Fibrosis in Idiopathic Pulmonary Fibrosis. International Journal of Molecular Sciences, 2020, 21, 2269.	1.8	202
1720	Therapeutic Use of Extracellular Vesicles for Acute and Chronic Lung Disease. International Journal of Molecular Sciences, 2020, 21, 2318.	1.8	63
1721	Acute Exacerbation of Idiopathic Pulmonary Fibrosis. , 2020, , .		2
1722	Familial Interstitial Lung Disease. Seminars in Respiratory and Critical Care Medicine, 2020, 41, 229-237.	0.8	10
1723	Nintedanib in patients with systemic sclerosis-associated interstitial lung disease: A Japanese population analysis of the SENSCIS trial. Modern Rheumatology, 2021, 31, 141-150.	0.9	14
1724	Idiopathic pulmonary fibrosis and pulmonary hypertension: Heracles meets the Hydra. British Journal of Pharmacology, 2021, 178, 172-186.	2.7	20
1725	Refining the unilateral ureteral obstruction mouse model: No sham, no shame. Laboratory Animals, 2021, 55, 21-29.	0.5	3
1726	Diversity and Biology of Cancer-Associated Fibroblasts. Physiological Reviews, 2021, 101, 147-176.	13.1	521
1727	The characteristics and outcomes of patients with idiopathic pulmonary fibrosis admitted to the ICU with acute respiratory failure. Heart and Lung: Journal of Acute and Critical Care, 2021, 50, 192-196.	0.8	6
1728	Synergistic Inhibition of Renal Fibrosis by Nintedanib and Gefitinib in a Murine Model of Obstructive Nephropathy. Kidney Diseases (Basel, Switzerland), 2021, 7, 34-49.	1.2	14
1729	Effect of Nintedanib on Lung Function in Patients With Systemic Sclerosisâ€'Associated Interstitial Lung Disease: Further Analyses of a Randomized, Doubleâ€Blind, Placeboâ€Controlled Trial. Arthritis and Rheumatology, 2021, 73, 671-676.	2.9	24
1730	Molecular approach to the classification of chronic fibrosing lung diseaseâ€"there and back again. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 89-99.	1.4	1
1731	Multikinase inhibitor-induced liver injury in patients with cancer: A review for clinicians. Critical Reviews in Oncology/Hematology, 2021, 157, 103127.	2.0	8
1732	Mortality Trends of Idiopathic Pulmonary Fibrosis in the United States From 2004 Through 2017. Chest, 2021, 159, 228-238.	0.4	28
1733	Pirfenidone plus inhaled N-acetylcysteine for idiopathic pulmonary fibrosis: a randomised trial. European Respiratory Journal, 2021, 57, 2000348.	3.1	31

#	Article	IF	Citations
1734	A novel tree shrew model of pulmonary fibrosis. Laboratory Investigation, 2021, 101, 116-124.	1.7	9
1735	Chemokine Receptor 2â€“targeted Molecular Imaging in Pulmonary Fibrosis. A Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 78-89.	2.5	61
1736	Pharmacological management of Idiopathic Pulmonary Fibrosis: current and emerging options. Expert Opinion on Pharmacotherapy, 2021, 22, 191-204.	0.9	16
1737	Using forced vital capacity (FVC) in the clinic to monitor patients with idiopathic pulmonary fibrosis (IPF): pros and cons. Expert Review of Respiratory Medicine, 2021, 15, 175-181.	1.0	7
1738	Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs). Annals of the Rheumatic Diseases, 2021, 80, 143-150.	0.5	120
1739	Phase 2 trial to assess lebrikizumab in patients with idiopathic pulmonary fibrosis. European Respiratory Journal, 2021, 57, 1902442.	3.1	43
1740	Systematic Review and Meta-analysis of Pirfenidone, Nintedanib, and Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis. Annals of Pharmacotherapy, 2021, 55, 723-731.	0.9	23
1741	Standardization of the 6-min walk test in clinical trials of idiopathic pulmonary fibrosis. Contemporary Clinical Trials, 2021, 100, 106227.	0.8	4
1742	What parameters can be used to identify early idiopathic pulmonary fibrosis?. Respiratory Investigation, 2021, 59, 53-65.	0.9	7
1743	Overcoming interferon (IFN)-Î³ resistance ameliorates transforming growth factor (TGF)-Î²-mediated lung fibroblast-to-myofibroblast transition and bleomycin-induced pulmonary fibrosis. Biochemical Pharmacology, 2021, 183, 114356.	2.0	20
1744	BTS Clinical Statement on pulmonary sarcoidosis. Thorax, 2021, 76, 4-20.	2.7	90
1746	Rictor-targeting exosomal microRNA-16 ameliorates lung fibrosis by inhibiting the mTORC2-SPARC axis. Experimental Cell Research, 2021, 398, 112416.	1.2	12
1747	Beneficial impact of weight loss on respiratory function in interstitial lung disease patients with obesity. Respiratory Investigation, 2021, 59, 247-251.	0.9	9
1748	Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis. European Respiratory Journal, 2021, 57, 2002559.	3.1	106
1749	Safety and efficacy of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis and carrying a telomere-related gene mutation. European Respiratory Journal, 2021, 57, 2003198.	3.1	36
1750	The DIAMORFOSIS (DIAgnosis and Management Of lung canceR and FibrOSIS) survey: international survey and call for consensus. ERJ Open Research, 2021, 7, 00529-2020.	1.1	22
1751	Keloid disorder: Fibroblast differentiation and gene expression profile in fibrotic skin diseases. Experimental Dermatology, 2021, 30, 132-145.	1.4	59
1752	Fibroblasts and their responses to chronic injury in pulmonary fibrosis. Seminars in Arthritis and Rheumatism, 2021, 51, 310-317.	1.6	12

#	Article	IF	Citations
1754	Nintedanib promotes antitumour immunity and shows antitumour activity in combination with PD-1 blockade in mice: potential role of cancer-associated fibroblasts. British Journal of Cancer, 2021, 124, 914-924.	2.9	37
1755	NOâ€sensitive guanylyl cyclase in the lung. British Journal of Pharmacology, 2021, , .	2.7	8
1756	Betulinic acid attenuated bleomycin-induced pulmonary fibrosis by effectively intervening Wnt/Î²-catenin signaling. Phytomedicine, 2021, 81, 153428.	2.3	14
1757	Targeting the tumor microenvironment in cholangiocarcinoma: implications for therapy. Expert Opinion on Investigational Drugs, 2021, 30, 429-438.	1.9	13
1758	Discharge may not be the end of treatment: Pay attention to pulmonary fibrosis caused by severe COVIDâ€19. Journal of Medical Virology, 2021, 93, 1378-1386.	2.5	70
1759	Real-World Study Analysing Progression and Survival of Patients with Idiopathic Pulmonary Fibrosis with Preserved Lung Function on Antifibrotic Treatment. Advances in Therapy, 2021, 38, 268-277.	1.3	13
1760	Tolerability and safety of nintedanib in elderly patients with idiopathic pulmonary fibrosis. Respiratory Investigation, 2021, 59, 99-105.	0.9	13
1761	Leukocyte telomere length and mycophenolate therapy in chronic hypersensitivity pneumonitis. European Respiratory Journal, 2021, 57, 2002872.	3.1	32
1762	Associations of Ï‰-3 Fatty Acids With Interstitial Lung Disease and Lung Imaging Abnormalities Among Adults. American Journal of Epidemiology, 2021, 190, 95-108.	1.6	11
1763	Clinical Molecular Imaging of Pulmonary CXCR4 Expression to Predict Outcome of Pirfenidone Treatment in Idiopathic Pulmonary Fibrosis. Chest, 2021, 159, 1094-1106.	0.4	23
1764	Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respiratory Medicine,the, 2021, 9, 85-95.	5.2	96
1765	Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study). European Respiratory Journal, 2021, 57, 2002718.	3.1	103
1766	Effectiveness of Proton Pump Inhibitors in Idiopathic Pulmonary Fibrosis. Chest, 2021, 159, 673-682.	0.4	31
1767	MUC4 is overexpressed in idiopathic pulmonary fibrosis and collaborates with transforming growth factor Î² inducing fibrotic responses. Mucosal Immunology, 2021, 14, 377-388.	2.7	16
1768	Progressive fibrosing interstitial lung diseases: A new concept and indication of nintedanib. Modern Rheumatology, 2021, 31, 13-19.	0.9	20
1769	Cause of mortality and sarcopenia in patients with idiopathic pulmonary fibrosis receiving <scp>antifibrotic</scp> therapy. Respirology, 2021, 26, 171-179.	1.3	24
1770	Deep Learning of Computed Tomography Virtual Wedge Resection for Prediction of Histologic Usual Interstitial Pneumonitis. Annals of the American Thoracic Society, 2021, 18, 51-59.	1.5	22
1771	Delphi Consensus Recommendations on Management of Dosing, Adverse Events, and Comorbidities in the Treatment of Idiopathic Pulmonary Fibrosis with Nintedanib. Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, 2021, 15, 117954842110060.	0.5	7

#	Article	IF	Citations
1772	Pulmonary fibrosing diseases: A short review and a therapeutic alternative. GSC Biological and Pharmaceutical Sciences, 2021, 14, 137-148.	0.1	0
1773	Spectrum of Pulmonary Fibrosis from Interstitial Lung Abnormality to Usual Interstitial Pneumonia: Importance of Identification and Quantification of Traction Bronchiectasis in Patient Management. Korean Journal of Radiology, 2021, 22, 811.	1.5	20
1774	Treatment of systemic sclerosis-associated interstitial lung disease: a work in progress. Lancet Respiratory Medicine,the, 2021, 9, 5-7.	5.2	4
1775	Pneumothorax in patients with idiopathic pulmonary fibrosis: a real-world experience. BMC Pulmonary Medicine, 2021, 21, 5.	0.8	10
1776	Lung organoids and other preclinical models of pulmonary fibrosis. QJM - Monthly Journal of the Association of Physicians, 2021, 114, 167-173.	0.2	9
1777	Patients With Idiopathic Pulmonary Fibrosis Admitted to the ICU With Acute Respiratory Failureâ€"A Reevaluation of the Risk Factors and Outcomes. Journal of Intensive Care Medicine, 2022, 37, 342-351.	1.3	7
1778	Update in Diagnosis of Idiopathic Pulmonary Fibrosis and Interstitial Lung Abnormality. Journal of the Korean Society of Radiology, 2021, 82, 770.	0.1	0
1779	Radiation-induced lung injury: current evidence. BMC Pulmonary Medicine, 2021, 21, 9.	0.8	131
1780	Antifibrotic Therapy: Is There a Role in Myositis-Interstitial Lung Disease?. Respiration, 2021, 100, 923-932.	1.2	1
1781	Clinical Significance of Continuable Treatment with Nintedanib Over 12 Months for Idiopathic Pulmonary Fibrosis in a Real-World Setting. Drug Design, Development and Therapy, 2021, Volume 15, 223-230.	2.0	10
1782	Idiopathic pulmonary fibrosis patients with severe physiologic impairment: characteristics and outcomes. Respiratory Research, 2021, 22, 5.	1.4	10
1783	Monitoring and management of fibrosing interstitial lung diseases: a narrative review for practicing clinicians. Therapeutic Advances in Respiratory Disease, 2021, 15, 175346662110397.	1.0	11
1784	Histologic factors associated with nintedanib efficacy in patients with idiopathic pulmonary fibrosis. PLoS ONE, 2021, 16, e0245147.	1.1	3
1785	Three cases of sequential treatment with nintedanib following pulsed-dose corticosteroids for acute exacerbation of interstitial lung diseases. Respiratory Medicine Case Reports, 2021, 33, 101385.	0.2	3
1786	Idiopathic pulmonary fibrosisâ€"A challenging disease with new horizons and changing therapeutic landscape. Clinical Respiratory Journal, 2021, 15, 369-373.	0.6	0
1787	Establishing content-validity of a disease-specific health-related quality of life instrument for patients with chronic hypersensitivity pneumonitis. Journal of Patient-Reported Outcomes, 2021, 5, 9.	0.9	4
1788	The efficacy of nintedanib in 158 patients with idiopathic pulmonary fibrosis in real-world settings: A multicenter retrospective study. SAGE Open Medicine, 2021, 9, 205031212110233.	0.7	5
1789	Fibrotic interstitial lung disease occurring as sequelae of COVID-19 pneumonia despite concomitant steroids. Lung India, 2021, 38, 61.	0.3	15

#	Article	IF	Citations
1790	Serum calprotectin as new biomarker for disease severity in idiopathic pulmonary fibrosis: a cross-sectional study in two independent cohorts. BMJ Open Respiratory Research, 2021, 8, e000827.	1.2	13
1791	Weiterentwicklung in der Therapie rheumatischer Erkrankungen bei Kindern und Jugendlichen. Springer Reference Medizin, 2021, , 1-19.	0.0	0
1792	Interstitial lung abnormality (ILA) and nonspecific interstitial pneumonia (NSIP). European Journal of Radiology Open, 2021, 8, 100336.	0.7	8
1793	ERS International Congress 2020: highlights from the Thoracic Surgery and Transplantation Assembly. ERJ Open Research, 2021, 7, 00743-2020.	1.1	0
1794	New pulmonary rehabilitation exercise for pulmonary fibrosis to improve the pulmonary function and quality of life of patients with idiopathic pulmonary fibrosis: a randomized control trial. Annals of Palliative Medicine, 2021, 10, 0-0.	0.5	10
1796	Targeting Molecular and Cellular Mechanisms in Idiopathic Pulmonary Fibrosis. , 2021, , 287-310.		0
1798	Mouse Models of Lung Fibrosis. Methods in Molecular Biology, 2021, 2299, 291-321.	0.4	8
1799	Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial. Lancet Respiratory Medicine,the, 2021, 9, 96-106.	5.2	118
1800	Co-delivery of siPTPN13 and siNOX4 via (myo)fibroblast-targeting polymeric micelles for idiopathic pulmonary fibrosis therapy. Theranostics, 2021, 11, 3244-3261.	4.6	14
1802	Efficacy and Tolerability of Nintedanib in Idiopathic-Inflammatory-Myopathy-Related Interstitial Lung Disease: A Pilot Study. Frontiers in Medicine, 2021, 8, 626953.	1.2	17
1803	Power and sample size for random coefficient regression models in randomized experiments with monotone missing data. Biometrical Journal, 2021, 63, 806-824.	0.6	4
1804	Association of proangiogenic and profibrotic serum markers with lung function and quality of life in sarcoidosis. PLoS ONE, 2021, 16, e0247197.	1.1	3
1805	Use of nintedanib in interstitial lung disease other than idiopathic pulmonary fibrosis: much caution is warranted. Pulmonary Pharmacology and Therapeutics, 2021, 66, 101987.	1.1	6
1806	Baseline characteristics and survival of patients of idiopathic pulmonary fibrosis: a longitudinal analysis of the Swedish IPF Registry. Respiratory Research, 2021, 22, 40.	1.4	36
1807	Clinical course of IPF in Italian patients during 12Âmonths of observation: results from the FIBRONET observational study. Respiratory Research, 2021, 22, 66.	1.4	11
1808	Chronic Lung Allograft Dysfunction: Review of CT and Pathologic Findings. Radiology: Cardiothoracic Imaging, 2021, 3, e200314.	0.9	15
1809	Pulmonary rehabilitation for interstitial lung disease. The Cochrane Library, 2021, 2021, CD006322.	1.5	67
1810	Transcriptional and Proteomic Characterization of Telomere-Induced Senescence in a Human Alveolar Epithelial Cell Line. Frontiers in Medicine, 2021, 8, 600626.	1.2	8

#	Article	IF	Citations
1812	Hermanskyâ€“Pudlak syndrome pulmonary fibrosis: a rare inherited interstitial lung disease. European Respiratory Review, 2021, 30, 200193.	3.0	18
1813	Long nonâ€coding RNAs: Promising new targets in pulmonary fibrosis. Journal of Gene Medicine, 2021, 23, e3318.	1.4	25
1814	Hermansky-Pudlak syndrome-2 alters mitochondrial homeostasis in the alveolar epithelium of the lung. Respiratory Research, 2021, 22, 49.	1.4	5
1815	The natural history of idiopathic pulmonary fibrosis in a large European population: the role of age, sex and comorbidities. Internal and Emergency Medicine, 2021, 16, 1793-1802.	1.0	18
1816	Practical Imaging Interpretation in Patients Suspected of Having Idiopathic Pulmonary Fibrosis: Official Recommendations from the Radiology Working Group of the Pulmonary Fibrosis Foundation. Radiology: Cardiothoracic Imaging, 2021, 3, e200279.	0.9	27
1817	GSE4â€loaded nanoparticles a potential therapy for lung fibrosis that enhances pneumocyte growth, reduces apoptosis and DNA damage. FASEB Journal, 2021, 35, e21422.	0.2	9
1818	Lung gene expression and single cell analyses reveal two subsets of idiopathic pulmonary fibrosis (IPF) patients associated with different pathogenic mechanisms. PLoS ONE, 2021, 16, e0248889.	1.1	10
1819	Initial therapeutic dose of corticosteroid for an acute exacerbation of IPF is associated with subsequent early recurrence of another exacerbation. Scientific Reports, 2021, 11, 5782.	1.6	8
1820	Immune Stroma in Lung Cancer and Idiopathic Pulmonary Fibrosis: A Common Biologic Landscape?. International Journal of Molecular Sciences, 2021, 22, 2882.	1.8	10
1821	FGF/FGFR Signaling in Hepatocellular Carcinoma: From Carcinogenesis to Recent Therapeutic Intervention. Cancers, 2021, 13, 1360.	1.7	24
1822	Blood Transcriptomics Predicts Progression of Pulmonary Fibrosis and Associated Natural Killer Cells. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 197-208.	2.5	27
1823	Real-world retrospective observational study exploring the effectiveness and safety of antifibrotics in idiopathic pulmonary fibrosis. BMJ Open Respiratory Research, 2021, 8, e000782.	1.2	22
1824	Methicillin-Resistant Staphylococcus Aureus (MRSA) Pyruvate Kinase (PK) Inhibitors and their Antimicrobial Activities. Current Medicinal Chemistry, 2022, 29, 908-923.	1.2	1
1825	Exposure to PM2.5 is a risk factor for acute exacerbation of surgically diagnosed idiopathic pulmonary fibrosis: a caseâ€“control study. Respiratory Research, 2021, 22, 80.	1.4	23
1826	Nintedanib: A Review in Fibrotic Interstitial Lung Diseases. Drugs, 2021, 81, 575-586.	4.9	51
1827	Pharmacological Interventions for Pulmonary Involvement in Rheumatic Diseases. Pharmaceuticals, 2021, 14, 251.	1.7	2
1828	Gene therapy strategies for idiopathic pulmonary fibrosis: recent advances, current challenges, and future directions. Molecular Therapy - Methods and Clinical Development, 2021, 20, 483-496.	1.8	21
1829	Progression in the Management of Non-Idiopathic Pulmonary Fibrosis Interstitial Lung Diseases, Where Are We Now and Where We Would Like to Be. Journal of Clinical Medicine, 2021, 10, 1330.	1.0	11

#	Article	IF	Citations
1830	Endâ€toâ€end domain knowledgeâ€assisted automatic diagnosis of idiopathic pulmonary fibrosis (IPF) using computed tomography (CT). Medical Physics, 2021, 48, 2458-2467.	1.6	3
1831	The Diagnosis and Treatment of Pulmonary Fibrosis. Deutsches Ärzteblatt International, 2021, 118, .	0.6	10
1832	Membrane particles from mesenchymal stromal cells reduce the expression of fibrotic markers on pulmonary cells. PLoS ONE, 2021, 16, e0248415.	1.1	1
1833	A mixed-methods pilot study of handheld fan for breathlessness in interstitial lung disease. Scientific Reports, 2021, 11, 6874.	1.6	8
1834	Pharmacological treatment of idiopathic pulmonary fibrosis and fibrosing interstitial lung diseases: current trends and future directions. Precision and Future Medicine, 2021, 5, 31-40.	0.5	2
1835	Study design of a randomised, placebo-controlled trial of nintedanib in children and adolescents with fibrosing interstitial lung disease. ERJ Open Research, 2021, 7, 00805-2020.	1.1	14
1836	Interstitial lung disease. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2021, 5, 93-96.	0.2	0
1837	Remarkable response of nonâ€small cell lung cancer to nintedanib treatment in a patient with idiopathic pulmonary fibrosis. Thoracic Cancer, 2021, 12, 1457-1460.	0.8	12
1838	Management and Prognosis of Interstitial Lung Disease With Lung Cancer (ILD-LC): A Real-World Cohort From Three Medical Centers in China. Frontiers in Molecular Biosciences, 2021, 8, 660800.	1.6	7
1839	Evaluation of the efficacy of pirfenidone in progressive chronic hypersensitivity pneumonitis. Egyptian Journal of Bronchology, 2021, 15, .	0.3	1
1840	Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases. Respiratory Research, 2021, 22, 84.	1.4	33
1841	Cardiovascular safety of the tyrosine kinase inhibitor nintedanib. British Journal of Clinical Pharmacology, 2021, 87, 3690-3698.	1.1	8
1842	The Protective Effects of IL-31RA Deficiency During Bleomycin-Induced Pulmonary Fibrosis. Frontiers in Immunology, 2021, 12, 645717.	2.2	13
1843	A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating Nintedanib Versus Placebo as Prophylaxis Against Radiation Pneumonitis in Patients With Unresectable NSCLC Undergoing Chemoradiation Therapy. Journal of Thoracic Oncology, 2021, 16, e19-e20.	0.5	10
1844	The Effect of Nintedanib on T-Cell Activation, Subsets and Functions. Drug Design, Development and Therapy, 2021, Volume 15, 997-1011.	2.0	11
1845	Disparate Interferon Signaling and Shared Aberrant Basaloid Cells in Single-Cell Profiling of Idiopathic Pulmonary Fibrosis and Systemic Sclerosis-Associated Interstitial Lung Disease. Frontiers in Immunology, 2021, 12, 595811.	2.2	54
1846	Simple method for detecting idiopathic interstitial pneumonias by measuring vertical lung length on chest X-ray. Scientific Reports, 2021, 11, 7669.	1.6	2
1847	Wound dehiscence with nintedanib after cardiac surgery: A cautionary tale. JTCVS Techniques, 2021, 6, 99-101.	0.2	6

#	Article	IF	Citations
1848	Changes in Neutrophilâ€“Lymphocyte or Plateletâ€“Lymphocyte Ratios and Their Associations with Clinical Outcomes in Idiopathic Pulmonary Fibrosis. Journal of Clinical Medicine, 2021, 10, 1427.	1.0	17
1849	Remote Assessment of Lung Disease and Impact on Physical and Mental Health (RALPMH): Protocol for a Prospective Observational Study. JMIR Research Protocols, 2021, 10, e28873.	0.5	10
1850	Diverse Pathological Findings of Interstitial Lung Disease in a Patient with Dyskeratosis Congenita. Internal Medicine, 2021, 60, 1257-1263.	0.3	3
1851	The transition from normal lung anatomy to minimal and established fibrosis in idiopathic pulmonary fibrosis (IPF). EBioMedicine, 2021, 66, 103325.	2.7	16
1852	Protective Effects of Extracellular Matrix-Derived Hydrogels in Idiopathic Pulmonary Fibrosis. Tissue Engineering - Part B: Reviews, 2022, 28, 517-530.	2.5	5
1853	Antifibrotic drugs for pulmonary sarcoidosis: A treatment in search of an indication. Respiratory Medicine, 2021, 180, 106371.	1.3	5
1854	Inhibition of the Proliferation of Human Lung Fibroblasts by Prostacyclin Receptor Agonists is Linked to a Sustained cAMP Signal in the Nucleus. Frontiers in Pharmacology, 2021, 12, 669227.	1.6	16
1855	Fibroblasts as immune regulators in infection, inflammation and cancer. Nature Reviews Immunology, 2021, 21, 704-717.	10.6	229
1856	Current and future treatment for idiopathic pulmonary fibrosis. Journal of the Korean Medical Association, 2021, 64, 256-263.	0.1	1
1857	Extracellular matrix proteins produced by stromal cells in idiopathic pulmonary fibrosis and lung adenocarcinoma. PLoS ONE, 2021, 16, e0250109.	1.1	15
1858	H. sinensis mycelium inhibits epithelial-mesenchymal transition by inactivating the midkine pathway in pulmonary fibrosis. Frontiers of Medicine, 2021, 15, 313-329.	1.5	3
1859	Impact of bronchoalveolar lavage lymphocytosis on the effects of anti-inflammatory therapy in idiopathic non-specific interstitial pneumonia, idiopathic pleuroparenchymal fibroelastosis, and unclassifiable idiopathic interstitial pneumonia. Respiratory Research, 2021, 22, 115.	1.4	5
1860	Precision medicine in idiopathic pulmonary fibrosis therapy: From translational research to patient-centered care. Current Opinion in Pharmacology, 2021, 57, 71-80.	1.7	7
1861	Pulmonary fibrosis secondary to COVID-19: a narrative review. Expert Review of Respiratory Medicine, 2021, 15, 791-803.	1.0	64
1862	Post-COVID-19 pneumonia lung fibrosis: a worrisome sequelae in surviving patients. Egyptian Journal of Radiology and Nuclear Medicine, 2021, 52, .	0.3	60
1863	Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis who are elderly or have comorbidities. Respiratory Research, 2021, 22, 125.	1.4	22
1864	Regulatory Immune Cells in Idiopathic Pulmonary Fibrosis: Friends or Foes?. Frontiers in Immunology, 2021, 12, 663203.	2.2	33
1865	Prognostic classification in acute exacerbation of idiopathic pulmonary fibrosis: a multicentre retrospective cohort study. Scientific Reports, 2021, 11, 9120.	1.6	9

#	Article	IF	Citations
1866	Prognostic role of MUC5B rs35705950 genotype in patients with idiopathic pulmonary fibrosis (IPF) on antifibrotic treatment. Respiratory Research, 2021, 22, 98.	1.4	21
1867	Isolation and characterisation of lymphatic endothelial cells from lung tissues affected by lymphangioleiomyomatosis. Scientific Reports, 2021, 11, 8406.	1.6	5
1868	Inhibitory effects of somatostatin analogue in bleomycin-induced pulmonary fibrosis. Experimental Lung Research, 2021, 47, 280-288.	0.5	1
1871	The Role of Macrophages in the Development of Acute and Chronic Inflammatory Lung Diseases. Cells, 2021, 10, 897.	1.8	97
1872	The NLRP3-Inflammasome-Caspase-1 Pathway Is Upregulated in Idiopathic Pulmonary Fibrosis and Acute Exacerbations and Is Inducible by Apoptotic A549 Cells. Frontiers in Immunology, 2021, 12, 642855.	2.2	27
1873	Exposure-efficacy analyses of nintedanib in patients with chronic fibrosing interstitial lung disease. Respiratory Medicine, 2021, 180, 106369.	1.3	9
1874	Treatment of chronic fibrosing interstitial lung diseases. Journal of the Korean Medical Association, 2021, 64, 277-285.	0.1	1
1875	Current advances in the treatment of autoimmune-associated interstitial lung diseases. Journal of the Korean Medical Association, 2021, 64, 264-276.	0.1	0
1876	Endobronchial autologous bone marrowâ€“mesenchymal stromal cells in idiopathic pulmonary fibrosis: a phase I trial. ERJ Open Research, 2021, 7, 00773-2020.	1.1	10
1877	A role for cardiopulmonary exercise testing in detecting physiological changes underlying health status in Idiopathic pulmonary fibrosis: a feasibility study. BMC Pulmonary Medicine, 2021, 21, 147.	0.8	1
1878	Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis. Respiratory Research, 2021, 22, 135.	1.4	18
1879	Usual interstitial pneumonia progressing to nonspecific interstitial pneumonia-like pattern on high-resolution CT with histologic confirmation. Radiology Case Reports, 2021, 16, 1019-1022.	0.2	1
1880	Aberrant B Cell Receptor Signaling in NaÃ¯ve B Cells from Patients with Idiopathic Pulmonary Fibrosis. Cells, 2021, 10, 1321.	1.8	12
1882	Chronic Lung Allograft Dysfunction: Evolving Concepts and Therapies. Seminars in Respiratory and Critical Care Medicine, 2021, 42, 392-410.	0.8	4
1883	Deep Learning Approach for Auto-Detecting Idiopathic Pulmonary Fibrosis Prediction. , 2021, , .		0
1884	Antibody-mediated depletion of CCR10+ EphA3+ cells ameliorates fibrosis in IPF. JCI Insight, 2021, 6, .	2.3	9
1885	Antifibrotic Drugs for COVID-19: From Orphan Drugs to Blockbusters?. Current Respiratory Medicine Reviews, 2021, 17, 8-12.	0.1	2
1886	Nurse-Led Palliative Care Clinical Trial Improves Knowledge and Preparedness in Caregivers of Patients with Idiopathic Pulmonary Fibrosis. Annals of the American Thoracic Society, 2021, 18, 1811-1821.	1.5	25

#	Article	IF	Citations
1887	The long non-coding RNA PFI protects against pulmonary fibrosis by interacting with splicing regulator SRSF1. Cell Death and Differentiation, 2021, 28, 2916-2930.	5.0	22
1888	Pirfenidone in patients with non-IPF progressive fibrotic interstitial lung diseases: expert guidance is urgently needed. Lancet Respiratory Medicine,the, 2021, 9, 437-438.	5.2	5
1889	Safety and tolerability of combination therapy with pirfenidone and nintedanib for idiopathic pulmonary fibrosis: A multicenter retrospective observational study in Japan. Respiratory Investigation, 2021, 59, 819-826.	0.9	10
1890	An updated safety review of the drug treatments for idiopathic pulmonary fibrosis. Expert Opinion on Drug Safety, 2021, 20, 1035-1048.	1.0	6
1891	A study design for statistical learning technique to predict radiological progression with an application of idiopathic pulmonary fibrosis using chest CT images. Contemporary Clinical Trials, 2021, 104, 106333.	0.8	3
1892	Baseline plasma KL-6 level predicts adverse outcomes in patients with idiopathic pulmonary fibrosis receiving nintedanib: a retrospective real-world cohort study. BMC Pulmonary Medicine, 2021, 21, 165.	0.8	9
1893	Recent advances in the diagnosis and management of interstitial pneumonia with autoimmune features: the perspective of rheumatologists. Korean Journal of Internal Medicine, 2021, 36, 515-526.	0.7	3
1894	Azithromycin for the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis: A Randomized Controlled Crossover Trial. Annals of the American Thoracic Society, 2021, 18, 2018-2026.	1.5	19
1895	Patient-reported outcomes and patient-reported outcome measures in interstitial lung disease: where to go from here?. European Respiratory Review, 2021, 30, 210026.	3.0	17
1896	TGFÎ²1 induces resistance of human lung myofibroblasts to cell death via downâ€regulation of TRPA1 channels. British Journal of Pharmacology, 2021, 178, 2948-2962.	2.7	8
1897	Antifibrotic Therapies and Progressive Fibrosing Interstitial Lung Disease (PF-ILD): Building on INBUILD. Journal of Clinical Medicine, 2021, 10, 2285.	1.0	18
1898	Micellar Hyaluronidase and Spiperone as a Potential Treatment for Pulmonary Fibrosis. International Journal of Molecular Sciences, 2021, 22, 5599.	1.8	6
1899	PerFECT 2.0: A Web-Based Platform Designed to Facilitate and Support the Diagnosis of Patients with Idiopathic Pulmonary Fibrosis in Italy. Pulmonary Therapy, 2021, 7, 267-279.	1.1	0
1900	Postâ€translational regulation of PGCâ€1Î± modulates fibrotic repair. FASEB Journal, 2021, 35, e21675.	0.2	6
1901	Longitudinal Changes in Clinical Features, Management, and Outcomes of Idiopathic Pulmonary Fibrosis. A Nationwide Cohort Study. Annals of the American Thoracic Society, 2021, 18, 780-787.	1.5	14
1902	Putting the spotlight on macrophage-derived cathepsin in the pathophysiology of obliterative bronchiolitis. European Respiratory Journal, 2021, 57, 2004607.	3.1	1
1903	COVIDâ€19 and pulmonary fibrosis: A potential role for lung epithelial cells and fibroblasts. Immunological Reviews, 2021, 302, 228-240.	2.8	126
1904	Increased monocyte count and red cell distribution width as prognostic biomarkers in patients with Idiopathic Pulmonary Fibrosis. Respiratory Research, 2021, 22, 140.	1.4	37

#	Article	IF	Citations
1905	Effect of a Patient Support Program for Idiopathic Pulmonary Fibrosis Patients on Medication Persistence: A Retrospective Database Analysis. Advances in Therapy, 2021, 38, 3888-3899.	1.3	6
1906	Use of Nintedanib and Pirfenidone in Nonâ€"Idiopathic Pulmonary Fibrosis Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 92-94.	2.5	2
1907	A systematic review of the incidence, risk factors and prognosis of acute exacerbation of systemic autoimmune disease-associated interstitial lung disease. BMC Pulmonary Medicine, 2021, 21, 150.	0.8	11
1908	Treatment of Idiopathic Pulmonary Fibrosis. Cureus, 2021, 13, e15360.	0.2	4
1909	Ground glass and fibrotic change in children with surfactant protein C dysfunction mutations. Pediatric Pulmonology, 2021, 56, 2223-2231.	1.0	10
1910	Travel Distance to Subspecialty Clinic and Outcomes in Patients with Fibrotic Interstitial Lung Disease. Annals of the American Thoracic Society, 2022, 19, 20-27.	1.5	16
1911	Identification of Potential Pathogenic Super-Enhancers-Driven Genes in Pulmonary Fibrosis. Frontiers in Genetics, 2021, 12, 644143.	1.1	6
1912	Antifibrotic Role of Nintedanib in Tracheal Stenosis After a Tracheal Wound. Laryngoscope, 2021, 131, E2496-E2505.	1.1	11
1913	The safety of nintedanib for the treatment of interstitial lung disease: A systematic review and meta-analysis of randomized controlled trials. PLoS ONE, 2021, 16, e0251636.	1.1	13
1914	Awake or intubated surgery in diagnosis for interstitial lung diseases? A prospective study. ERJ Open Research, 2021, 7, 00630-2020.	1.1	12
1915	Anti-angiogenic Agents: A Review on Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) Inhibitors. Current Medicinal Chemistry, 2021, 28, 2540-2564.	1.2	27
1916	Molecular pathways in idiopathic pulmonary fibrosis pathogenesis: Transcending barriers to optimally targeted pharmacotherapies. EBioMedicine, 2021, 67, 103373.	2.7	1
1917	Expectations about treatment of idiopathic pulmonary fibrosis: Comparative survey of patients, carers and physicians (the RESPIR French survey). Respiratory Medicine and Research, 2021, 79, 100811.	0.4	1
1918	Esomeprazole attenuates inflammatory and fibrotic response in lung cells through the MAPK/Nrf2/HO1 pathway. Journal of Inflammation, 2021, 18, 17.	1.5	9
1919	Emerging drugs for the treatment of idiopathic pulmonary fibrosis: 2020 phase II clinical trials. Expert Opinion on Emerging Drugs, 2021, 26, 93-101.	1.0	6
1920	Biomarkers in Progressive Fibrosing Interstitial Lung Disease: Optimizing Diagnosis, Prognosis, and Treatment Response. Frontiers in Medicine, 2021, 8, 680997.	1.2	31
1921	Looking Ahead. Clinics in Chest Medicine, 2021, 42, 375-384.	0.8	2
1922	IL-18 binding protein can be a prognostic biomarker for idiopathic pulmonary fibrosis. PLoS ONE, 2021, 16, e0252594.	1.1	11

#	Article	IF	Citations
1923	A contemporary practical approach to the multidisciplinary management of unclassifiable interstitial lung disease. European Respiratory Journal, 2021, 58, 2100276.	3.1	19
1924	Automated Digital Quantification of Pulmonary Fibrosis in Human Histopathology Specimens. Frontiers in Medicine, 2021, 8, 607720.	1.2	13
1925	Cellular Senescence in Lung Fibrosis. International Journal of Molecular Sciences, 2021, 22, 7012.	1.8	33
1926	Genetically increased circulating FUT3 level leads to reduced risk of Idiopathic Pulmonary Fibrosis: a Mendelian Randomisation Study. European Respiratory Journal, 2021, , 2003979.	3.1	9
1927	Rheumatological evaluation of patients with interstitial lung disease. Scandinavian Journal of Rheumatology, 2022, 51, 34-41.	0.6	6
1928	Efficacy and safety of nintedanib in Japanese patients with early-stage idiopathic pulmonary fibrosis: a study protocol for an observational study. BMJ Open, 2021, 11, e047249.	0.8	1
1929	Detection and Early Referral of Patients With Interstitial Lung Abnormalities. Chest, 2022, 161, 470-482.	0.4	26
1930	Protocol for long-term effect of pulmonary rehabilitation under nintedanib in idiopathic pulmonary fibrosis. ERJ Open Research, 2021, 7, 00321-2021.	1.1	3
1931	Treatment of Persistent Cough in Subjects with Idiopathic Pulmonary Fibrosis (IPF) with Gefapixant, a P2X3 Antagonist, in a Randomized, Placebo-Controlled Clinical Trial. Pulmonary Therapy, 2021, 7, 471-486.	1.1	25
1932	Minimal clinically important difference in idiopathic pulmonary fibrosis. Breathe, 2021, 17, 200345.	0.6	0
1933	An update on targeted therapies in systemic sclerosis based on a systematic review from the last 3â€‰years. Arthritis Research and Therapy, 2021, 23, 155.	1.6	42
1934	Interstitial Lung Disease in 2020. Clinics in Chest Medicine, 2021, 42, 229-239.	0.8	8
1935	Importance of chest HRCT in the diagnostic evaluation of fibrosing interstitial lung diseases. Jornal Brasileiro De Pneumologia, 2021, 47, e20200096.	0.4	11
1936	Resistance Training for Rehabilitation in Patients with Idiopathic Pulmonary Fibrosis. Translational Medicine and Exercise Prescription, 0, , 62-69.	0.0	0
1937	Antifibrotics Modify B-Cellâ€“induced Fibroblast Migration and Activation in Patients with Idiopathic Pulmonary Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2021, 64, 722-733.	1.4	26
1938	VEGFR1-tyrosine kinase signaling in pulmonary fibrosis. Inflammation and Regeneration, 2021, 41, 16.	1.5	14
1939	A birdâ€™s eye view of fibroblast heterogeneity: A panâ€disease, panâ€cancer perspective. Immunological Reviews, 2021, 302, 299-320.	2.8	23
1940	Clinical Trials for Idiopathic Pulmonary Fibrosis and the Role of Health Systems. Clinics in Chest Medicine, 2021, 42, 287-294.	0.8	3

#	Article	IF	Citations
1941	Rethinking Idiopathic Pulmonary Fibrosis. Clinics in Chest Medicine, 2021, 42, 263-273.	0.8	1
1942	Management of Idiopathic Pulmonary Fibrosis. Clinics in Chest Medicine, 2021, 42, 275-285.	0.8	7
1945	New Insights into Profibrotic Myofibroblast Formation in Systemic Sclerosis: When the Vascular Wall Becomes the Enemy. Life, 2021, 11, 610.	1.1	14
1946	Reliability of histopathologic diagnosis of fibrotic interstitial lung disease:Âan international collaborative standardization project. BMC Pulmonary Medicine, 2021, 21, 184.	0.8	0
1947	Differentiation of Idiopathic Pulmonary Fibrosis from Connective Tissue Disease-Related Interstitial Lung Disease Using Quantitative Imaging. Journal of Clinical Medicine, 2021, 10, 2663.	1.0	11
1948	Diagnosis and Management of Fibrotic Interstitial Lung Diseases. Clinics in Chest Medicine, 2021, 42, 321-335.	0.8	7
1949	Idiopathic pulmonary fibrosis: Disease mechanisms and drug development. , 2021, 222, 107798.		216
1950	Molecular Markers and the Promise of Precision Medicine for Interstitial Lung Disease. Clinics in Chest Medicine, 2021, 42, 357-364.	0.8	4
1951	Molecular Pathogenesis of Pulmonary Fibrosis, with Focus on Pathways Related to TGF-Î² and the Ubiquitin-Proteasome Pathway. International Journal of Molecular Sciences, 2021, 22, 6107.	1.8	55
1952	Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study. Lancet Respiratory Medicine,the, 2021, 9, 1266-1274.	5.2	62
1953	Disease Behaviour During the Peri-Diagnostic Period in Patients with Suspected Interstitial Lung Disease: The STARLINER Study. Advances in Therapy, 2021, 38, 4040-4056.	1.3	6
1954	Salvianolic acid B inhalation solution enhances antifibrotic and anticoagulant effects in a rat model of pulmonary fibrosis. Biomedicine and Pharmacotherapy, 2021, 138, 111475.	2.5	18
1955	Efficacy of nintedanib in the treatment of interstitial lung disease associated with systemic scleroderma. Pulmonologiya, 2021, 31, 391-396.	0.2	0
1956	Antifibrotic drugs in lung transplantation and chronic lung allograft dysfunction: a review. European Respiratory Review, 2021, 30, 210050.	3.0	8
1957	Idiopathic pulmonary fibrosis complications: what a radiologist should know. Journal of Radiological Review, 2021, 8, .	0.1	1
1958	Mesenchymal growth hormone receptor deficiency leads to failure of alveolar progenitor cell function and severe pulmonary fibrosis. Science Advances, 2021, 7, .	4.7	10
1959	Morbidity and mortality reduction associated with polysomnography testing in idiopathic pulmonary fibrosis: a population-based cohort study. BMC Pulmonary Medicine, 2021, 21, 185.	0.8	2
1960	Clinical Features and Outcomes of Combined Pulmonary Fibrosis and Emphysema After Lung Transplantation. Chest, 2021, 160, 1743-1750.	0.4	12

#	Article	IF	Citations
1961	Idiopathic pulmonary fibrosis and systemic sclerosis: pathogenic mechanisms and therapeutic interventions. Cellular and Molecular Life Sciences, 2021, 78, 5527-5542.	2.4	22
1962	Myofibroblast fate plasticity in tissue repair and fibrosis: Deactivation, apoptosis, senescence and reprogramming. Wound Repair and Regeneration, 2021, 29, 678-691.	1.5	20
1963	Unclassifiable, or simply unclassified interstitial lung disease?. Current Opinion in Pulmonary Medicine, 2021, 27, 405-413.	1.2	5
1964	Clinical Significance of Interstitial Lung Disease and Its Acute Exacerbation in Microscopic Polyangiitis. Chest, 2021, 159, 2334-2345.	0.4	18
1965	The Role of miRNAs in Extracellular Matrix Repair and Chronic Fibrotic Lung Diseases. Cells, 2021, 10, 1706.	1.8	13
1966	In vivo assessment of pulmonary fibrosis and edema in rodents using the backscatter coefficient and envelope statistics. Journal of the Acoustical Society of America, 2021, 150, 183-192.	0.5	5
1967	Validation and minimum important difference of the UCSD Shortness of Breath Questionnaire in fibrotic interstitial lung disease. Respiratory Research, 2021, 22, 202.	1.4	5
1968	Kindlin-2 Acts as a Key Mediator of Lung Fibroblast Activation and Pulmonary Fibrosis Progression. American Journal of Respiratory Cell and Molecular Biology, 2021, 65, 54-69.	1.4	8
1969	Serum Biomarkers in Differential Diagnosis of Idiopathic Pulmonary Fibrosis and Connective Tissue Disease-Associated Interstitial Lung Disease. Journal of Clinical Medicine, 2021, 10, 3167.	1.0	10
1970	Prognostic significance of serum cytokines during acute exacerbation of idiopathic interstitial pneumonias treated with thrombomodulin. BMJ Open Respiratory Research, 2021, 8, e000889.	1.2	2
1971	Potential for inhibition of checkpoint kinases 1/2 in pulmonary fibrosis and secondary pulmonary hypertension. Thorax, 2022, 77, 247-258.	2.7	11
1972	Broad Adoption of Antifibrotics in Idiopathic Pulmonary Fibrosis: Still a Long Way to Go. Annals of the American Thoracic Society, 2021, 18, 1115-1116.	1.5	2
1973	Early Intervention of Pulmonary Rehabilitation for Fibrotic Interstitial Lung Disease Is a Favorable Factor for Short-Term Improvement in Health-Related Quality of Life. Journal of Clinical Medicine, 2021, 10, 3153.	1.0	9
1974	Turnover of type I and III collagen predicts progression of idiopathic pulmonary fibrosis. Respiratory Research, 2021, 22, 205.	1.4	20
1975	Repurposing Nintedanib for pathological cardiac remodeling and dysfunction. Pharmacological Research, 2021, 169, 105605.	3.1	10
1976	Outcomes of patients with advanced idiopathic pulmonary fibrosis treated with nintedanib or pirfenidone in a realâ€world multicentre cohort. Respirology, 2021, 26, 982-988.	1.3	13
1977	New insights into the Hippo/YAP pathway in idiopathic pulmonary fibrosis. Pharmacological Research, 2021, 169, 105635.	3.1	18
1978	Effects of Exercise Training on Cardiopulmonary Function and Quality of Life in Elderly Patients with Pulmonary Fibrosis: A Meta-Analysis. International Journal of Environmental Research and Public Health, 2021, 18, 7643.	1.2	9

#	Article	IF	Citations
1980	Exposureâ€“safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease. BMC Pulmonary Medicine, 2021, 21, 244.	0.8	9
1981	Nintedanib for treatment of progressive interstitial lung disease after peripheral blood stem cell transplantation in a patient with recurrent acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2021, 68, e29211.	0.8	2
1982	NOX4 regulates macrophage apoptosis resistance to induce fibrotic progression. Journal of Biological Chemistry, 2021, 297, 100810.	1.6	12
1983	Harnessing the Role of HDAC6 in Idiopathic Pulmonary Fibrosis: Design, Synthesis, Structural Analysis, and Biological Evaluation of Potent Inhibitors. Journal of Medicinal Chemistry, 2021, 64, 9960-9988.	2.9	26
1984	Efficacy of early antifibrotic treatment for idiopathic pulmonary fibrosis. BMC Pulmonary Medicine, 2021, 21, 218.	0.8	9
1985	Co-trimoxazole to reduce mortality, transplant, or unplanned hospitalisation in people with moderate to very severe idiopathic pulmonary fibrosis: the EME-TIPAC RCT. Efficacy and Mechanism Evaluation, 2021, 8, 1-110.	0.9	1
1986	Calycosin attenuates pulmonary fibrosis by the epithelial-mesenchymal transition repression upon inhibiting the AKT/GSK3Î²/Î²-catenin signaling pathway. Acta Histochemica, 2021, 123, 151746.	0.9	14
1987	Management and support of patients with fibrosing interstitial lung diseases. Nurse Practitioner, 2021, 46, 39-44.	0.2	2
1988	Outcomes for hospitalized patients with idiopathic pulmonary fibrosis treated with antifibrotic medications. BMC Pulmonary Medicine, 2021, 21, 239.	0.8	6
1989	Extracellular matrix and Hippo signaling as therapeutic targets of antifibrotic compounds for uterine fibroids. Clinical and Translational Medicine, 2021, 11, e475.	1.7	27
1990	Recognition of Connective Tissue Disease-Related Interstitial Pneumonia Based on Histological Scoreâ€”A Validation Study of an Online Diagnostic Decision Support Tool. Diagnostics, 2021, 11, 1359.	1.3	0
1991	50-gene risk profiles in peripheral blood predict COVID-19 outcomes: A retrospective, multicenter cohort study. EBioMedicine, 2021, 69, 103439.	2.7	20
1992	Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. Journal of Heart and Lung Transplantation, 2021, 40, 1349-1379.	0.3	293
1993	Efficacy and safety of nintedanib for pulmonary fibrosis in severe pneumonia induced by COVID-19: An interventional study. International Journal of Infectious Diseases, 2021, 108, 454-460.	1.5	65
1994	Adoption of the Antifibrotic Medications Pirfenidone and Nintedanib for Patients with Idiopathic Pulmonary Fibrosis. Annals of the American Thoracic Society, 2021, 18, 1121-1128.	1.5	37
1996	Switching antifibrotics in patients with idiopathic pulmonary fibrosis: a multi-center retrospective cohort study. BMC Pulmonary Medicine, 2021, 21, 221.	0.8	15
1997	Elucidation of prognostic factors and the effect of anti-fibrotic therapy on waitlist mortality in lung transplant candidates with idiopathic interstitial pneumonias. Respiratory Investigation, 2021, 59, 428-435.	0.9	5
1998	Impact of Antifibrotic Therapy on Mortality and Acute Exacerbation in Idiopathic Pulmonary Fibrosis. Chest, 2021, 160, 1751-1763.	0.4	88

#	Article	IF	Citations
1999	Nintedanib-Induced Renal Thrombotic Microangiopathy. Case Reports in Nephrology and Dialysis, 2021, 11, 227-232.	0.3	5
2000	The Paradigm of Targeting an Oncogenic Tyrosine Kinase: Lesson from BCR-ABL. , 0, , .		3
2001	Patient-centered Outcomes Research in Interstitial Lung Disease: An Official American Thoracic Society Research Statement. American Journal of Respiratory and Critical Care Medicine, 2021, 204, e3-e23.	2.5	41
2002	Pterostilbene alleviates pulmonary fibrosis by regulating ASIC2. Chinese Medicine, 2021, 16, 66.	1.6	6
2003	Characteristics and evaluation of acute exacerbations in chronic interstitial lung diseases. Respiratory Medicine, 2021, 183, 106400.	1.3	6
2004	An update on interstitial lung disease. British Journal of Hospital Medicine (London, England: 2005), 2021, 82, 1-14.	0.2	2
2005	Clinical course and prognosis in survivors of acute exacerbations of idiopathic pulmonary fibrosis. Respiratory Investigation, 2021, 59, 408-413.	0.9	3
2006	The Development of 3-substituted Indolin-2-one Derivatives as Kinase Inhibitors for Cancer Therapy. Current Medicinal Chemistry, 2022, 29, 1891-1919.	1.2	7
2007	The histologic diagnosis of usual interstitial pneumonia of idiopathic pulmonary fibrosis. Where we are and where we need to go. Modern Pathology, 2022, 35, 8-14.	2.9	13
2008	Lung transplantation for interstitial lung disease. European Respiratory Review, 2021, 30, 210017.	3.0	36
2009	Fibrometabolismâ€"An emerging therapeutic frontier in pulmonary fibrosis. Science Signaling, 2021, 14, .	1.6	31
2010	Human bronchial epithelial cellâ€derived extracellular vesicle therapy for pulmonary fibrosis via inhibition of TGFâ€Î²â€WNT crosstalk. Journal of Extracellular Vesicles, 2021, 10, e12124.	5.5	74
2011	Clusters of comorbidities in idiopathic pulmonary fibrosis. Respiratory Medicine, 2021, 185, 106490.	1.3	13
2012	Survival after inpatient or outpatient pulmonary rehabilitation in patients with fibrotic interstitial lung disease: a multicentre retrospective cohort study. Thorax, 2022, 77, 589-595.	2.7	21
2013	Inhibition of the Arp2/3 complex represses human lung myofibroblast differentiation and attenuates bleomycinâ€induced pulmonary fibrosis. British Journal of Pharmacology, 2022, 179, 125-140.	2.7	4
2014	Modeling Extracellular Matrix-Cell Interactions in Lung Repair and Chronic Disease. Cells, 2021, 10, 2145.	1.8	16
2015	Pharmacological Interactions of Nintedanib and Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis in Times of COVID-19 Pandemic. Pharmaceuticals, 2021, 14, 819.	1.7	12
2016	Decision-Making Strategy for the Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease (RA-ILD). Journal of Clinical Medicine, 2021, 10, 3806.	1.0	22

#	Article	IF	Citations
2017	A Phase I Randomized, Controlled, Clinical Trial of Valganciclovir in Idiopathic Pulmonary Fibrosis. Annals of the American Thoracic Society, 2021, 18, 1291-1297.	1.5	4
2018	Cellular Senescence in Idiopathic Pulmonary Fibrosis. Current Molecular Biology Reports, 2021, 7, 31-40.	0.8	29
2019	Enzymatic cross-linking of collagens in organ fibrosis â€“ resolution and assessment. Expert Review of Molecular Diagnostics, 2021, 21, 1049-1064.	1.5	20
2020	Surgical treatment for patients with idiopathic pulmonary fibrosis and lung cancer: postoperative acute exacerbation of idiopathic pulmonary fibrosis and outcomes. Surgery Today, 2022, 52, 736-744.	0.7	12
2021	Small Airway Reduction and Fibrosis Is an Early Pathologic Feature of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 1048-1059.	2.5	31
2022	Pleuroparenchymal fibroelastosis in idiopathic pulmonary fibrosis: Survival analysis using visual and computer-based computed tomography assessment. EClinicalMedicine, 2021, 38, 101009.	3.2	6
2023	3-Carbamoyl-proxyl nitroxide radicals attenuate bleomycin-induced pulmonary fibrosis in mice. Free Radical Biology and Medicine, 2021, 171, 135-142.	1.3	7
2024	Global research hotspots and research trends on idiopathic pulmonary fibrosis: a bibliometric and visualization analysis. Annals of Palliative Medicine, 2021, 10, 9057-9068.	0.5	9
2025	Clinical Impact of Surgical Lung Biopsy for Interstitial Lung Disease in a Reference Center. Annals of Thoracic Surgery, 2021, , .	0.7	0
2026	Inspiratory muscle training in interstitial lung disease: a systematic scoping review. Jornal Brasileiro De Pneumologia, 2021, 47, e20210089.	0.4	6
2027	An updated approach to determine minimal clinically important differences in idiopathic pulmonary fibrosis. ERJ Open Research, 2021, 7, 00142-2021.	1.1	4
2029	CD148 Deficiency in Fibroblasts Promotes the Development of Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 312-325.	2.5	24
2030	Diagnostic Accuracy of Endobronchial Optical Coherence Tomography for the Microscopic Diagnosis of Usual Interstitial Pneumonia. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 1164-1179.	2.5	32
2031	Serial Measurements of Circulating KL-6, SP-D, MMP-7, CA19-9, CA-125, CCL18, and Periostin in Patients with Idiopathic Pulmonary Fibrosis Receiving Antifibrotic Therapy: An Exploratory Study. Journal of Clinical Medicine, 2021, 10, 3864.	1.0	14
2032	Novel Artificial Intelligence-based Technology for Chest Computed Tomography Analysis of Idiopathic Pulmonary Fibrosis. Annals of the American Thoracic Society, 2022, 19, 399-406.	1.5	29
2033	COPD, Pulmonary Fibrosis and ILAs in Aging Smokers: The Paradox of Striking Different Responses to the Major Risk Factors. International Journal of Molecular Sciences, 2021, 22, 9292.	1.8	14
2034	Nintedanib downregulates the transition of cultured systemic sclerosis fibrocytes into myofibroblasts and their pro-fibrotic activity. Arthritis Research and Therapy, 2021, 23, 205.	1.6	10
2036	Diagnostic and prognostic implications of 2018 guideline for the diagnosis of idiopathic pulmonary fibrosis in clinical practice. Scientific Reports, 2021, 11, 16481.	1.6	8

#	Article	IF	Citations
2037	Radiation pneumonitis after palliative radiotherapy in cancer patients with interstitial lung disease. Radiotherapy and Oncology, 2021, 161, 47-54.	0.3	8
2038	CT of Post-Acute Lung Complications of COVID-19. Radiology, 2021, 301, E383-E395.	3.6	115
2039	Fibrotic Idiopathic Interstitial Lung Disease: The Molecular and Cellular Key Players. International Journal of Molecular Sciences, 2021, 22, 8952.	1.8	27
2040	Endothelial-Specific Loss of Sphingosine-1-Phosphate Receptor 1 Increases Vascular Permeability and Exacerbates Bleomycin-induced Pulmonary Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2022, 66, 38-52.	1.4	21
2041	Interstitial lung disease and obstructive sleep apnea. Sleep Medicine Reviews, 2021, 58, 101442.	3.8	22
2042	A phase 1, randomized study to evaluate safety, tolerability, and pharmacokinetics of GDC-3280, a potential novel anti-fibrotic small molecule, in healthy subjects. Pulmonary Pharmacology and Therapeutics, 2021, 69, 102051.	1.1	2
2043	The impact of SARS-COV2 pandemic on the management oF IPF patients: Our narrative experience. Pulmonary Pharmacology and Therapeutics, 2021, 69, 102038.	1.1	2
2044	Targeting Cpt1a-Bcl-2 interaction modulates apoptosis resistance and fibrotic remodeling. Cell Death and Differentiation, 2022, 29, 118-132.	5.0	18
2045	Bleomycin-induced Pneumonitis in a Child Treated With Nintedanib: Report of the First Case in a Childhood. Journal of Pediatric Hematology/Oncology, 2022, 44, e500-e502.	0.3	4
2046	Myeloperoxidase and associated lung disease: Review of the latest developments. International Journal of Rheumatic Diseases, 2021, 24, 1460-1466.	0.9	8
2047	Dose Optimization of Sotorasib: Is the US Food and Drug Administration Sending a Message?. Journal of Clinical Oncology, 2021, 39, 3423-3426.	0.8	25
2048	Computed Tomography Findings Suggestive of Connective Tissue Disease in the Setting of Usual Interstitial Pneumonia. Journal of Computer Assisted Tomography, 2021, 45, 776-781.	0.5	5
2049	Effect of antifibrotic therapy in patients with idiopathic pulmonary fibrosis undergoing lung transplant in the peri and post-operative period. Respiratory Medicine, 2021, 190, 106599.	1.3	5
2050	Design of phase 2 study of TAS-115, a novel oral multi-kinase inhibitor, in patients with idiopathic pulmonary fibrosis. Contemporary Clinical Trials Communications, 2021, 23, 100832.	0.5	2
2051	Progression of Idiopathic Pulmonary Fibrosis Is Associated with Silica/Silicate Inhalation. Environmental Science and Technology Letters, 2021, 8, 903-910.	3.9	8
2052	<scp>SHP2</scp>: The protein tyrosine phosphatase involved in chronic pulmonary inflammation and fibrosis. IUBMB Life, 2022, 74, 131-142.	1.5	6
2053	Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial. European Respiratory Journal, 2022, 59, 2004538.	3.1	47
2054	Special considerations for pulmonary rehabilitation in conditions other than COPD. , 2021, , 145-164.		3

#	Article	IF	Citations
2055	Updates in Systemic Sclerosis Treatment and Applicability to Pediatric Scleroderma. Rheumatic Disease Clinics of North America, 2021, 47, 757-780.	0.8	5
2056	Progressive Fibrosing Interstitial Lung Diseases: A Current Perspective. Biomedicines, 2021, 9, 1237.	1.4	10
2057	Clinical Utility of Home versus Hospital Spirometry in Fibrotic Interstitial Lung Disease: Evaluation after INJUSTIS Interim Analysis. Annals of the American Thoracic Society, 2022, 19, 506-509.	1.5	12
2058	Effect of sildenafil added to antifibrotic treatment in idiopathic pulmonary fibrosis. Scientific Reports, 2021, 11, 17824.	1.6	5
2059	Nintedanib, a multitarget tyrosine kinase inhibitor, suppresses postoperative peritoneal adhesion formation in a rat model. Surgery, 2021, 170, 806-812.	1.0	1
2060	Early diagnosis of fibrotic interstitial lung disease: challenges and opportunities. Lancet Respiratory Medicine,the, 2021, 9, 1065-1076.	5.2	55
2061	Pharmacologic Treatment of Anti-MDA5 Rapidly Progressive Interstitial Lung Disease. Current Treatment Options in Rheumatology, 2021, 7, 319-333.	0.6	17
2062	GED-0507 attenuates lung fibrosis by counteracting myofibroblast transdifferentiation in vivo and in vitro. PLoS ONE, 2021, 16, e0257281.	1.1	5
2063	Therapeutic targets in lung tissue remodelling and fibrosis. , 2021, 225, 107839.		98
2064	Suppression of epithelial abnormalities by nintedanib in induced-rheumatoid arthritis-associated interstitial lung disease mouse model. ERJ Open Research, 2021, 7, 00345-2021.	1.1	12
2067	Combined assessment of the GAP index and body mass index at antifibrotic therapy initiation for prognosis of idiopathic pulmonary fibrosis. Scientific Reports, 2021, 11, 18579.	1.6	4
2068	Global and regional burden of interstitial lung disease and pulmonary sarcoidosis from 1990 to 2019: results from the Global Burden of Disease study 2019. Thorax, 2022, 77, 596-605.	2.7	13
2069	Therapeutic Approaches to Systemic Sclerosis: Recent Approvals and Future Candidate Therapies. Clinical Reviews in Allergy and Immunology, 2023, 64, 239-261.	2.9	20
2070	An IPF-like disease course in disorders other than IPF: how can this be anticipated, recognized, and managed?. Expert Review of Clinical Immunology, 2021, 17, 1091-1101.	1.3	4
2071	The Aggregate Index of Systemic Inflammation (AISI): A Novel Prognostic Biomarker in Idiopathic Pulmonary Fibrosis. Journal of Clinical Medicine, 2021, 10, 4134.	1.0	32
2072	Can acute exacerbations occurring late after surgery with interstitial lung diseases be predicted?. General Thoracic and Cardiovascular Surgery, 2021, , 1.	0.4	0
2073	Interstitial Lung Diseases and the Impact of Gender. Clinics in Chest Medicine, 2021, 42, 531-541.	0.8	5
2074	From ARDS to pulmonary fibrosis: the next phase of the COVID-19 pandemic?. Translational Research, 2022, 241, 13-24.	2.2	68

#	Article	IF	Citations
2075	Ageing mechanisms that contribute to tissue remodeling in lung disease. Ageing Research Reviews, 2021, 70, 101405.	5.0	22
2076	Development of antifibrotic therapy for stricturing Crohnâ€™s disease: lessons from randomized trials in other fibrotic diseases. Physiological Reviews, 2022, 102, 605-652.	13.1	31
2077	Treatment of fibrotic interstitial lung disease: current approaches and future directions. Lancet, The, 2021, 398, 1450-1460.	6.3	47
2078	Improved Radiolytic Stability of a 68Ga-labelled Collagelin Analogue for the Imaging of Fibrosis. Pharmaceuticals, 2021, 14, 990.	1.7	3
2079	Synthesis and biological evaluation of selenogefitinib for reducing bleomycin-induced pulmonary fibrosis. Bioorganic and Medicinal Chemistry Letters, 2021, 48, 128238.	1.0	2
2080	Management of Acute Exacerbation of Idiopathic Pulmonary Fibrosis in Specialised and Non-specialised ILD Centres Around the World. Frontiers in Medicine, 2021, 8, 699644.	1.2	8
2081	Ten Commandments for Randomized Trials of Pharmacological Therapy for COPD and Other Lung Diseases. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2021, 18, 1-8.	0.7	1
2082	The effect of additional antimicrobial therapy on the outcomes of patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Respiratory Research, 2021, 22, 243.	1.4	2
2083	Diagnosis Yield and Safety of Surgical Biopsy in Interstitial Lung Diseases: A Prospective Study. Annals of Thoracic Surgery, 2022, 114, 1911-1917.	0.7	2
2084	Ion therapy of pulmonary fibrosis by inhalation of ionic solution derived from silicate bioceramics. Bioactive Materials, 2021, 6, 3194-3206.	8.6	15
2085	Hyperpolarized ¹²⁹Xe MRI and Spectroscopy of Gas-Exchange Abnormalities in Nonspecific Interstitial Pneumonia. Radiology, 2021, 301, 211-220.	3.6	11
2086	An update on recent randomized clinical trials in systemic sclerosis. Joint Bone Spine, 2021, 88, 105184.	0.8	2
2087	Beyond TGFÎ²1 - novel treatment strategies targeting lung fibrosis. International Journal of Biochemistry and Cell Biology, 2021, 141, 106090.	1.2	2
2088	Defining and predicting progression in non-IPF interstitial lung disease. Respiratory Medicine, 2021, 189, 106626.	1.3	5
2089	Molecular Signatures of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2021, 65, 430-441.	1.4	23
2090	Incidence of acute exacerbation of idiopathic pulmonary fibrosis in patients receiving antifibrotic agents: Real-world experience. Respiratory Medicine, 2021, 187, 106551.	1.3	8
2091	Moving beyond usual interstitial pneumonia to define progressive fibrotic interstitial lung disease. Lancet Respiratory Medicine,the, 2021, 9, 1087-1089.	5.2	0
2092	Interstitial Lung Abnormalities: State of the Art. Radiology, 2021, 301, 19-34.	3.6	63

#	Article	IF	Citations
2093	Mortality differences in pulmonary fibrosis among the most populated states in the United States. Respiratory Medicine, 2021, 187, 106565.	1.3	0
2094	Efficacy and safety of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases: Subgroup analysis of the randomised, double-blind, placebo-controlled, phase 3 INBUILD trial. Respiratory Medicine, 2021, 187, 106574.	1.3	6
2095	The Role of Surgical Lung Biopsy in the Diagnosis of Fibrotic Interstitial Lung Disease: Perspective from the Pulmonary Fibrosis Foundation. Annals of the American Thoracic Society, 2021, 18, 1601-1609.	1.5	8
2096	Tyrosine kinases regulate chondrocyte hypertrophy: promising drug targets for Osteoarthritis. Osteoarthritis and Cartilage, 2021, 29, 1389-1398.	0.6	17
2097	Peptide DR8 analogs alleviate pulmonary fibrosis via suppressing TGF-Î²1 mediated epithelial-mesenchymal transition and ERK1/2 pathway in vivo and in vitro. European Journal of Pharmaceutical Sciences, 2021, 167, 106009.	1.9	11
2098	The phosphodiesterase 4 inhibitor AA6216 suppresses activity of fibrosis-specific macrophages. Biochemistry and Biophysics Reports, 2021, 28, 101118.	0.7	1
2099	Scleroderma Associated Interstitial Lung Disease. , 2022, , 319-325.		0
2100	Rheumatoid Arthritis Interstitial Lung Disease. , 2022, , 307-318.		0
2101	Interstitial Pneumonia With Autoimmune Features. , 2022, , 298-306.		1
2103	A Comprehensive Guide to Lung Transplantation for the Recipient With Pulmonary Fibrosis. , 2022, , 661-675.		0
2104	Other Idiopathic Interstitial Pneumonias and Unclassifiable Interstitial Lung Disease. , 2022, , 257-274.		0
2105	Comprehensive Care of Interstitial Lung Disease. , 2022, , 64-78.		0
2106	Idiopathic Pulmonary Fibrosis-Treatment and Management. , 2022, , 218-233.		0
2107	The Role of the Innate Immune System in Interstitial Lung Disease. , 2022, , 135-143.		0
2108	Palliative Care in Interstitial Lung Disease. Respiratory Medicine, 2021, , 189-207.	0.1	0
2109	Patient-Centredness and Patient-Reported Measures (PRMs) in Palliation of Lung Disease. Respiratory Medicine, 2021, , 43-75.	0.1	1
2110	An Introduction to Advanced Lung Disease. Respiratory Medicine, 2021, , 11-25.	0.1	0
2111	Hirsutella sinensis mycelium regulates autophagy of alveolar macrophages via TLR4/NF-ÎºB signaling pathway. International Journal of Medical Sciences, 2021, 18, 1810-1823.	1.1	7

#	Article	IF	Citations
2112	HFpEF without elevated right ventricular systolic pressure is a favorable prognostic indicator in patients with IPF requiring hospitalization for heart failure. PLoS ONE, 2021, 16, e0245778.	1.1	1
2113	Phase three clinical trials in idiopathic pulmonary fibrosis. Expert Opinion on Orphan Drugs, 2021, 9, 1-11.	0.5	2
2114	Chronic Fibrosing Interstitial Lung Disease with Progressive Phenotype. Nauchno-Prakticheskaya Revmatologiya, 2021, 58, 631-636.	0.2	3
2115	Pulmonary and Critical Care Medicine. , 2021, , 325-338.		0
2116	Post-COVID lung fibrosis: The tsunami that will follow the earthquake. Lung India, 2021, 38, 41.	0.3	69
2117	Immune dysregulation as a driver of idiopathic pulmonary fibrosis. Journal of Clinical Investigation, 2021, 131, .	3.9	114
2118	Molecular Imaging of Fibrosis. , 2021, , 1447-1468.		0
2119	S2K Guideline for Diagnosis of Idiopathic Pulmonary Fibrosis. Respiration, 2021, 100, 238-271.	1.2	19
2120	Antifibrotic drugs in connective tissue disease-related interstitial lung disease (CTD-ILD): from mechanistic insights to therapeutic applications. Drugs in Context, 2021, 10, 1-13.	1.0	5
2121	The Promise (and Pitfalls) of Administrative Data for Idiopathic Pulmonary Fibrosis. Chest, 2021, 159, 9-10.	0.4	0
2122	Spontaneous pneumothorax during nintedanib therapy in patients with systemic sclerosisâ€associated interstitial lung disease. Respirology Case Reports, 2021, 9, e00716.	0.3	3
2123	Home spirometry in patients with idiopathic pulmonary fibrosis: data from the INMARK trial. European Respiratory Journal, 2021, 58, 2001518.	3.1	30
2124	Post-COVID-19 pulmonary fibrosis: A case series and review of literature. Journal of Family Medicine and Primary Care, 2021, 10, 2028.	0.3	11
2125	Combined Pulmonary Fibrosis and Emphysema (CPFE) Clinical Features and Management. International Journal of COPD, 2021, Volume 16, 167-177.	0.9	16
2126	Pulmonary Fibrosis Progression Prediction Using Image Processing and Machine Learning. Advances in Science, Technology and Innovation, 2021, , 159-177.	0.2	1
2127	Pretreatment of aged mice with retinoic acid supports alveolar regeneration via upregulation of reciprocal PDGFA signalling. Thorax, 2021, 76, 456-467.	2.7	19
2128	Monocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 74-81.	2.5	107
2129	Genetic Risk Factors for Idiopathic Pulmonary Fibrosis: Insights into Immunopathogenesis. Journal of Inflammation Research, 2020, Volume 13, 1305-1318.	1.6	29

#	Article	IF	Citations
2130	Genetics of Idiopathic Pulmonary Fibrosis. Respiratory Medicine, 2020, , 71-85.	0.1	1
2131	Mesenchymal Stromal Cell-Based Therapies for Lung Disease. Pancreatic Islet Biology, 2015, , 225-242.	0.1	1
2133	Risk Factors and Biomarkers of RA-ILD. Respiratory Medicine, 2018, , 59-72.	0.1	3
2134	Clinical Trials in IPF: What Are the Best Endpoints?. Respiratory Medicine, 2019, , 433-453.	0.1	6
2135	Pharmacotherapy of IPF Using Antifibrotic Compounds. , 2016, , 147-159.		1
2136	Therapeutic effects of obeticholic acid (OCA) treatment in a bleomycin-induced pulmonary fibrosis rat model. Journal of Endocrinological Investigation, 2019, 42, 283-294.	1.8	17
2137	Cardiovascular implications of idiopathic pulmonary fibrosis: A way forward together?. American Heart Journal, 2020, 226, 69-74.	1.2	7
2138	Circulating Plasma Biomarkers of Survival in Antifibrotic-Treated Patients With Idiopathic Pulmonary Fibrosis. Chest, 2020, 158, 1526-1534.	0.4	31
2139	CPAP Adherence, Mortality, and Progression-Free Survival in Interstitial Lung Disease and OSA. Chest, 2020, 158, 1701-1712.	0.4	19
2140	Evolution and treatment of idiopathic pulmonary fibrosis. Presse Medicale, 2020, 49, 104025.	0.8	15
2141	Nintedanib decreases muscle fibrosis and improves muscle function in a murine model of dystrophinopathy. Cell Death and Disease, 2018, 9, 776.	2.7	36
2142	Self DNA perpetuates IPF lung fibroblast senescence in a cGAS-dependent manner. Clinical Science, 2020, 134, 889-905.	1.8	28
2143	Pamrevlumab for the treatment of idiopathic pulmonary fibrosis. Expert Opinion on Investigational Drugs, 2020, 29, 771-777.	1.9	40
2144	Forced Vital Capacity (FVC) decline, mortality and healthcare resource utilization in idiopathic pulmonary fibrosis. European Clinical Respiratory Journal, 2020, 7, 1702618.	0.7	16
2145	New Developments in Imaging Idiopathic Pulmonary Fibrosis With Hyperpolarized Xenon Magnetic Resonance Imaging. Journal of Thoracic Imaging, 2019, 34, 136-150.	0.8	43
2150	Safety and effectiveness of pirfenidone combined with carboplatinâ€based chemotherapy in patients with idiopathic pulmonary fibrosis and nonâ€small cell lung cancer: A retrospective cohort study. Thoracic Cancer, 2020, 11, 3317-3325.	0.8	20
2151	Ambulatory oxygen for treatment of exertional hypoxaemia in pulmonary fibrosis (PFOX trial): a randomised controlled trial. BMJ Open, 2020, 10, e040798.	0.8	9
2152	Impact of an interstitial lung disease service in the diagnosis and management of interstitial lung disease in Singapore. Singapore Medical Journal, 2020, 61, 302-307.	0.3	6

#	Article	IF	Citations
2153	Combination Therapy and the Start of a New Epoch for Idiopathic Pulmonary Fibrosis?. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 283-284.	2.5	7
2154	Interstitial Lung Disease in Relatives of Patients with Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 1240-1248.	2.5	65
2155	CCR10+ epithelial cells from idiopathic pulmonary fibrosis lungs drive remodeling. JCI Insight, 2018, 3, .	2.3	30
2156	Fibulin-1c regulates transforming growth factorâ€“Î² activation in pulmonary tissue fibrosis. JCI Insight, 2019, 4, .	2.3	42
2157	Soluble Thy-1 reverses lung fibrosis via its integrin-binding motif. JCI Insight, 2019, 4, .	2.3	20
2158	Transcriptional regulatory model of fibrosis progression in the human lung. JCI Insight, 2019, 4, .	2.3	113
2159	Brd4-p300 inhibition downregulates Nox4 and accelerates lung fibrosis resolution in aged mice. JCI Insight, 2020, 5, .	2.3	45
2160	Vaccinia vaccineâ€“based immunotherapy arrests and reverses established pulmonary fibrosis. JCI Insight, 2016, 1, e83116.	2.3	22
2161	Attenuation of lung fibrosis in mice with a clinically relevant inhibitor of glutathione-S-transferase Ï€. JCI Insight, 2016, 1, .	2.3	32
2162	Three-dimensional characterization of fibroblast foci in idiopathic pulmonary fibrosis. JCI Insight, 2016, 1, .	2.3	73
2163	Uncoupling of the profibrotic and hemostatic effects of thrombin in lung fibrosis. JCI Insight, 2017, 2, .	2.3	67
2164	miR-323a-3p regulates lung fibrosis by targeting multiple profibrotic pathways. JCI Insight, 2016, 1, e90301.	2.3	37
2165	Cannabinoid CB1 receptor overactivity contributes to the pathogenesis of idiopathic pulmonary fibrosis. JCI Insight, 2017, 2, .	2.3	59
2166	Molecular imaging of fibrosis: recent advances and future directions. Journal of Clinical Investigation, 2019, 129, 24-33.	3.9	86
2167	Fra-2â€“expressing macrophages promote lung fibrosis. Journal of Clinical Investigation, 2019, 129, 3293-3309.	3.9	67
2168	Increased flux through the mevalonate pathway mediates fibrotic repair without injury. Journal of Clinical Investigation, 2019, 129, 4962-4978.	3.9	22
2169	Contributions of alveolar epithelial cell quality control to pulmonary fibrosis. Journal of Clinical Investigation, 2020, 130, 5088-5099.	3.9	135
2170	FVC variability in patients with idiopathic pulmonary fibrosis and role of 6-min walk test to predict further change. European Respiratory Journal, 2020, 55, 1902151.	3.1	19

#	Article	IF	Citations
2171	Two sides of the same coin? A review of the similarities and differences between idiopathic pulmonary fibrosis and rheumatoid arthritis-associated interstitial lung disease. European Respiratory Journal, 2021, 57, 2002533.	3.1	33
2172	The therapy of idiopathic pulmonary fibrosis: what is next?. European Respiratory Review, 2019, 28, 190021.	3.0	157
2173	A feasibility, randomised controlled trial of a complex breathlessness intervention in idiopathic pulmonary fibrosis (BREEZE-IPF): study protocol. ERJ Open Research, 2019, 5, 00186-2019.	1.1	3
2174	Idiopathic pulmonary fibrosis in the UK: analysis of the British Thoracic Society electronic registry between 2013 and 2019. ERJ Open Research, 2021, 7, 00187-2020.	1.1	17
2176	Pharmacological management. , 0, , 196-217.		1
2177	Progression of fibrosing interstitial lung disease. Respiratory Research, 2020, 21, 32.	1.4	94
2178	Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient Registry. Respiratory Research, 2020, 21, 48.	1.4	31
2179	Application of Isobaric Tags for Relative and Absolute Quantification (iTRAQ) Coupled with Two-Dimensional Liquid Chromatography/Tandem Mass Spectrometry in Quantitative Proteomic Analysis for Discovery of Serum Biomarkers for Idiopathic Pulmonary Fibrosis. Medical Science Monitor, 2018, 24, 4146-4153.	0.5	14
2180	Recent advances in managing idiopathic pulmonary fibrosis. F1000Research, 2017, 6, 2052.	0.8	12
2181	BRD4 inhibition for the treatment of pathological organ fibrosis. F1000Research, 2017, 6, 1015.	0.8	47
2182	Developing better drugs for pulmonary sarcoidosis: determining indications for treatment and endpoints to assess therapy based on patient and clinician concerns. F1000Research, 2019, 8, 2149.	0.8	8
2183	Therapeutic potential of targeting kinase inhibition in patients with idiopathic pulmonary fibrosis. Yeungnam University Journal of Medicine, 2020, 37, 269-276.	0.7	4
2184	The hospitalized patient with interstitial lung disease: a hospitalist primer. Journal of Hospital Medicine, 2017, 12, 580-584.	0.7	1
2185	Promising new treatment targets in patients with fibrosing lung disorders. World Journal of Clinical Cases, 2014, 2, 668.	0.3	4
2186	A Critical Role for the mTORC2 Pathway in Lung Fibrosis. PLoS ONE, 2014, 9, e106155.	1.1	49
2187	Normal Lung Quantification in Usual Interstitial Pneumonia Pattern: The Impact of Threshold-based Volumetric CT Analysis for the Staging of Idiopathic Pulmonary Fibrosis. PLoS ONE, 2016, 11, e0152505.	1.1	39
2188	Immune Inflammation and Disease Progression in Idiopathic Pulmonary Fibrosis. PLoS ONE, 2016, 11, e0154516.	1.1	87
2189	Six-SOMAmer Index Relating to Immune, Protease and Angiogenic Functions Predicts Progression in IPF. PLoS ONE, 2016, 11, e0159878.	1.1	43

#	Article	IF	Citations
2190	A Phase I Dose Escalation Study of the Triple Angiokinase Inhibitor Nintedanib Combined with Low-Dose Cytarabine in Elderly Patients with Acute Myeloid Leukemia. PLoS ONE, 2016, 11, e0164499.	1.1	11
2191	Burden of Idiopathic Pulmonary Fibrosis Progression: A 5-Year Longitudinal Follow-Up Study. PLoS ONE, 2017, 12, e0166462.	1.1	52
2192	Quantification of Pulmonary Fibrosis in a Bleomycin Mouse Model Using Automated Histological Image Analysis. PLoS ONE, 2017, 12, e0170561.	1.1	66
2193	The usefulness of monomeric periostin as a biomarker for idiopathic pulmonary fibrosis. PLoS ONE, 2017, 12, e0174547.	1.1	54
2194	Spectrum of interstitial lung diseases at a tertiary center in a developing country: A study of 803 subjects. PLoS ONE, 2018, 13, e0191938.	1.1	51
2195	The resolution of the Expert Council on Interstitial Lung Diseases in Systemic Scleroderma (Moscow,) Tj ETQq1 1 0.784314 rgBT /Ove	0.1	6
2196	Pirfenidone and Nintedanib for Treatment of Idiopathic Pulmonary Fibrosis. Southern Medical Journal, 2017, 110, 393-398.	0.3	22
2197	MUC5B and Idiopathic Pulmonary Fibrosis. Annals of the American Thoracic Society, 2015, 12, S193-S199.	1.5	67
2198	Inhibition of Aurora Kinase B attenuates fibroblast activation and pulmonary fibrosis. EMBO Molecular Medicine, 2020, 12, e12131.	3.3	28
2199	Human Adipose-derived Mesenchymal Stem Cells Attenuate Early Stage of Bleomycin Induced Pulmonary Fibrosis: Comparison with Pirfenidone. International Journal of Stem Cells, 2016, 9, 192-206.	0.8	68
2200	Antioxidants in respiratory diseases: Basic science research and therapeutic alternatives. Clinical Research and Trials, 2016, 3, .	0.1	8
2202	Familial pulmonary fibrosis: a world without frontiers. Jornal Brasileiro De Pneumologia, 2019, 45, e20190303.	0.4	3
2203	CCAAT/enhancer binding protein delta (C/EBPÎ´) deficiency does not affect bleomycin-induced pulmonary fibrosis. Journal of Clinical and Translational Research, 0, , .	0.3	3
2204	Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis. Federal Guidelines. Pulmonologiya, 2016, 26, 399-419.	0.2	33
2205	The purinergic receptor subtype P2Y2 mediates chemotaxis of neutrophils and fibroblasts in fibrotic lung disease. Oncotarget, 2017, 8, 35962-35972.	0.8	28
2206	The histone deacetylase inhibitor, romidepsin, as a potential treatment for pulmonary fibrosis. Oncotarget, 2017, 8, 48737-48754.	0.8	48
2207	Ilomastat, a synthetic inhibitor of MMPs, prevents lung injury induced by Î³-ray irradiation in mice. Oncotarget, 2017, 8, 60789-60808.	0.8	12
2208	Limited fibrosis accompanies triple-negative breast cancer metastasis in multiple model systems and is not a preventive target. Oncotarget, 2018, 9, 23462-23481.	0.8	9

#	Article	IF	Citations
2209	Preclinical characterization of tyrosine kinase inhibitor-based targeted therapies for neuroendocrine thyroid cancer. Oncotarget, 2018, 9, 37662-37675.	0.8	5
2210	Protease activated receptor-1 regulates macrophage-mediated cellular senescence: a risk for idiopathic pulmonary fibrosis. Oncotarget, 2015, 6, 35304-35314.	0.8	20
2211	Getting to the core of fibrosis: targeting redox imbalance in aging. Annals of Translational Medicine, 2016, 4, 93-93.	0.7	7
2212	A retrospective study of the tolerability of nintedanib for severe idiopathic pulmonary fibrosis in the real world. Annals of Translational Medicine, 2019, 7, 262-262.	0.7	18
2213	Stereotactic body radiotherapy for early stage non-small cell lung cancer in patients with subclinical interstitial lung disease. Translational Lung Cancer Research, 2020, 9, 2328-2336.	1.3	7
2214	Updated Evaluation of the Safety, Efficacy and Tolerability of Pirfenidone in the Treatment of Idiopathic Pulmonary Fibrosis . Drug, Healthcare and Patient Safety, 2020, Volume 12, 85-94.	1.0	25
2215	Use of Chouâ€™s 5-Steps Rule to Reveal Active Compound and Mechanism of Shuangshen Pingfei San on Idiopathic Pulmonary Fibrosis. Current Molecular Medicine, 2020, 20, 220-230.	0.6	26
2216	Outcome Measures for Clinical Trials in Interstitial Lung Diseases. Current Respiratory Medicine Reviews, 2015, 11, 163-174.	0.1	29
2217	MDM2-p53 Interaction Inhibitors: The Current State-of-Art and Updated Patent Review (2010-Present). Recent Patents on Anti-Cancer Drug Discovery, 2020, 14, 324-369.	0.8	16
2218	Effects of Nintedanib on Quantitative Lung Fibrosis Score in Idiopathic Pulmonary Fibrosis. Open Respiratory Medicine Journal, 2020, 14, 22-31.	1.3	21
2219	Effectiveness of support groups to improve the quality of life of people with idiopathic pulmonary fibrosis a pre-post test pilot study. Acta Biomedica, 2017, 88, 5-12.	0.2	10
2220	Treatment of systemic sclerosis associated fibrotic manifestations: Current options and future directions. Mediterranean Journal of Rheumatology, 2019, 30, 33-37.	0.3	14
2221	Insights Into Development and Progression of Idiopathic Pulmonary Fibrosis From Single Cell RNA Studies. Frontiers in Medicine, 2020, 7, 611728.	1.2	7
2222	Iacta Alea Est: The Inexorable Advance of Tofacitinib in the Treatment of Dermatomyositis-Associated Rapidly Progressive Interstitial Lung Disease. A Case Report. Frontiers in Pharmacology, 2020, 11, 585761.	1.6	6
2223	Interstitial Pneumonia with Autoimmune Features: Why Rheumatologist-Pulmonologist Collaboration Is Essential. Biomedicines, 2021, 9, 17.	1.4	12
2224	The Interactions of Nintedanib and Oral Anticoagulantsâ€”Molecular Mechanisms and Clinical Implications. International Journal of Molecular Sciences, 2021, 22, 282.	1.8	18
2225	Brazilian guidelines for the pharmacological treatment of idiopathic pulmonary fibrosis. Official document of the Brazilian Thoracic Association based on the GRADE methodology. Jornal Brasileiro De Pneumologia, 2020, 46, e20190423-e20190423.	0.4	7
2226	Histopathologic heterogeneity of acute respiratory distress syndrome revealed by surgical lung biopsy and its clinical implications. Korean Journal of Internal Medicine, 2018, 33, 532-540.	0.7	11

#	Article	IF	Citations
2227	New Diagnostic Guidelines for Idiopathic Pulmonary Fibrosis. Korean Journal of Medicine, 2019, 94, 173-181.	0.1	2
2228	Managing interstitial lung disease detected on CT during lung cancer screening. Cleveland Clinic Journal of Medicine, 2016, 83, 55-65.	0.6	9
2229	Idiopathic pulmonary fibrosis: What primary care physicians need to know. Cleveland Clinic Journal of Medicine, 2018, 85, 377-386.	0.6	4
2230	Patients with interstitial lung disease and pulmonary sarcoidosis are at high risk for severe illness related to COVID-19. Cleveland Clinic Journal of Medicine, 2020, , .	0.6	25
2231	Acute exacerbation of idiopathic pulmonary fibrosis-a review of current and novel pharmacotherapies. Journal of Thoracic Disease, 2015, 7, 499-519.	0.6	70
2232	Combined pulmonary fibrosis and emphysema (CPFE): an entity different from emphysema or pulmonary fibrosis alone. Journal of Thoracic Disease, 2015, 7, 767-79.	0.6	66
2233	Palladium-Catalyzed One-Pot Approach to 3-(1,3-Diarylprop-2-yn-1-ylidene)oxindoles. Heterocycles, 2018, 96, 1795.	0.4	3
2234	New Era of Management Concept on Pulmonary Fibrosis with Revisiting Framework of Interstitial Lung Diseases. Tuberculosis and Respiratory Diseases, 2020, 83, 195-200.	0.7	2
2235	Practice guidelines for interstitial lung diseases: Widening the reach. Lung India, 2020, 37, 289.	0.3	1
2236	Idiopathic Pulmonary Fibrosis Ã¢â‚¬â€œ Diagnosis and Treatment. General Medicine (Los Angeles, Calif), 2014, 03, .	0.2	28
2237	Idiopathic pulmonary fibrosis: the turning point is now!. Swiss Medical Weekly, 2015, 145, w14139.	0.8	18
2238	Pharmacological treatment of pulmonary fibrosis. Journal of the Korean Medical Association, 2020, 63, 47.	0.1	4
2239	Diagnosis and treatment of interstitial lung disease: focusing on idiopathic pulmonary fibrosis. Journal of the Korean Medical Association, 2020, 63, 159.	0.1	2
2240	Acute Exacerbation of Idiopathic Pulmonary Fibrosis. Eurasian Journal of Medicine, 2017, 49, 204-206.	0.2	2
2241	Interstitial Lung Diseases in Developing Countries. Annals of Global Health, 2019, 85, .	0.8	37
2242	Combinations of vascular endothelial growth factor pathway inhibitors with metronomic chemotherapy: Rational and current status. World Journal of Experimental Medicine, 2014, 4, 58.	0.9	12
2243	Usual Interstitial Pneumonia in Contemporary Surgical Pathology Practice: Impact of International Consensus Guidelines for Idiopathic Pulmonary Fibrosis on Pathologists. Archives of Pathology and Laboratory Medicine, 2021, 145, 717-727.	1.2	3
2245	Identification of key modules and hub genes associated with lung function in idiopathic pulmonary fibrosis. PeerJ, 2020, 8, e9848.	0.9	8

#	Article	IF	Citations
2246	Palliative Care in Lung Disease. Respiratory Medicine, 2021, , 1-10.	0.1	0
2247	Management of Progressive Fibrosing Interstitial Lung Diseases (PF-ILD). Frontiers in Medicine, 2021, 8, 743977.	1.2	11
2248	Pulmonary fibrosis from molecular mechanisms to therapeutic interventions: lessons from post-COVID-19 patients. Biochemical Pharmacology, 2021, 193, 114812.	2.0	40
2249	Pulmonary Rehabilitation in Idiopathic Pulmonary Fibrosis and COPD. Chest, 2022, 161, 728-737.	0.4	19
2251	Nintedanib in idiopathic and secondary pleuroparenchymal fibroelastosis. Orphanet Journal of Rare Diseases, 2021, 16, 419.	1.2	20
2252	Home monitoring of physiology and symptoms to detect interstitial lung disease exacerbations and progression: a systematic review. ERJ Open Research, 2021, 7, 00441-2021.	1.1	12
2253	Revue des rÃ©cents essais randomisÃ©s dans la sclÃ©rodermie systÃ©mique. Revue Du Rhumatisme (Edition) Tj ETQq0 0 0 rgBT /Ove	0.0	0
2254	Antifibrotic therapies for idiopathic pulmonary fibrosis. The Cochrane Library, 2021, 2021, .	1.5	0
2255	Cough in Idiopathic Pulmonary Fibrosis. Frontiers in Rehabilitation Sciences, 2021, 2, .	0.5	9
2256	Tetrathiomolybdate Treatment Attenuates Bleomycin-Induced Angiogenesis and Lung Pathology in a Sheep Model of Pulmonary Fibrosis. Frontiers in Pharmacology, 2021, 12, 700902.	1.6	3
2258	Pirfenidone vs. nintedanib in patients with idiopathic pulmonary fibrosis: a retrospective cohort study. Respiratory Research, 2021, 22, 268.	1.4	24
2259	Evaluation of Pirfenidone and Nintedanib in a Human Lung Model of Fibrogenesis. Frontiers in Pharmacology, 2021, 12, 679388.	1.6	18
2260	Health Related Quality of Life in Interstitial Lung Disease: Can We Use the Same Concepts Around the World?. Frontiers in Medicine, 2021, 8, 745908.	1.2	2
2261	Dual inhibition of Î±vÎ²6 and Î±vÎ²1 reduces fibrogenesis in lung tissue explants from patients with IPF. Respiratory Research, 2021, 22, 265.	1.4	28
2262	A Drugâ€“Drug Interaction Study to Investigate the Effect of Nintedanib on the Pharmacokinetics of Microgynon (Ethinylestradiol and Levonorgestrel) in Female Patients with Systemic Sclerosis-Associated Interstitial Lung Disease. European Journal of Drug Metabolism and Pharmacokinetics, 2022, 47, 81-89.	0.6	3
2263	A Phase-2 Exploratory Randomized Controlled Trial of INOpulse in Patients with Fibrotic Interstitial Lung Disease Requiring Oxygen. Annals of the American Thoracic Society, 2022, 19, 594-602.	1.5	17
2264	Commonalities Between ARDS, Pulmonary Fibrosis and COVID-19: The Potential of Autotaxin as a Therapeutic Target. Frontiers in Immunology, 2021, 12, 687397.	2.2	22
2265	Management of patients with fibrosing interstitial lung diseases. American Journal of Health-System Pharmacy, 2022, 79, 129-139.	0.5	6

#	Article	IF	Citations
2266	Deficiency of CARMA3 attenuates the development of bleomycin induced pulmonary fibrosis. Biochemical and Biophysical Research Communications, 2021, 581, 81-88.	1.0	4
2267	Idiopathic interstitial pneumonias. , 2013, , 386-394.		0
2268	Idiopathische Lungenfibrose. , 2014, , 1-8.		0
2269	Fibrose pulmonaire idiopathique : progrÃ¨s Ã©tiologiques, diagnostiques, et thÃ©rapeutiques. Bulletin De L'Academie Nationale De Medecine, 2014, 198, 1353-1366.	0.0	0
2270	Directed Differentiation of Human Pluripotent Stem Cells into Lung and Airway Epithelial Cells. Pancreatic Islet Biology, 2015, , 265-285.	0.1	0
2272	Role of Progenitors in Pulmonary Fibrosis and Asthma. Pancreatic Islet Biology, 2015, , 71-91.	0.1	0
2273	Idiopathic Pulmonary Fibrosis: Treatment Strategies. Clinical Anti-Inflammatory and Anti-Allergy Drugs, 2015, 1, 87-94.	0.0	0
2275	ADVANCES IN THERAPIES FOR INTERSTITIAL LUNG DISEASES. , 2015, , 257-282.		0
2276	Treatment of lymphangioleiomyomatosis and CamÃµes. Jornal Brasileiro De Pneumologia, 2015, 41, 295-296.	0.4	0
2277	Neue Arzneimittel 2015. , 2016, , 49-134.		2
2278	Acute Exacerbation of IPF. , 2016, , 27-42.		0
2280	Pharmacotherapy of IPF (Corticosteroids, Immunosuppressants, Etc.). , 2016, , 161-170.		0
2281	Pharmacotherapy of Acute Exacerbation of IPF (Corticosteroids, Immunosuppressants, and Direct) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50		0
2282	Pulmonary Hypertension in Patients Without Pulmonary Arterial Hypertension. , 2016, , 29-61.		0
2283	Grundlagen der medikamentÃ¶sen Therapie. , 2016, , 37-54.		0
2284	Nintedanib Ameliorates Lipopolysaccharide-Induced Pulmonary Fibrosis after Acute Respiratory Distress Syndrome through Suppression of VEGF/PDGF/FGF. , 2016, 6, .		0
2285	New drugs: Nintedanib. Australian Prescriber, 2016, 39, 62-63.	0.5	3
2286	Idiopathic pulmonary fibrosis can be a transient diagnosis. Jornal Brasileiro De Pneumologia, 2016, 42, 74-75.	0.4	1

#	Article	IF	Citations
2287	Do New Drugs Meet the Expectations in the Treatment of Idiopathic Pulmonary Fibrosis?. Eurasian Journal of Pulmonology, 2016, 18, 1-2.	0.2	0
2288	Current pharmacotherapy of idiopathic pulmonary fibrosis. Klinicka Farmakologie A Farmacie, 2016, 30, 30-34.	0.1	0
2289	Tratamiento de la fibrosis pulmonar idiopÃ¡tica. Revista Colombiana De NeumologÃa, 2016, 26, .	0.1	0
2291	Idiopathic pulmonary fibrosis - or what new in idiopathic interstitial pneumonia. Interni Medicina Pro Praxi, 2016, 18, 61-65.	0.0	0
2292	Multidisciplinary discussion for diagnosis of interstitial lung disease in real life. Swiss Medical Weekly, 2016, 146, w14318.	0.8	5
2293	New Insights on Mechanisms and Treatment in Idiopathic Pulmonary Fibrosis. Global Journal of Respiratory Care, 2016, 3, 10-14.	0.2	0
2294	The Role of Mesenchymal Stromal Cells in Idiopathic Pulmonary Fibrosis. International Journal of Stem Cell Research and Therapy, 2016, 3, .	1.0	1
2295	Pulmonary and Critical Care Medicine. , 2017, , 325-337.		0
2296	Investigative Approaches to Drug Therapy. , 2017, , 583-594.		0
2297	Progressive Interstitial Lung Disease Nonresponse to Cyclophosphamide. , 2017, , 707-712.		0
2299	Respiratory Failure in a Patient with Idiopathic Pulmonary Fibrosis. , 2017, , 265-271.		0
2300	Pathology of Vascular Changes in Interstitial Lung Diseases. , 2017, , 45-66.		0
2301	Lung Transplantation in Interstitial Lung Disease. , 2017, , 85-102.		1
2302	Treatment of Pulmonary Hypertension in Interstitial Lung Disease. , 2017, , 67-84.		0
2303	Prognosis of adults with idiopathic pulmonary fibrosis without treatment or without effective therapies. The Cochrane Library, 0, , .	1.5	0
2304	Current concepts of idiopathic pulmonary fibrosis: focus on biomarkers. Pulmonologiya, 2017, 27, 56-64.	0.2	0
2305	Modern approach to therapy of patients with idiopathic pulmonary
fibrosis. Klinicheskaia Meditsina, 2017, 95, 281-285.	0.2	0
2307	Idiopathic pulmonary fibrosis. Can we always diagnose and treat it right?. Vnitrni Lekarstvi, 2017, 63, 796-801.	0.1	0

#	Article	IF	Citations
2308	Idiopathic pulmonary fibrosis in Brazil: challenges for epidemiological characterization and management. Jornal Brasileiro De Pneumologia, 2017, 43, 401-402.	0.4	1
2309	Respiratory Organ Aging and Cancer. , 2018, , 1-30.		0
2310	Gastroesophageal Reflux and Idiopathic Pulmonary Fibrosis. , 2018, , 195-204.		0
2311	Fibrostenotic Inflammatory Bowel Disease: A Cinderella Story. , 2018, , 1-4.		0
2313	Single- and Bilateral Lung Transplantation: Indications, Contraindications, Evaluation, and Requirements for Patients to Be Considered Eligible. , 2018, , 17-40.		0
2314	Interstitielle Lungenerkrankungen. , 2018, , 268-275.		0
2315	4. Recent Progress in Diagnosis and Treatment of Interstitial Pneumonias. The Journal of the Japanese Society of Internal Medicine, 2018, 107, 505-509.	0.0	1
2316	It takes a village to care for the patient with idiopathic pulmonary fibrosis. Cleveland Clinic Journal of Medicine, 2018, 85, 387-389.	0.6	0
2317	Fibrobronchoskopijos galimybÄ—s diagnozuojant plauÄ¡Å³ ligas. Pulmonology and Allergology, 2018, 2, .	0.0	0
2318	Chronic Lung Allograft Dysfunction: Phenotypes and the Future. , 2019, , 119-129.		0
2319	Acute exacerbation of idiopathic pulmonary fibrosis. Pulmonologiya, 2018, 28, 469-482.	0.2	1
2320	Antifibrotic therapy of idiopathic pulmonary fibrosis: efficiency / safety ratio. Meditsinskiy Sovet, 2018, , 131-136.	0.1	2
2321	The Role of Pulmonary Rehabilitation and Supplemental Oxygen Therapy in theÂTreatment of Patients with Idiopathic Pulmonary Fibrosis. Respiratory Medicine, 2019, , 389-399.	0.1	0
2322	Acute Exacerbation of Idiopathic Pulmonary Fibrosis. Respiratory Medicine, 2019, , 401-417.	0.1	1
2323	Pharmacologic Treatment of IPF. Respiratory Medicine, 2019, , 325-364.	0.1	1
2325	Gastroesophageal Reflux and IPF. Respiratory Medicine, 2019, , 379-387.	0.1	0
2326	Idiopathic interstitial pneumonias. , 2019, , 568-580.		0
2329	Complications of Transbronchial Cryobiopsy. , 2019, , 59-65.		0

#	Article	IF	Citations
2330	Interstitial Lung Disease. , 2019, , 139-158.		0
2331	Interstitielle Lungenerkrankungen. , 2019, , 157-165.		0
2332	Use of nintedanib in patients with idiopathic pulmonary fibrosis: Initial Indian experience. Lung India, 2019, 36, 465.	0.3	4
2333	Idiopathic pulmonary fibrosis: accurate diagnosis and early treatment. Jornal Brasileiro De Pneumologia, 2019, 45, e20190353.	0.4	0
2334	Chronic Lung Pathologies That Require Repair and Regeneration. , 2019, , 1-12.		1
2336	Benefit and clinical characteristics after the use of nintedanib in idiopathic pulmonary fibrosis. Journal of Lung, Pulmonary & Respiratory Research, 2019, 6, 29-30.	0.3	0
2338	Investigation of Fungal Colonization Among Iranian Patients with Idiopathic Pulmonary Fibrosis; Molecular Identification and Antifungal Susceptibility Pattern. Archives of Clinical Infectious Diseases, 2019, In Press, .	0.1	0
2340	End-of-Life Care of Patients with Idiopathic Pulmonary Fibrosis. , 2020, , 289-304.		1
2343	An efficacy of ninedanib in patients with idiopathic pulmonary fibrosis (two case reports). Pulmonologiya, 2019, 29, 486-492.	0.2	0
2345	Nintedanib for the treatment of idiopathic pulmonary fibrosis: An Indian perspective. The Journal of Association of Chest Physicians, 2020, 8, 48.	0.1	1
2347	The cardiovascular system in idiopathic pulmonary fibrosis. , 2020, , 198-211.		0
2349	Lung transplantation for idiopathic pulmonary fibrosis. Presse Medicale, 2020, 49, 104026.	0.8	9
2350	Beyond standard care?â€"idiopathic pulmonary fibrosis patientsâ€™ perception of care coordinators. Journal of Thoracic Disease, 2020, 12, 3930-3933.	0.6	0
2351	Humoral Immune Status in Relation to Outcomes in Patients with Idiopathic Pulmonary Fibrosis. Lung, 2021, 199, 667-676.	1.4	3
2352	Case Report: Nintedaninb May Accelerate Lung Recovery in Critical Coronavirus Disease 2019. Frontiers in Medicine, 2021, 8, 766486.	1.2	10
2353	Discovery of an Oxycyclohexyl Acid Lysophosphatidic Acid Receptor 1 (LPA₁) Antagonist BMS-986278 for the Treatment of Pulmonary Fibrotic Diseases. Journal of Medicinal Chemistry, 2021, 64, 15549-15581.	2.9	21
2354	Progressive fibrosing interstitial lung disease: prevalence and clinical outcome. Respiratory Research, 2021, 22, 282.	1.4	28
2355	Antifibrotic drugs for idiopathic pulmonary fibrosis: What we should know?. Indian Journal of Medical Research, 2020, 152, 177.	0.4	5

#	Article	IF	Citations
2357	MAP3K8 Regulates Cox-2â€“Mediated Prostaglandin E2 Production in the Lung and Suppresses Pulmonary Inflammation and Fibrosis. Journal of Immunology, 2021, 206, 607-620.	0.4	17
2358	Home spirometry to assess efficacy of pirfenidone in progressive unclassifiable interstitial lung disease: better the devil you know than the devil you donâ€™t. Annals of Translational Medicine, 2020, 8, 1615-1615.	0.7	0
2361	Image-Based Phenotyping, Deep Learning (DL), and Artificial Intelligence (AI) Applications in Clinical and Research Radiology and Chest Imaging. Medical Radiology, 2021, , 319-335.	0.0	0
2362	Diarrhoea in systemic sclerosis patients as a nocebo effect of nintedanib. European Respiratory Journal, 2021, 57, 2003021.	3.1	3
2363	Interstitial lung abnormalities â€“ current knowledge and future directions. European Clinical Respiratory Journal, 2021, 8, 1994178.	0.7	7
2364	Interstitial Lung Disease. , 2020, , 93-131.		0
2365	Pirfenidone Solution for Inhalation (AP01) for Idiopathic Pulmonary Fibrosis (ATLAS Study): A Randomized, Open-Label, Dose-Response Trial. SSRN Electronic Journal, 0, , .	0.4	0
2366	Acute Hypoxemic Respiratory Failure: Idiopathic Pulmonary Fibrosis. , 2020, , 115-122.		0
2367	Respiratory Organ Aging and Cancer. , 2020, , 215-244.		0
2369	Stereoselective Synthesis of (Z)-3-Arylidene-2-oxindoles via a Palladium-Catalyzed Tandem Reaction. Heterocycles, 2020, 100, 2050.	0.4	0
2370	Distinct improvement of pulmonary function, ground-glass opacity, hypoxia and physical findings in an idiopathic pulmonary fibrosis patient after pirfenidone treatment : a case report with a review of the literature. Journal of Medical Investigation, 2020, 67, 358-361.	0.2	0
2371	ERKRANKUNGEN DER ATMUNGSORGANE. , 2020, , C-1-C22-4.		0
2372	Pharmacological treatment of idiopathic pulmonary fibrosis: time to step out of the comfort zone?. Jornal Brasileiro De Pneumologia, 2020, 46, e20200193-e20200193.	0.4	0
2373	Nintedanibâ€”A Potential New Therapy for Systemic Sclerosis-associated Interstitial Lung Disease. US Respiratory & Pulmonary Diseases, 2020, 5, 28.	0.2	0
2374	Use of biologics in the treatment of asthma, COPD, ACOS, and idiopathic pulmonary fibrosis. , 2020, , 97-115.		0
2375	SEVERE HEPATOTOXICITY SECONDARY TO NINTEDANIB. Revista Espanola De Enfermedades Digestivas, 2020, , .	0.1	1
2377	Fibrosis-Net: A Tailored Deep Convolutional Neural Network Design for Prediction of Pulmonary Fibrosis Progression From Chest CT Images. Frontiers in Artificial Intelligence, 2021, 4, 764047.	2.0	11
2378	Antifibrotic Therapy for Idiopathic Pulmonary Fibrosis. Chest, 2021, 160, 1589-1591.	0.4	1

#	Article	IF	Citations
2379	Impact of Lung Biopsy Information on Treatment Strategy of Patients with Interstitial Lung Diseases. Annals of the American Thoracic Society, 2022, 19, 737-745.	1.5	9
2380	Nintedanib in treating interstitial lung disease associated with systemic scleroderma. Klinicka Farmakologie A Farmacie, 2021, 35, 80-86.	0.1	0
2381	Nintedanib-Induced Colitis Treated Effectively With Budesonide. Cureus, 2020, 12, e9489.	0.2	0
2382	Acute exacerbations of interstitial lung disease. , 0, , 117-131.		0
2383	IPF: treatment and prevention of pulmonary exacerbations. , 0, , 199-223.		0
2384	Key diagnostic issues. , 0, , 50-56.		0
2386	The evaluation of disease severity/staging for prognosis. , 0, , 97-105.		1
2387	Acute exacerbations. , 0, , 143-150.		1
2388	Symptom management: dyspnoea and cough. , 0, , 218-229.		0
2389	Key ongoing issues in trial design. , 0, , 253-259.		0
2390	Perspectives for the future. , 0, , 260-274.		1
2393	IPF: definition, severity and impact of pulmonary exacerbations. , 0, , 58-65.		0
2394	Coexistent COPD and ILD. , 0, , 109-120.		1
2395	Patterns of cardiopulmonary response to exercise in fibrotic ILD. , 0, , 128-145.		0
2396	Ways to improve the diagnosis and treatment of interstitial lung disease associated with systemic sclerosis in the Siberian Federal District (materials of the advisory board of rheumatologists and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 1		1
2399	Differentiating combined pulmonary fibrosis and emphysema from pure emphysema: utility of late gadolinium-enhanced MRI. European Radiology Experimental, 2020, 4, 61.	1.7	3
2400	CHRONIC NEUROGENIC PAIN PROMOTES DEVELOPMENT AND GROWTH OF M1 SARCOMA CHANGING LOCAL LEVELS OF GROWTH FACTORS. Siberian Journal of Oncology, 2020, 19, 68-75.	0.1	0
2401	Clinical Improvement and Effectiveness of Exercise-Based Pulmonary Rehabilitation in Patients With Idiopathic Pulmonary Fibrosis. Journal of Cardiopulmonary Rehabilitation and Prevention, 2021, 41, 52-57.	1.2	6

#	Article	IF	Citations
2402	Bicornuate Uterus with Unilateral Fibroid - Surgical Procedure or LNG-IUS â€“ A Conservative Approach in a Patient Who Opted LNG as Contraception. Journal of Evolution of Medical and Dental Sciences, 2020, 9, 2924-2926.	0.1	0
2403	Current therapy of interstitial pneumonia associated with systemic scleroderma. Nauchno-Prakticheskaya Revmatologiya, 2020, 58, 520-531.	0.2	4
2404	Efficacy study of edaravone and acetylcysteine towards bleomycin-induced rat pulmonary fibrosis. International Journal of Clinical and Experimental Medicine, 2015, 8, 8730-9.	1.3	4
2405	Ofev (Nintedanib): First Tyrosine Kinase Inhibitor Approved for the Treatment of Patients with Idiopathic Pulmonary Fibrosis. American Health and Drug Benefits, 2015, 8, 101-4.	0.5	17
2406	Rheumatoid Arthritis-Associated Interstitial Lung Disease and Idiopathic Pulmonary Fibrosis: Shared Mechanistic and Phenotypic Traits Suggest Overlapping Disease Mechanisms. Revista De Investigacion Clinica, 2015, 67, 280-6.	0.2	42
2407	Nintedanib inhibits TGF-Î²-induced myofibroblast transdifferentiation in human Tenon's fibroblasts. Molecular Vision, 2018, 24, 789-800.	1.1	11
2408	CCAAT/enhancer binding protein delta (C/EBPÎ´) deficiency does not affect bleomycin-induced pulmonary fibrosis. Journal of Clinical and Translational Research, 2018, 3, 358-365.	0.3	3
2409	Protective Effects of Thymoquinon on Pulmonary Disorders in Experimental Studies. Tanaffos, 2018, 17, 211-222.	0.5	4
2410	Pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis: comparison with chronic obstructive pulmonary disease. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2017, 34, 283-289.	0.2	3
2411	The association between health-related quality of life and disease progression in idiopathic pulmonary fibrosis: a prospective cohort study. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2017, 34, 226-235.	0.2	1
2412	Association of low body surface area with dose reduction and/or discontinuation of nintedanib in patients with idiopathic pulmonary fibrosis: a pilot study. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2019, 36, 74-78.	0.2	3
2413	Newly defined acute exacerbation of idiopathic pulmonary fibrosis with surgically-proven usual interstitial pneumonia: risk factors and outcome. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2019, 36, 39-46.	0.2	3
2415	Management of interstitial lung diseases: A consensus statement of the Indian Chest Society (ICS) and National College of Chest Physicians (NCCP). Lung India, 2020, 37, 359-378.	0.3	2
2416	Treatment of primary sjÃ¶gren's syndrome-related interstitial lung disease: a retrospective cohort study. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2020, 37, 136-147.	0.2	2
2417	A real-world study of the dosing and tolerability of pirfenidone and its effect on survival in idiopathic pulmonary fibrosis. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2020, 37, 148-157.	0.2	7
2418	The effect of the walk-bike on quality of life and exercise capacity in patients with idiopathic pulmonary fibrosis: a feasibility study. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2020, 37, 192-202.	0.2	3
2419	ThOracic Ultrasound in Idiopathic Pulmonary Fibrosis Evolution (TOUPIE): research protocol of a multicentric prospective study. BMJ Open, 2021, 11, e039078.	0.8	0
2420	The Extent of Inflammatory Cell Infiltrate and Fibrosis in Lungs of Telomere- and Surfactant-Related Familial Pulmonary Fibrosis. Frontiers in Medicine, 2021, 8, 736485.	1.2	0

#	Article	IF	Citations
2421	The clinical relevance of lymphocyte to monocyte ratio in patients with Idiopathic Pulmonary Fibrosis (IPF). Respiratory Medicine, 2022, 191, 106686.	1.3	4
2422	Tetrandrine Modulates Rheb-mTOR Signaling-Mediated Selective Autophagy and Protects Pulmonary Fibrosis. Frontiers in Pharmacology, 2021, 12, 739220.	1.6	9
2423	Neighborhood-Level Disadvantage Impacts on Patients with Fibrotic Interstitial Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 459-467.	2.5	25
2424	Longitudinal serological assessment of type VI collagen turnover is related to progression in a real-world cohort of idiopathic pulmonary fibrosis. BMC Pulmonary Medicine, 2021, 21, 382.	0.8	5
2425	Connective Tissue Growth Factor Single Nucleotide Polymorphisms in (Familial) Pulmonary Fibrosis and Connective Tissue Disease Associated Interstitial Lung Disease. Lung, 2021, 199, 659-666.	1.4	3
2426	Impact of concomitant idiopathic pulmonary fibrosis on prognosis in lung cancer patients: A meta-analysis. PLoS ONE, 2021, 16, e0259784.	1.1	3
2427	Variables Associated With Response to Therapy in Patients With Interstitial Pneumonia With Autoimmune Features. Journal of Clinical Rheumatology, 2022, 28, 84-88.	0.5	9
2428	Morin inhibits the transformation of fibroblasts towards myofibroblasts through regulating â€œPPAR-Î³-glutaminolysis-DEPTORâ€•pathway in pulmonary fibrosis. Journal of Nutritional Biochemistry, 2022, 101, 108923.	1.9	3
2429	Interstitial lung disease on the acute take for the non-respiratory physician. Clinical Medicine, 2021, 21, e584-e590.	0.8	2
2430	Survival of patients with idiopathic pulmonary fibrosis and pulmonary hypertension under therapy with nintedanib or pirfenidone. Internal and Emergency Medicine, 2022, 17, 815-822.	1.0	3
2431	Collagen 1a1 Expression by Airway Macrophages Increases In Fibrotic ILDs and Is Associated With FVC Decline and Increased Mortality. Frontiers in Immunology, 2021, 12, 645548.	2.2	17
2432	Treatment of Idiopathic Pulmonary Fibrosis with Capsule or Tablet Formulations of Pirfenidone in the Real-Life French RaDiCo-ILD Cohort. Advances in Therapy, 2022, 39, 405-420.	1.3	2
2433	Naringenin: A Promising Therapeutic Agent against Organ Fibrosis. Oxidative Medicine and Cellular Longevity, 2021, 2021, 1-13.	1.9	23
2434	TELO-SCOPE study: a randomised, double-blind, placebo-controlled, phase 2 trial of danazol for short telomere related pulmonary fibrosis. BMJ Open Respiratory Research, 2021, 8, e001127.	1.2	13
2435	Tolerability and efficacy of second-line antifibrotics in patients with idiopathic pulmonary fibrosis. Pulmonary Pharmacology and Therapeutics, 2021, 71, 102099.	1.1	2
2436	Antifibrotic therapies reduce mortality and hospitalization among Medicare beneficiaries with idiopathic pulmonary fibrosis. Journal of Managed Care & Specialty Pharmacy, 2021, 27, 1724-1733.	0.5	6
2437	A scalable 3D tissue culture pipeline to enable functional therapeutic screening for pulmonary fibrosis. APL Bioengineering, 2021, 5, 046102.	3.3	4
2438	COVID-related fibrosis: insights into potential drug targets. Expert Opinion on Investigational Drugs, 2021, 30, 1183-1195.	1.9	7

#	Article	IF	Citations
2439	Management of interstitial lung diseases: A consensus statement of the Indian Chest Society (ICS) and National College of Chest Physicians (NCCP). Lung India, 2020, 37, 359.	0.3	9
2440	Addition of antifibrotic therapy to immunosuppression in hypersensitivity pneumonitis: A case series. Respiratory Medicine Case Reports, 2021, 34, 101562.	0.2	2
2441	Role of antifibrotics in the management of idiopathic inflammatory myopathy associated interstitial lung disease. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2110609.	1.2	7
2442	Inhibiting TGF-Î² 1-Mediated Cellular Processes as an Effective Strategy for the Treatment of Pulmonary Fibrosis with Chinese Herbal Medicines. The American Journal of Chinese Medicine, 2021, 49, 1965-1999.	1.5	3
2443	Differential Discontinuation Profiles between Pirfenidone and Nintedanib in Patients with Idiopathic Pulmonary Fibrosis. Cells, 2022, 11, 143.	1.8	13
2444	Impact of Concomitant Medication Burden on Tolerability of Disease-targeted Therapy and Survival in Interstitial Lung Disease. Annals of the American Thoracic Society, 2022, 19, 962-970.	1.5	5
2445	Integrative omics analysis identifies biomarkers of idiopathic pulmonary fibrosis. Cellular and Molecular Life Sciences, 2022, 79, 66.	2.4	8
2446	The Interaction Between Pulmonary Fibrosis and COVID-19 and the Application of Related Anti-Fibrotic Drugs. Frontiers in Pharmacology, 2021, 12, 805535.	1.6	19
2447	Clodronate-nintedanib-loaded exosomeâ€“liposome hybridization enhances the liver fibrosis therapy by inhibiting Kupffer cell activity. Biomaterials Science, 2022, 10, 702-713.	2.6	12
2448	Shifting Paradigms for Suppressing Fibrosis in Kidney Transplants: Supplementing Perfusion Solutions With Anti-fibrotic Drugs. Frontiers in Medicine, 2021, 8, 806774.	1.2	6
2449	The antifibrotic effect of pheretima protein is mediated by the TGF-Î²1/Smad2/3 pathway and attenuates inflammation in bleomycin-induced idiopathic pulmonary fibrosis. Journal of Ethnopharmacology, 2022, 286, 114901.	2.0	6
2450	Methotrexate and The Lung in Rheumatoid Arthritis. European Medical Journal Rheumatology, 0, , 80-90.	0.0	1
2451	Pulmonary Fibrosis. , 2021, , .		1
2452	Immunological Regulation of Intestinal Fibrosis in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2022, 28, 337-349.	0.9	20
2453	PROMising developments in IPF patient-reported outcome measures. European Respiratory Journal, 2022, 59, 2102312.	3.1	3
2454	Aggravation of pulmonary fibrosis after knocking down the Aryl hydrocarbon receptor in the Insulinâ€like growth factor 1 receptor pathway. British Journal of Pharmacology, 2022, , .	2.7	4
2455	Automatic quantitative computed tomography measurement of longitudinal lung volume loss in interstitial lung diseases. European Radiology, 2022, 32, 4292-4303.	2.3	11
2456	Pulmonary Function and Chest Computed Tomography (CT) Scan Findings After Antifibrotic Treatment for COVID-19-Related Pulmonary Fibrosis. American Journal of Case Reports, 2022, 23, e934830.	0.3	5

#	Article	IF	Citations
2457	Mechanism of hepatobiliary toxicity of the LPA1 antagonist BMS-986020 developed to treat idiopathic pulmonary fibrosis: Contrasts with BMS-986234 and BMS-986278. Toxicology and Applied Pharmacology, 2022, 438, 115885.	1.3	11
2458	Effect of continued antifibrotic therapy after forced vital capacity decline in patients with idiopathic pulmonary fibrosis; a real world multicenter cohort study. Respiratory Medicine, 2022, 191, 106722.	1.3	3
2459	Overexpression of bone morphogenetic protein receptor type 2 suppresses transforming growth factor Î²-induced profibrotic responses in lung fibroblasts. Experimental Lung Research, 2022, 48, 35-51.	0.5	1
2460	The use of exhaled air analysis in discriminating interstitial lung diseases: a pilot study. Respiratory Research, 2022, 23, 12.	1.4	10
2461	Disparities in Lung Transplant among Patients with Idiopathic Pulmonary Fibrosis: An Analysis of the IPF-PRO Registry. Annals of the American Thoracic Society, 2022, 19, 981-990.	1.5	14
2464	Radiologic-pathologic correlation of interstitial lung abnormalities and predictors for progression and survival. European Radiology, 2022, 32, 2713-2723.	2.3	19
2465	Idiopathic pulmonary fibrosis: Current and future treatment. Clinical Respiratory Journal, 2022, 16, 84-96.	0.6	77
2466	Time-Dependent Molecular Motifs of Pulmonary Fibrogenesis in COVID-19. International Journal of Molecular Sciences, 2022, 23, 1583.	1.8	16
2467	Selective multi-kinase inhibition sensitizes mesenchymal pancreatic cancer to immune checkpoint blockade by remodeling the tumor microenvironment. Nature Cancer, 2022, 3, 318-336.	5.7	42
2468	Proteomic biomarkers of progressive fibrosing interstitial lung disease: a multicentre cohort analysis. Lancet Respiratory Medicine,the, 2022, 10, 593-602.	5.2	31
2469	Gender and racial equity in clinical research for idiopathic pulmonary fibrosis: a systematic review and meta-analysis. European Respiratory Journal, 2022, , 2102969.	3.1	8
2470	Induced pluripotent stem cells. , 2022, , 1-58.		0
2471	BAL Transcriptomes Characterize Idiopathic Pulmonary Fibrosis Endotypes With Prognostic Impact. Chest, 2022, 161, 1576-1588.	0.4	8
2472	Long-Term Effects of COVID-19. Mayo Clinic Proceedings, 2022, 97, 579-599.	1.4	49
2473	PercepciÃ³n de los pacientes en cuanto al manejo de la fibrosis pulmonar idiopÃ¡tica. Proyecto Explora-IPF. Open Respiratory Archives, 2022, 4, 100158.	0.0	0
2474	Challenges for Clinical Drug Development in Pulmonary Fibrosis. Frontiers in Pharmacology, 2022, 13, 823085.	1.6	20
2475	Idiopathic Pulmonary Fibrosis Complicated by Adenocarcinoma and Organizing Pneumonia. Cureus, 2022, 14, e20916.	0.2	0
2476	The role of antifibrotic therapies in the treatment of systemic sclerosisâ€“associated interstitial lung disease. Therapeutic Advances in Musculoskeletal Disease, 2022, 14, 1759720X2110666.	1.2	0

#	Article	IF	Citations
2477	Mortality and survival in idiopathic pulmonary fibrosis: a systematic review and meta-analysis. ERJ Open Research, 2022, 8, 00591-2021.	1.1	25
2478	Demystifying idiopathic interstitial pneumonia: time for more etiology-focused nomenclature in interstitial lung disease. Expert Review of Respiratory Medicine, 2022, 16, 235-245.	1.0	2
2479	Three-Month FVC Change: A Trial Endpoint for Idiopathic Pulmonary Fibrosis Based on Individual Participant Data Meta-analysis. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 936-948.	2.5	11
2480	Idiopathic pulmonary fibrosis in the practice of a family doctor. SpravoÄnik VraÄa ObÅ¡ej Praktiki, 2022, , 34-43.	0.0	0
2481	Cost-effectiveness of the anti-fibrotics for the treatment of idiopathic pulmonary fibrosis in the United States. BMC Pulmonary Medicine, 2022, 22, 18.	0.8	9
2482	Novedades diagnÃ³sticas y terapÃ©uticas en fibrosis pulmonar progresiva. Archivos De Bronconeumologia, 2022, , .	0.4	7
2483	CC-90001, a c-Jun N-terminal kinase (JNK) inhibitor, in patients with pulmonary fibrosis: design of a phase 2, randomised, placebo-controlled trial. BMJ Open Respiratory Research, 2022, 9, e001060.	1.2	17
2484	Inhibition of RUNX1 blocks the differentiation of lung fibroblasts to myofibroblasts. Journal of Cellular Physiology, 2022, 237, 2169-2182.	2.0	16
2485	Analysis of Forced Vital Capacity (FVC) Trajectories in Idiopathic Pulmonary Fibrosis (IPF) Identifies Four Distinct Clusters of Disease Behaviour. SSRN Electronic Journal, 0, , .	0.4	0
2486	The Design of Multi-target Drugs to Treat Cardiovascular Diseases: Two (or more) Birds on One Stone. Current Topics in Medicinal Chemistry, 2022, 22, 366-394.	1.0	5
2487	Pemafibrate Attenuates Pulmonary Fibrosis by Inhibiting Myofibroblast Differentiation. SSRN Electronic Journal, 0, , .	0.4	0
2488	The Accuracy of Japanese Administrative Data in Identifying Acute Exacerbation of Idiopathic Pulmonary Fibrosis. Annals of Clinical Epidemiology, 2022, 4, 53-62.	0.3	4
2489	Longitudinal and Comparative Measures of Serum Chitotriosidase and YKL-40 in Patients With Idiopathic Pulmonary Fibrosis. Frontiers in Immunology, 2022, 13, 760776.	2.2	11
2490	Tolerability of nintedanib in the elderly with idiopathic pulmonary fibrosis: A single-center retrospective study. PLoS ONE, 2022, 17, e0262795.	1.1	7
2491	Identification of targetable kinases in idiopathic pulmonary fibrosis. Respiratory Research, 2022, 23, 20.	1.4	8
2492	Medical treatments for idiopathic pulmonary fibrosis: a systematic review and network meta-analysis. Thorax, 2022, 77, 1243-1250.	2.7	31
2493	Chasing a Breath of Fresh Air in Cystic Fibrosis (CF): Therapeutic Potential of Selective HDAC6 Inhibitors to Tackle Multiple Pathways in CF Pathophysiology. Journal of Medicinal Chemistry, 2022, 65, 3080-3097.	2.9	10
2494	Therapeutic effects of eperisone on pulmonary fibrosis via preferential suppression of fibroblast activity. Cell Death Discovery, 2022, 8, 52.	2.0	4

#	Article	IF	Citations
2495	Prospective machine learning CT quantitative evaluation of idiopathic pulmonary fibrosis in patients undergoing anti-fibrotic treatment using low- and ultra-low-dose CT. Clinical Radiology, 2022, 77, e208-e214.	0.5	10
2496	Outcomes for Elective Open and Thoracoscopic Surgical Lung Biopsies in the United States and Temporal Trends. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2022, 6, 87-97.	1.2	1
2497	Fatty acid nitroalkene reversal of established lung fibrosis. Redox Biology, 2022, 50, 102226.	3.9	9
2498	Vardenafil Activity in Lung Fibrosis and In Vitro Synergy with Nintedanib. Cells, 2021, 10, 3502.	1.8	6
2499	Myositis-associated interstitial lung disease: a comprehensive approach to diagnosis and management. Clinical and Experimental Rheumatology, 2021, , .	0.4	0
2500	Role of antifibrotic drugs in the management of post-COVID-19 interstitial lung disease: A review of literature and report from an expert working group. Lung India, 2022, 39, 177.	0.3	5
2501	Interstitial lung disease and rheumatoid arthritis. Handbook of Systemic Autoimmune Diseases, 2022, , 21-40.	0.1	0
2503	The role of antifibrotics in the treatment of rheumatoid arthritisâ€“associated interstitial lung disease. Therapeutic Advances in Musculoskeletal Disease, 2022, 14, 1759720X2210744.	1.2	7
2505	Differential Diagnosis on Diffuse Interstitial Lung Disease by Quantifying Imaging Patterns with Multi-Tasks Deep Learning in High-Resolution Ct of the Lungs. SSRN Electronic Journal, 0, , .	0.4	0
2507	Perioperative Management of Patients with Idiopathic Pulmonary Fibrosis Undergoing Noncardiac Surgery: A Narrative Review. International Journal of General Medicine, 2022, Volume 15, 2087-2100.	0.8	1
2508	Nintedanib in Patients With Autoimmune Diseaseâ€“Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the <scp>INBUILD</scp> Trial. Arthritis and Rheumatology, 2022, 74, 1039-1047.	2.9	44
2509	Usual interstitial pneumonia: a clinically significant pattern, but not the final word. Modern Pathology, 2022, 35, 589-593.	2.9	4
2510	Comparative Analysis of Gene Expression in Fibroblastic Foci in Patients with Idiopathic Pulmonary Fibrosis and Pulmonary Sarcoidosis. Cells, 2022, 11, 664.	1.8	12
2511	Integrated bioinformatics analysis identifies established and novel TGFÎ²1-regulated genes modulated by anti-fibrotic drugs. Scientific Reports, 2022, 12, 3080.	1.6	5
2512	Emerging Evidence and Treatment Perspectives from Randomized Clinical Trials in Systemic Sclerosis: Focus on Interstitial Lung Disease. Biomedicines, 2022, 10, 504.	1.4	2
2513	Cholesterol Significantly Affects the Interactions between Pirfenidone and DPPC Liposomes: Spectroscopic Studies. Biophysica, 2022, 2, 79-88.	0.6	3
2514	The experience of people with idiopathic pulmonary fibrosis living through the COVIDâ€19 pandemic. Journal of Advanced Nursing, 2022, 78, 2232-2244.	1.5	6
2515	Myositis-associated interstitial lung disease: a comprehensive approach to diagnosis and management. Clinical and Experimental Rheumatology, 2022, 40, 373-383.	0.4	18

#	Article	IF	Citations
2516	MIXTURE of human expertise and deep learningâ€"developing an explainable model for predicting pathological diagnosis and survival in patients with interstitial lung disease. Modern Pathology, 2022, 35, 1083-1091.	2.9	21
2517	Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases. Respirology, 2022, 27, 294-300.	1.3	15
2518	Pleiotropic Long-Term Effects of Atorvastatin on Posttraumatic Joint Contracture in a Rat Model. Pharmaceutics, 2022, 14, 523.	2.0	3
2519	Natural Product-Based Potential Therapeutic Interventions of Pulmonary Fibrosis. Molecules, 2022, 27, 1481.	1.7	10
2520	Impact of timing of nintedanib initiation among patients newly diagnosed with idiopathic pulmonary fibrosis. Journal of Medical Economics, 2022, 25, 532-540.	1.0	2
2521	Understanding and Therapeutically Targeting the Scleroderma Myofibroblast. Current Treatment Options in Rheumatology, 2022, 8, 1-18.	0.6	0
2523	Progress of Statin Therapy in the Treatment of Idiopathic Pulmonary Fibrosis. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-18.	1.9	10
2525	Post-COVID-19 Pulmonary Fibrosis. Cureus, 2022, 14, e22770.	0.2	17
2526	Nintedanib ameliorates oxidized low-density lipoprotein -induced inflammation and cellular senescence in vascular endothelial cells. Bioengineered, 2022, 13, 6196-6207.	1.4	13
2527	Investigation of clinical predictors of survival in idiopathic pulmonary fibrosis patients: A cohort study in Taiwan. Journal of the Chinese Medical Association, 2022, 85, 578-583.	0.6	2
2528	Caveolin-1-Derived Peptide Reduces ER Stress and Enhances Gelatinolytic Activity in IPF Fibroblasts. International Journal of Molecular Sciences, 2022, 23, 3316.	1.8	1
2529	Interobserver agreement regarding the Fleischner Society diagnostic criteria for usual interstitial pneumonia patterns on computed tomography. Radiologia Brasileira, 2022, 55, 71-77.	0.3	3
2530	Editorial: Mechanisms of Lung Fibrosis: Is Immunity Back in the Game?. Frontiers in Immunology, 2022, 13, 882979.	2.2	0
2531	Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial. European Respiratory Journal, 2022, 60, 2200380.	3.1	34
2532	Study on the Mechanism of Astragalus Polysaccharide in Treating Pulmonary Fibrosis Based on â€œDrug-Target-Pathwayâ€•Network. Frontiers in Pharmacology, 2022, 13, 865065.	1.6	13
2533	Responsiveness and meaningful change thresholds of the Living with Pulmonary Fibrosis (L-PF) questionnaire Dyspnoea and Cough scores in patients with progressive fibrosing interstitial lung diseases. BMJ Open Respiratory Research, 2022, 9, e001167.	1.2	6
2534	Clinical Overview of Progressive Fibrotic Interstitial Lung Disease. Frontiers in Medicine, 2022, 9, 858339.	1.2	3
2535	Validation of diagnostic coding for interstitial lung diseases in an electronic health record system in <scp>Hong Kong</scp>. Pharmacoepidemiology and Drug Safety, 2022, 31, 519-523.	0.9	15

#	Article	IF	Citations
2536	Cough-Specific Quality of Life Predicts Disease Progression Among Patients With Interstitial Lung Disease. Chest, 2022, 162, 603-613.	0.4	10
2537	BMP1 is not required for lung fibrosis in mice. Scientific Reports, 2022, 12, 5466.	1.6	3
2538	Prevalence and prognosis of chronic fibrosing interstitial lung diseases with a progressive phenotype. Respirology, 2022, 27, 333-340.	1.3	18
2539	A phase <scp>II</scp> feasibility study of carboplatin and nabâ€paclitaxel for advanced nonâ€small cell lung cancer patients with interstitial lung disease (<scp>YLOG0114</scp>). Thoracic Cancer, 2022, , .	0.8	3
2540	EGFR Signaling in Lung Fibrosis. Cells, 2022, 11, 986.	1.8	18
2541	PDGF/PDGFR: A Possible Molecular Target in Scleroderma Fibrosis. International Journal of Molecular Sciences, 2022, 23, 3904.	1.8	13
2542	Emerging Roles of Airway Epithelial Cells in Idiopathic Pulmonary Fibrosis. Cells, 2022, 11, 1050.	1.8	23
2543	Targeting Chitinase 1 and Chitinase 3-Like 1 as Novel Therapeutic Strategy of Pulmonary Fibrosis. Frontiers in Pharmacology, 2022, 13, 826471.	1.6	7
2544	Pre-exposure to Aerosolized Polyvalent Bacterial Lysates Protects Against Bleomycin-Induced Pulmonary Fibrosis in Mice. Inflammation, 2022, 45, 1692-1699.	1.7	1
2545	Editorial: Interstitial Lung Disease Around the World. Frontiers in Medicine, 2022, 9, 865334.	1.2	0
2546	Arsenic trioxide inhibits the functions of lung fibroblasts derived from patients with idiopathic pulmonary fibrosis. Toxicology and Applied Pharmacology, 2022, 441, 115972.	1.3	6
2547	Integrated multicomponent analysis based on UHPLCâ€Qâ€Exactive Orbitrapâ€MS and network pharmacology to elucidate the potential mechanism of Baoyuan decoction against idiopathic pulmonary fibrosis. Phytochemical Analysis, 2022, 33, 678-695.	1.2	1
2548	Disparities in Rural Populations With Idiopathic Pulmonary Fibrosis. Chest, 2022, 162, 630-634.	0.4	10
2549	Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial. Respiratory Research, 2022, 23, 85.	1.4	17
2551	Chronic Obstructive Pulmonary Disease Combined with Interstitial Lung Disease. Tuberculosis and Respiratory Diseases, 2022, 85, 122-136.	0.7	3
2552	Limited efficacy of nintedanib for idiopathic pleuroparenchymal fibroelastosis. Respiratory Investigation, 2022, 60, 562-569.	0.9	14
2553	Screening for Inhibitors of YAP Nuclear Localization Identifies Aurora Kinase A as a Modulator of Lung Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2022, , .	1.4	6
2554	Clinical Features, Diagnosis, Management, and Outcomes of Idiopathic Pulmonary Fibrosis in Korea: Analysis of the Korea IPF Cohort (KICO) Registry. Tuberculosis and Respiratory Diseases, 2022, 85, 185-194.	0.7	11

#	Article	IF	Citations
2555	Treating Pulmonary Fibrosis with Non-Viral Gene Therapy: From Bench to Bedside. Pharmaceutics, 2022, 14, 813.	2.0	4
2556	Caveolin-1 peptide regulates p53-microRNA-34a feedback in fibrotic lung fibroblasts. IScience, 2022, 25, 104022.	1.9	3
2557	Impact of Palliative Care in End-of-Life of Fibrotic Interstitial Lung Disease Patients. American Journal of Hospice and Palliative Medicine, 2022, 39, 1443-1451.	0.8	4
2558	C/EBP homologous protein promotes Sonic Hedgehog secretion from type II alveolar epithelial cells and activates Hedgehog signaling pathway of fibroblast in pulmonary fibrosis. Respiratory Research, 2022, 23, 86.	1.4	7
2559	Pemafibrate attenuates pulmonary fibrosis by inhibiting myofibroblast differentiation. International Immunopharmacology, 2022, 108, 108728.	1.7	9
2560	Interstitial pneumonia with autoimmune features: challenges and controversies. European Respiratory Review, 2021, 30, 210177.	3.0	16
2561	Advances with pharmacotherapy for the treatment of interstitial lung disease. Expert Opinion on Pharmacotherapy, 2022, 23, 483-495.	0.9	0
2562	Distinct roles of KLF4 in mesenchymal cell subtypes during lung fibrogenesis. Nature Communications, 2021, 12, 7179.	5.8	22
2563	Real-life prevalence of progressive fibrosing interstitial lung diseases. Scientific Reports, 2021, 11, 23988.	1.6	15
2564	Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis. BMC Pulmonary Medicine, 2021, 21, 411.	0.8	47
2565	E4 engages uPAR and enolase-1 and activates urokinase to exert antifibrotic effects. JCI Insight, 2021, 6, .	2.3	12
2566	Mortality and Respiratory-Related Hospitalizations in Idiopathic Pulmonary Fibrosis Not Treated With Antifibrotics. Frontiers in Medicine, 2021, 8, 802989.	1.2	8
2567	Validation of the risk stratification score in idiopathic pulmonary fibrosis: study protocol of a prospective, multi-centre, observational, 3-year clinical trial. BMC Pulmonary Medicine, 2021, 21, 396.	0.8	0
2568	Investigation of effect of nintedanib in experimental uveitis model. Cutaneous and Ocular Toxicology, 2021, , 1-5.	0.5	0
2569	The Impact of the Envisia Genomic Classifier in the Diagnosis and Management of Patients with Idiopathic Pulmonary Fibrosis. Annals of the American Thoracic Society, 2022, 19, 916-924.	1.5	12
2570	Pirfenidone in Unclassifiable Interstitial Lung Disease: A Subgroup Analysis by Concomitant Mycophenolate Mofetil and/or Previous Corticosteroid Use. Advances in Therapy, 2022, 39, 1081-1095.	1.3	6
2571	Recovering from a pandemic: pulmonary fibrosis after SARS-CoV-2 infection. European Respiratory Review, 2021, 30, 210194.	3.0	43
2572	Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA₁) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD). BMJ Open Respiratory Research, 2021, 8, e001026.	1.2	20

#	Article	IF	Citations
2573	Phenotypic drug screening in a human fibrosis model identified a novel class of antifibrotic therapeutics. Science Advances, 2021, 7, eabb3673.	4.7	15
2574	Pharmacological Management of Idiopathic Pulmonary Fibrosis. , 0, , .		0
2575	Disease progression in patients with the restrictive and mixed phenotype of Chronic Lung Allograft dysfunctionâ€"A retrospective analysis in five European centers to assess the feasibility of a therapeutic trial. PLoS ONE, 2021, 16, e0260881.	1.1	1
2576	Telehealth for patients with interstitial lung diseases (ILD): results of an international survey of clinicians. BMJ Open Respiratory Research, 2021, 8, e001088.	1.2	11
2577	Idiopathic pulmonary fibrosis diagnosed concomitantly with diffuse squamous cell lung cancer on surgical lung biopsy: aÂcase report. Journal of Medical Case Reports, 2021, 15, 595.	0.4	1
2578	Challenges in the Diagnosis and Management of Patients with Fibrosing Interstitial Lung Disease. Case Reports in Pulmonology, 2022, 2022, 1-7.	0.2	1
2579	LncRNA DACH1 protects against pulmonary fibrosis by binding to SRSF1 to suppress CTNNB1 accumulation. Acta Pharmaceutica Sinica B, 2022, 12, 3602-3617.	5.7	10
2580	Lung tissue shows divergent gene expression between chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. Respiratory Research, 2022, 23, 97.	1.4	7
2581	Identification of Hub Genes in Idiopathic Pulmonary Fibrosis and NSCLC Progression:Evidence From Bioinformatics Analysis. Frontiers in Genetics, 2022, 13, 855789.	1.1	7
2582	Evaluation for clinical benefit of metformin in patients with idiopathic pulmonary fibrosis and type 2 diabetes mellitus: a national claims-based cohort analysis. Respiratory Research, 2022, 23, 91.	1.4	16
2583	Radiomics for the Prediction of Response to Antifibrotic Treatment in Patients with Idiopathic Pulmonary Fibrosis: A Pilot Study. Diagnostics, 2022, 12, 1002.	1.3	8
2584	[Translated article] Diagnostic and Therapeutic Developments in Progressive Pulmonary Fibrosis. Archivos De Bronconeumologia, 2022, , .	0.4	0
2585	Quality of Life and Healthcare Resource Use in a Real-world Patient Population with Idiopathic Pulmonary Fibrosis: The PROOF Registry. Pulmonary Therapy, 2022, 8, 181-194.	1.1	2
2586	Therapie der Lungenfibrosen: InterdisziplinÃre Diagnostik bessert Therapiechancen. , 0, , .		0
2587	Current Beliefs and Practices Regarding the Management of Obesity in Patients with Progressive Interstitial Lung Disease. Annals of the American Thoracic Society, 2022, 19, 1602-1605.	1.5	2
2620	ThOracic Ultrasound in Idiopathic Pulmonary Fibrosis Evolution (TOUPIE): research protocol of a multicentric prospective study. BMJ Open, 2021, 11, e039078.	0.8	0
2621	Pulmonary vascular volume is associated with DLCO and fibrotic score in idiopathic pulmonary fibrosis: an observational study. BMC Medical Imaging, 2022, 22, 76.	1.4	5
2622	The pathogenesis and pathology of idiopathic pleuroparenchymal fibroelastosis. Histology and Histopathology, 2021, 36, 291-303.	0.5	4

#	Article	IF	Citations
2623	Time for Prevention of Idiopathic Pulmonary Fibrosis Exacerbation. Annals of the American Thoracic Society, 2015, 12, S181-S185.	1.5	17
2624	The Extent of Inflammatory Cell Infiltrate and Fibrosis in Lungs of Telomere- and Surfactant-Related Familial Pulmonary Fibrosis. Frontiers in Medicine, 2021, 8, 736485.	1.2	4
2632	Raising awareness on physician-patient communication in IPF: an Italian multicenter study exploring the pulmonologist's perspective. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2021, 38, e2021042.	0.2	0
2633	Impact of progressive fibrosing interstitial lung disease (ILD) in ILD patients complicated with secondary spontaneous pneumothorax.. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2022, 38, e2021042.	0.2	0
2635	Interstitielle Lungenerkrankungen. , 2022, , 92-102.		0
2636	Anti-fibrotic effects of pharmacologic FGF-2: a review of recent literature. Journal of Molecular Medicine, 2022, 100, 847-860.	1.7	3
2637	Development and Validation of a Novel Gene Signature for Predicting the Prognosis of Idiopathic Pulmonary Fibrosis Based on Three Epithelial-Mesenchymal Transition and Immune-Related Genes. Frontiers in Genetics, 2022, 13, 865052.	1.1	4
2638	Immunophenotyping of Acute Inflammatory Exacerbations of Lung Injury Driven by Mutant Surfactant Protein-C: A Role for Inflammatory Eosinophils. Frontiers in Pharmacology, 2022, 13, 875887.	1.6	4
2639	Interstitial lung disease incidence and mortality in the UK and the European Union: an observational study, 2001â€“2017. ERJ Open Research, 2022, 8, 00058-2022.	1.1	11
2640	Malnutrition and decreased food intake at diagnosis are associated with hospitalization and mortality of idiopathic pulmonary fibrosis patients. Clinical Nutrition, 2022, 41, 1335-1342.	2.3	15
2641	Targeting Histone Deacetylases in Idiopathic Pulmonary Fibrosis: A Future Therapeutic Option. Cells, 2022, 11, 1626.	1.8	22
2642	Contemporary Concise Review 2021: Interstitial lung disease. Respirology, 2022, 27, 539-548.	1.3	8
2643	Nintedanib in Progressive Pulmonary Fibrosis: A Systematic Review and Meta-Analysis. Annals of the American Thoracic Society, 2022, 19, 1040-1049.	1.5	24
2644	Lung cancer in patients with fibrosing interstitial lung diseases: an overview of current knowledge and challenges. ERJ Open Research, 2022, 8, 00115-2022.	1.1	13
2646	Outpatient Pharmacologic Management of Lung Transplant Candidates on the Waiting List. Thoracic Surgery Clinics, 2022, 32, 111-119.	0.4	1
2647	Chronic Lung Allograft Dysfunction. Thoracic Surgery Clinics, 2022, 32, 231-242.	0.4	8
2648	Association between bevacizumab with cancer drug therapies and drug-induced interstitial lung disease in patients with solid tumor: A systematic review and meta-analysis of randomized clinical trials. Critical Reviews in Oncology/Hematology, 2022, 174, 103703.	2.0	2
2649	Nintedanib reduces alloimmune-induced chronic airway changes in murine tracheal allografts. Transplant Immunology, 2022, 73, 101608.	0.6	4

#	Article	IF	Citations
2650	A near-infrared fluorescent probe was used to evaluate the role of histone deacetylase in pulmonary fibrosis cells and mice. Sensors and Actuators B: Chemical, 2022, 366, 132012.	4.0	1
2651	Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis. New England Journal of Medicine, 2022, 386, 2178-2187.	13.9	77
2652	GSK3 inhibition rescues growth and telomere dysfunction in dyskeratosis congenita iPSC-derived type II alveolar epithelial cells. ELife, 2022, 11, .	2.8	6
2653	Meta-Analysis of Effect of Nintedanib on Reducing FVC Decline Across Interstitial Lung Diseases. Advances in Therapy, 2022, 39, 3392-3402.	1.3	12
2654	From the Gut to the Lung: Evidence of Antifibrotic Activity of Endocrine Fibroblast Growth Factor (FGF)19. American Journal of Respiratory Cell and Molecular Biology, 2022, , .	1.4	0
2655	The influence of green tea extract on nintedanibâ€™s bioavailability in patients with pulmonary fibrosis. Biomedicine and Pharmacotherapy, 2022, 151, 113101.	2.5	7
2656	The state of the art for artificial intelligence in lung digital pathology. Journal of Pathology, 2022, 257, 413-429.	2.1	31
2657	CRTH2 Mediates Profibrotic Macrophage Differentiation and Promotes Lung Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2022, 67, 201-214.	1.4	6
2658	Research Burden of Interstitial Lung Diseases in Turkey - RBILD.. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2022, 39, e2022006.	0.2	0
2659	A multicenter survey study of antifibrotic use for symptomatic patients with post-COVID-19 interstitial lung abnormalities. Lung India, 2022, 39, 254.	0.3	3
2660	Human Lung Tissue Implanted on the Chick Chorioallantoic Membrane as a Novel In Vivo Model of IPF. American Journal of Respiratory Cell and Molecular Biology, 0, , .	1.4	0
2661	Baseline serum Krebs von den Lungen-6 as a biomarker for the disease progression in idiopathic pulmonary fibrosis. Scientific Reports, 2022, 12, .	1.6	7
2663	Oxygen Therapy during Exercise in Patients with Interstitial Lung Diseases. Biomolecules, 2022, 12, 717.	1.8	0
2664	Endocannabinoid signalling/cannabinoid receptor 2 is involved in icariin-mediated protective effects against bleomycin-induced pulmonary fibrosis. Phytomedicine, 2022, 103, 154187.	2.3	5
2665	Formulated Herbal Medicines for Idiopathic Pulmonary Fibrosis: A Case Series. SSRN Electronic Journal, 0, , .	0.4	0
2666	Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study. Journal of Thoracic Oncology, 2022, 17, 1098-1108.	0.5	51
2667	Acute Exacerbation of Idiopathic Pulmonary Fibrosis. , 0, , .		0
2668	Long-term evaluation of the safety and efficacy of recombinant human pentraxin-2 (rhPTX-2) in patients with idiopathic pulmonary fibrosis (IPF): an open-label extension study. Respiratory Research, 2022, 23, .	1.4	17

#	Article	IF	Citations
2669	Insights gained in the pathology of lung disease through singleâ€cell transcriptomics. Journal of Pathology, 2022, 257, 494-500.	2.1	7
2670	Liver Injury with Nintedanib: A Pharmacovigilanceâ€“Pharmacokinetic Appraisal. Pharmaceuticals, 2022, 15, 645.	1.7	5
2672	Targeting Growth Factor and Cytokine Pathways to Treat Idiopathic Pulmonary Fibrosis. Frontiers in Pharmacology, 2022, 13, .	1.6	15
2673	Evaluation of nintedanib as a new postoperative antiscarring agent in experimental extraocular muscle surgery. International Journal of Ophthalmology, 2022, 15, 914-923.	0.5	3
2674	Standardised 3D-CT lung volumes for patients with idiopathic pulmonary fibrosis. Respiratory Research, 2022, 23, .	1.4	4
2675	Interstitial Pneumonia with Autoimmune Features: What the Rheumatologist Needs to Know. Current Rheumatology Reports, 0, , .	2.1	3
2676	Latin American Registry of Idiopathic Pulmonary Fibrosis (REFIPI): Clinical Characteristics, Evolution and Treatment. Archivos De Bronconeumologia, 2022, 58, 794-801.	0.4	5
2677	Randomized phase II study of nintedanib with or without pirfenidone in patients with idiopathic pulmonary fibrosis who experienced disease progression during prior pirfenidone administration. Medicine (United States), 2022, 101, e29232.	0.4	1
2678	Case Report: Pirfenidone in the Treatment of Post-COVID-19 Pulmonary Fibrosis. Frontiers in Medicine, 0, 9, .	1.2	9
2680	Coronary artery calcium score is a prognostic factor for mortality in idiopathic pulmonary fibrosis. Minerva Medica, 2024, 114, .	0.3	3
2681	Integration and Application of Clinical Practice Guidelines for the Diagnosis of Idiopathic Pulmonary Fibrosis and Fibrotic Hypersensitivity Pneumonitis. Chest, 2022, 162, 614-629.	0.4	19
2682	Anti-Angiogenic Drugs Inhibit Interstitial Lung Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer. Frontiers in Oncology, 0, 12, .	1.3	2
2683	Antifibrotic therapy and its indications for interstitial pulmonary fibrosis. Vnitrni Lekarstvi, 2022, 68, 212-215.	0.1	0
2684	Interstitial lung disease in ANCA-associated vasculitis: associated factors, radiographic features and mortality. Rheumatology, 2023, 62, 716-725.	0.9	4
2685	Construction and Validation of a Novel Prognostic Signature of Idiopathic Pulmonary Fibrosis by Identifying Subtypes Based on Genes Related to 7-Methylguanosine Modification. Frontiers in Genetics, 0, 13, .	1.1	1
2686	Preferential PDE4B Inhibition â€" A Step toward a New Treatment for Idiopathic Pulmonary Fibrosis. New England Journal of Medicine, 2022, 386, 2235-2236.	13.9	6
2687	Granulocyte colony-stimulating factor in bronchoalveolar lavage fluid is a potential biomarker for prognostic prediction of idiopathic pulmonary fibrosis. Korean Journal of Internal Medicine, 2022, 37, 979-988.	0.7	4
2689	Digital quantification of p16-positive foci in fibrotic interstitial lung disease is associated with a phenotype of idiopathic pulmonary fibrosis with reduced survival. Respiratory Research, 2022, 23, .	1.4	3

#	Article	IF	Citations
2690	Elevated Expression of Growth Differentiation Factor-15 Is Associated With Acute Exacerbation of Idiopathic Pulmonary Fibrosis. Frontiers in Immunology, 0, 13, .	2.2	6
2691	Nintedanib induces gene expression changes in the lung of induced-rheumatoid arthritisâ€“associated interstitial lung disease mice. PLoS ONE, 2022, 17, e0270056.	1.1	2
2692	A Small Molecule That Promotes Cellular Senescence Prevents Fibrogenesis and Tumorigenesis. International Journal of Molecular Sciences, 2022, 23, 6852.	1.8	2
2693	Physiotherapy management of interstitial lung disease. Journal of Physiotherapy, 2022, , .	0.7	2
2694	Lung Fibrosis and Fibrosis in the Lungs: Is It All about Myofibroblasts?. Biomedicines, 2022, 10, 1423.	1.4	27
2695	BMP3b Is a Novel Antifibrotic Molecule Regulated by Meflin in Lung Fibroblasts. American Journal of Respiratory Cell and Molecular Biology, 2022, 67, 446-458.	1.4	3
2696	Postâ€“Coronavirus Disease 2019 Pulmonary Fibrosis: Wait or Needs Intervention. Tuberculosis and Respiratory Diseases, 2022, 85, 320-331.	0.7	5
2697	Ginkgolic acid improves bleomycin-induced pulmonary fibrosis by inhibiting SMAD4 SUMOylation. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-18.	1.9	6
2699	Nintedanib vs pirfenidone in the management of COVID-19 lung fibrosis: A single-centre study. Journal of the Royal College of Physicians of Edinburgh, The, 2022, 52, 100-104.	0.2	13
2700	Immunity, Ciliated Epithelium, and Mortality. Chest, 2022, 161, 1440-1441.	0.4	2
2701	An Overview of Herbal Medicines for Idiopathic Pulmonary Fibrosis. Processes, 2022, 10, 1131.	1.3	3
2703	Post-COVID lung disease(s). Annals of Thoracic Medicine, 2022, 17, 137.	0.7	12
2704	A Phase IIb Randomized Clinical Study of an Anti-Î±_vÎ²₆ Monoclonal Antibody in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 1128-1139.	2.5	29
2705	Characterization of the PF-ILD phenotype in patients with advanced pulmonary sarcoidosis. Respiratory Research, 2022, 23, .	1.4	10
2706	New Insights into Hippo/YAP Signaling in Fibrotic Diseases. Cells, 2022, 11, 2065.	1.8	29
2707	Pregnancy Considerations for Patients With Interstitial Lung Disease. Chest, 2022, 162, 1093-1105.	0.4	2
2708	Road Toward a New Model of Care for Idiopathic Pulmonary Fibrosis in the Lazio Region. Frontiers in Medicine, 0, 9, .	1.2	1
2709	Forced Oscillation Measurements in Patients with Idiopathic Interstitial Pneumonia Subjected to Pulmonary Rehabilitation. Journal of Clinical Medicine, 2022, 11, 3657.	1.0	2

#	Article	IF	Citations
2710	Quantitative Interstitial Abnormality Progression and Outcomes in the Genetic Epidemiology of COPD and Pittsburgh Lung Screening Study Cohorts. Chest, 2023, 163, 164-175.	0.4	7
2711	Targeting fibrosis: mechanisms and clinical trials. Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	97
2712	Advances in the management of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. BMJ, The, 0, , e066354.	3.0	14
2713	Federal clinical guidelines on diagnosis and treatment of idiopathic pulmonary fibrosis. Pulmonologiya, 2022, 32, 473-495.	0.2	7
2714	Platelet-derived growth factor (PDGF)-BB regulates the airway tone via activation of MAP2K, thromboxane, actin polymerisation and Ca2+-sensitisation. Respiratory Research, 2022, 23, .	1.4	3
2715	Anti-Inflammatory and/or Anti-Fibrotic Treatment of MPO-ANCA-Positive Interstitial Lung Disease: A Short Review. Journal of Clinical Medicine, 2022, 11, 3835.	1.0	4
2716	Lung Organoidsâ€"The Ultimate Tool to Dissect Pulmonary Diseases?. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	12
2717	Exophilone, a Tetrahydrocarbazol-1-one Analogue with Anti-Pulmonary Fibrosis Activity from the Deep-Sea Fungus Exophiala oligosperma MCCC 3A01264. Marine Drugs, 2022, 20, 448.	2.2	3
2718	Pulmonary Issues. , 2022, , 270-285.		0
2719	The relationship between interstitial lung abnormalities, mortality, and multimorbidity: a cohort study. Thorax, 2023, 78, 559-565.	2.7	2
2720	SARS-CoV-2 infection produces chronic pulmonary epithelial and immune cell dysfunction with fibrosis in mice. Science Translational Medicine, 2022, 14, .	5.8	55
2721	Tissue mechanics coevolves with fibrillar matrisomes in healthy and fibrotic tissues. Matrix Biology, 2022, 111, 153-188.	1.5	11
2722	The kidney matrisome in health, aging, and disease. Kidney International, 2022, 102, 1000-1012.	2.6	11
2723	Effect of Nintedanib on Progression of Systemic <scp>Sclerosisâ€Associated</scp> Interstitial Lung Disease Over 100â€‰Weeks: Data From a Randomized <scp>Controlled</scp> Trial. ACR Open Rheumatology, 2022, 4, 837-844.	0.9	8
2724	Management of fibrotic hypersensitivity pneumonitis. Current Opinion in Pulmonary Medicine, 2022, 28, 421-431.	1.2	2
2725	The Association between Exposures and Disease Characteristics in Familial Pulmonary Fibrosis. Annals of the American Thoracic Society, 2022, 19, 2003-2012.	1.5	7
2726	Proposed clinical phases for the improvement of personalized treatment of checkpoint inhibitorâ€"related pneumonitis. Frontiers in Immunology, 0, 13, .	2.2	7
2727	Frequency and impact on clinical outcomes of sarcopenia in patients with idiopathic pulmonary fibrosis. Chronic Respiratory Disease, 2022, 19, 147997312211172.	1.0	6

#	Article	IF	Citations
2728	Leveraging Therapy-Specific Polygenic Risk Scores to Predict Restrictive Lung Defects in Childhood Cancer Survivors. Cancer Research, 2022, 82, 2940-2950.	0.4	3
2729	Perioperative Oxygen Concentration for Patients with Interstitial Pneumonia. The Journal of Japan Society for Clinical Anesthesia, 2022, 42, 396-399.	0.0	0
2730	Nintedanib Inhibits Endothelial Mesenchymal Transition in Bleomycin-Induced Pulmonary Fibrosis via Focal Adhesion Kinase Activity Reduction. International Journal of Molecular Sciences, 2022, 23, 8193.	1.8	7
2731	Diagnosis and management of idiopathic pulmonary fibrosis. The Prescriber, 2022, 33, 12-17.	0.1	0
2732	Mesenchymal Stem Cell-Derived Extracellular Vesicles as Idiopathic Pulmonary Fibrosis Microenvironment Targeted Delivery. Cells, 2022, 11, 2322.	1.8	8
2733	Novel PDE4B inhibitor offers breakthrough for IPF. , 0, , .		0
2734	<scp>Antiâ€MDA5</scp> and <scp>antiâ€SSA</scp>/Ro52 antibodies doubleâ€positive dermatomyositis overlapping with rheumatoid arthritisâ€associated interstitial lung disease: A case report. International Journal of Rheumatic Diseases, 2022, 25, 1437-1440.	0.9	2
2735	French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis â€“ 2021 update. Full-length version. Respiratory Medicine and Research, 2023, 83, 100948.	0.4	1
2736	Modern principles and prospects for drug therapy of interstitial lung diseases in children. Rossiyskiy Vestnik Perinatologii I Pediatrii, 2022, 67, 18-22.	0.1	1
2739	Interstitial lung diseases. Lancet, The, 2022, 400, 769-786.	6.3	99
2740	Successful treatment with docetaxel plus nintedanib in a patient with lung adenocarcinoma and pulmonary fibrosis: A case report and literature review. Frontiers in Oncology, 0, 12, .	1.3	2
2741	Pulmonary hypertension in interstitial lung disease: an area of unmet clinical need. ERJ Open Research, 2022, 8, 00272-2022.	1.1	5
2742	FGF10 Therapeutic Administration Promotes Mobilization of Injury-Activated Alveolar Progenitors in a Mouse Fibrosis Model. Cells, 2022, 11, 2396.	1.8	8
2743	Correlating SFTPC gene variants to interstitial lung disease in Egyptian children. Journal of Genetic Engineering and Biotechnology, 2022, 20, 117.	1.5	1
2744	Effects of nintedanib on disease progression and safety in Japanese patients with progressive fibrosing interstitial lung diseases: Further subset analysis from the whole INBUILD trial. Respiratory Investigation, 2022, 60, 787-797.	0.9	3
2745	The Remarkable Roles of the Receptor for Advanced Glycation End Products (RAGE) and Its Soluble Isoforms in COVID-19: The Importance of RAGE Pathway in the Lung Injuries. Indian Journal of Clinical Biochemistry, 2023, 38, 159-171.	0.9	4
2746	New Era in Systemic Sclerosis Treatment: Recently Approved Therapeutics. Journal of Clinical Medicine, 2022, 11, 4631.	1.0	18
2747	Cost-Effectiveness of Nintedanib for Patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD). PharmacoEconomics - Open, 2022, 6, 647-656.	0.9	1

#	Article	IF	Citations
2748	Syndrome of Combined Pulmonary Fibrosis and Emphysema: An Official ATS/ERS/JRS/ALAT Research Statement. American Journal of Respiratory and Critical Care Medicine, 2022, 206, e7-e41.	2.5	53
2749	Extracellular vesicles in idiopathic pulmonary fibrosis: pathogenesis and therapeutics. Inflammation and Regeneration, 2022, 42, .	1.5	11
2750	Cell-Type-Specific Effects of the Ovarian Cancer G-Protein Coupled Receptor (OGR1) on Inflammation and Fibrosis; Potential Implications for Idiopathic Pulmonary Fibrosis. Cells, 2022, 11, 2540.	1.8	2
2751	Promises and Challenges of Cell-Based Therapies to Promote Lung Regeneration in Idiopathic Pulmonary Fibrosis. Cells, 2022, 11, 2595.	1.8	6
2752	Double Lung Transplantation for Idiopathic Pulmonary Fibrosis in a Patient with a History of Liver Transplantation and Prolonged Journey for Disease-Specific Antifibrotic Therapy. Case Reports in Pulmonology, 2022, 2022, 1-5.	0.2	1
2753	Two cases of nintedanib-induced diarrhoea treated using a 5-hydroxytryptamine type 3 receptor antagonist. ERJ Open Research, 2022, 8, 00242-2022.	1.1	3
2754	Changes in serum metabolomics in idiopathic pulmonary fibrosis and effect of approved antifibrotic medication. Frontiers in Pharmacology, 0, 13, .	1.6	7
2758	HER2 drives lung fibrosis by activating a metastatic cancer signature in invasive lung fibroblasts. Journal of Experimental Medicine, 2022, 219, .	4.2	8
2759	Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON. Annals of the Rheumatic Diseases, 2022, 81, 1722-1729.	0.5	19
2760	The role of immune response in the pathogenesis of idiopathic pulmonary fibrosis: far beyond the Th1/Th2 imbalance. Expert Opinion on Therapeutic Targets, 2022, 26, 617-631.	1.5	7
2761	The Effectiveness of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis, Familial Pulmonary Fibrosis and Progressive Fibrosing Interstitial Lung Diseases: A Real-World Study. Biomedicines, 2022, 10, 1973.	1.4	10
2762	Saracatinib, a Selective Src Kinase Inhibitor, Blocks Fibrotic Responses in Preclinical Models of Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 1463-1479.	2.5	29
2763	Epidemiology and real-life experience in progressive pulmonary fibrosis. Current Opinion in Pulmonary Medicine, 2022, 28, 407-413.	1.2	10
2764	Two Distinct Mechanisms Underlying Î³Î´ T Cell-Mediated Regulation of Collagen Type I in Lung Fibroblasts. Cells, 2022, 11, 2816.	1.8	0
2765	Let's talk about sex in interstitial lung disease. Lancet Rheumatology, The, 2022, 4, e648-e650.	2.2	0
2766	Safety and tolerability of nintedanib in patients with interstitial lung diseases in subgroups by sex: a post-hoc analysis of pooled data from four randomised controlled trials. Lancet Rheumatology, The, 2022, 4, e679-e687.	2.2	7
2767	Verbascoside and isoverbascoside ameliorate transforming growth factor Î²1-induced collagen expression by lung fibroblasts through Smad/non-Smad signaling pathways. Life Sciences, 2022, 308, 120950.	2.0	1
2768	COVID-19 and fibrosis: Mechanisms, clinical relevance, and future perspectives. Drug Discovery Today, 2022, 27, 103345.	3.2	6

#	Article	IF	Citations
2769	A near-infrared fluorescent probe for visualizing viscosity fluxes in live cells and idiopathic pulmonary fibrosis. Sensors and Actuators B: Chemical, 2022, 371, 132575.	4.0	4
2770	A decade of approved first-in-class small molecule orphan drugs: Achievements, challenges and perspectives. European Journal of Medicinal Chemistry, 2022, 243, 114742.	2.6	1
2771	Role of cancer-associated fibroblasts in tumor microenvironment. , 2022, , 59-86.		6
2772	Therapeutic decisions in a cohort of patients with idiopathic pulmonary fibrosis: a multicenter, prospective survey from Poland. Therapeutic Advances in Chronic Disease, 2022, 13, 204062232211179.	1.1	0
2773	Immunomodulatory treatment of interstitial lung disease. Therapeutic Advances in Respiratory Disease, 2022, 16, 175346662211170.	1.0	15
2774	Impact of Reduction in Antifibrotic Treatment on Mortality in Idiopathic Pulmonary Fibrosis. SSRN Electronic Journal, 0, , .	0.4	0
2775	Challenges in the Management of Post-COVID-19 Pulmonary Fibrosis for the Latin American Population. Journal of Personalized Medicine, 2022, 12, 1393.	1.1	4
2776	Novel mediators of idiopathic pulmonary fibrosis. Clinical Science, 2022, 136, 1229-1240.	1.8	8
2777	Nintedanib-Induced Delayed Mucosal Healing after Adjuvant Radiation in a Case of Oropharyngeal Carcinoma. Case Reports in Oncology, 2022, 15, 776-782.	0.3	2
2778	Antifibrotics and lung transplantation: A Spanish multicentre caseâ€controlled study. Respirology, 2022, 27, 1054-1063.	1.3	5
2779	The Role of Nrf2 in Pulmonary Fibrosis: Molecular Mechanisms and Treatment Approaches. Antioxidants, 2022, 11, 1685.	2.2	12
2780	Nintedanib in children and adolescents with fibrosing interstitial lung diseases. European Respiratory Journal, 2023, 61, 2201512.	3.1	31
2781	Clinical Predictors of Lung-Function Decline in Systemic-Sclerosis-Associated Interstitial Lung Disease Patients with Normal Spirometry. Biomedicines, 2022, 10, 2129.	1.4	5
2782	Bioinformatic identification and analysis of immune-related chromatin regulatory genes as potential biomarkers in idiopathic pulmonary fibrosis. Annals of Translational Medicine, 2022, 10, 896-896.	0.7	3
2783	Exosomal Micro-RNAs as Intercellular Communicators in Idiopathic Pulmonary Fibrosis. International Journal of Molecular Sciences, 2022, 23, 11047.	1.8	5
2784	Pulmonary Hypertension in Sclerodermaâ€“ Evaluation and Management. Disease-a-Month, 2022, , 101468.	0.4	1
2785	Compound heterozygous mutation of <scp>RTEL1</scp> in interstitial lung disease complicated with pneumothorax and emphysema: A case report and literature review. Respirology Case Reports, 2022, 10, .	0.3	2
2786	A novel gene signature based on the hub genes of COVID-19 predicts the prognosis of idiopathic pulmonary fibrosis. Frontiers in Pharmacology, 0, 13, .	1.6	1

#	Article	IF	Citations
2787	A novel and low-toxic peptide DR3penA alleviates pulmonary fibrosis by regulating the MAPK/miR-23b-5p/AQP5 signaling axis. Acta Pharmaceutica Sinica B, 2023, 13, 722-738.	5.7	8
2788	Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Respiratory Medicine,the, 2023, 11, 87-96.	5.2	54
2789	Effectiveness and Safety of Pirfenidone and Nintedanib for Pulmonary Fibrosis in COVID-19-Induced Severe Pneumonia: An Interventional Study. Cureus, 2022, , .	0.2	3
2790	Diagnosing interstitial lung disease by multidisciplinary discussion: A review. Frontiers in Medicine, 0, 9, .	1.2	4
2791	The road to hell is paved with good intentions: a look back at the PANTHER-IPF trial. Breathe, 2022, 18, 220074.	0.6	0
2792	Benefits of Pulmonary Rehabilitation in Patients with Idiopathic Pulmonary Fibrosis Receiving Antifibrotic Drug Treatment. Journal of Clinical Medicine, 2022, 11, 5336.	1.0	3
2793	The microtubule cytoskeleton: An old validated target for novel therapeutic drugs. Frontiers in Pharmacology, 0, 13, .	1.6	15
2794	Longitudinal study of patients with antimelanoma differentiation-associated gene 5 antibody-positive dermatomyositis-associated interstitial lung disease. Rheumatology, 0, , .	0.9	3
2796	Plasticity towards Rigidity: A Macrophage Conundrum in Pulmonary Fibrosis. International Journal of Molecular Sciences, 2022, 23, 11443.	1.8	10
2797	The Role of Myofibroblasts in Physiological and Pathological Tissue Repair. Cold Spring Harbor Perspectives in Biology, 2023, 15, a041231.	2.3	31
2798	Survival and lung function decline in patients with definite, probable and possible idiopathic pulmonary fibrosis treated with pirfenidone. PLoS ONE, 2022, 17, e0273854.	1.1	3
2799	The emerging roles of interstitial macrophages in pulmonary fibrosis: A perspective from scRNA-seq analyses. Frontiers in Immunology, 0, 13, .	2.2	16
2800	Screening for idiopathic pulmonary fibrosis using comorbidity signatures in electronic health records. Nature Medicine, 2022, 28, 2107-2116.	15.2	9
2801	NICEFITâ€"A Prospective, Non-Interventional, and Multicentric Study for the Management of Idiopathic Pulmonary Fibrosis with Antifibrotic Therapy in Taiwan. Biomedicines, 2022, 10, 2362.	1.4	1
2803	Incidence and changes in treatment of acute exacerbation of idiopathic pulmonary fibrosis in Japan: A claims-based retrospective study. Respiratory Investigation, 2022, 60, 798-805.	0.9	4
2804	The novel role of ER protein TXNDC5 in the pathogenesis of organ fibrosis: mechanistic insights and therapeutic implications. Journal of Biomedical Science, 2022, 29, .	2.6	7
2805	Clinical management and acute exacerbations in patients with idiopathic pulmonary fibrosis in Spain: results from the OASIS study. Respiratory Research, 2022, 23, .	1.4	1
2806	Virtual screening and activity evaluation of multitargeting inhibitors for idiopathic pulmonary fibrosis. Frontiers in Pharmacology, 0, 13, .	1.6	2

#	Article	IF	Citations
2807	The Effect of Nintedanib in Post-COVID-19 Lung Fibrosis: An Observational Study. Critical Care Research and Practice, 2022, 2022, 1-7.	0.4	6
2808	Hermansky-Pudlak syndrome: Gene therapy for pulmonary fibrosis. Molecular Genetics and Metabolism, 2022, 137, 187-191.	0.5	1
2809	Current treatment status of patients with idiopathic pulmonary fibrosis in Japan based on a claims database analysis. Respiratory Investigation, 2022, , .	0.9	0
2810	Resveratrol alleviates bleomycin-induced pulmonary fibrosis by inhibiting epithelial-mesenchymal transition and down-regulating TLR4/NF-Î³B and TGF-Î²1/smad3 signalling pathways in rats. Tissue and Cell, 2022, 79, 101953.	1.0	7
2814	Therapeutic effects of adipose-derived mesenchymal stem/stromal cells with enhanced migration ability and hepatocyte growth factor secretion by low-molecular-weight heparin treatment in bleomycin-induced mouse models of systemic sclerosis. Arthritis Research and Therapy, 2022, 24, .	1.6	6
2815	Stem cell-based therapy for pulmonary fibrosis. Stem Cell Research and Therapy, 2022, 13, .	2.4	10
2816	Deep-learning algorithm to detect fibrosing interstitial lung disease on chest radiographs. European Respiratory Journal, 2023, 61, 2102269.	3.1	9
2817	Effect of nintedanib on acute exacerbations of fibrosing interstitial lung diseases: a national database study in Japan. ERJ Open Research, 2022, 8, 00209-2022.	1.1	3
2818	Factors associated with interstitial lung disease and the progressive fibrosing phenotype in rheumatoid arthritisâ€“related interstitial lung disease. Medical Journal Armed Forces India, 2022, , .	0.3	2
2819	Pathological collagen targeting and penetrating liposomes for idiopathic pulmonary fibrosis therapy. Journal of Controlled Release, 2022, 351, 623-637.	4.8	18
2820	Diagnosis and Treatment of Lung Cancer in the Setting of Interstitial Lung Disease. Radiologic Clinics of North America, 2022, 60, 993-1002.	0.9	6
2821	Systemic delivery of nintedanib using PLGA-based discoidal polymeric particles for idiopathic pulmonary fibrosis treatment. Materials Today Chemistry, 2022, 26, 101181.	1.7	1
2822	Antifibrotic in interstitial lung diseases: When, where, and how long?. Lung India, 2022, 39, 491.	0.3	2
2823	Glucocorticoid Therapy in Respiratory Illness: Bench to Bedside. Journal of Investigative Medicine, 2022, 70, 1662-1680.	0.7	2
2824	Idiopathic pulmonary fibrosis: Diagnosis, biomarkers and newer treatment protocols. Disease-a-Month, 2023, 69, 101484.	0.4	5
2825	Salt-inducible kinase 2 regulates fibrosis during bleomycin-induced lung injury. Journal of Biological Chemistry, 2022, 298, 102644.	1.6	3
2826	The lymphocyte-specific protein tyrosine kinase-specific inhibitor A-770041 attenuates lung fibrosis via the suppression of TGF-Î² production in regulatory T-cells. PLoS ONE, 2022, 17, e0275987.	1.1	3
2827	End-of-life care for idiopathic pulmonary fibrosis patients with acute exacerbation. Respiratory Research, 2022, 23, .	1.4	1

#	Article	IF	Citations
2828	Impact of reduction in antifibrotic treatment on mortality in idiopathic pulmonary fibrosis. Respiratory Medicine, 2022, 204, 107015.	1.3	2
2829	Frequency, proportion of PF-ILD, and prognostic factors in patients with acute exacerbation of ILD related to systemic autoimmune diseases. BMC Pulmonary Medicine, 2022, 22, .	0.8	3
2830	Plumbagin attenuates Bleomycin-induced lung fibrosis in mice. Allergy, Asthma and Clinical Immunology, 2022, 18, .	0.9	8
2831	Dysregulated Cellâ€“Cell Communication Characterizes Pulmonary Fibrosis. Cells, 2022, 11, 3319.	1.8	4
2833	Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor. Thoracic Cancer, 2022, 13, 3420-3430.	0.8	5
2835	Small molecule inhibitors targeting the cancers. MedComm, 2022, 3, .	3.1	25
2836	Antifibrotic Drug Nintedanib Inhibits CSF1R to Promote IL-4â€“associated Tissue Repair Macrophages. American Journal of Respiratory Cell and Molecular Biology, 2023, 68, 366-380.	1.4	3
2837	Efficacy and safety of traditional Chinese medicine treatment for idiopathic pulmonary fibrosis: An exploratory, randomized, double-blinded and placebo controlled trial. Frontiers in Pharmacology, 0, 13, .	1.6	3
2838	Early corticosteroid dose tapering in patients with acute exacerbation of idiopathic pulmonary fibrosis. Respiratory Research, 2022, 23, .	1.4	5
2839	Diagnosis of pleuroparenchymal fibroelastosis: A review. Monaldi Archives for Chest Disease, 0, , .	0.3	0
2840	Encouraging results of nintedanib in children with fibrosing ILDÂ. , 0, , .		0
2841	The Emerging Role of Extracellular Vesicles from Mesenchymal Stem Cells and Macrophages in Pulmonary Fibrosis: Insights into miRNA Delivery. Pharmaceuticals, 2022, 15, 1276.	1.7	6
2843	High-Resolution Computed Tomography of Fibrotic Interstitial Lung Disease. Seminars in Respiratory and Critical Care Medicine, 0, , .	0.8	0
2844	Therapeutic potential for P2Y2 receptor antagonism. Purinergic Signalling, 0, , .	1.1	3
2845	GLPG1205 for idiopathic pulmonary fibrosis: a phase 2 randomised placebo-controlled trial. European Respiratory Journal, 2023, 61, 2201794.	3.1	12
2846	Forced vital capacity trajectories in patients with idiopathic pulmonary fibrosis: a secondary analysis of a multicentre, prospective, observational cohort. The Lancet Digital Health, 2022, 4, e862-e872.	5.9	8
2847	DDR1 activation in macrophage promotes IPF by regulating NLRP3 inflammasome and macrophage reaction. International Immunopharmacology, 2022, 113, 109294.	1.7	6
2848	TREM-1 exacerbates bleomycin-induced pulmonary fibrosis by aggravating alveolar epithelial cell senescence in mice. International Immunopharmacology, 2022, 113, 109339.	1.7	2

#	Article	IF	Citations
2849	Alveolar epithelial cells and microenvironmental stiffness synergistically drive fibroblast activation in three-dimensional hydrogel lung models. Biomaterials Science, 2022, 10, 7133-7148.	2.6	10
2850	Organizing Pneumonia Versus Usual Interstitial Pneumonia. , 2022, , 247-252.		0
2851	Senescent AECâ...¡ and the implication for idiopathic pulmonary fibrosis treatment. Frontiers in Pharmacology, 0, 13, .	1.6	4
2852	Design and rationale of the Japanese Idiopathic Interstitial Pneumonias (JIPS) Registry. Respiratory Investigation, 2023, 61, 95-102.	0.9	1
2853	Ameliorating Fibrosis in Murine and Human Tissues with END55, an Endostatin-Derived Fusion Protein Made in Plants. Biomedicines, 2022, 10, 2861.	1.4	2
2854	Content Analysis of Idiopathic Pulmonary Fibrosis-related Information on Twitter. ATS Scholar, 2022, 3, 576-587.	0.5	2
2855	Management of Interstitial Lung Diseases: A Consensus Statement of the Indian Chest Society and National College of Chest Physicians (India). The Indian Journal of Chest Diseases & Allied Sciences, 2022, 62, 73-98.	0.1	0
2856	Clinical, imaging, and blood biomarkers to assess 1-year progression risk in fibrotic interstitial lung diseasesâ€"Development and validation of the honeycombing, traction bronchiectasis, and monocyte (HTM)-score. Frontiers in Medicine, 0, 9, .	1.2	2
2857	Differences in lung and lobe volumes between supine and upright computed tomography in patients with idiopathic lung fibrosis. Scientific Reports, 2022, 12, .	1.6	2
2859	Chest CT in covid-19 pneumonia's follow-up: A 30 patients case series. Annals of Medicine and Surgery, 2022, 84, .	0.5	1
2860	Entrectinib ameliorates bleomycin-induced pulmonary fibrosis in mice by inhibiting TGF-Î²1 signaling pathway. International Immunopharmacology, 2022, 113, 109427.	1.7	2
2861	Nintedanib alleviates pulmonary fibrosis in vitro and in vivo by inhibiting the FAK/ERK/S100A4 signalling pathway. International Immunopharmacology, 2022, 113, 109409.	1.7	4
2862	Consensus Statement for the Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis in Resource Constrained Settings. The Indian Journal of Chest Diseases & Allied Sciences, 2022, 60, 91-119.	0.1	1
2863	Design, synthesis and biological evaluation of novel diarylacylhydrazones derivatives for the efficient treatment of idiopathic pulmonary fibrosis. European Journal of Medicinal Chemistry, 2023, 245, 114918.	2.6	4
2864	S-allylmercapto-N-acetylcysteine ameliorates pulmonary fibrosis in mice via Nrf2 pathway activation and NF-Î²B, TGF-Î²1/Smad2/3 pathway suppression. Biomedicine and Pharmacotherapy, 2023, 157, 114018.	2.5	6
2865	Machine learning in radiology: the new frontier in interstitial lung diseases. The Lancet Digital Health, 2023, 5, e41-e50.	5.9	18
2866	CT predictors of outcomes in patients with connective tissue disease and progressive lung fibrosis. Clinical Imaging, 2023, 94, 42-49.	0.8	4
2867	Healthcare resource use and associated costs in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis. Respiratory Medicine and Research, 2023, 83, 100951.	0.4	0

#	Article	IF	Citations
2868	Pharmacological Activities of Ginkgolic Acids in Relation to Autophagy. Pharmaceuticals, 2022, 15, 1469.	1.7	3
2869	Plasma cells: a feasible therapeutic target in pulmonary fibrosis?. European Respiratory Journal, 2022, 60, 2201748.	3.1	2
2871	Combination of esomeprazole and pirfenidone enhances antifibrotic efficacy in vitro and in a mouse model of TGFÎ²-induced lung fibrosis. Scientific Reports, 2022, 12, .	1.6	4
2872	Pulmonary Fibrosis as a Result of Acute Lung Inflammation: Molecular Mechanisms, Relevant In Vivo Models, Prognostic and Therapeutic Approaches. International Journal of Molecular Sciences, 2022, 23, 14959.	1.8	42
2873	Analysis of the safety and efficacy of different plasma concentrations of pirfenidone in patients with idiopathic pulmonary fibrosis. Frontiers in Pharmacology, 0, 13, .	1.6	2
2874	VISTA (PD-1H) Is a Crucial Immune Regulator to Limit Pulmonary Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2023, 69, 22-33.	1.4	3
2875	Pediatric pulmonology 2021 year in review: Rare and diffuse lung disease. Pediatric Pulmonology, 2023, 58, 374-381.	1.0	1
2876	Development and validation of the prognostic model based on autophagy-associated genes in idiopathic pulmonary fibrosis. Frontiers in Immunology, 0, 13, .	2.2	2
2877	Radiological Assessment in Idiopathic Pulmonary Fibrosis (IPF) Patients According to MUC5B Polymorphism. International Journal of Molecular Sciences, 2022, 23, 15890.	1.8	1
2878	Nintedanib for non-IPF progressive pulmonary fibrosis: 12-month outcome data from a real-world multicentre observational study. ERJ Open Research, 2023, 9, 00423-2022.	1.1	5
2879	Deciphering the Antifibrotic Property of Metformin. Cells, 2022, 11, 4090.	1.8	3
2880	Association between weight loss and mortality in idiopathic pulmonary fibrosis. Respiratory Research, 2022, 23, .	1.4	4
2881	Long-Term Safety of Antifibrotic Drugs in IPF: A Real-World Experience. Biomedicines, 2022, 10, 3229.	1.4	3
2882	Blood Krebs von den Lungen-6 levels predict treatment response to antifibrotic therapy in patients with idiopathic pulmonary fibrosis. Respiratory Research, 2022, 23, .	1.4	3
2883	Interstitial lung disease progression after genomic usual interstitial pneumonia testing. European Respiratory Journal, 2023, 61, 2201245.	3.1	6
2884	MRONJ Mimicking post COVID-19 mucormycosis; A diagnostic dilemma. Advances in Oral and Maxillofacial Surgery, 2022, , 100383.	0.1	0
2885	Progressive pulmonary fibrosis: an expert group consensus statement. European Respiratory Journal, 2023, 61, 2103187.	3.1	25
2886	The relative contribution of co-morbidities to health-related quality of life of people with idiopathic pulmonary fibrosis using the Assessment of Quality of Life-8-Dimension multi-attribute utility instrument. Quality of Life Research, 0, , .	1.5	1

#	Article	IF	Citations
2888	Nintedanib: a review of the properties, function, and usefulness to minimize COVID-19-induced lung injury. Expert Review of Anti-Infective Therapy, 2023, 21, 7-14.	2.0	3
2889	Diverse functions of apolipoprotein A-I in lung fibrosis. American Journal of Physiology - Cell Physiology, 2023, 324, C438-C446.	2.1	7
2890	Transforming Growth Factor-Î²1 Regulates Peroxisomal Genes/Proteins via Smad Signaling in Idiopathic Pulmonary Fibrosis Fibroblasts and TransgenicÂMouse Models. American Journal of Pathology, 2023, 193, 259-274.	1.9	2
2891	Protective effect of ebselen on bleomycin-induced lung fibrosis: analysis of the molecular mechanism of lung fibrosis mediated by oxidized diacylglycerol. Free Radical Research, 2022, 56, 473-482.	1.5	2
2892	Better to Be an Agnostic than a Believer (at Least in Pulmonary Fibrosis). American Journal of Respiratory and Critical Care Medicine, 2022, 206, 1439-1440.	2.5	0
2893	The Genetic and Epigenetic Footprint in Idiopathic Pulmonary Fibrosis and Familial Pulmonary Fibrosis: A State-of-the-Art Review. Diagnostics, 2022, 12, 3107.	1.3	11
2895	Hypersensitivity pneumonitis: An infrequent cause of chronic lung fibrosis in Africa?. African Journal of Thoracic and Critical Care Medicine, 0, , 144.	0.3	1
2896	The role of PD-1/PD-L1 axis in idiopathic pulmonary fibrosis: Friend or foe?. Frontiers in Immunology, 0, 13, .	2.2	5
2897	Design and rationale for the prospective treatment efficacy in IPF using genotype for NAC selection (PRECISIONS) clinical trial. BMC Pulmonary Medicine, 2022, 22, .	0.8	8
2898	Idiopathic pulmonary fibrosis and intestinal disorders: An observational study. Annals of Diagnostic Pathology, 2023, 62, 152072.	0.6	2
2899	Impact of Antifibrotic Treatment on Postoperative Complications in Patients with Interstitial Lung Diseases Undergoing Lung Transplantation: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2023, 12, 655.	1.0	0
2900	Nintedanib in Asian patients with progressive fibrosing interstitial lung diseases: Results from the <scp>INBUILD</scp> trial. Respirology, 2023, 28, 465-474.	1.3	2
2901	Clinical outcomes of dose modification during pirfenidone treatment for IPF: A nationwide post-marketing surveillance study. Frontiers in Pharmacology, 0, 13, .	1.6	3
2903	Is Carob Flour Helpful in Reducing Diarrhoea Associated With Nintedanib?. Archivos De Bronconeumologia, 2023, 59, 341-343.	0.4	1
2904	Diagnosing lung involvement in inflammatory rheumatic diseasesâ€"Where do we currently stand?. Frontiers in Medicine, 0, 9, .	1.2	2
2905	Therapeutic Targeting of Cancer-Associated Fibroblasts in the Non-Small Cell Lung Cancer Tumor Microenvironment. Cancers, 2023, 15, 335.	1.7	4
2906	Nintedanib in an elderly non-small-cell lung cancer patient with severe steroid-refractory checkpoint inhibitor-related pneumonitis: A case report and literature review. Frontiers in Immunology, 0, 13, .	2.2	3
2907	Transcriptomic and proteomic profiling of young and old mice in the bleomycin model reveals high similarity. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2023, 324, L245-L258.	1.3	1

#	Article	IF	Citations
2908	TRIB3 promotes pulmonary fibrosis through inhibiting SLUG degradation by physically interacting with MDM2. Acta Pharmaceutica Sinica B, 2023, 13, 1631-1647.	5.7	5
2909	Enhanced secretion of hepatocyte growth factor in human umbilical cord mesenchymal stem cells ameliorates pulmonary fibrosis induced by bleomycin in rats. Frontiers in Pharmacology, 0, 13, .	1.6	3
2910	Aspirin alleviates pulmonary fibrosis through PI3K/AKT/mTOR-mediated autophagy pathway. Experimental Gerontology, 2023, 172, 112085.	1.2	9
2911	Invadosome Formation by Lung Fibroblasts in Idiopathic Pulmonary Fibrosis. International Journal of Molecular Sciences, 2023, 24, 499.	1.8	2
2912	Inhibition of MRTF activation as a clinically achievable anti-fibrotic mechanism for pirfenidone. European Respiratory Journal, 2023, 61, 2200604.	3.1	7
2914	Regulation of Mesenchymal Cell Fate by Transfer of Active Gasdermin-D via Monocyte-Derived Extracellular Vesicles. Journal of Immunology, 2023, 210, 832-841.	0.4	2
2915	Epigenetics of the pathogenic myofibroblast in lung disease. , 2023, , 353-392.		0
2916	miRNA Expression in Fibroblastic Foci within Idiopathic Pulmonary Fibrosis Lungs Reveals Novel Disease-Relevant Pathways. American Journal of Pathology, 2023, 193, 417-429.	1.9	1
2917	Pneumatosis intestinalis with free air in the abdominal cavity caused by nintedanib. Respirology Case Reports, 2023, 11, .	0.3	2
2919	Fibrosis. Journal of Translational Medicine, 2023, 21, .	1.8	1
2920	What Do We Need to Know About Rising Rates of Idiopathic Pulmonary Fibrosis? A Narrative Review and Update. Advances in Therapy, 2023, 40, 1334-1346.	1.3	4
2921	Mechanisms by Which Liposomes Improve Inhaled Drug Delivery for Alveolar Diseases. Advanced NanoBiomed Research, 2023, 3, .	1.7	6
2922	Predictors of pulmonary sequelae after COVID-19 pneumonia: A 12-month follow-up study. Frontiers in Medicine, 0, 10, .	1.2	7
2923	Russian Registry of Idiopathic Pulmonary Fibrosis: Clinical Features, Treatment Management, and Outcomes. Life, 2023, 13, 435.	1.1	0
2924	Nerves, Cough, and Idiopathic Pulmonary Fibrosis. European Medical Journal Respiratory, 0, , 38-45.	1.0	3
2926	Interstitial Pneumonia with Autoimmune Features. , 2023, , 241-250.		0
2927	Transcriptional factor RUNX1: A potential therapeutic target for fibrotic pulmonary disease. Biocell, 2023, 47, 697-705.	0.4	0
2928	Early Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis: A Narrative Review. Pulmonary Therapy, 2023, 9, 177-193.	1.1	2

#	Article	IF	Citations
2929	Assessing prognostic factors correlating with response to nintedanib for connective tissue diseaseâ€associated interstitial lung disease: A realâ€world singleâ€center study. International Journal of Rheumatic Diseases, 2023, 26, 682-688.	0.9	0
2930	PCSK6 and Survival in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2023, 207, 1515-1524.	2.5	11
2931	Identification of immune biomarkers associated with basement membranes in idiopathic pulmonary fibrosis and their pan-cancer analysis. Frontiers in Genetics, 0, 14, .	1.1	0
2932	Astaxanthin: A promising therapeutic agent for organ fibrosis. Pharmacological Research, 2023, 188, 106657.	3.1	11
2933	Classical monocyte-derived macrophages as therapeutic targets of umbilical cord mesenchymal stem cells: comparison of intratracheal and intravenous administration in a mouse model of pulmonary fibrosis. Respiratory Research, 2023, 24, .	1.4	6
2934	Interstitial Lung Disease. Rheumatic Disease Clinics of North America, 2023, 49, 279-293.	0.8	3
2935	Connective Tissue Disease Associated Interstitial Lung Disease. Immunology and Allergy Clinics of North America, 2023, 43, 229-244.	0.7	1
2936	Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis. Immunology and Allergy Clinics of North America, 2023, 43, 209-228.	0.7	1
2937	Clinically Relevant Biomarkers in Connective Tissue Disease-Associated Interstitial Lung Disease. Immunology and Allergy Clinics of North America, 2023, 43, 411-433.	0.7	0
2938	Anlotinib prove to be a potential therapy for the treatment of pulmonary fibrosis complicated with lung adenocarcinoma. Pulmonary Pharmacology and Therapeutics, 2023, 80, 102202.	1.1	0
2939	Predicting the preclinical efficacy of anti-fibrosis agents using a force-sensing fibrosis on chip system. Biosensors and Bioelectronics, 2023, 228, 115194.	5.3	3
2940	Delivery of anti-microRNA-21 by lung-targeted liposomes for pulmonary fibrosis treatment. Molecular Therapy - Nucleic Acids, 2023, 32, 36-47.	2.3	8
2941	Serum and bronchoalveolar lavage fluid levels of soluble B7H3 in patients with interstitial lung diseases. Respiratory Medicine, 2023, 212, 107224.	1.3	1
2942	Weight loss in nintedanib-treated patients with idiopathic pulmonary fibrosis. Pulmonary Pharmacology and Therapeutics, 2023, 80, 102213.	1.1	0
2943	Myofibroblast-specific inhibition of the Rho kinase-MRTF-SRF pathway using nanotechnology for the prevention of pulmonary fibrosis. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2023, 324, L190-L198.	1.3	1
2944	Repurposing digoxin for geroprotection in patients with frailty and multimorbidity. Ageing Research Reviews, 2023, 86, 101860.	5.0	2
2945	â€œHitâ€•to lead optimization and chemoinformatic studies for a new series of Autotaxin inhibitors. European Journal of Medicinal Chemistry, 2023, 249, 115130.	2.6	2
2946	Real-World Safety and Tolerability of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Interim Report of a Post-Marketing Surveillance in Japan. Advances in Therapy, 2023, 40, 1474-1493.	1.3	5

#	Article	IF	Citations
2947	BI 1015550: an investigational phosphodiesterase 4B (PDE4B) inhibitor for lung function decline in idiopathic pulmonary fibrosis (IPF). Expert Opinion on Investigational Drugs, 2023, 32, 17-23.	1.9	3
2948	Idiopathic pulmonary fibrosis: state of the art for 2023. European Respiratory Journal, 2023, 61, 2200957.	3.1	37
2949	The Efficacy of Pulmonary Rehabilitation in Patients with Idiopathic Pulmonary Fibrosis. Life, 2023, 13, 403.	1.1	1
2950	Study protocol of an international patient-led registry in patients with pulmonary fibrosis using online home monitoring: I-FILE. BMC Pulmonary Medicine, 2023, 23, .	0.8	3
2951	Wilms Tumor 1-Driven Fibroblast Activation and Subpleural Thickening in Idiopathic Pulmonary Fibrosis. International Journal of Molecular Sciences, 2023, 24, 2850.	1.8	1
2952	Nintedanib in chILD: a small step, yesâ€¦ but at least a step forward in a marathon!. European Respiratory Journal, 2023, 61, 2201797.	3.1	1
2953	Metformin attenuates fibroblast activation during pulmonary fibrosis by targeting S100A4 via AMPK-STAT3 axis. Frontiers in Pharmacology, 0, 14, .	1.6	6
2954	Epidemiology and comorbidities in idiopathic pulmonary fibrosis: a nationwide cohort study. BMC Pulmonary Medicine, 2023, 23, .	0.8	6
2955	Small-molecule-mediated OGG1 inhibition attenuates pulmonary inflammation and lung fibrosis in a murine lung fibrosis model. Nature Communications, 2023, 14, .	5.8	19
2956	The clinical efficacy of a mixture of ivy leaf extract and coptidis rhizome in patients with idiopathic pulmonary fibrosis. Medicine (United States), 2023, 102, e32786.	0.4	0
2958	ILD-GAP Combined with the Charlson Comorbidity Index Score (ILD-GAPC) as a Prognostic Prediction Model in Patients with Interstitial Lung Disease. Canadian Respiratory Journal, 2023, 2023, 1-10.	0.8	4
2959	Cellular and Molecular Control of Lipid Metabolism in Idiopathic Pulmonary Fibrosis: Clinical Application of the Lysophosphatidic Acid Pathway. Cells, 2023, 12, 548.	1.8	3
2960	The Lung Transplant Candidate, Indications, Timing, and Selection Criteria. Clinics in Chest Medicine, 2023, 44, 15-33.	0.8	0
2961	Effects of Pirfenidone on Idiopathic Pulmonary Fibrosis Progression and Safety: Results of Multicenter Prospective Observational Study. Life, 2023, 13, 483.	1.1	1
2962	Trials and Treatments: An Update on Pharmacotherapy for Idiopathic Pulmonary Fibrosis. Life, 2023, 13, 486.	1.1	4
2963	Targeting ATP12A, a Nongastric Proton Pump Î± Subunit, for Idiopathic Pulmonary Fibrosis Treatment. American Journal of Respiratory Cell and Molecular Biology, 2023, 68, 638-650.	1.4	7
2964	Interstitial lung abnormalities in a large clinical lung cancer screening cohort: association with mortality and ILD diagnosis. Respiratory Research, 2023, 24, .	1.4	5
2967	Machine Learning and BMI Improve the Prognostic Value of GAP Index in Treated IPF Patients. Bioengineering, 2023, 10, 251.	1.6	3

#	Article	IF	Citations
2968	Pharmacological Activities of Mogrol: Potential Phytochemical against Different Diseases. Life, 2023, 13, 555.	1.1	3
2969	Nintedanib in Idiopathic Pulmonary Fibrosis: Tolerability and Safety in a Real Life Experience in a Single Centre in Patients also Treated with Oral Anticoagulant Therapy. Pharmaceuticals, 2023, 16, 307.	1.7	7
2970	Disparities in Antifibrotic Medication Utilization Among Veterans With Idiopathic Pulmonary Fibrosis. Chest, 2023, 164, 441-449.	0.4	3
2971	Clinical Profile of Patients with Idiopathic Pulmonary Fibrosis in Real Life. Journal of Clinical Medicine, 2023, 12, 1669.	1.0	6
2972	Topological data analysis identifies molecular phenotypes of idiopathic pulmonary fibrosis. Thorax, 2023, 78, 682-689.	2.7	3
2973	Diagnosis and Pharmacologic Management of Fibrotic Interstitial Lung Disease. Life, 2023, 13, 599.	1.1	2
2974	A predictive model for acute exacerbation of idiopathic interstitial pneumonias. European Respiratory Journal, 2023, 61, 2201634.	3.1	3
2976	Predictors of Stability/Improvement of Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis After One Year of Treatment With Nintedanib. Archivos De Bronconeumologia, 2023, 59, 464-466.	0.4	1
2977	The anti-scar effect of tyrosine-kinase inhibitor nintedanib in experimental glaucoma filtration surgery in rabbits. Experimental Eye Research, 2023, 229, 109431.	1.2	1
2978	Expert Consensus on the Diagnosis and Treatment of Anticancer Drug-Induced Interstitial Lung Disease. Current Medical Science, 2023, 43, 1-12.	0.7	1
2979	Frail Children with Chronic Lung Disease. , 2023, , 51-60.		0
2980	Pulmonary sarcoidosis complicated by rheumatoid arthritis in a patient presenting with progressive fibrosing interstitial lung disease and treated with nintedanib: a case report and literature review. Therapeutic Advances in Respiratory Disease, 2023, 17, 175346662311582.	1.0	1
2981	Eligibility criteria from pharmaceutical randomised controlled trials of idiopathic pulmonary fibrosis: a registry-based study. European Respiratory Journal, 2023, 61, 2202163.	3.1	6
2982	Therapeutic Effects of Coumarins with Different Substitution Patterns. Molecules, 2023, 28, 2413.	1.7	23
2983	Randomized Phase 2 Placebo-Controlled Trial of Nintedanib for the Treatment of Radiation Pneumonitis. International Journal of Radiation Oncology Biology Physics, 2023, 116, 1091-1099.	0.4	5
2984	Health Care Disparities in Pulmonary Fibrosisâ€"Time to Move the Needle Forward. JAMA Network Open, 2023, 6, e232442.	2.8	1
2985	Extracting patient-level data from the electronic health record: Expanding opportunities for health system research. PLoS ONE, 2023, 18, e0280342.	1.1	0
2987	Interstitial Lung Disease in Mixed Connective Tissue Disease: An Advanced Search. Cureus, 2023, , .	0.2	1

#	Article	IF	Citations
2988	Prognostic value of the qSOFA in patients with acute exacerbation of idiopathic pulmonary fibrosis. Respiratory Investigation, 2023, 61, 339-346.	0.9	0
2989	Application and Study of ROCK Inhibitors in Pulmonary Fibrosis: Recent Developments and Future Perspectives. Journal of Medicinal Chemistry, 2023, 66, 4342-4360.	2.9	6
2990	SH2 Domain-Containing Phosphatase-SHP2 Attenuates Fibrotic Responses through Negative Regulation of Mitochondrial Metabolism in Lung Fibroblasts. Diagnostics, 2023, 13, 1166.	1.3	0
2991	Evaluating the Effect of Hydrogen Sulfide in the Idiopathic Pulmonary Fibrosis Model with a Fluorescent Probe. Analytical Chemistry, 2023, 95, 5514-5521.	3.2	7
2992	Inhaled pirfenidone solution (AP01) for IPF: a randomised, open-label, doseâ€“response trial. Thorax, 2023, 78, 882-889.	2.7	8
2993	Palliative care for interstitial lung disease: A nationwide survey of pulmonary specialists. Respirology, 0, , .	1.3	1
2994	Efficacy and Safety of Nintedanib in Patients with Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD): A Real-World Single Center Experience. Diagnostics, 2023, 13, 1221.	1.3	1
2995	Change in gait speed and adverse outcomes in patients with idiopathic pulmonary fibrosis: A prospective cohort study. Respirology, 0, , .	1.3	1
2996	A Narrative Review of Real-World Data on the Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis. Advances in Therapy, 2023, 40, 2038-2050.	1.3	3
2997	Prognostic value of deep learningâ€“based fibrosis quantification on chest CT in idiopathic pulmonary fibrosis. European Radiology, 2023, 33, 3144-3155.	2.3	3
2998	Use of a pulmosphere model to evaluate drug antifibrotic responses in interstitial lung diseases. Respiratory Research, 2023, 24, .	1.4	3
2999	Effect of Antifibrotic Therapy on Survival in Patients With Idiopathic Pulmonary Fibrosis. Clinical Therapeutics, 2023, 45, 306-315.	1.1	5
3000	Protective effects of Qing-Re-Huo-Xue formula on bleomycin-induced pulmonary fibrosis through the p53/IGFBP3 pathway. Chinese Medicine, 2023, 18, .	1.6	2
3001	Idiopathic Pulmonary Fibrosis and Post-COVID-19 Lung Fibrosis: Links and Risks. Microorganisms, 2023, 11, 895.	1.6	13
3002	Long-term effect of pulmonary rehabilitation in idiopathic pulmonary fibrosis: a randomised controlled trial. Thorax, 2023, 78, 784-791.	2.7	3
3003	Safety and feasibility of carboplatin and paclitaxel in combination with nintedanib for non-small cell lung cancer patients with idiopathic pulmonary fibrosis: a prospective pilot study. Translational Lung Cancer Research, 2023, 12, 719-726.	1.3	2
3004	Idiopathische Lungenfibrose. Springer Reference Medizin, 2023, , 1-11.	0.0	0
3005	Immunologic Lung Diseases. , 2023, , 919-935.		0

#	Article	IF	Citations
3006	Acute exacerbation of pleuroparenchymal fibroelastosis with lower lobe usual interstitial pneumonia: An autopsy case. Respiratory Medicine Case Reports, 2023, 43, 101846.	0.2	1
3007	Pharmacological management of systemic sclerosis associated interstitial lung disease. Expert Opinion on Pharmacotherapy, 0, , 1-10.	0.9	0
3008	Nonspecific, Unclassifiable, and Rare Idiopathic Interstitial Pneumonia: Acute Interstitial Pneumonia, Respiratory Bronchiolitis Interstitial Pneumonia, Desquamative Interstitial Pneumonia, Nonspecific Interstitial Pneumonia. , 2023, , 589-603.		0
3009	The Syndrome of Combined Pulmonary Fibrosis and Emphysema. , 2023, , 561-588.		0
3010	Unclassifiable Interstitial Lung Disease. , 2023, , 671-682.		0
3011	Pulmonary Alveolar Proteinosis Syndrome. , 2023, , 389-404.		0
3012	Idiopathic Pulmonary Fibrosis and the Many Faces of UIP. , 2023, , 549-560.		0
3013	A novel corpus of molecular to higher-order events that facilitates the understanding of the pathogenic mechanisms of idiopathic pulmonary fibrosis. Scientific Reports, 2023, 13, .	1.6	0
3014	Identification and validation of chemokine system-related genes in idiopathic pulmonary fibrosis. Frontiers in Immunology, 0, 14, .	2.2	1
3016	Management of interstitial lung disease in patients with autoimmune disease-related interstitial lung disease. Multidisciplinary Respiratory Medicine, 0, 18, .	0.6	2
3017	Positron Emission-Computed Tomography, Cryobiopsy versus Bronchoalveolar Lavage and Computed Tomography Findings for Interstitial Lung Disease: A Long-Term Follow-Up. Medicina (Lithuania), 2023, 59, 787.	0.8	1
3018	Anti-fibrotic therapy and lung transplant outcomes in patients with idiopathic pulmonary fibrosis. Therapeutic Advances in Respiratory Disease, 2023, 17, 175346662311659.	1.0	2
3022	Anti-fibrotic strategies and pulmonary fibrosis. Advances in Pharmacology, 2023, , .	1.2	1
3034	Case Report: Nintedanib for immune-related pneumonitis triggered by anti-PD-1 treatment in a patient with SMARCA4-mutant NSCLC: a case report. Frontiers in Pharmacology, 0, 14, .	1.6	1
3036	Research and development of N,Nâ€²-diarylureas as anti-tumor agents. RSC Medicinal Chemistry, 0, , .	1.7	0
3039	An Introduction to Engineering and Modeling the Lung. Advances in Experimental Medicine and Biology, 2023, , 1-13.	0.8	0
3063	Chronic Respiratory Disease: COPD, IPF. Practical Issues in Geriatrics, 2023, , 311-330.	0.3	0
3091	Cryobiopsy in Interstitial Lung Disease: Is It Prime Time?. Current Pulmonology Reports, 0, , .	0.5	0

#	Article	IF	Citations
3125	Pulmonary Disease. , 2023, , 1-26.		0
3186	Idiopathic Interstitial Pneumonias. , 2023, , 1-44.		0
3212	Osteopontin: an essential regulatory protein in idiopathic pulmonary fibrosis. Journal of Molecular Histology, 0, , .	1.0	0
3217	What Special Considerations Are Needed for Patients With Advanced Lung Disease?. , 2023, , 448-459.		0
3235	Traditional Herbal Medicines, Bioactive Compounds, and Plant Products as Therapeutic Approach Against Interstitial Lung Disease. , 2023, , 339-380.		0
3242	Nintedanib-associated enterocolitis with intractable diarrhea: a case report. Clinical Journal of Gastroenterology, 0, , .	0.4	0
3273	Case report: anti-synthase syndrome associated with SARS-Cov-2 infection. , 0, , .		0
3275	Macrolides and Interstitial Lung Diseases. , 2024, , 161-176.		0
3323	Pulmonary Disease. , 2024, , 571-596.		0